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Abstract 
Background: ST2 has been identified in playing an important role in Th2-
mediated inflammation and asthma. IL-33 acts as the ligand for ST2; it is a novel 
cytokine that induces innate Th2/type-2 responses when delivered to the lung. 
The hierarchy of IL-33 and type-2 cytokines and chemokines in Th2 inflammation 
in the lung has not been fully elucidated. Furthermore, the role of IL-33 in the 
adaptive response in allergic mediated airways disease is unclear. 
Epithelial cells (ECs) are increasingly recognised as having an immunological role 
in airway inflammation and asthma, in particular releasing cytokines such as IL-
33. Little is known about whether ST2 is expressed on these cells and what 
function IL-33 responsive ECs may have in Th2 diseases. 
Soluble ST2 (sST2) has emerged as a biomarker correlating with disease activity 
in cardiovascular disease. It is not known if there is a clear association between 
sST2 and asthma, nor whether measurable IL-33 concentrations are present and 
if so, their association with disease severity. The influence of smoking and 
corticosteroid treatment on these parameters has also not been determined. 
Aim: To ascertain the levels of systemic sST2 and IL-33 in asthmatic patients. To 
determine cytokine, chemokine and airway dynamics of IL-33-driven innate 
airway inflammation. To determine the role of epithelial cells in IL-33-driven 
innate airway inflammation.  To investigate the function of ST2/IL-33 axis in the 
innate and adaptive responses in allergic airways inflammation and asthma.  
Methods and Results: sST2 and IL-33 levels in plasma of never smokers, ex-
smokers and smokers were determined by immunoassay before and after a 
corticosteroid trial. Corticosteroid treatment resulted in increased sST2 levels in 
all smoking status patient groups; there was no effect attributable to smoking. 
Time course and dosage interval experiments were performed in mice treated 
with intranasal IL-33. IL-5, IL-13, eotaxin/CCL11 and eotaxin2/CCL24 mediated 
eosinophilic airway inflammation (AI). Treatment of mice with both anti- CCL11 
and -CCL24 partially ameliorated the AI. IL-4 gene deficient mice were 
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protected from IL-33-induced inflammation. BALB/c mice displayed airways 
hyperreactivity following IL-33 treatment. 
Murine, human cell line and primary human ECs were assessed for ST2 expression 
by immunohistochemistry and fluorescence activated cell sorting (FACS). ST2 
expression was clearly demonstrated in the ECs. Subsequently ECs were treated 
with IL-33 in an in vitro setting including in a pseudostratifed epithelium model. 
ECs produced a range of inflammatory and angiogenic mediators in response to 
IL-33. In particular IL-33 driven EC-derived VEGF promoted angiogenesis in vitro.  
Intranasal IL-33 induced increased endothelial cells and vascular remodelling in 
vivo. 
Experimental allergic airways inflammation (AAI) was generated in BALB/c mice 
which were co-treated with IL-33 or PBS at allergen sensitisation.  IL-33 induced 
the polarisation of IL-5+IL-4- T cells in the draining lymph nodes and these mice 
developed more severe inflammation. 
AAI was induced in WT, ST2-deficient, IL-4-deficient and ST2/IL-4 deficient 
mice. These experiments showed IL-4 was necessary for generation of AAI which 
could not be overcome by ST2-pathway stimulation in an adjuvant-free model.  
Conclusions:  The data presented further extends the current understanding of 
the ST2/IL-33 axis in the innate and adaptive aspects of Th2 inflammation in AAI 
and asthma. In particular the hierarchy of mediators and cells involved in Th2 
inflammation, including at the sensitisation phase, have been explored. This 
identifies ST2/IL-33 as a potential target in the development of biological 
therapies for asthma.  
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GATA   trans-acting T-cell-specific transcription factor 
GINA  Global Initiative for Asthma 
GM  growth medium  
GM-CSF  granulocyte-macrophage colony-stimulating factor 
H&E   haematoxylin and eosin  
HBSS  Hank’s Balanced Salt Solution 
HDAC  histone deacetylase 
HDM   house dust mite 
HF   heart failure  
HMGB  high motility group box 
HRP   horseradish peroxidase  
HUVEC  Human Umbilical Vein Endothelial cells  
IC   intracellular  
ICS  inhaled corticosteroid 
ICOS   inducible T-cell costimulator  
IFN  interferon 
Ig  Immunoglobulin 
IL  interleukin 
IL-1RAcP  IL-1 receptor accessory protein  
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ILC  Innate lymphoid cell 
i.n.  Intranasal  
iNKT  invariant NKT 
iNOS   inducible nitric oxide synthase 
i.p.  intraperitoneal  
IP-10   interferon gamma-induced protein 10 
IRAK1  IL-1R associated kinase 1  
i.v.  intravenous  
JNK  c-Jun N-termainal kinase  
kDa   kiloDalton 
LPS   Lipopolysaccharide  
LVEF   Left ventricular ejection fraction  
LXA4  Lipoxin AX4  
MBP   Major basic protein  
MC  Mast cell 
MDCK  Madin-Darby canine kidney 
MHC   Major histocompatibility complex  
MMP  matrix metalloproteinase 
MI   Myocardial infarction 
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mRNA  messenger ribonucleic acid  
MTT   3,[4,5-dimethykthiazol-2-yl]-2,5-diphenyltetrazolium bromide  
MyD88  myeloid differentiation primary response protein 88  
NBF  neutral buffered formalin 
NF-kB  nuclear factor-kB 
NHBE  normal Human Bronchial Epithelial 
NK  natural killer 
NKT  natural killer T  
NLRP3  nod-like receptor family pyrin domain containing 3 
NO  nitric oxide 
NRAD  National Review of Asthma Deaths 
NSTEMI  non-ST elevation myocardial infarction 
OCT   optimum cutting temperature medium 
OVA   ovalbumin  
PAMP   pathogen associated molecular pattern 
RANTES  regulated on activation, normal T cell expressed and secreted  
PAS  Periodic Acid-Schiff 
PBS   phosphate buffered saline  
PCR  polymerase chain reaction 
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PEF   Peak Expiratory Flow  
Penh  enhanced pause  
pHBE   primary human bronchial epithelial cells  
PMA  phorbol 12-myristate 13-acetate  
PRR   pattern recognition receptor 
RAG  recombination-activating gene  
RNA  ribonucleic acid 
RT  room temperature 
Sca  stem cell antigen 
SEM   standard errors of the mean  
SIGN  Scottish Intercollegiate Guideline Network 
SLE   systemic lupus erythematosus  
SSC  side scatter 
ST2   Shoji Tominaga 2 
sST2  soluble sST2 
ST2L  longer ST2 
STAT   signal transducer and activator of transcription  
STEMI   ST elevation myocardial infarction 
TAE  tris-acetate-EDTA 
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T-bet   T-box transcription factor 
TBST   tris buffered saline  
TEER   Trans-epithelial electrical resistance 
TG2   transglutaminase 2 
TGF  transforming growth factor 
TCR  T cell receptor 
Th  T helper cell 
TIR   Toll-IL-1R 
TLR  Toll-like receptor 
TMB   3,3’,5,5’-tetramethylbenzidine 
TNF   tumour necrosis factor 
TRAF  TNF receptor associated factor 
TReg   regulatory T cells  
TSLP   thymic stromal lymphoprotein  
UA  uric acid  
UK   United Kingdom  
UV  ultraviolet  
vWF   von-Willebrand factor 
VEGF  vascular endothelial growth factor 
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1 Introduction 
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1.1 Asthma 
1.1.1 Clinical asthma and epidemiology 
Asthma is a chronic inflammatory condition of the airways. It is defined clinically 
by reversible airflow obstruction (AFO) and results in symptoms of wheeze, 
breathlessness and cough. The cardinal pathophysiological features are airway 
hyperresponsiveness (AHR) and airway inflammation (AI), the latter giving rise to 
mucus hypersecretion. Furthermore, structural changes and lung remodelling are 
now recognised as increasingly important features1.  
The global burden of asthma is staggering with as many as 300 million people 
worldwide estimated to suffer from asthma according to The Global Initiative for 
Asthma 2014 (GINA)(www.ginasthma.org) and the worldwide incidence is 
increasing (World Health Organisation, www.who.int/en/).  As well as the effect 
on the individual, huge healthcare cost and economic impact ensures it is a 
serious global healthcare issue.  In the United Kingdom (UK) alone, 5.4 million 
people (www.asthma.org.uk) are currently receiving treatment for asthma. The 
National Review of Asthma Deaths (NRAD) attributes approximately 1200 deaths 
each year in the UK to asthma, a figure which has not changed in many years 
(www.rcplondon.ac.uk); 90% of these are potentially preventable. In addition to 
understanding how life-threatening conditions arise, healthcare policies are 
targeted to improve the quality of life for people with this long term condition. 
Locally, the Scottish Government considers asthma one of the 4 main health 
challenges facing children today (www.scotland.gov.uk). 
Susceptibility to the development of asthma is controlled by genetic and 
environmental factors. Risk factors include family history, premature or low 
birthweight, viral infection in early childhood, maternal smoking and sex (male 
for development of asthma in children and female for persistence of asthma into 
adulthood). There is up to a 30 fold difference in prevalence between countries 
with a trend towards an increase in developed nations. Socioeconomic factors 
may play a role with the incidence of asthma highest amongst low-income 
populations (www.isaac.auckland.ac.nz/). 
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Despite efforts to raise awareness and improve education amongst patients and 
healthcare providers, suboptimal control is widespread. One contributing factor 
to this is that only recently has asthma been recognised as a heterogeneous 
condition and a number of asthma phenotypes exist within the spectrum of 
chronic airways disease; therefore, some phenotypes may not be appropriately 
treated2.  
The most common classification of asthma is based on the level of asthma 
control. Other clinical descriptions are used such as brittle, refractory, late-
onset or steroid-resistant phenotypes. Classification can also be based on 
pathological type: atopic (extrinsic) or non-atopic (intrinsic) being one historical 
distinction 3. Atopic asthma is defined by the presence of elevated serum 
immunoglobulin (Ig)-E antibody to common inhalant allergens and accounts for 
approximately 55-80% of cases 4. Atopic asthma has a genetic predisposition and 
tends to develop at a younger age3. Targeted treatment to selected patients in 
this phenotypic group with anti-IgE therapy has been very successful 5,6. 
However, only one third of individuals with atopy and raised IgE have asthma 1. 
Furthermore, the pathological changes seen in atopic and non-atopic asthma are 
similar and these relationships are not fully understood 7.  
Other phenotypes can be considered on the basis of the predominant 
inflammatory cellular infiltrate such as eosinophilic or neutrophilic asthma8,9, or 
other physiological variables such exhaled nitric oxide concentration 10. All of 
these serve as biomarkers and have been evaluated as the basis for directed 
treatment.  Overall, asthma comprises multiple and incompletely understood 
clinical phenotypes and clinico-pathological correlates. Thus efforts to 
understand these phenotypes on a basic and cellular level are paramount with 
the ultimate aim of targeted treatments and promoting the concept of 
individualised care. 
1.1.2 Management of asthma 
The mainstay of asthma management is aimed at suppressing chronic airway 
inflammation, predominantly by using inhaled corticosteroids (ICS), and relieving 
acute bronchoconstriction with inhaled bronchodilators. Guidelines produced by 
the British Thoracic Society (BTS) and Scottish Intercollegiate Guideline network 
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(SIGN) aid physicians in the management of acute and chronic asthma based on a 
step-wise approach (www.sign.ac.uk). 
Corticosteroid (CS) therapy is the most effective anti-asthma treatment 
currently available and its mode of action switches off gene transcription for 
multiple inflammatory pathways; the molecular basis of these mechanisms is still 
unresolved 11. One view is that CS recruit the nuclear enzyme histone 
deacetylase 2 (HDAC2) to hyperacetylated inflammatory genes leading to 
deacetylation and reduced inflammation 11. Clinically, CS resistance in severe 
asthmatics has been linked to impairment in the function of (HDAC2) 12. 
The main limitation of steroids is their side effects although this is somewhat 
mitigated by using inhaled preparations. However, a proportion of asthmatics, 
around 5%, require regular oral steroids yet despite this they often remain 
symptomatic 13. The economic impact of this small proportion is substantial 14. 
Other asthmatic patients are relatively resistant to steroid effects and this is 
particularly the case for smokers 15; more concerningly, worsening of 
neutrophilic asthma with CS has been described 16. A number of other immune 
modulating drugs (cyclosporine, tacrolimus, methotrexate, azathioprine) have 
been trialled with varying degrees of success, but all carry a significant side 
effect profile 17. Omalizumab is a monoclonal antibody against IgE that is the 
only licensed treatment for severe asthma. Thus there is a significant unmet 
clinical need for novel therapies, which in turn requires research and suitable 
disease models.  
Other non-biological treatments currently available for asthma include: 
anticholinergics; leukotrine receptor antagonists; cromoglycates (mast cell 
stabilisers); and theophylline (a bronchodilator). 
1.1.3 Immune responses in asthma 
A complex interaction of genetic and environmental factors is thought to give 
rise to asthma. In atopic asthma, this interaction somehow drives the immune 
response to direct an active response resulting in inflammation to an otherwise 
innocuous antigen. Since the Mossman classification of adaptive T helper (Th) 
cells as Th1 (mainly Interferon-γ [IFN-γ] producing) or Th2 (mainly type-2 
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cytokine producing) 18, this immune response has been described as 
predominantly Th2 driven. Further sub-classification is now suggested based on 
the degree of Th2-inflammation, dividing into Th2-low and Th2-high phenotypes 
19. A multitude of inflammatory and immune cells and mediators have been 
described in the development and persistence of asthma. The following sections 
outline in more detail the evidence for some of these and their role in asthma, 
whilst acknowledging there is obviously cross-talk between cells and the 
importance of their individual roles is debated. 
1.1.3.1 Adaptive immune system in asthma 
Adaptive immune responses are antigen-specific and exhibit memory. Specificity 
is achieved by the random recombination of genes in the T-cell receptor (TCR) 
and the somatic hypermutation of the variable region of immunoglobulin genes 
that produce antibodies.  
1.1.3.1.1 T lymphocytes 
 
There are increased numbers of cluster of differentiation 4 (CD4) T cells in the 
airways of asthmatic patients. These are predominantly Th2 cells as opposed to 
predominating Th1 cells found in the normal airway 20. These Th2 cells secrete 
Th2 cytokines; for example interleukin (IL)-4, IL-5 and IL-13 21. However, they 
are not the only cells that contribute to Th2 or type-2 cytokine production and 
inflammation. 
Studies in animal models further demonstrate a role for Th2 cells in asthma. 
Transfer of antigen-specific T cells into antigen-naïve mice induces AI and AHR 
22. In models of allergic airways inflammation (AAI), transfer of CD4 cells into 
recombination-activating gene (RAG) deficient mice deficient in an adaptive 
immune response, restores the ability of these mice to develop AI and AHR when 
sensitised to allergen 23. In support of this, CD4 cell depletion in wild-type mice 
impairs the induction of AI and AHR 24. However, this effect is not sustained in 
models of chronic inflammation and there is no effect on subsequent 
remodelling 25. 
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Further evidence for involvement of CD4 cells in asthma comes from increased 
understand of their molecular signalling. T-box transcription factor (T-bet) is a 
key Th1 lymphocyte transcription factor and its expression is reduced in the 
airway cells of asthmatics. Experimentally, mice gene-deficient in T-bet show 
spontaneous features of Th2 inflammation and remodelling 26. Similarly, trans-
acting T-cell-specific transcription factor (GATA) binding protein 3 (GATA3), the 
key Th2 lymphocyte transcription factor was increased in airway cells of 
asthmatics 27 and blockade of this molecule in mice prevented the development 
of AHR and AI 28.  
Other Th subsets have been implicated in asthma and these likely reflect the 
potential phenotypic difference previously mentioned. The detection of IFNγ in 
the bronchoalveolar lavage (BAL) T cells has led to the possibility that Th1 cells 
may have a role in some phenotypes of asthma 29. Novel Th subsets including 
Th17 cells which secrete interleukin (IL)-17 and may be particularly important in 
the neutrophilic asthma phenotype 30 and Th9 cells, which secrete IL-9, have 
been linked to asthma 31. 
CD4+CD25+ regulatory T cells (TReg) can suppress both Th1 and Th2 development 
and function 32,33. Some investigators have found reduced numbers or function of 
TRegs in asthmatics 34. One study of T cell phenotypes found that CD4+CD25+ 
cells with correlated Foxp3 messenger ribonucleic acid (mRNA) expression in 2% 
of blood and 6% of BAL cells in asthmatic patients suggesting a role for Tregs. 
These cells were increased in patients treated with CS suggesting that CS effects 
are in part mediated by Treg cells secreting IL-10 34. Experimentally, CD4+CD25+ 
cells were seen to reverse AI and moreover prevent the development of airway 
remodelling, suggesting there may be substantial gain from investigating the 
mechanisms of these cells 35.  
Another subset of CD4 T cells, the invariant natural killer T (iNKT) cell might 
account for a significant proportion of the CD4+ cells described in asthmatic 
airways as these cells also produce the Th2 cytokines IL-4 and IL-13. 
Approximately 60% of CD4 T cells noted in the bronchial biopsies from asthmatic 
patients were iNKT cells 36. However, this was not confirmed in a further study 
so the presence and role of these cells remains uncertain 37. 
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CD8 cells are present in the asthmatic airway in patients with more severe 
disease and irreversible airflow obstruction. These cells include cytotoxic T cell 
(Tc)1 or Tc2 and may reflect a change in phenotype skewing towards a type-1 
response at this end of the clinical severity spectrum 21. 
1.1.3.1.2 Th2 inflammation 
 
In addition to the canonical Th2 cytokines IL-4 and IL-5, additional cytokines that 
can be produced by Th2 cells have been described and include IL-13, IL-6 and IL-
9. Th2 cytokines can also be produced by many other cells.  In the following 
section these cytokines that contribute to the resulting Th2 or type-2 
inflammation in this distinct cytokine pattern will discussed regardless of the 
cellular source.  
Type 2 cytokine concentrations are increased in sputum 38 as well as in airway 
lavage from asthmatics 39. Similarly type-2 cytokine mRNA expression is 
increased in asthmatic bronchial biopsies 40. Genome-wide searches have 
provided evidence of linkage of asthma to the 5q31-33 region, which contains 
the Th2 cytokine cluster (IL-4, IL-13, IL-5, and IL-9) 41. 
Originally described as a B cell growth factor, and for its ability to initiate class-
switching from IgM to the Th2 isotypes IgG1 and IgE in mice, IL-4 was 
subsequently described in relation to Th2 development 42,43 and involved in 
eosinophil chemotaxis. B lymphocytes and IgE will be further discussed in section 
1.1.3.1.3 and Th2 development in section 1.1.3.1.3. 
Interleukin-4 can be secreted by Th2 cells, mast cells, basophils, eosinophils and 
alveolar macrophages 44. In mice, administration of IL-4 directly into the airway 
results in features of AI and AHR; moreover, in IL-4 receptor (IL-4Rα) knockout 
mice, this effect was lost 45. However, as this cytokine shares a receptor subunit 
with IL-13, the lack of response could be attributed to the loss of IL-13 effects. 
In the allergic airways model, IL-4 knockout (-/-) mice had reduced but not 
abolished AI and AHR compared to their wildtype (+/+) comparators 46; the effect 
on AHR in has been replicated by some but not by all studies 47. Transfer of      
IL-4-/- or IL-4 +/+ Th2 cells into IL-4-/- showed IL-4 was required for eosinophilic 
inflammation but not for AHR 47. 
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These findings have led to clinical trials directed at antagonising IL-4 with anti-
IL-4 monoclonal antibodies or a soluble recombinant receptor but also by binding 
targeting the IL-4Rα subunit with the protein Pitrakinra and the monoclonal 
antibody dubilumab. The latter of these has been the most promising in 
advanced clinical trials with improved success likely as the target inhibits both 
IL-4 and IL-13 activity 48,49.  
As partial redundancy in the function of IL-4 was found in IL-13, focus of Th2 
cytokine involvement in asthma has been directed towards the role of IL-13 as a 
key regulator in pathogenesis of asthma. As noted above, IL-13 binds to the α-
chain of the IL-4 receptor. IL-I3 is located on chromosome 5q31 and has been 
linked to asthma in genetic linkage studies. Specifically, the IL-13 R110A genetic 
polymorphism has been linked to asthma or allergy 50. IL-13 is present in the 
sputum51 and BAL of asthmatics 52. 
IL-13 shares some functionality with IL-4; overexpression or administration of IL-
13 induces asthma-like phenotype namely, AI, mucus hypersecretion, chemokine 
induction (e.g. CCL11/eotaxin), airway fibrosis and AHR by increasing 
contractility of airway smooth muscle (ASM) 53,54. In comparison, neutralisation 
of IL-13 abrogates these features as well as reducing associated airway 
remodelling 54.  A number of downstream pathways for IL-13 effects are 
described:  via signal transducer and activator of transcription (STAT)-6 
dependent effect on epithelial cells for AHR and mucus production driven by IL-
13 53; via chitin from epithelial cells or macrophages 55; via or in association IL-
5/eotaxin(CCL11)-dependent eosinophil recruitment 56; or IL-5 /eotaxin(CCL11)-
independent AHR 57. IL-13 is produced in large quantities by CD4 Th2 
lymphocytes and innate lymphoid cells (ILC), and lesser amounts by natural killer 
cells, mast cells and basophils 54,58. 
Human clinical trials examining the role of IL-13 antagonists in the treatment of 
asthma and related allergic diseases are in development. Along with the 
Pitrakinra trials detailed above, monoclonal antibody trials are in phase I and II 
clinical trials. Beneficial effects are seen in particular on bronchial 
hyperresponsiveness. Indeed, Lebrikizumab in a phase II trial (MILLY) showed 
more improvement in lung function of a subgroup of patients with high levels of 
periostin, an extracellular matrix protein produced by bronchial epithelial cells, 
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indicating a further biomarker that can aid individualised targeted treatments 59. 
Other Phase II trials have shown benefit and Phase III trials are underway (Table 
1.1). 
Interleukin-5 is inextricably linked to eosinophils and controls their growth, 
differentiation and activation 60. In animal studies, over-expression of IL-5 leads 
to pathological changes characteristic of asthma 61 and deficiency of IL-5 
minimises eosinophilia and AHR 62. 
IL-5 mRNA is found at increased levels in cells from the sputum, bronchial 
biopsies as well as elevated concentrations of IL-5 in the serum of asthmatic 
patients; this correlates with disease severity 63-65. Inhalation of IL-5 results in 
sputum eosinophilia and AHR 66. The primary source of IL-5 in the airways 
includes Th2 cells, ILC, eosinophils and mast cells 58,67. 
In terms of biological therapy, as with IL-4 and IL-13, there have been a number 
of clinical trials targeting IL-5. Early trials have shown these agents 
(mepolizumab, resilizumab) are effective in reducing eosinophilia but were not 
associated with a reduction of symptoms 68. More recently, three trials of 
Mepolizumab in patients with a particular asthma phenotype consisting of 
eosinophilia and frequent exacerbations, demonstrated clinical improvements 
along with a reduction in sputum and blood eosinophilia and a reduction in 
exhaled nitric oxide (NO); an easily measurable biomarker used in the DREAM 
trial 69,70. Other promising Phase III studies involving antibodies in these selected 
patients have just been published providing an opportunity for future licensed 
therapy (Table 1.1). 
Interleukin-9 and the IL-9 producing T cell subset Th9 play a role in the 
promotion and regulation of asthma 31. IL-9 promotes the production of 
epithelial growth factor, the proliferation of goblet cells and increased mucus 
production.  IL-9 mRNA is expressed more highly in bronchial biopsy studies in 
asthmatics and levels correlated with AHR 71. In vivo, overexpression of IL-9 
results in features of asthma developing in mice 72. These findings have led to 
the development of clinical trials antagonising IL-9. These recent trials have 
shown a trend towards efficacy but further trials to confirm this are awaited 73. 
More recently, a link between IL-9, mast cell function and fibrosis has been 
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described in a chronic inflammation model suggesting that extended therapeutic 
inhibition of IL-9 may be necessary to observe significant changes74.  
 
Target Biological Drug Clinical trial 
stage 
Outcome 
Omalizumab Binds free IgE Approved; in use ÈExacerbation, 
symptoms. Çquality of 
life 
Pascolizumab Blocks IL-4 Phase II No benefit 
Altrakincept Soluble IL-4R Phase II No benefit 
Pitrakinra Inhibits IL-4Rα 
binding 
Phase II ÈBronchoprovocation 
Dupilumab Inhibits IL-4Rα 
binding 
Phase II/III ÈExacerbation 
Tralokinumab Blocks IL-13 Phase I/ II ÈEosinophilia 
Anrukinzumab Blocks IL-13 Phase II ÈDecrease late 
asthmatic response 
Lebrikizumab Blocks IL-13 Phase II Ç Lung function if high 
periostin (MILLY) 
  Phase III Awaited (NCT-
01868061,1867125, 
01875003, 01545440 
(LUTE), 01545453(VERSE) 
Bendralizumb Blocks binding to 
IL-5Rα 
Phase I/II ÈBlood eosinophilia 
Reslizumab Blocks IL-5 Phase II ÈSputum eosinophilia 
and improve lung 
function (primary 
outcome exacerbations 
no benefit)  
  Phase III Awaited 
Mepolizumab Blocks IL-5 Phase II ÈEosinophilia, steroid 
use, exacerbations 
(DREAM) 
  Phase III (Sept 
2014) 
ÈExacerbations (MENSA 
trial) and steroid use 
(SIRIUS trial) 
MEDI-528 Blocks IL-9 Phase II ÈExercise related 
bronchoconstriction 
Infliximab Blocks TNFα Phase II ÈExacerbations 
Etanercept Soluble TNFα 
receptor 
Phase II ÈAHR and Çquality of 
life. Safety issues 
Golimumab Blocks TNFα Phase II Terminated-safety issues 
Lumiliximab Binds CD23 Phase I Safety study 
Table 1.1: Biological drugs used in the treatment of asthma 
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1.1.3.1.3 B lymphocytes and IgE 
 
The serum substance first described in relation to allergy and development of 
type 1 hypersensitivity reactions was subsequently identified as IgE 75.The 
finding of elevated concentrations in the serum of asthmatics led to research 
into its role in asthma 76. The role of B cells in asthma has not been studied as 
extensively as that of T cells but their ability to produce IgE means they occupy 
a place in asthma pathophysiology. 
In sensitised individuals, the majority of IgE is bound to the surface of mast cells 
and basophils by the high affinity IgE receptor FcεRI 77. Allergen crosslinking of 
this bound IgE leads to receptor mast cell or basophil degranulation with release 
of preformed mediators and the initiation of an rapid inflammatory cascade 77. 
Most asthmatics have increased levels of circulating IgE and this correlates with 
severity of disease 78. 
In murine models of allergic airway inflammation, IgE appears to be a 
requirement for AHR and eosinophilia 79. However, others have found that the 
requirement for IgE was not obligatory80 but it is likely that the choice of model 
and mouse strains used have influenced the findings and this may have relevance 
to different asthma phenotypes.  
Anti-IgE therapy has unambiguously confirmed the role of IgE in the pathogenesis 
of allergic asthma. Omalizumab is currently the only anti-IgE biologic approved 
for the treatment of moderate-to-severe persistent asthma in adults and 
children 12 years and older, whose symptoms are inadequately controlled with 
inhaled CS. Omalizumab is a recombinant DNA-derived humanised monoclonal 
antibody to the Fc portion of the IgE antibody that prevents the binding of IgE to 
FcεRI, thus blocking FcεRI cross-linking and reducing the release of inflammatory 
mediators in response to allergen exposure. Three large randomised control 
trials have shown a significant decrease in the incidence of asthma 
exacerbations as well as in hospitalisations and ICS usage in asthmatics given 
omalizumab 81-83. In addition, significant improvements in quality of life 
measures were seen5 (Table 1.1). 
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In allergy, the respiratory tract mucosa is a major source of IgE production 77. 
IgE synthesis as well as class switch recombination (CSR) of antibody class to IgE 
in B cells can occur 84. Non-atopic asthmatics can also synthesise IgE in the 
bronchial mucosa but the specificity of this IgE antibody is unclear 84. 
Nethertheless, trials of omalizumab in non-atopic asthma are ongoing and should 
answer some questions about IgE in these particular asthmatics with early results 
showing a possible benefit 85.  
In the absence of IL-4, IL-13 promotes IgE class switching 54. However, in animal 
models it has been shown that IL-4/13 may not actually be essential in IgE 
generation under certain conditions 86. 
In addition to IgE production, B lymphocytes may have further roles including 
production of other immunoglobulin isotypes and cytokines as well as in antigen 
presentation. To consider this, in experiments using B cell deficient mice with 
impaired IgE production, no requirement was found for B cells in the 
development of eosinophilia or AHR in an ovalbumin model of AAI 87. However, a 
requirement for B cells in the development of AHR is unclear with contradictory 
results identifying a role for B cells in AHR in other AAI models 88 89. Different 
sensitisation protocols used in these models suggests this can influence the 
development of AHR.  
1.1.3.1.4 Allergen sensitisation 
 
There is growing interest in the early allergen sensitisation phase of allergic 
disease. As antigen priming is likely to occur early in life, a therapeutic strategy 
at this stage seems implausible. However, the possibility to intervene before 
development of allergy is still intriguing. With the increasing development of 
biomarkers, it is entirely possible that sensitisation could be detected in 
children, for example by measuring increased CD23 (low affinity IgE receptors) 
or serum IgE concentrations 77. Furthermore, our increased understanding in this 
area could help to define therapeutic targets and inform immunotherapy 
strategies aimed at inducing immunological tolerance 90. 
Many factors affect the likelihood of developing clinically significant 
sensitisation: type of allergen, allergen concentration, pattern of allergen 
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contact; co-exposure to other agents including endotoxins, chitin, environmental 
pollutants; and host genotype 91. 
Defects in epithelial barrier function, including the inherited FLG mutation 
which encodes for filaggrin, a protein involved in barrier function, are associated 
with increased risk of developing asthma presumably by increasing exposure to 
allergens 92.  
As the allergen enters the tissue either via a disrupted epithelium or using 
endogenous protease activity, it is taken up by a local antigen presenting cell 
(APC), most likely a dendritic cell. Activated dendritic cells (DC) migrate to 
regional lymph nodes or local mucosa where peptides derived from the 
processed allergen are presented in the molecular context of major 
histocompatibility complex (MHC) class II molecules to naïve T cells. In the 
presence of IL-4, these cells develop characteristics of Th2 cells, which go on to 
produce Th2 cytokines and stimulate B cell CSR 93. Professional APCs require the 
ability to process and present MHC class 2 restricted peptide and to provide 
second-signal co-stimulation and initiate responses in antigen-naïve T cells.  
As discussed above, IL-4 appears to be a key cytokine in the early stages of 
allergen activation including by the priming of Th2 cells and their initial 
differentiation 93,94. The cellular source of the early IL-4 is unclear but basophils, 
mast cells, esoniophils, NKT cells and T cells are candidates 95-99. 
1.1.3.2 Innate immune system in asthma 
Unlike adaptive immune responses, innate immune responses are immediate and 
efficient but have no ability for memory.  The respiratory tract is accessible to 
environmental elements and the non-specific barrier epithelium is the first line 
of defence. The innate system also has to some extent specific responses, 
facilitated by a more recently recognised receptor network of pattern-
recognition receptors (PRRs) 100. Furthermore, the innate immune system also 
has an important role in shaping the adaptive response. 
To sense immediate danger or injury, virtually all cells express PRRs which bind 
to pathogen associated molecular patterns (PAMPs), highly preserved motifs on 
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pathogens, but also endogenous damage associated molecular patterns (DAMPs) 
100.  PRRs consist of membrane and cystolic located forms. The Nobel Prize 
winning discovery of the membrane associated PRR Toll-like receptor (TLRs) by 
Hoffmann and Beutler, have been identified in many species 101. There are 
numerous TLRs (1-13) and once activated, lead to a MyD88-dependent or TRIF-
dependent pathway and downstream gene expression 100,101. Defects in many 
TLRs are correlated to disease including asthma 102.  
In Th2 development from naïve T cells discussed in section 1.1.3.1.4 above, the 
T cell requires: priming into an effector antigen-specific T cell population and; 
differentiation, determining the nature of the T cell responses which is 
dependent on the surrounding conditions and cytokine environment. TLRs may 
influence these processes. PAMPs induce TLR signalling on immature DCs 
providing signals for priming and promoting Th2 differentiation by secretion of 
Th2-stimulating or non-secretion of Th1 stimulating factors 100,103.  TLRs can have 
dual contrary roles exemplified by the TLR2 agonist, Pam3CSK4: when this is 
given during sensitisation, it worsened murine AAI; and when given to 
established airway inflammation Pam3CSK4 attenuated the AAI 104. When high 
dose lipopolysaccharide (LPS) a TLR4 agonist is administered intranasally to mice 
with established AAI, it is associated with downregulated Th2 responses 105. 
However, at low LPS doses, Th2 responses actually predominate 106 and 
moreover, LPS is required for Th2 priming 103. Hence the activation of Th1 or Th2 
development is likely to depend on timing, dose and nature of TLR agonist as 
well as genetic background 103. 
A further mechanism for TLR influence on the adaptive immune response is via 
regulation of co-stimulatory molecules on APCs. Along with signals on MHC and 
co-receptor, T cell and DC engagement is enhanced by a 3rd signal from the 
Notch family of receptors on T cells. Notch ligands on the APC are upregulated 
by different stimuli and interaction of the ligand Jagged with Notch induces IL-4 
production in T cells 107.  This engagement of Notch at the surface of the T cell 
with the Jagged on the DC is up regulated by PAMPs106. 
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1.1.3.2.1 Macrophages and dendritic cells  
 
As the most abundant inflammatory cell in the lung, the role of macrophages in 
the pathogenesis of asthma must be considered 108. Along with their 
predominant role in maintaining homeostasis and a sterile airway by 
phagocytosing and removing pathogens and particles, they also direct immune 
response by cytokine release and can present antigen. Pulmonary macrophages 
are divided into subpopulations by location: as intravascular, interstitial or 
alveolar.  More recently a distinction by activation is described: classically 
activated (or M1) macrophages and alternatively activated (or M2) macrophages 
(AAM). M1 macrophages are activated by TLR ligands and by IFN-γ, express pro-
inflammatory cytokines and produce inducible nitric oxide synthase (iNOS). M2 
macrophages are stimulated by IL-4 or IL-13 and produce arginase instead of 
iNOS, and express the scavenger mannose receptor CD206 and IL-4Rα on their 
surface 109. In mice, the role of macrophages in asthma models is not clear. 
Some studies have shown depletion reduces AI and AHR 110 whilst others have 
shown depletion exacerbates AI 111 or that M2 are responsible for persisting 
inflammation 112.  Recent developments suggest there is plasticity in macrophage 
phenotypes depending on the prevailing inflammatory conditions which could 
reconcile these contradictory results 113. 
Dendritic cells are the professional APC and transport antigen to the draining 
lymph node114.  Increased numbers of DCs are seen in the airway of atopic 
asthmatics 115. The murine lung DC population consists of a variety of DC 
subsets. Myeloid DCs promote T cell priming 114 whereas plasmacytoid DCs 
promote regulatory T cells and tolerance 116. The nature of the DC that 
determine their role in Th1 or Th2 differentiation include the type of DC117, the 
types of cytokines produced by the DCs such as IL-12 and IL-6118, the maturity of 
the DC and surrounding environment 119 as well as costimulation provided by the 
DCs to T cells 114. A further role for DCs is in the effector stage of airway 
inflammation, by sustaining AI; this is demonstrated by abrogated airway 
eosinophilia and AHR in mice lacking DCs during antigen challenge 120.  
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1.1.3.2.2 Eosinophils 
 
Airway eosinophilia is a hallmark feature of the allergen-induced late-phase 
response in asthma although the pathogenic role of eosinophils is debated.  A 
number of early post mortem studies described the presence of these cells in 
airways of patients who died of asthma 121.  Subsequently, eosinophil numbers 
have been found to be elevated in sputum, BAL, biopsies and peripheral blood in 
50-80% of asthmatics, compared with normal controls 8,122,123.  Furthermore, 
sputum eosinophilia correlates with asthma severity and treatment directed at 
normalisation of the sputum eosinophil count reduces asthma exacerbations and 
admissions, without the need for additional anti-inflammatory treatment 8. 
IL-5 is critical for eosinophil recruitment, differentiation, proliferation and 
maturation and its role in asthma has been discussed in section 1.1.3.1.2 60,124.  
IL-3, granulocyte-macrophage colony-stimulating factor (GM-CSF) and eotaxin 
along with a number of adhesion molecules are also important in the 
development, adhesion and survival of eosinophils 60,124. The question of whether 
eosinophils are an effective treatment target in asthma cannot currently be fully 
answered. In clinical trials, anti-IL-5 treatment did not alter AHR following 
allergen challenge despite significantly reduced blood eosinophilia68. However, 
tissue eosinophil numbers were lowered by 60% leaving a potentially clinically 
significant proportion of these cells 125. 
On activation eosinophils can: contribute to the ‘respiratory burst’ by rapidly 
releasing highly reactive oxidative species 126; and degranulate releasing pre-
formed proteins such as major basic protein (MBP) eosinophil cationic protein 
(ECP), or enzymes such as eosinophil peroxidase (EP) and lipid eicosanoids 127. 
They can also produce Th2 cytokines and have potential to regulate Th2 cells in 
an antigen dependent manner 128. 
In asthma, the presence of eosinophilic inflammation and associated 
inflammatory products correlate with AHR and disease severity 129. 
Experimentally, there is conflicting evidence about an association with AHR that 
is predominantly explained by differences in model or mouse strain used. 
Dissociation of eosinophils and AHR is seen in Udbl-GATA mice, deficient of 
eosinophils, where similar mucus and AHR levels were measured compared to 
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wildtype (WT) in an AAI model 130.  Alternatively, others have seen an 
association of eosinophils with AHR in PHIL mice, another eosinophil deficient 
mouse 131. 
In addition to the effector roles of eosinophils in asthma, their repertoire of 
potential pathological functions is increasing. Shi et al showed that eosinophils 
can act as antigen processing cells, by processing allergen in the airway and 
travelling to regional lymph nodes in mice 132. Furthermore, these allergen 
containing eosinophils activate naïve T cells 133. In particular, a role in 
remodelling is now described. Mice given a prolonged antigen challenge have 
sustained tissue eosinophilia and features of remodelling that persist without 
further challenge 134. Furthermore, mice genetically deficient of eosinophils 
were protected from remodelling in a prolonged airway challenge model 130. In 
clinical asthma, patients with severe asthma who had mucosal eosinophilia, 
exhibited deposition of collagen in the lamina reticularis 135 and in milder 
asthmatics, in comparison to non-eosinophilic groups or healthy controls, the 
eosinophilic group had increased thickness of the subepithelial collagen layer 123.  
In support of this association of eosinophils and remodelling, patients given anti-
IL-5 treatment had reduced extracellular matrix (ECM) deposition 125. The 
mechanism for this appears to be due to eosinophil production of transforming 
growth factor(TGF)-β. TGFβ mRNA levels are raised in bronchial mucosa and are 
associated with eosinophilia and fibrosis in asthma patients 136 and 
experimentally, were reduced in IL-5-/- mice 137. 
IgE production and the presence of eosinophils are associated with allergy and 
asthma. Anti-IgE therapy reduces blood eosinophil count indicating eosinophilia 
may be a potential biomarker of successful response to this treatment 138. 
However, systemic measurements may not always reflect the local environment. 
Balzar et al demonstrated a correlation between local lung eosinophil count and 
higher local IgE concentrations with more severe exacerbations. This was despite 
similar serum IgE concentrations in patients with and without eosinophilia 139. 
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1.1.3.2.3 Mast cells and basophils 
 
Mast cells (MCs) have long been associated with asthma and allergy. As stated 
previously, activation via FCεR bound IgE, cross-linked by specific allergen 
triggers degranulation and the release of a number of proteases, histamine and 
leukotrines 140. The presence of the released mediators results in 
bronchoconstriction, vasodilation, increased vascular permeability and increased 
mucus production. Increased numbers of MCs are seen in airways of asthmatics 
and whilst their role in immediate hypersensitivity is accepted there is a poor 
clinical response to mast cell stabiliser treatment141. This suggests that de novo 
eicosanoid synthesis and release has a more important role in chronic asthma 
and blockade of this is the basis for leukotrine receptor antagonist therapy, e.g. 
montelukast.  In recent years interest has focused again on MCs and their role in 
later phase responses and chronic inflammation. 
In humans, bronchial biopsies in asthmatics had significantly increased numbers 
of MCs within ASM bundles when compared those with eosinophilic bronchitis, a 
condition with eosinophilic AI but no AHR. The number of these MCs correlated 
with the degree of AHR suggesting the relationship between MCs and AHR is 
critical in asthma placing them centrally in asthma pathogenesis 141. Supportive 
data for MCs in AHR comes from mast cell knockout animal models where AHR 
was dependent on MCs along with eosinophilia, possibly through tumour necrosis 
factor (TNF)α production, but only in model protocols where no allergen 
adjuvant was used 142. 
MCs can influence Th2 priming and can contribute to Th2 inflammation through 
promoting an influx of inflammatory cells, up-regulation of adhesion molecules, 
and production of cytokines and chemokines in the late phase response in 
experimental AAI 40,143. In chronic inflammation, MCs located in the ASM 
potentially influence remodelling 93, by mechanisms including via angiogenesis in 
response to MC vascular endothelial growth factor (VEGF) production 144. A role 
for MCs in non-atopic individuals has also been described in which the 
mechanism of mast cell activation is non-IgE-dependent 145. 
Like MCs, basophils become activated through IgE-mediated antigen stimulation 
with resultant mediator release 77. Basophil numbers are increased in the 
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airways of asthmatics and basophil histamine release decreases during 
omalizumab therapy 146. More recently, a deeper appreciation of their role in the 
initiation and amplification of asthma has emerged. This involves a newly 
described APC role of basophils 147; a role in IL-4 dependent Th differentiation 
148; enhanced production of thymic stromal lymphoprotein (TSLP) following 
protease allergen activation 95; and a role in IgE mediated chronic inflammation 
149. 
1.1.3.2.4 Neutrophils 
Neutrophils are polymorphonuclear leukocytes that act as a first line of defence 
in bacterial and fungal infections. Neutrophilic AI is associated with particular 
phenotypes of asthma including severe 150 and corticosteroid resistant 9 as well 
as in non-infectious asthma exacerbations 151 and sudden death associated with 
asthma 152. Furthermore, the concentration of IL-8, a neutrophil chemo-
attractant, is elevated in asthmatic sputum and production is unresponsive to 
steroid treatment 150.   Animal models support this clinical observation; with 
neither neutrophilic accumulation nor AHR suppressed by corticosteroid 
treatment in a model of acute exacerbations 153. Neutrophilic asthma has been 
associated with TNFα and the Th17 population. In human studies, inhalation of 
TNFα results in AHR and neutrophilic inflammation 154 and increased levels of 
TNFα are seen in the airways of asthmatic patients 155. IL-17 induces maturation 
of neutrophilic progenitors and in the sputum of asthmatic patients, expression 
levels of IL-17 mRNA correlates with neutrophil numbers 156.  Neutrophils release 
mediators that contribute to asthma pathophysiology. In particular IL-8, TGF-β, 
matrix metalloproteinases (MMPs) and proteases which together can contribute 
to inflammation and remodelling depending on the clinical phenotype.  
1.1.3.2.5 Innate lymphoid cells 
Since the conclusion of this work, an important population of multi-potent 
innate cells derived from murine lymphoid tissue and capable of expressing type 
2 cytokines have been described in three landmark independent studies 157-159. 
Collectively termed type-2 innate lymphoid cells (ILC2) 160 these cells appear to 
have important role in Th2 cell-dependent immunity or inflammation and thus 
their role in asthma pathology should be explored.  The phenotype had some 
years previously been described as non-B/non-T cells producing IL-5 and IL-13 in 
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response to IL-25 161,162. Although differences in phenotyping and markers are 
reported, all cell types appear to be characterised as lineage negative along 
with a lymphoid morphology, CD45+, and expressing stem cell antigen-1 (Sca-1+) 
157,158 and stem cell factor receptor receptor tyrosine kinase (c-kitint) 157, 
inducible T-cell costimulator (ICOS) 158 and importantly ST2 157,158. The 
importance of these cells in vivo was demonstrated as they appeared to be the 
main source of type-2 cytokines in parasite models 157-159. A comparable cell type 
have been reported in humans and make up a small proportion of CD45+ cells; 
0.2-0.3% in fetal and 0.02-0.08% in the adult lung 163. Their role in asthma will be 
discussed in chapter 7 in relation to the data presented here.  
 
1.1.3.3 Chronic inflammation 
Inflammation is the response of the immune system to injury and is normally 
beneficial to the host. In asthma, an aberrant immune response to non-
pathogenic stimuli leads to a chronic inflammatory response characterised not 
only by the presence of large numbers of innate and adaptive immune cells but 
also by airway remodelling. Remodelling describes a substantial change in the 
extracellular matrix with alterations in the number, phenotype and function of 
structural cells in the affected tissues, altering their functional properties.  
Once established the repetitive cycle of tissue damage and inflammatory-cell 
recruitment and repair becomes chronic even in the absence of sustained 
allergen contact 164.  Furthermore, there is evidence for individual components 
of the inflammatory response contributing to airway remodelling as well as an 
imbalance with pro-resolution mediators. Lipoxin AX4 (LXA4), a polyunsaturated 
fatty acid derivative, is one such factor produced to promote resolution of 
inflammation and patients with severe asthma have been shown to have lower 
circulating levels of LXA4 165. Levels of IL-8 correlate with LXA4 in sputum from 
mild asthmatics however in severe patients, an imbalance is seen with deficient 
production of the anti-inflammatory LXA4 166. With remodelling changes reported 
before symptoms of asthma develop 167, it is not entirely clear if remodelling is a 
sequential or parallel process to chronic inflammation, or co-dependent which is 
the most probable.  The structural cells themselves recruit, activate and 
promote survival of multiple inflammatory cells as well as orchestrate 
remodelling. 
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1.1.3.4 Structural cells in asthma 
Asthmatics display exaggerated rates of lung function decline which is primarily 
related to remodelling of the airway wall and loss of airway calibre 168,169. Most if 
not all elements of the airway wall can become dysfunctional. The major 
features of remodelling include epithelial damage and hypertrophy, smooth 
muscle cell hyperplasia and hypertrophy, goblet cell hyperplasia, subepithelial 
fibrosis and angiogenesis 169. 
AHR is associated with airway remodelling but not with sustained inflammatory 
cell recruitment in asthmatic patients 170.  A better understanding of these 
mechanisms is required as current therapies are primarily aimed at reducing 
inflammation typically by using CS, however these have limited effects on 
remodelling 171. Future studies aim to address whether omalizumab is capable of 
reversing or attenuating aspects of airway remodelling.  Furthermore, 
remodelling itself can affect treatment efficacy with loss of bronchodilator 
response to β2 receptor agonist associated with increased remodelling reported 
172.  
Many mediators participate in airway remodelling including TGF-β, MMP9 and 
ADAM-33. ADAM-33 is a metalloprotease and the identification of a genetic 
polymorphism in ADAM-33 is associated with accelerated decline in lung function 
over time 173. Although its biological function is not clear, its expression in 
epithelium, myo/fibrobalasts and the ASM make it a target for further 
investigation and highlights there may be many genetic factors that contribute 
to enhance remodelling in a subset of patients. Osteopontin is a glycoprotein 
that can act as an ECM molecule and as a cytokine and elevated levels have been 
shown in the sputum from severe but not mild asthmatics. It was strongly 
associated with remodelling factors, in particular TGF-β1 levels 174. 
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1.1.3.4.1 Epithelial cells 
 
The airway is covered by a continuous layer of epithelial cells (EC) which is of 
considerable size, approximately 100m2  175. It is the direct interface with 
inhaled air and forms the initial defence in the lungs comprising barrier function 
and a mucocilary escalator particle clearance.  Primary disordered epithelium is 
itself associated with asthma 175. Defects in antioxidant and interferon 
production increase susceptibility to air pollution and viral infection respectively 
176,177.  Airway epithelial cells (AEC) can be secretory, ciliated or basal; distally 
the alveolar epithelium can be subdivided into the majority type 1 AEC 
population which perform gas exchange and type 2 AECs, which release 
surfactant.   
Beyond their physical barrier role, bronchial ECs are now recognised as 
important components of both innate and adaptive immunity and also contribute 
to lung remodelling. The concept of the epithelial-mesenchymal trophic unit 
(EMTU) has been proposed to play a role in remodelling in asthma (Figure 1.1). 
Epithelial-mesenchymal transition is a process of cellular reprogramming or de-
differentiation whereby epithelial cells can contribute to the fibroblast 
population and this process has been described in a number of diseases. A 
number of types of lung and airway epithelial cell undergo EMT in vitro. ECs lose 
cellular polarity and markers of polarised cells and acquire mesenchymal cell 
markers 178. In turn, this expanded fibroblast population contribute to ECM 
deposition and thus remodelling 179. Human epithelial cells exposed to TGF-β can 
undergo EMT 180. TGF-β released from eosinophils and from the EMTU 
(myofibroblasts) itself, in combination is thought to be a key signal in this 
phenotypic transition 181. TGF-β stimulates fibroblasts to produce the increased 
amounts of ECM proteins. Mice deficient in Smad-3, which mediates TGF-β 
signalling, have reduced number of peribronchial myofibroblasts 182 and TGF-β 
expression correlates with subepithelial fibrosis in human asthmatic bronchial 
biopsies, suggesting a role for TGF-β in vivo 183. Another member of the TGF-β 
superfamily, activin-A, also signals through the Smad-3 pathway and drives AI. 
Mice administered follistatin, an endogenously produced protein which inhibits 
activin-A, had attenuated remodelling in a chronic inflammation model 
suggesting a further potential target in the TGF-β family 184. 
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Figure 1.1: The epithelial-mesenchymal trophic unit (EMTU) 
Repetitive epithelial injury due to chronic inflammation plus exposure to further insult (virus, 
bacteria, smoke, pollution, oxidative stress) and repair process results in the formation of an 
epithelial-mesenchymal trophic unit. Along with sustaining and promoting Th2 inflammation (not 
shown) this unit regulates remodelling. Myofibroblast activation, airway wall thickening, deposition 
of extracellular matrix proteins, goblet cell hyperplasia and increased vasculature. Myofibroblasts 
are predominantly responsible for repair after injury. In asthma subepithelial myofibroblasts are 
increased in number; migrating fibrocytes, smooth muscle cells, fibroblasts, loss of epithelial cell 
characteristics to develop a fibroblast/myofibroblast phenotype are responsible.  
Following activation of surface PRRs, epithelial cells produce antimicrobial 
molecules as well as cytokines and chemokines leading to cell recruitment and 
inflammation 185. By differential production of cytokines, the EC influences and 
regulates local DC and subsequent adaptive response to allergen in favour of 
either Th1, Th2 or Treg responses indicating a further important role for EC at 
sensitisation 185. Experiments with restricted TLR expression in bone marrow-
chimeric mice, have shown that TLR expression on structural cells is necessary 
for activation of DC in a house dust mite (HDM) or in a low-dose OVA-LPS AAI 
model which favours Th2 sensitisation 106,186.  The mice restricted of 
haematopoietic cell TLR4 were unable to generate a Th1 response to high dose 
OVA-LPS and instead were able to generate a Th2 response via structural cell 
TLR4 activation 106.  As well as activation, EC can induce DC migration into 
epithelium via the production of C-C motif ligand (CCL)-20 (MIP-3α) chemokine 
187.  
Epithelial cells are an important source of cytokines which contribute to the Th2 
inflammation including TSLP, GM-CSF, IL-1, and IL-25 185,186. Chemoattractants 
for Th2 cells including CCL1, CCL17 and CCL22 are produced by EC and this is 
further induced by the presence of Th2 cytokines 188. The epithelium is a source 
of IL-8, contributing to neutrophil chemotaxis. IL-28 and IL-29 are a new family 
of cytokines also called λ or type III interferons and are important in innate 
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immunity. IL-28 produced by APC in response to TLR activation, acts on 
epithelial cell IL-28 receptor IL-28RA suppressing Th2 inflammation 189. On the 
other hand, IL-29 is secreted by type II AEC in response to viral infection and 
may have a role in asthma exacerbation 190. 
Mucous cell hyperplasia is a fundamental pathological change in asthma. EC 
responding to IL-13 in a STAT6-dependent fashion appear to be a critical in 
mucous overproduction 53. Furthermore, IL-13 induces apoptosis in EC and 
upregulation of pro-fibrotic genes in fibroblasts 191 and in agreement, using an 
antibody to block IL-13 reduced airway remodelling in a mouse model 54. Notch, 
an evolutionarily conserved signalling factor has been shown to affect the 
balance of EC differentiation to ciliated or secretory cells in the developing 
lung. In vivo, Notch inactivation results in an imbalance of EC differentiation 
resulting in the absence of goblet cells, thus preventing mucous metaplasia 192. 
In vitro, Notch-mediated down regulation of MUC5AC, a major component of 
airway mucus has also been demonstrated however the role of Notch in asthma 
is as yet unclear 193.  
1.1.3.4.2 Smooth muscle cells 
 
The ASM is dysfunctional in asthma and undergoes hyperplasia and hypertrophy 
194. AHR is said to be dependent on ASM remodelling in vitro and in vivo and 
contributes to the severity of asthma 195. 
ASM may play a more active role in modulating airway remodelling as a source of 
inflammatory mediators, proteins and expression of cell adhesion molecules 
suggesting some autocrine responses and interactions with inflammatory cells 
194. ASM cells secrete extracellular proteins including collagen I, IV, V, 
fibronectin, laminin and hyaluranon and contribute to subepithelial fibrosis 194. 
The localisation of MCs into the ASM has been described 141. MCs are thought to 
directly modulate the ASM causing proliferation and contraction via the release 
of inflammatory mediators 40. There is evidence that MCs can mediate chronic 
inflammation by cytokine induction of chemokine release from the ASM 196. ASM 
is a source of the proangiogenic factor VEGF, also released from ASM in response 
to Th2 cytokine activation 197. ASM cells from subjects with asthma promoted 
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angiogenesis in vitro suggesting their fundamental contribution to the 
neovascularisation that is observed in asthmatic airways 198. 
Taken together, the ASM clearly has an important pathophysiological role in 
asthma and thus an appropriate target of therapeutic strategies. For example, 
recently, the development of bronchial thermoplasty, the delivery of controlled 
radiofrequency energy to the airway wall to ablate smooth muscle, was shown to 
be effective in a subgroup of asthmatics. A reduction in asthma exacerbations, 
hospitalisation as well as symptoms was demonstrated in the clinical trials (AIR, 
RISA and AIR2) 199. The mechanism of this clinical improvement is unknown but 
reports suggest heat denatures protein impairing the ability of the ASM to 
contract and a reduction in ASM mass is observed 200. In addition there may well 
be an effect of inhibiting ASM secretory function.  
1.1.3.4.3 Vasculature 
Angiogenesis and microvascular remodelling are features of severe and fatal 
asthma 201,202 but are also observed in milder disease 202,203. An imbalance of pro- 
and anti-angiogenic factors leads to abnormal growth of new vessels in asthma 
airways 204. A role for the most potent pro-angiogenic factor, VEGF in mediating 
these changes is proposed. Associative studies in humans have identified 
increased concentrations of VEGF in sputum of asthmatic patients as well as 
mRNA expression of VEGF and its receptor in airway mucosa 202,205. Supportive 
evidence from animal models indicate a role for VEGF not only in vascular 
remodelling but also in extravascular remodelling, as well as in promoting 
allergen sensitisation and Th2 inflammation 206. The cellular sources of VEGF are 
epithelial cells, smooth muscle cells, fibroblasts as well as alveolar 
macrophages, eosinophils and MCs 204,205. TGF-β can further promote EC VEGF 
production 207. Treatment with the anti-VEGF monoclonal antibody Bevacizumab, 
already licensed in humans for anti-cancer treatment, caused reduction in 
remodelling parameters in mice suggesting this may have therapeutic potential 
in severe asthma 208. 
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1.1.3.5 Cytokines and chemokines in asthma 
Cytokines play a critical role in orchestrating, perpetuating and amplifying the 
inflammatory response in asthma and one of major targets of CS treatment is to 
reverse the abnormal expression of cytokines. The movement or trafficking of 
the immune cells discussed above is primarily performed by cytokines and 
chemokines. The cytokines IL-4, IL-5, IL-13 and IL-9 have been considered under 
classical Th2 inflammation (section 1.1.3.1.2). Selected other cytokines with a 
proposed role in asthma are described here.  
TNFα is an inflammatory cytokine involved in the acute response to infection, 
inducing neutrophil proliferation and also has a role in tumour necrosis. As 
stated, TNFα is linked to neutrophilic asthma; its concentration is increased in 
the BAL and it is produced by macrophages, MCs, lymphocytes and eosinophils 
155,209,210. MCs in particular are a rapid source and release pre-formed TNFα on 
activation and degranulation 93. The importance of TNFα in asthma pathogenesis 
is indicated by clinical trials of treatment with Etanercept, a recombinant 
soluble TNFα receptor, which improved AHR and quality of life in asthmatic 
patients 211. The critical issue for anti-TNFα therapies is their narrow therapeutic 
index with an increased risk of malignancy, thus limiting future prospects for 
their use212. 
IL-17(IL-17A) is a member of the IL-17 family of six pro-inflammatory cytokines 
with a role in host defence and autoimmunity. There has been considerable 
interest in the subset of Th cells identified by their IL-17 producing properties, 
Th17 cells. Th-17 cells also produce IL-21, IL-17F and IL-22 213. Along with their 
link with neutrophilic asthma, there is an association with Th2-mediated 
inflammation; levels of IL-17 and IL-5 mRNA in sputum of asthmatics are 
correlated 156. Furthermore, both Th17 cells and IL-17 plasma levels correlate 
with disease severity 214. Taken together there is a sufficient evidence for a role 
of IL-17 in asthma and hence a move to clinical trials aimed at blocking IL-17 
signalling. However, a recent large randomised double blind placebo control trial 
of brodalumab, an anti-IL-17 receptor monoclonal antibody, failed to determine 
any clinical benefit in most subjects with asthma 215.  IL-21 is a pluripotent 
cytokine that regulates Th17 cells. A recent discovery that IL-21 enhances Th2 
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cytokine production in a model of AAI through multiple mechanisms, identifies a 
further target for in the Th17 pathway warranting investigation 216.  
IL-6 is a pleiotropic cytokine with pro-inflammatory and anti-inflammatory 
properties. It is not clear if IL-6 is a marker of ongoing inflammation in asthma 
or has a specific functional role, as the evidence is conflicting. The 
concentration of IL-6 in sputum correlates inversely with lung function 217. IL-6 is 
reported to be necessary for mucus secretion by epithelial cells218 and IL-6 
blockade ameliorates AHR suggesting a pathological role for IL-6 219. However, 
most in vivo evidence suggests an anti-inflammatory role 220.  There also appears 
to be a regulatory role for IL-6 in effector CD4 T cell fate, promoting IL-4 
production during Th2 differentiaton as well as inhibiting Th1 differentiation 221. 
The airway cytology characterises the late-phase asthma response, therefore the 
ability of cells to infiltrate the lungs is important and this is predominantly 
controlled by chemotactic cytokines or chemokines. The expression of a wide 
range of chemokines has been described in asthma.  The interaction between 
chemokines and their receptors is complex; one chemokine can bind to multiple 
receptors and one receptor can recognise and bind multiple chemokines. This 
complexity provides control of cell movement however dissecting the essential 
nature of each chemokine is challenging (Table 1.2). The receptor C-C motif 
receptor(CCR)-8 is found exclusively on Th2 cells and using knockout mice, a 
reduction in Th2 cytokines and airway eosinophils was observed upon allergen 
challenge by some 222 but not by others in these mice 223. The chemokine CCL1 
(TCA3), a ligand for CCR8 is detected at increased levels in asthmatic airways 
thus making it an attractive therapeutic target 224.  However, it appears these 
experimental findings have not yet been translated into an essential role for 
CCR8 as its inhibition was ineffective in a pre-clinical primate model of asthma 
225. Other potential receptor and chemokine pair relevant for asthma include, 
for Th2 cells and eosinophil: CCR3 with ligands CCL11 (eotaxin), CCL24 (eotaxin-
2) and CCL5 (regulated on activation, normal T cell expressed and secreted 
(RANTES)); and CCR4 with ligand CCL17 (thymus and activation regulated 
chemokine(TARC)); on T cells: CCR5 with ligands CCL11 (eotaxin), 
CCL5(RANTES), CCL3 (MIP-1α) and CCL4 (MIP-1β); on endothelial cells:  CXCR3A 
and ligand CXCL10 (interferon gamma-induced protein 10(IP-10)) are also of 
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interest.  The main eosinophil-specific chemotactic pathway CCL11/CCR3 is a 
potential attractive target for asthma therapy. The concentration of 
CCL11/eotaxin is: up-regulated in mice following allergen challenge 226; along 
with CCR3 mRNA highly expressed in atopic asthmatic bronchial biopsies 227;  
elevated in plasma during acute exacerbations of asthma 228; and correlates with 
levels of forced expiratory volume (FEV1), a marker of AFO in patients with 
asthma 229. The sources of eotaxins are predominantly ECs, macrophages and 
fibroblasts 227,230. Blocking eotaxin by neutralising antibodies, partially reduces 
eosinophil recruitment in an ova challenge mouse AAI model 231. In a similar 
model using double eotaxin (CCL11/CCL24) knockout but not single knockout 
mice, eosinophilic inflammation is significantly attenuated 232. In CCR3-/- mice, 
eosinophil recruitment following antigen challenge was severely impaired but 
the affect of CCR3 on AHR is conflicting 232-234. Attenuated AHR is described by 
some 233 but in contrast worsening of AHR, attributed to altered mast cell 
location, reported by others234.  One explanation for this may be different modes 
of sensitisation used in these studies but as CCR3 has effects on basophils, MCs, 
Th2 cells and platelets along with eosinophils dissecting these interacting roles is 
complex. As chemokine eosinophil regulation through non-CCR3 pathways are 
also described, the complexity of chemokine interactions are increased 235. 
CCR4 gene-deficient mice develop less airway eosinophilia and AHR in a chronic 
lung allergy model (Aspergillus Fumigatus) 236 but not in an allergic allergen 
model in guinea pigs possibly reflecting different animal model requirements 237. 
Additional evidence to support the contribution of chemokines to asthma include 
the concentration/expression of both CCL5/RANTES and CCL17/TARC elevated in 
asthmatic airway samples238,239. CCL5/RANTES concentration is also elevated in 
exhaled breath condensate of asthmatic patients and in particular correlates 
with to patients with the most unstable symptoms and is a potential biomarker 
239.  Serum concentrations of CXCL10/IP-10 were increased in patients with viral 
induced compared to non-viral acute asthma exacerbations 240 but serum levels 
were reduced in another study in stable asthmatics compared to controls 241. 
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Receptor Chemokine Receptor expression 
CCR3 CCL7/MCP3 
CCL5/RANTES 
CCL15 
CCL16 
CCL11/Eotaxin 
CCL24/Eotaxin-2 
CCL26/Eotaxin-3 
Eosinophils, Basophils, Th2, 
Dendritic cells 
CCR4 CCL17/TARC 
CCL22/MDC 
Dendritic cell, Th2, Natural 
killer cell, monocyte 
CCR8 CCL1/TCA3 
CCL4/MIP1β 
CCL17/TARC 
Monocyte, Dendritic cell, 
Th2, Treg 
CCR5 CCL8/MCP-2 
CCL4/MIP1β 
CCL3/ MIP1α 
Monocytes, macrophage, 
Th1, Natural killer cell 
CXCR3  CXCL10/IP-10 
CXCL9/MIG 
CXCL11 
Th1, Natural killer cell 
Table 1.2:  Selected chemokine receptor and chemokine expression profiles implicated in 
the pathogenesis of asthma 
 
1.1.3.5.1 Novel cytokines in asthma 
 
IL-25 (IL-17E), a member of the IL-17 family is implicated in Th2 responses 161. In 
the mouse it is produced mainly by Th2 cells 161, epithelial cells in response to 
protease allergen exposure 242, and MCs 243; and in humans is predominantly 
produced by eosinophils and basophils 162. Ballantyne et al demonstrated that 
the administration of anti-IL-25 antibody to mice inhibited eosinophilic 
inflammation, Th2 cytokine response and reduced AHR suggesting an important 
role in asthma pathogenesis244. IL-25 induces the production of Th2 cytokines 
from Th2 cells 245. However IL-25 can also induce the production of Th2 
cytokines in T-cell deficient mice suggesting other sources 162. More recently, 
non-B, non-T target populations have been identified including the innate 
lymphoid cell, the nuocyte 246 as well as a type 2 myeloid granulocytic 
population, the later cells being steroid resistant and present in asthmatic blood 
samples 247.  IL-25 has the ability to promote Th2 differentiation in an IL-4 
dependent manner in vitro 242 and in vivo, IL-25 blockade at sensitisation 
prevented AHR and reduced other features of asthma in an AAI model 244. IL-25 
dependent antigen-induced AHR is mediated by NKT cell function 248. In 
addition, IL-25 modulates Jagged1, the Th2 polarising ligand for Notch on DCs 
249. However, the role of IL-25 in antigen-specific sensitisation does not appear 
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essential as this develops normally in IL-25-/- mice but here, the structural cell 
IL-25 production was found to be essential for the effector phase in an OVA 
model of AAI 250. More recently, a role for IL-25 has been described in the 
remodelling phase, in a HDM model of AAI 251.  
Thymic stromal lymphoprotein (TSLP) is generated from epithelial cells following 
activation of TLRs1-3 252 and influences Th2 differentiation predominantly via 
effects on dendritic cells 253,254. The TSLP-stimulated DC induce naïve T cells to 
differentiate into IL-4, IL-13 and TNFα producing cells253.  Furthermore, TSLP 
induces upregulation of MHC and co-stimulatory molecules on DCs including 
OX40L the ligand for OX40 on T cells 253,254. In addition, induction by microbial 
products of epithelial-derived TSLP can activate MCs contributing to Th2 
inflammation in non-atopic disease 252. Interestingly, the presence of IL-4 
enhances ds-DNA and rhinovirus dependent TSLP production, suggesting a 
mechanism whereby a viral infection can further amplify existing Th2 
inflammation in asthma 255. Clinically, elevated numbers of TSLP mRNA+ve cells 
have been described in endobronchial biopsies from asthmatic patients 238. 
Furthermore, mice lacking the TSLP receptor failed to develop an inflammatory 
response to antigen and exhibited enhanced Th1 responses 256. Crosstalk of TSLP 
with IL-25 further amplifies Th2 inflammation in particular via DC-memory Th2 
cell interactions 245. Taken together, there is evidence for TSLP in the 
pathogenesis of asthma and accordingly clinical trials with TSLP/OX40L blockage 
are underway. A proof-of-concept small clinical trial with anti-OX40L antibody 
did not show any benefit in mild asthmatics257. Most recently, a trial of anti-TSLP 
antibody in mild asthmatics showed attenuated allergen-triggered inflammatory 
and AHR responses but further studies will be required to ascertain if this results 
in clinical benefit 258. 
A role in asthma for many other cytokines has been described. The reports 
include including IL-11259, IL-15 260, IL-16261, IL-18262, IL-19 263, IL-21264, IL-27265, 
IL-31266, IL-32267and IL-35268.  
In summary, interactions between the innate immune response, structural cells 
and the adaptive Th2 response, orchestrated by many inflammatory mediators 
are required to produce the spectrum of pathophysiological and clinical 
phenotypes associated with asthma. In particular, despite the close association 
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of eosinophils with asthma, this is not an exclusive feature and eosinophilic 
asthma can be considered as a distinct phenotype associated pathologically with 
a thickened basement membrane and pharmacologically with steroid 
responsiveness. In contrast, neutrophilic asthma is particularly associated with 
severe or non-atopic asthma and with asthma exacerbations. Of course, these 
phenotypes are not mutually exclusive and overlap 2. 
1.1.4 Animal models of asthma 
The need for novel therapies in asthma, particularly for the severe end of the 
clinical spectrum, requires suitable research and disease models in conjunction 
with human studies. Mice allow us to perform mechanistic studies, evaluate the 
importance of specific cell types in asthma pathogenesis, and test potential new 
treatments. 
Mice are the most commonly used species for modelling human immune-
mediated disease. The allergic airways inflammation model of asthma in the 
mouse is well established. The use of mice is advantageous as they can be bred 
easily with uniformity in inbred genetic strains and a wide variety of appropriate 
reagents are available. In addition, knowledge of the mouse immune system and 
genome is now extensive and technology to manipulate the genome to 
specifically consider genetic influence is available. However, mice do not 
spontaneously develop AHR or asthma-like disease. Mice have structurally 
different airways to humans with fewer bronchial divisions and smooth muscle 
present only in larger airways. They also have a different distribution of 
eosinophilic inflammation and lack MCs in the ASM 134. These are limitations that 
must be considered along with ethical considerations when designing and 
interpreting experiments. 
1.1.4.1 Protocols 
The clinical features of eosinophilic inflammation and AHR in asthma are those 
most often replicated in murine models of AAI 269. Most commonly, mice are 
sensitised peripherally to a protein antigen and after a time interval 
subsequently challenged via the airways with the same antigen 269.  Other 
models of AAI include: passive cell transfer 22; employing transgenic mice where 
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features of asthma develop spontaneously 61; or models of viral infection which 
cause airway inflammation 270.  
Ovalbumin (OVA), a well characterised chicken egg protein, in a highly purified 
form is the commonest antigen used to sensitise mice in the AAI model.  Mice 
expressing an ova-specific T cell receptor are available which increases the 
usefulness of this antigen choice. Other antigens used include those from 
Aspergillus236, cockroach271 and HDM74, which may have a greater clinical 
relevance. Using the OVA model reproduces features of asthma including 
elevated IgE antibody, eosinophilic airway inflammation and AHR 269.  One 
criticism of acute OVA challenge models is that AI and AHR resolve and thus mice 
don’t show features of remodelling 272. To investigate the more chronic features 
of asthma such as airway remodelling or persistent AHR, a number of chronic 
allergic inflammation models have been developed using repeated challenge 
with OVA 134 or using HDM allergen extracts 74. In both acute and chronic allergen 
models, dissociation between inflammation, AHR and remodelling has been 
described 273,274.  
When using OVA to sensitise, the response is often boosted with an 
immunological adjuvant because administration of OVA alone can lead to 
tolerance 275. The use of adjuvants is non-physiological and is a weakness to this 
approach, however, sensitisation has been shown to develop without adjuvant in 
some models and these may be more informative of clinical disease 276.  The 
most widely used adjuvant aluminium hydroxide (alum) strongly induces Th2 
responses 277. Furthermore, there are alternative routes of administration of the 
sensitising antigen and some protocols exist without an antigen sensitisation 
phase using HDM, which are used to generate AAI 74,278. 
Despite its common use, significant differences exist in OVA AAI model protocols 
in terms of duration, sensitisation route, number of challenges, route of 
challenge and mouse strain, therefore it is vital to be aware of the advantages 
and limitation of an antigen when determining a model of choice 134,274,279,280. 
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1.1.4.2 Measurement of experimental parameters 
Irrespective of the AAI protocol used, the gold standard method for assessment 
of airway inflammation is quantification of differential cell counts in the BAL. 
This can be done by the Romanovsky staining method and microscopy however, 
more detailed flow cytometric analysis and fluorescence-assisted cell sorting 
(FACS) techniques have been described and are being increasingly employed to 
analyse the BAL with improved knowledge, speed and accuracy 281. Cytokine, 
chemokine and immunoglobulin quantification as well as histological assessment 
of inflammation in lung tissue are often undertaken. Additional assessment of 
inflammatory cell profile in the lung can be performed by cell counting or FACS 
following lung digestion, but this is less commonly performed 282.  
Perhaps the most controversial aspect of murine asthma models is the 
assessment of AHR. Whole animal assessment of AHR in rodents may not 
distinguish between airway and contractile sources of airway obstruction 283. 
Furthermore, the methods used to assess AHR are diverse. The gold standard is 
an invasive measurement of direct airway resistance in intubated, anaesthetised 
mice. This technique requires considerable time and expense as well as 
expertise and therefore non-invasive alternatives are often preferred. The most 
popular of these is using whole body plethysmography measuring a derived 
variable named enhanced pause (Penh) 284.  Although there are criticisms of this 
technique 285, it is none the less widely used and Penh has been shown to 
correlate with airways obstruction measured by the more invasive techniques 270. 
1.1.4.3 Genetic background 
The choice of mouse strain used in models must be carefully considered. The 
Bagg Albino, (BALB)/c, strain is the commonest choice for antigen models 
because they develop robust Th2 responses but other strains (C57Bl/6 and A/J) 
have been used successfully 286. However, differences in all measured 
parameters can be dramatic when the same model is applied concurrently to 
different strains to exclude genetic differences 276. Others have found that one 
strain may be more susceptible to develop particular disease characteristics; 
particularly BALB/c mice to AHR and C57Bl/6 to airway eosinophilia 287. In a 
chronic allergen exposure model, only A/J mice were shown to develop 
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sustained inflammation as well as persistent AHR and changes of airway 
remodelling 279.  Certain mouse strain genomes are easier to target than others, 
therefore the development of transgenic mice are favoured to these genetic 
backgrounds 288.  
Taken together, the relevance of the use of animal models to investigate 
experimental airways disease has been questioned and humans remain the best 
biological model 289. Studies in humans with biopsies or BAL or sputum can 
characterise the presence of immune and inflammatory cells, cytokines and 
expressed mediators, and these can be correlated with clinical parameters. 
However, these studies are limited in defining cause and effect and this aspect 
can be usefully explored in experimental models. It is clear that asthma is a 
complex multifactorial disease, it is thus unlikely that a single animal model is 
able to replicate all these features. Instead we can use animal models to study 
specific features to characterise detailed cellular information. Choosing the 
most appropriate model with the relevant phenotypic features of interest rather 
than necessarily the most common model used is imperative. In addition, 
improved understanding of chronic models, better techniques to measure lung 
function, developing better models to reflect exacerbations or non-atopic 
disease will be useful. As long as the caveats associated with the models are 
borne in mind when planning and interpreting experimental data, they remain a 
useful experimental tool.  
1.2 ST2  
St2 is a gene first described when induced in fibroblast cell lines during the 
G0/G1 transitional cell cycle phase, by two independent research groups. 
Referred by one group as T1 290 and by Tominaga et al as St2 291 it was induced 
by mitogen or serum stimulation. This gene encoded a protein with similarities 
to the immunoglobulin super family receptor interleukin 1 receptor (IL-1R) but 
without an apparent cytoplasmic domain 291. Subsequent studies identified 
further products of the St2 gene and one of these with an intracellular domain 
named ST2L292. Ultimately, 16 years later the ligand for this ST2L receptor was 
described as IL-33 293.  
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1.2.1 ST2  gene 
The discovered St2 gene was identified as a late gene expressed in mouse 
fibroblasts entering the cell cycle, was found only during growth and was not 
constitutively expressed 291. The presence of St2 was described in a human T cell 
line and was found to have 68% homology with the murine gene 294.  
Further cloning studies of the St2 gene in mice mapped it to chromosome 1, near 
to the Il1R1 locus suggesting a link with this IL-1 super family 295. In humans, the 
St2 gene was mapped to chromosome 2 again close to the Il1R1 locus 296. The St2 
gene has been shown to be homologous in a number of other species including 
chicken, fish and rat 297-299  and it is highly conserved from Drosophila and 
consistent with IL-1 receptor family signalling 300.  
Four types of ST2 gene products can be produced by alternative splicing. In the 
original descriptions, the St2 gene was a 2.7 kilobase (kb) mRNA sequence giving 
rise to a secreted cell product which was subsequently termed soluble or sST2 
291,301. The secreted sST2 protein appears to require the peptide sequence to be 
heavily glycosylated 301. It comprises 3 immunoglobulin domains and a short tail 
with similarities to extracellular IL-1R1 and IL-1R2 291 (Figure 1.2). An additional, 
less abundant and longer 5 kb mRNA was subsequently identified and this 
generated an ST2 protein with a similar structure to the entire IL-1R1; with an 
identical extracellular portion to sST2 but possessing a transmembrane as well as 
cytoplasmic portion 302. This membrane anchored product was named ST2L and 
from herein will be referred to as ST2 or ST2L 302.  A third gene product 
identified in human cells and termed ST2V is a shortened form of sST2303.  It has 
also been identified in chickens as has a fourth variant ST2LV, but the in vivo 
function of both are unclear at present 297. 
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Figure 1.2: Schematic representation of TLR-IL-1R family of receptors 
 
 
1.2.2 ST2 product expression and regulation 
As described above, sST2 synthesis in fibroblasts appears to be induced in 
growing cells. On the other hand ST2L, is less abundantly expressed in 
fibroblasts and more highly expressed on haematopoietic cells such as CD4+Th2 
cells, MCs and macrophages, indicating differential expression 304-306. In mice the 
differing expression patterns appears to be regulated by distinct transcriptional 
promoters with mutually exclusive promoter start sites determined by cell type; 
a distal promoter in haematopoietic MCs and 10.5kb away a proximal promoter 
in the fibroblasts. Promoters can result in sST2 or ST2L production by 3’ splicing 
but each promoter is influenced by transcription factors, in particular GATA2, 
and environmental factors which ultimately determines the dominant protein 307. 
The expression of ST2 by cell types is summarised in Table 1.3.  
More recently ST2 expression has been identified on other cells that could play a 
role in asthma or AAI. Basophils show little or no constitutive sST2 and ST2L 
expression but both are induced by IL-3 stimulation, with sST2 responding 
rapidly and ST2L after 8 hours 308. These authors could not detect ST2 expression 
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on eosinophils but in other studies, these cells did respond to IL-33 suggesting 
that expression levels for ST2 were below detection limits, and others have 
identified ST2 mRNA in eosinophils 309,310. Subsequently, work from our 
laboratory identified low levels of ST2L expression which was inducible in mice 
in eosinophils 311 and also neutrophils 312. ST2 mRNA is expressed in murine lung 
313,314 and sST2 and STL mRNA in human lung tissue 315,316.  
Cell Mouse 
sST2 
Mouse 
ST2L 
Ref Human 
sST2 
Human 
ST2L 
Ref 
Fibroblast RNA and 
protein 
RNA and 
protein 
290,291 
305,315,31
7,318  
RNA and 
protein 
RNA and 
Protein*# 
315 314  
306,319 
Epithelial cell RNA RNA 318 RNA* and 
protein*# 
RNA* 306,314 
316,320 
Endothelial 
cell 
- - 315 RNA* and 
protein*# 
RNA*# and 
protein*# 
306,315,321 
320 319 
Smooth 
muscle cell 
- -  RNA* RNA* 306,321 
Th2 cell RNA RNA and 
protein 
304,322 
323 
RNA  RNA and 
protein 
324,325 326 
B cell - RNA and 
Protein 
305,327 - RNA and 
protein 
315 319 
NK cell - Protein 328 - RNA 326 
Mast cell  Protein Protein 293,305   RNA and 
Protein 
307,319,329   
330 
Basophil - Protein 328 RNA and 
protein 
RNA and 
protein 
308,310,326 
Monocyte  - -  RNA RNA and 
protein 
331 
Macrophage RNA RNA and 
protein 
305,306 RNA RNA and 
protein*# 
306,319 
Dendritic cell - RNA and 
protein 
332 - RNA 326 
Eosinophil - Protein*# 311 - RNA and 
protein 
309,310 
Neutrophil - RNA and 
Protein# 
312,333 - -  
Innate 
lymphoid 
cells 
 Protein#* 334,335  RNA# and 
protein*# 
163 
Table 1.3: Cellular expression of ST2  
 *pulmonary expression  # observation since 2010 
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ST2 is a member of the TLR/IL-1R super family of receptors. There are 3 main 
subtypes according to the structure of the extracellular ligand binding portion, 
but all share a Toll-IL-1R (TIR) intracellular domain. Type 1 or IL-1R receptors 
include receptors for IL-1α, Il-1β and IL-1R antagonist (IL-1ra) as well as the IL-
18 receptor (IL-18R) 336. The IL-1R family have 3 immunoglobulin domains, 
consistent with that described for sST2 and ST2L 291,302, with ST2L having a 
transmembrane and intracellular component in keeping with the other IL-1R 
receptors302. Part of the regulation of IL-1 is the production of a soluble receptor 
type 2 or IL-1R2 which is an antagonist to potent IL-1 activity336. IL-1R2 acts as a 
‘decoy’ receptor by binding IL-1 in solution and not mediating any biological 
signals. The similarity with sST2 suggests it may also act as a ‘decoy’ receptor.  
The ST2L/IL-33 complex is represented in Figure 1.2. 
1.2.3 ST2 function 
1.2.3.1 ST2 in Th2 inflammation 
The evidence of a role for ST2 in Th2 or type-2 inflammation comes primarily 
from the discovery of its preferential expression on CD4+Th2 subset of T cells as 
well as on MCs suggesting a functional role in adaptive and innate immune cells 
that contribute to this inflammatory phenotype.  
A number of studies have conclusively demonstrated that ST2 is expressed on 
CD4+Th2 cells 304,322,323 and not on naïve T cells 323, Th1 cells which express       
IL-18R337  or on Th17 CD4+ cells 324. Furthermore, ST2 was confirmed to be a 
stable and selective marker to distinguish Th2 from other helper cell subtypes in 
cell lines and ex vivo cells expressing IL-4, IL-5 or IL-10 but not IFNγ or IL-2 
304,322. Although CD4+Th2 ST2L expression is not dependent on Th2 cytokine 
expression 322, their presence increases ST2 expression 323. In humans ST2 is 
expressed on activated Th2 cells, which can also produce sST2324. These studies 
demonstrating selective ST2 expression on Th2 cells went onto first show a 
functional role for ST2 using antibody or a recombinant fusion protein. In these 
studies, ST2 blockade increased resistance to leishmaniasis, exacerbated 
collagen-induced arthritis 304 or reduced eosinophilic airway inflammation 322. 
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The development of ST2-/- mice facilitated further study into the functional role 
of ST2. These mice appear to have normal development and normal cell 
populations 338,339, including of Th2 cells supported by in vitro studies 338. 
However, the antigen mediated Th2 responses appear affected.  Using a 
Schistosoma mansoni parasite granuloma formation model, ST2-/- Th2 cell 
cytokine production was reduced but clinically, the magnitude of effect was 
influenced by a primary or secondary challenge 339.  In vivo, all forms of ST2 will 
be deficient and so attributing influences cannot be assumed to be loss of ST2 
receptor and could be due to loss of sST2. 
MCs contribute to innate type-2 inflammation as previously discussed. Mast cells 
constitutively express high levels of surface ST2 that are the highest among 
haematopoietic cells 293,305. Despite this, there is no evidence that lack of ST2 
affects mast cell development or function 340. 
1.2.3.2 ST2 in murine AAI in vivo 
Apart from the possible contribution to AAI identified by the presence on Th2 
and MCs, the role of ST2 in asthma has been further assessed in context of 
disease models including using ST2-/- mice, were studies have shown conflicting 
results. The studies with ST2-IgG fusion protein, sST2 gene transfer or anti-ST2 
antibodies indicated a role for ST2 in Th2-mediated disease, in particular AAI 
313,322.  A further study using both ST2-Ab and ST2-Ig in a murine AAI model also 
identified a requirement for ST2 in developing Th2-inflammation and 
furthermore that this is due to a direct effect of ST2 on CD4+ cells 341. 
Elevated concentrations of sST2 in sera of mice following allergen challenge 
agree with a pro-inflammatory functional role for ST2 313. In the same study, 
sST2 added to OVA-stimulated splenocytes in vitro attenuated Th2 cytokine 
production. This effect was mirrored in vivo where following administration of 
sST2 by gene vector, to mice before sensitisation and challenge, reduced airway 
eosinophilia and Th2 cytokine production 313. In other AAI models, ST2 expression 
on CD4+ cells was increased during antigen challenge 342 and correspondingly in a 
model generating a Th1 response following over expression of IP-10, ST2 
expression on CD4+ cells suppressed 343.  
Chapter 1                                                                                                                                          61 
However, some studies investigating the AAI model in the ST2-/- mice conclude 
there is no critical role for ST2 in murine asthma.  Hoshino et al found no 
requirement for ST2 in an OVA-induced AAI model or in a Th2-driven parasitic 
model 338. This finding was challenged by Townsend et al who found abrogated 
Th2 responses in a pulmonary granuloma model in ST2-/- mice; however, this 
group used a short-term parasite model and therefore sensitisation and 
challenge pathways and role of ST2 may differ 339. However, Mangan and 
colleagues contradicted this reporting that loss of ST2, in particular on Th2 cells, 
demonstrated by adoptive transfer models in transgenic mice, actually 
exacerbated eosinophilic pulmonary inflammation and AHR 344. In the OVA-
induced model in AAI similar to that used by Hoshino et al they similarly showed 
no change in many parameters including AHR compared to WT mice, although 
worsened eosinophilia was consistent with the transfer model findings 344. This 
phenomenon of ST2 knockout exacerbating Th2 inflammation was also observed 
in studies within our group; ST2-/- CD4 cells in vitro produced increased amounts 
of Th2 cytokines and exacerbated AI when adoptively transferred into WT mice 
indicating complexities in loss of ST2 in intact organism versus an individual cell 
type 345. 
1.2.3.3 ST2 in Th1 and innate inflammation 
ST2 is a regulator of additional aspects of inflammation and in keeping with 
other members of the Toll/IL-1R super family; ST2 is involved in innate 
immunity. ST2-/- mice developed more severe LPS-induced endotoxin shock with 
increased production of pro-inflammatory cytokines in comparison to WT mice, 
although mortality was unchanged, suggesting a role for ST2 in tolerance to gram 
negative microbial infection 346. The toxic effects of LPS are primarily conferred 
by macrophages and further analysis in vitro, demonstrated that ST2-/- 
macrophages produced higher amounts of cytokines in response to LPS or IL-1346. 
The effect of ST2 on macrophages is most likely indirect via sequestering MyD88 
and Mal which prevent NF-κB activation, the signalling pathway through which 
most TLR members activate responsive genes. Similarly, blockade of ST2 by 
monoclonal antibody exacerbated LPS-mediated mortality 347. On the other 
hand, blockade of ST2 signalling by pre-treatment of sST2 suppressed in vitro 
and in vivo LPS-induced inflammation highlighting distinct roles for ST2L and 
sST2 347.  
Chapter 1                                                                                                                                          62 
An in vivo role for ST2 has also been described in: liver damage whereby sST2 is 
protective in an ischaemia-reperfusion model 348; a streptomycin induced 
pancreatic damage and diabetes model whereby ST2 deletion worsened 
inflammation 349; a pulmonary fibrosis model with unexplained upregulation of 
ST2 identified 314. ST2 expression was induced in cultured myocytes undergoing 
biomechanical strain and in an in vivo model of myocardial infarction (MI), 
elevated concentrations of serum sST2 in mice was also detected350. Mice 
treated with bleomycin, a model of acute lung injury, transiently 
overexspressing sST2 by gene transfer, exhibited suppressed levels of injury 351. 
1.2.4 ST2 in disease 
ST2 has been associated with a number of diseases. St2 gene polymorphisms in 
the distal promoter have been associated with asthma 352 and with atopic 
dermatitis, functionally correlating with clinical parameters 353. The role of ST2 
in disease and as a biomarker will now be considered further. 
1.2.4.1 sST2 as a biomarker 
Following the development of an enzyme-linked immunosorbant assay (ELISA) to 
measure levels of sST2, assessment of its association with various clinical 
conditions has been performed 354. 
In terms of respiratory pathology, the concentration of sST2 is increased in the 
sera of patients with asthma 354, and this in particular is associated with acute 
exacerbations 355. In addition, levels are raised in patients with pulmonary 
fibrosis 356 and in sera and BAL of patients with eosinophilic bronchitis 357; 
returning to normal following CS treatment. In patients admitted as an 
emergency with acute shortness of breath due to pulmonary diseases, the serum 
sST2 concentration was an independent predictor for 1 year mortality 358. In 
admissions with shortness of breath of all causes, sST2 levels were again a 
predictor of mortality at 1 year 359,360 or 4 years 361. In breathless patients with 
preserved left ventricular ejection fraction (LVEF) sST2 levels were independent 
of but provided additional prognostic stratification to other biomarkers 362. In 
atopic patients, sST2 is elevated in patients with allergic rhinitis 363.  
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A rise in sST2 has also been associated with Th-1 mediated inflammatory 
disease. Patients with autoimmune disease including rheumatoid arthritis and 
SLE have elevated serum levels 364.  
Patients in intensive care had high serum sST2 levels compared to healthy 
controls and amongst these the subgroup of patients with sepsis had with highest 
levels; sST2 concentrations correlated with serum IL-10 in this cohort 365. 
Hoogerwerf et al demonstrated that sustained levels of sST2 correlated with 
severity as well as mortality in the patients with sepsis 366. Studies of patients 
with other inflammatory conditions demonstrated elevated sST2 concentrations: 
in cerebrospinal fluid of patients suffering subarachnoid haemorrhage 367; and in 
diabetic patients with critical limb ischaemia, predicting mortality in this group 
368. In stable diabetic patients, the concentration of sST2 in serum was 
associated with diabetes but not with established vascular risk factors in a cross-
sectional study, suggesting that it reflected an independent inflammatory 
component of diabetes 369. 
ST2 is related to cell growth and proliferation and there are a number of 
associations of ST2 with malignancy which might reflect this 325. Concentrations 
of sST2 in malignant pleural effusions were significantly higher than in effusions 
caused by heart failure or Mycobacterium Tuberculosis infection. Transfecting 
sST2 into a tumour cell line reduced the ability of cells to proliferate when not 
anchored, suggesting a role for ST2 in tumour survival 370. 
The most common area of interest in sST2 as a biomarker and as a predictor of 
morbidity and mortality, is in the field of cardiovascular disease. Following on 
from the findings of Weinberg et al suggesting that ST2 participates in 
cardiovascular injury in mice, these authors found elevated concentrations of 
serum sST2 in patients after MI 350 and this finding has been consistently 
demonstrated by others since 371. Following MI, sST2 correlates positively with 
creatine kinase, inversely with left ventricular ejection fraction (LVEF) 350 and 
independently predicts 20-30 day mortality as well as the development of 
subsequent heart failure (HF), suggesting an association of sST2 with extent of 
injury 371. Other studies have demonstrated a correlation of sST2 with mortality 
in stable HF 372 and exacerbations of chronic HF (not in the context of acute MI) 
with synergistic prognostication with other biomarkers 359,373.  The studies 
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discussed above of patients with acute presentations of shortness of breath will 
clearly include some of these HF patients. Further evaluation of the relationship 
with sST2 and HF following acute MI in our local population has shown an 
association of sST2 with LVEF, related infarct size and remodelling parameters 
over time 374. The findings in MI in patients alluded to so far are in those with ST 
elevation myocardial infarction (STEMI) and investigators have now extended 
these findings to Non-STEMI patients where an association with risk of HF post 
non-STEMI is reported 375. Some studies have also now shown that sST2 
measurement can selectively predict patient responders to drug treatment 
including with aldosterone antagonists 374 and increased beta-blockade 376, 
further extending the clinical value of sST2 as a biomarker. Overall there is clear 
relationship between serum sST2 concentration and worse outcomes in patients 
with dyspnoea and in MI with or without HF. 
As ST2 was acknowledged as having significant homology with IL-1R (also called 
IL-1R4), the search to identify the ligand for ST2 was focused on the IL-1 family. 
IL-1α and IL-β itself were excluded because they do not bind or signal through 
ST2 377,378. Other proteins bound ST2 but were found to be non-functional ligands 
377,378 until the discovery of an IL-1 family member with binding and functional 
capacities which subsequently named IL-33 293.  
1.3 IL-33 
The cytokine IL-33 is the 11th member of the IL-1 family and was identified by 
Schimtz and colleagues at the end of 2005. Although a role for ST2 in the 
pathogenesis of disease has been demonstrated, functional mechanisms were 
lacking to explain its effect.  The identification of the ligand for ST2 has 
provided insights into the role of the ST2/IL-33 pathway in the pathogenesis of 
immune-inflammatory diseases. 
The majority of current knowledge regarding IL-33 biology was accrued during or 
following completion of the experimental works in this thesis. In the following 
sections, a summary of relevant literature forming the basis for the work of this 
thesis will be presented along with the current understanding of IL-33 biology 
unrelated to the data shown.  
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1.3.1 IL-33 gene and product processing 
The IL-33 gene was identified by searching a computational derived database of 
the IL-1 family members 293.  This gene had been previously described as a gene 
which was upregulated in canine cerebral vasospasm and called DVS27 379and as 
a nuclear factor identified in high endothelial venules and called NF-HEV 380 but 
its function in these locations was unclear.  The human and mouse gene 
sequences of IL-33 have been mapped to chromosomes 9 (9p24.1) and 19 (19qc1) 
respectively. The translated protein of human and mouse full-length IL-33 are 
270 and 266 amino acids respectively, is a 30 kiloDalton (kDa) pro-domain and 
like other members of the IL-1 family has a predicted basic structure of 12 β-
sheet trefoil fold. There is 55% homology between the amino acid sequences of 
human and mouse IL-33 293.  
As with IL-1β and IL-18, the synthesised 30 kDa propeptide IL-33 lacks a clear 
signal peptide for direct processing in the endoplasmic reticulum and golgi 
apparatus 293. Using the examples of IL-1β and IL-18, in vivo, caspase-1 cleaves 
the pro-IL-1β and pro-IL-18 to bioactive forms which is an essential step for their 
subsequent secretion 381.  A similar mechanism was proposed for IL-33, but 
supporting evidence is conflicting. At least in vitro, human IL-33 can be cleaved 
by caspase-1 to produce a 20-22 kDa mature form 293,382, and this cleavage can 
be blocked by a caspase-1 inhibitor 382. Supporting data demonstrates that 
triggering of the Nod-like receptor family pyrin domain containing 3 (NLRP3) 
inflammasome, which mediates caspase-1 activation, by the adjuvant alum, 
results in the cleavage of full length IL-33 (pro-IL-33) and subsequent secretion 
383.  The biological effects of extracellular IL-33 have largely been studied using 
an 18 kDa recombinant protein thought to represent this active mature cleaved 
product 293. However, lysates from cells overexpressing human or murine IL-33 
after incubation with caspase-1 predominantly contain the 30 kDa full length IL-
33, with only a small and variable amount of the 20-22 kDa protein identified.  
No difference was seen in the lysate content when mutations in potential 
caspase-1 binding sites were introduced.  Indeed, in a protease free 
environment, no caspase-1 dependent cleavage 20 kDa product was identified 
384. The described cleaved product, which can be blocked by a caspase-1 
inhibitor, actually appears to be a biologically inactive product with the 
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cleavage site being in the IL-1-like domain 382. Furthermore, in vitro caspase-1 
cleavage of full length pro-IL-33 to a 20 kDa product could be replicated by 
caspase-3 producing an inactive product 385. Mature IL-33 is found intracellularly 
independently of the presence of caspase-1, suggesting pro-IL-33 may not be a 
direct substrate for caspase-1 in vivo and other proteases could be involved 384.  
In addition, full-length IL-33 cleavage by apoptotic caspase-3 and-7 results in 
attenuated activity of the cleaved product and indicates a protective mechanism 
from the release of bioactive and inflammatory IL-33 from apoptotic cells during 
normal cell turnover 386. 
Before its description as a cytokine IL-33, HF-NEV was first described as a 
nuclear factor in the nucleus 380, and investigators have now established a role 
for the intracellular IL-33, as a nuclear factor in vivo 387-390. This indicates that 
IL-33 is a dual-function molecule both as a secreted cytokine and an intracellular 
nuclear factor. With a lack of caspase-1 binding site, uncertainty regarding a 
caspase-requiring release of ‘mature IL-33’ and the full length form of IL-33 
shown to be active extracellularly 382, hypotheses for how this pro-IL-33 form 
might be released to be biologically active by cell damage as an ‘alarmin’ and 
how the full-length and other forms function intracellularly as a nuclear factor 
were developed. Calpain-associated cleavage releases mature IL-33 (20 and 18 
kb products) but the full length IL-33 is released in cytotoxic conditions, 
however the biological activity of these released mature forms were not 
confirmed 390. Demonstration of release of pro-IL-33 was also seen from 
endothelial cells in response to mechanical injury or necrosis resulting from 
freeze/thaw cycles 382.  Further studies also show murine pro-IL-33 from 
transfected cell lysates, nuclear extracts or synthesised in vitro, induced ST2 
dependent release of IL-6 from MCs 384. 
Potential release of a biologically active full length form of IL-33 was likened to 
the alarmin high motility group box-1 (HMGB-1), a nuclear factor which 
modulates transcription but when released from a damaged cell, has a potent 
extracellular action 391. Like PAMPs, responding to exogenous danger patterns, 
alarmins can respond to endogenous danger signals with alarmin release also 
triggered by PAMPs; PAMPs and alarmins are collectively known as DAMPs. HMGB-
1 is inactivated during apoptosis 392 and is activated by TLRs as well as enhancing 
TLR-induced inflammation 393. 
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Secretion of mature IL-33 has been described in: a monocyte cell line (THP-1 
cells), in response to bacterial infection or the adjuvant alum and LPS383; culture 
supernatants of rat cardiac fibroblasts stimulated with phorbol 12-myristate 13-
acetate (PMA) 394; and in mixed murine glial cell cultures supernatants after 
stimulation by LPS and ATP 395 but the biological activity of cleaved mature IL-33 
is unclear.  More recently, biological activity of active secreted mature forms of 
IL-33 released following non-caspase protease cleavage (18-22 kDa), has been 
demonstrated and demonstrate increased potency 396.  Overall, it is clear that if 
released from the cell, both pro- and mature-IL-33 have biological function with 
the cell type and environment likely to influence the ‘type’ of IL-33 secreted or 
released in cell damage.  
1.3.2 IL-33 expression 
Using in vitro detection methods and cDNA libraries, IL-33 mRNA is found in 
virtually every murine tissue but particularly in the central nervous system and 
in surfaces exposed to the environment such as the stomach, lungs and skin 293. 
In the lung, IL-33 mRNA was observed in murine lung following ovalbumin 
challenge in an AAI model 344,397. In humans, mRNA is predominantly found in skin 
and lung tissues 293.  
At a cellular level, IL-33 is expressed primarily in smooth muscle, endothelial 
and epithelial cells 293,389. Levels of expression vary as constitutive or inducible 
and nuclear or cytoplasmic, different according to cell type. For example, 
resting MCs express very low IL-33 mRNA levels but high levels after ionomycin 
stimulation 398. Endothelial cells have high levels but these are further inducible 
and in fibroblasts and epithelial cells mRNA levels are high and unchanged with 
stimulation 398. Nuclear localisation predominates in epithelial and endothelial 
cells 388,389 whilst cytoplasmic location is predominant in MCs 398. A summary of 
cellular expression of mRNA and protein is shown in Table 1.4. 
 
 
 
Chapter 1                                                                                                                                          68 
Cell Mouse Reference Human Reference 
Endothelial cell 
(including HEV) 
RNA and 
Protein (rat) 
388,398 RNA and 
protein* 
293,387 
388,389 382 
Epithelial cell RNA 293 398 RNA 
*(bronchial and 
small 
airway)and 
Protein 
389,390 293 
Smooth muscle 
cell 
- - RNA* 
(pulmonary and 
bronchial) and 
protein* 
293,399 
Fibroblast RNA and 
protein 
400 394,398 RNA* and 
protein 
293,401 402 
Myofibroblasts - - Protein 403 
Keratinocyte - - RNA 293 
Adipocyte - - RNA 404,405 
Colonocyte - - RNA and 
protein 
406 
Glial cell RNA and 
protein 
395 - - 
Osteoblast - - RNA 405 
Monocyte - - RNA and 
protein 
293,384,386 
Dendritic cell RNA and 
protein 
293 400 RNA 293 
Macrophage RNA and 
protein 
293,400,407 408 RNA 293 
Neutrophil RNA 333 Protein 396 
Mast cell  RNA and 
Protein 
409 398 -  
T cell RNA 293 -  
B cell RNA 293 -  
Table 1.4: Cellular expression of IL-33  
 
1.3.3 IL-33 receptor binding and signalling 
IL-33 binds specifically to the IL-33 receptor, ST2L (Figure 1.2).  Recombinant 
human or murine IL-33 forms a complex with ST2L and does not bind to other IL-
1 receptor family members 293. Consistent with canonical IL-1-like signalling, 
ST2L recruits a number of signalling molecules via its cytoplasmic TIR domain. 
The binding of IL-33 to ST2L results in the recruitment of myeloid differentiation 
primary response protein 88 (MyD88) in vitro 409 and in vivo 410. Other signalling 
components recruited include IL-1R associated kinase 1 (IRAK1), IRAK4 and TNF 
receptor associated factor-6 (TRAF6) to the receptor complex in cytoplasmic 
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region of ST2 293.  Downstream this results in phosphorylation of transcription 
factor nuclear factor-κB (NF-κB) leading to up-regulation of pro-inflammatory 
genes. NF-κB upregulation can be inhibited by the administration of anti-ST2 
antibody 293.  Other signalling proteins induced include; inhibitor of NF-κB(IkBa), 
MAP kinase family members extracellular signal-regulated kinase 1 (ERK1), ERK2, 
p38 and c-Jun N-terminal kinase (JNK), and transcription factor AP-1, leading to 
the induction of production of inflammatory mediators 293,411.  
Adaptor molecule TRAF6-dependent pathways have been identified in fibroblasts 
412 and endothelial cells 413 with a TRAF6/NF-κB-independent, MyD88/p38-
dependent pathway in basophils 409. A study using tyrosine kinase inhibitors 
identified JAK2 as critical in the IL-33-mediated NF-κB pathway, identifying a 
target molecule for specific cell types 414. Drube et al report that c-Kit 
activation cross-reacts with ST2L for optimal IL-33 effects on mast cells in a 
STAT3, ERK1/2 and JNK-1 pathway 415. Overall this suggests cell-to-cell variation 
in signalling regulation to fine tune IL-33-mediated effects according to the 
needs of the cell type. 
The signalling mechanism of the other IL-R1 family members requires a co-
accessory protein for high affinity binding and this has also been demonstrated 
to be the case for ST2L.  The IL-1 receptor accessory protein (IL-1RAcP), which 
acts as a shared co-receptor with other members of the IL-1 family is the co-
receptor for ST2L-mediated signalling through its TIR domain 416.   In addition, 
IL-1RAcP increases ST2 affinity for IL-33 by a factor of four 410. The potent 
inflammatory effects of the administration of IL-33 to WT mice are completely 
absent in IL-1RAcP knockout mice 416. 
Because of the severe pathophysiological consequences of dysregulated 
expression, all IL-1 family members are tightly regulated. As mentioned, the 
soluble form of ST2 has been described as a decoy receptor for IL-33 as it 
attenuates inflammatory responses suggesting sequestration. In vitro direct 
blockade of IL-33 signalling by sST2 has been shown 397 394 whilst soluble IL-1RAcP 
enhances ability of sST2 to bind and inhibit IL-33 410. Single Ig IL-1 receptor-
related molecule (SIGGR), a further member of the IL-1/TLR superfamily acts as 
a negative regulator TLR-IL-1R-mediated signalling.  SIGGR directly inhibits IL-
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33-ST2 mediated signaling in vitro which may explain the exaggerated Th2 
responses seen in SIGGR deficiency in vivo 411.  
 
1.3.4 IL-33 function as a nuclear factor 
Pro-IL-33, which was originally described as a nuclear factor, accumulates in the 
nucleus 387,389. Here, it associates with heterochromatin and mitotic 
chromosomes through an evolutionary conserved localisation sequence, 
homeodomain-like helix-turn-helix (HTH) motif and thus acts with transcriptional 
repressor properties 387. In endothelial cell activation, non-proliferating cells 
express nuclear IL-33 that is strongly down-regulated in early angiogenesis 
further suggesting regulatory properties 388. This is supported by the observation 
that nuclear expression of IL-33 is not uniform but co-localises with chromatin-
rich domains containing high local concentrations of DNA 389.  A chromatin 
binding peptide (H2A-H2B), with similarity to the mechanism of the DNA Kaposi 
sarcoma tumour herpes virus, has been identified on IL-33, suggesting mimicry of 
the virus with a biological mechanism for nuclear association and latent 
infection417.  Full length pro-IL-33 can translocate to the nucleus and it has been 
shown to interact directly at its N-terminal region forming an IL-33/NF-κB 
complex suppressing proinflammatory gene transcription confirming its repressor 
function 418.  
1.3.5 IL-33 function as a cytokine 
Despite uncertainty over different forms of IL-33, it now seems that whatever 
the release mechanism, IL-33 is a biologically active cytokine in its cleaved and 
mature form. At the outset of this work the description of the biological effect 
of IL-33 was as a potent inducer of type-2 innate inflammation 293. Following the 
discovery of the IL33 gene, Schmitz and colleagues developed a recombinant 
(18ka) protein and tested its activity in vivo and in vitro. In mice, following 
systemic intraperitoneal (i.p.) administration of IL-33, splenomegaly, blood 
eosinophilia and severe pathological changes in the gut and lung developed.  
This was accompanied by a rise in the concentration of type-2 associated 
cytokines IL-5 and IL-13 in the serum as well as raised IgE and IgA 
immunoglobulins 293.   
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The cell populations targeted by IL-33 were poorly characterized but since then 
considerable work in clarifying the cellular responses have been established with 
multiple targets and a corresponding wide range of effects. The knowledge that 
the IL-33 receptor ST2L is expressed on innate MCs as well as adaptive Th2 cells 
suggests that IL-33 is a cytokine capable of involvement in multiple facets of 
asthma pathophysiology and may act as bridge between the innate and adaptive 
immune processes.  
1.3.5.1 IL-33 and innate cells 
MCs highly express ST2 and are therefore unsurprisingly sensitive to IL-33 
stimulation and as such are one the most studied responder cells.  IL-33 induces 
the activation of NF-κB and MAPKs in mouse MCs 293. In response a range of 
cytokines are produced including IL-6, IL-13, IL-1β, TNF-α, prostaglandin D2, 
MCP-1 in BMMCs 419 and IL-13, IL-5, IL-6, IL-10, TNF-α, GM-CSF, CXCL8/IL-8 and 
CCL1/TCA3 from human MCs 330. A synergistic effect of IL-33 with IgE crosslinking 
to enhance cytokine production has been described 330 However degranulation of 
MCs does not appear to occur 330,419.  IL-33 promotes the development of mast 
cell from CD34+progenitor cells 330 and promotes their survival and adhesion to 
ECM and endothelial vessels by upregulation of adhesion molecules 329. 
Basophils also secrete proinflammatory mediators including IL-4, IL-5, IL-6, GM-
CSF and histamine after with IL-33 treatment 310,326.  IL-3 enhances basophil ST2 
expression and cytokine release 308,310. Like in MCs cytokine production is 
enhanced by IgE crosslinking in basophils 310,328. Degranulation does not appear 
to occur, but IL-33 enhances IgE mediated degranulation at least in humans ex 
vivo 310. 
As previously discussed in section 1.2.3.3, ST2 is proposed to play a role in 
endotoxin tolerance by reduced cytokine production by sequestration and 
blocking MyD88 signalling 346. However, when macrophages are treated with the 
ST2 ligand IL-33 in vitro, the response to endotoxin was conversely enhanced 
and LPS desensitisation was not induced 420. IL-33 may increase MyD88 to 
enhance this TLR pathway but in the absence of a ligand binding to ST2, ST2 can 
sequester MyD88 thereby reducing its availability for TLR signalling. Importantly, 
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other macrophage phenotypes have been described but their response to IL-33 is 
hitherto unknown and will be further investigated in chapter 4.  
IL-33 activates the expression of cell surface molecules: MHC-II and co-
stimulatory molecules CD86 332; or co-stimulatory molecules CD40, CD80 and 
OX40L on murine DCs 421. IL-33 drives production of IL-6, IL-1β, TNFα and 
CCL17/TARC from DCs 332,421. In co-culture experiments these IL-33-stimulated 
DCs drive naïve T cells to a Th2 phenotype producing IL-5 and IL-13, but not IL-4 
or IFNγ, suggesting a role for IL-33 in initiation of Th2 inflammation 332. In vivo, 
in an AAI model, ST2-/- mice had attenuated inflammation which was reinstated 
by the adoptive transfer of these IL-33 treated DCs 421.  
Since the discovery of IL-33 and the recognition that its administration caused 
profound eosinophilia, some interest has turned to these granulocytes not known 
previously to express ST2L, as potential IL-33-mediated effector cells. ST2 mRNA 
expression was detected in human eosinophils but ST2L protein surface 
expression was only present in activated cells after 24 hours ex-vivo and this was 
enhanced by co-culture with GM-CSF 309. IL-33 drives modest IL-8 and MCP-1 
cytokine production, superoxide production and promotes survival in human 
eosinophils 309. In mice, IL-33 enhances eosinophil differentiation, stimulates in 
vitro eosinophils to produce IL-13, CCL17 and TGF-β, and enhances the 
differentiation of AAM in an airways inflammation model, suggesting an 
additional role for eosinophils directly in IL-33-mediated inflammation 311. Given 
the important roles for MCs, basophils and eosinophils in allergy and asthma, 
these findings suggest IL-33 is important in allergic responses. 
Neutrophil ST2L expression is significantly upregulated by IL-33 and furthermore, 
IL-33 is a neutrophil chemoattractant in a mouse sepsis model and in patients 
with RA, suggesting a mechanism for migration into inflamed joints 312,333. 
Neutrophils of patients treated with anti-TNFα therapy did not display this IL-33-
induced chemotaxis suggesting a possible mode of drug action 333. 
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1.3.5.2 IL-33 on adaptive cells 
Schmitz et al demonstrated type-2 inflammation in response to exogenous IL-33 
in mice. Th2 cells, known to selectively express ST2, through which a role in 
Th2/type-2 inflammation has already been described, places them central in a 
hypothesis of IL-33-driven inflammation 293. The initial in vitro stimulation of 
Th2 cells by Schmitz revealed IL-33 that enhances Th2 cytokine production from 
IL-4 stimulated Th2-polarised cells. In support of IL-33 driving a Th2 biased 
inflammatory response, Th1 cells incubated with IL-33 produced less IFNγ 293,326. 
Non-polarised T cells produce IL-4 and IL-13 and polarised antigen-dependent as 
well as antigen-independent T cells produce IL-5 and IL-13 when treated with IL-
33 326,422,423.   In antigen-dependent stimulation, IL-33 also enhances IFNγ 
production in blood-derived Th2 cells with loss of intracellular IL-4, although in 
these experiments there were other T cells sources capable of contributing to 
IFNγ production in the mixed cell culture 326. In Th2 cells, IL-33 plus IL-2 induced 
NF-κB dependent production of IL-13 in an antigen-independent pathway that 
required STAT5 activation but not nuclear factor of activated T cells (NFAT), a 
further example of differential cell signalling 423. Interestingly, IL-33 has also 
been found to act as a chemotactic factor for Th2 cells in both mice and 
humans424. 
Administration of IL-33 can induce the production of a type 2-immunoglobulin 
profile in naïve mice suggesting that IL-33 could interact with B cells directly293. 
Administration of i.p. IL-33 increased the population of B1 cells in an IL-5-
dependent manner. Naïve B1 cells expressed low levels of ST2, upregulated by 
IL-33 treatment producing IL-5, IL-13 and IgM. This direct response is augmented 
by IL-5 produced from mast cell and T-cells in response to IL-33 327.  
Extending the biological activities of IL-33 beyond Th2 immunity, invariant NKT 
(iNKT) cells are found in increased numbers in mice treated with systemic IL-33. 
IL-33 treatment in the presence of TCR stimulation enhanced IL-2, IL-4, IL-5, IL-
13 and TNFα production from human iNKT cells in vitro. In the absence of TCR 
stimulation and in the presence of IL-12, the production of IL-4 and to a greater 
extent IFNγ were enhanced. NK1.1 cells responded similarly indicating the 
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induction of a pro-type1/Th1 profile as well as type-2 responses 326. The 
cytokine responses of NK2 cells to IL-33 cells are not known. 
Recent studies show that CD8+ T cells express ST2 and respond to IL-33, and 
similar to iNKT cells this is augmented by IL-12 and TCR engagement 425. This has 
led to the investigation into potential IL-33 driven viral responses. Indeed, a 
responisve subset of antigen-specific CD8 T cells was found to mediate 
protective anti-viral T cell responses 426.  
1.3.6 IL-33 in disease 
Given the effects of ST2 and now demonstrated effects of IL-33 on cell 
populations relevant to asthma, this overwhelmingly suggests a role for IL-33 in 
AAI and asthma.  Following the description of abnormal lung pathology in mice 
systemically treated with IL-33, the next description of a role for IL-33 in 
airways disease was the 2007 description of increased sST2 and IL-33 mRNA 
expression in an AAI model. The IL-33-driven effects on ex vivo splenocytes was 
blocked by sST2 397. In humans, genome-wide association studies have identified 
single nucleotide polymorphisms or SNPs encoding IL-33 and asthma 427. 
Higher levels of serum IL-33 are reported in patients with allergic rhinitis 428; 
serum levels of IL-33 were also elevated in patients with atopic dermatitis 
compared to non-inflamed skin healthy controls or non-atopic psoriasis patients 
429. IL-33 gene polymorphisms are described in rhinitis patients 428 and allergic 
conjunctivitis patients 430.   
IL-33 helps clear the intestinal nematode, Trichuris muris primarily via the 
induction of Th2 responses. Some pathological changes were still seen in SCID 
mice, deficient in T and B cells, which displayed elevated NK numbers suggesting 
NK also contribute to the observed pathology 431.  Indeed ST2-/- mice have 
increased susceptibility to encephalitis secondary to Toxoplasma gondii in 
keeping with a protective effect of IL-33 in parasite responses 432. An innate 
source of cytokines induced by IL-33, is now known to be the recently discovered 
ILC; a population of cells which proliferate during Neppostrongylus Brasiliensis 
infection in mice158.  
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A further potentially beneficial effect of IL-33 administration has been shown in 
a murine model of atherosclerosis 321. IL-33 treatment attenuated 
atherosclerotic plaque development by inducing IL-5 stimulated ox-LDL antibody 
production 321, and reduced macrophage foam cell formation 433. IL-33 also 
appears to have a potential beneficial role in heart failure, enhancing fibroblast-
cardiomyocyte interaction 394. As noted previously in 1.2.4.1, sST2 is a biomarker 
for acute MI and increased serum concentrations were associated with 
remodelling and HF post acute MI. There are some mechanistic studies to explain 
anti-inflammatory effects of IL-33 in this setting. IL-33 prevents hypoxia-induced 
apoptosis of cardiomyocytes as well as improved LV function and survival post MI 
in WT but not ST2-/- mice 434. Furthermore, reduced macrophage infiltration and 
subsequent cytokine production in the myocardium along with suppressed NF-κB 
and p28MAPK signalling and remodelling was observed with IL-33 treatment in a 
murine MI model 435.  
Adipose tissue is now increasingly being considered as an immune ‘organ’. IL-33 
mRNA is expressed in human adipocytes and is upregulated by TNFα suggesting a 
role in obesity where increased levels of TNFα are seen 404. Treatment of 
genetically obese mice (ob/ob) with IL-33 led to protective metabolic effects 
and conversely the ST2-/- mice had worsened metabolic parameters 436. The 
highest levels of IL-33 were detected in the endothelial cells in human adipose 
tissue suggesting that the influence of IL-33 on obesity could be via the 
microvasculature 437. Interestingly, ILC were first described in adipose tissue 157 
and IL-33 responsive ILC subsequently increase eosinophil and AAM accumulation 
in adipose tissue by IL-5 and IL-13 production 158,438. 
IL-33 may play a role in fibrotic injury in the liver.  Increased expression of IL-33 
mRNA is reported in fibrotic livers of mice and humans and this was upregulated 
in hepatic stellate cells in response to proinflammatory cytokines 439. Serum IL-
33 levels are elevated in patients with liver failure admitted to intensive care 
unit or in those with chronic liver disease secondary to hepatitis C infection and 
correlates with other inflammatory mediators 440,441. Levels of sST2 in these 
patients tended to reflect the more acute presentation indicating a possible 
additional biomarker role 441. 
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IL-33 protein and mRNA expression is present in normal and diseased synovium in 
experimental arthritis and in patients with rheumatoid arthritis 387,401,402.   
Human RA synovial fibroblasts contain low levels of IL-33 mRNA and protein but 
the addition of TNFα and IL-1β to primary fibroblast culture, increases the 
expression of IL-33 mRNA and protein 401,402. Several studies have described a 
role of ST2L and sST2 in regulating inflammatory responses in arthritis401.  The 
administration of IL-33 exacerbates the inflammation associated with antigen-
induced and in auto-antibody-induced murine arthritis models, by mast cell 
activation 402,442. A genetic variant of IL-33 is associated with rheumatoid 
arthritis 443 and elevated IL-33 serum concentrations correlate with the number 
of inflamed joints and with disease activity 444.  
IL-33 protein expression is increased in skin biopsies of patients with psoriatic 
arthritis 445 and in vivo, IL-33 induces a psoriatic-like pathology in murine skin 
which is partially mast cell dependent 446. 
In patients with Crohn’s disease and ulcerative colitis, protein and mRNA 
expression of IL-33 and ST2 was observed in colonic biopsy specimens and 
moreover, serum concentrations of IL-33 and sST2 were raised in these patients 
387,406. Administration of exogenous IL-33 exacerbated experimental ulcerative 
colitis via an IL-4 dependent mechanism 447. Production of type-2 cytokines by 
colonic macrophages may in part contribute to the excessive inflammation in 
experimental colitis; increased numbers of IL-33 positive colonic macrophages 
were associated with a reduction in macrophage response to TGF-β, which is 
important in resolution of inflammation 407. 
In the nervous system, gene polymorphisms are associated with Alzheimer’s 
disease 448. In vitro, increased mRNA IL-33 expression is noted in activated glial 
cells 395 and in the brains of mice with parasite-driven mouse encephalitis model 
432. In an autoimmune encephalomyelitis model, the administration of exogenous 
IL-33 attenuated disease activity 449. 
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1.4 Objectives 
The preceding introduction discusses the current understanding regarding the 
pathophysiology of asthma. A great deal of research has provided the current 
paradigm of a Th2-mediated inflammatory disease of the airways with complex 
involvement of the innate and adaptive immune systems and increasing evidence 
suggesting that underlying abnormalities in the structural cells and matrix may 
be at least as important. Much of this information has come from animal models, 
but it is also apparent that such information can be conflicting due to the 
variability in models, stains and experimental conditions. As such, many 
fundamental questions are unanswered; in particular where novel cytokines are 
placed in the cytokine hierarchy orchestrating this inflammation. One of these 
cytokines, the recently discovered IL-33, drives type-2 inflammation and its 
receptor ST2L has been considered a potential modulator of type-2 responses in 
the airway in particular due to its expression on Th2 cells and MCs.  
Thus this thesis aims to address the hypothesis that the IL-33-ST2 axis is critical 
in the development, maintenance and persistence of AAI and asthma via effects 
on both the innate and adaptive immune systems. 
 The objectives of this thesis are therefore to: 
• Assess the expression of IL-33 and ST2 in the murine airway in vivo 
• Assess the presence of and quantify the amount of IL-33 and ST2 in airway 
fluid and plasma of asthmatic patients 
• Characterise the airway inflammation caused by IL-33 
• Assess the contribution of T cells to IL-33-induced airway inflammation  
• Ascertain the role of structural epithelial cells in IL-33-induced airway 
inflammation 
• Assess the contribution of IL-33 to the adaptive immune response in 
allergic airways inflammation in vivo  
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• Further investigate the role of ST2 to adaptive immune response in 
allergic airways inflammation in vivo 
By performing experiments to address these objectives this thesis aims to 
demonstrate that the IL-33-ST2 axis plays an important role in the innate and 
adaptive immune response in allergic mediated lung disease.  
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2.1 Reagents and buffers 
Commonly used buffers and reagents are indicated in Table 2.1. Other chemicals 
and reagents were purchased from Sigma-Aldrich unless otherwise stated. 
Reagent Composition 
Phospate buffered saline 
(PBS) 
8g NaCl, 1.16g Na2PO4, 0.2g KCL, 0.2g KH2PO4 in 1 litre distilled 
water, pH 7.4 
Complete medium (CM) RPMI (Invitrogen), 10% heat inactivated fetal calf serum (FCS), 5ml 
penicillin/streptomycin (pen/strep)(100IU), 5 ml L-glutamine 
(2mM), 50 μm B-mercaptoethanol 
Wash medium RPMI, 5 ml pen/strep, 5 ml L-glutamine (2mM) 
FACS buffer 2% FCS in PBS, ±5mM ethylenediaminetetraacedic acid (EDTA) 
ELISA wash Buffer 0.05% Tween-20 in PBS pH 7.4 
BD ELISA coating buffer 0.1M NaHCO3 pH8.4 
R&D ELISA coating buffer 8.4g NaHCO3, 3.56g Na2CO3 in 1 litre distilled water, pH 9.5 
OptEIA coating buffer 8.4g NaHCO3, 3.56g Na2CO3 in 1 litre distilled water, pH 9.5 
Biosource coating buffer PBS 
Biosource ELISA assay 
buffer 
0.5% bovine serum albumin (BSA), 0.01% Tween in PBS 
BD ELISA assay buffer 10% FCS in PBS 
R&D assay buffer 1% BSA in PBS 5% sucrose, 0.05%NaN3 in PBS 
70% ethanol 7 parts 100% ethanol, 3 parts distilled water 
Tail lysis buffer 10mM Tris pH 8.0, 50mM EDTA, 100mM NaCl, 0.5% Sodium Dodecy 
Sulphate. 500 μg/ml proteinase K (Qiagen, stock 20 mg/ml) added 
fresh before use 
Tris-acetate-EDTA 
(TAE)buffer (x50) 
242g Tris base, 57.1ml glacial acetic acid and 100 ml 0.5M EDTA 
(pH 8) in 1 litre distilled water.  
Citrate buffer 0.01M 2.1g citric acid in 1 litre distilled water, pH 6 
Tris Buffered saline (TBST) 
buffer 
6.05g Tris and 8.76g NaCl in 1 litre distilled water, pH 7.5 In 0.05 
Tween 
Avertin 1:1 weight volume solution of 2,2,2-tribromoethanol in tert amyl 
alcohol 
Table 2.1: Commonly used buffers and reagents 
 
IL-33 used was from three sources. Human and murine IL-33 produced and 
purified within the laboratory by Dr Damo Xu was used for in vivo experiments. 
IL-33 complementary deoxyribonucleic acid (cDNA) was cloned from IL-1 
stimulated human or murine fibroblasts by real time-polymerase chain reaction 
(RT-PCR) using specific primer pairs and this sequence was transformed into host 
Escherichia coli. IL-33 protein was induced by IPTG and purified by Ni-NTA 
affinity chromatography (Qiagen). Endotoxin was removed by a polymyxin B 
column purification. Endotoxin levels in the generated protein were less than 
0.01 EU/μg of as measured by Limulus amebocyte lysate QCL-1000 pyrogen 
testing (Cambrex). Purity of IL-33 was more than 95%. Detailed methods for IL-33 
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production have been published424. Bioactivity and specificity of recombinant IL-
33 were confirmed by IL-5 induction in lymph node cells (Figure 2.1). Human IL-
33 was injected into mice in the first description of IL-33 as a bioactive cytokine 
and there is a 55% homology between human and murine IL-33 293.  Others in our 
laboratory had determined the bioactivity of murine IL-33 produced was 
approximately half of human IL-33 in murine cells in an in vitro setting (Dr M 
Kurowska-Stolarska and Dr P Kewin) and thus the dose adjusted accordingly. 
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Figure 2.1: Example bioactivity of in-house murine recombinant IL-33 
Following processing, WT (ST2+/+) and ST2-/- peripheral lymph node cells at a concentration of 1 
x106/ml were cultured in 24 well plate with a combination of complete medium (cm), plate bound 
anti-CD3(αCD3) (2 μg/ml) or IL-33 (10 ng/ml). Cells were cultured for 72 hours following which 
supernatants were removed and IL-5 concentration measured by ELISA. Data is mean of 
experimental triplicates. Example shown is ‘Batch 6’ 115 μg/l IL-33 tested to confirm bioactivity.  
For in vitro experiments, recombinant human IL-33 (PeproTech, UK or Axxora, 
ALEXIS Corporation, Switzerland) were used. Comparable bioactivity of these 
reagents is shown in Figure 2.2 in the human mast cell line, HMC-1 cells. 
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Figure 2.2: Bioactivity of commercial human IL-33 
HMC-1 cells were grown in 12 well (2x 105 cells/well)  overnight and then IL-33 at 0-100 ng/ml 
added to culture media and supernatants removed 24 hours later and stored at -20°C until 
analysis. Human MIP-1α ELISA performed as per manufacturer’s instructions.  
2.2 Mouse strains 
All animals were housed in pathogen-free conditions in facilities managed by 
Biological Services staff, University of Glasgow in strict accordance with United 
Kingdom Home Office regulations under the Animals (Scientific Procedures) Act 
1986. 
2.2.1  Commercially available mice 
BALB/c and C57BL/6 mice were obtained from Harlan Olac (Bicester, Oxon, UK).  
2.2.2 Knockout mice 
ST2-/- mice were originally a gift from Dr A Mackenzie (University of Cambridge) 
and IL-4-/- mice from Prof J Alexander (University of Strathclyde) with colonies 
subsequently bred in-house by Biological Services, University of Glasgow. Rag-/- 
mice were donated by Dr A Michie (University of Glasgow). BALB/c-transgenic 
D011.10 mice were bred and housed at Biological Services, University of 
Glasgow. 
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2.2.3 Breeding IL-4-/-/St2-/-knockout mice 
Female ST2-/- mice were mated with male IL-4-/- mice to produce heterozygous 
F1 mice and this is discussed in more detail in section 6.3.1. F1 mice were re-
crossed to generate double homozygotes F2 (see Figure 6.17). Genotype was 
identified by PCR of DNA extracted from tail tips. The tail-tip was cut by 
Biological Services staff under isofluorane anaesthesia with tail cauterisation 
2.2.3.1 Screening for IL-4 and ST2 expression by PCR 
All techniques were performed using gloves and guaranteed DNase/RNase free 
plastic ware.  
Tail tips were digested overnight at 55°C in 0.5 ml tail lysis buffer.  
Phenol/chloroform/isoamyl alcohol (0.5 ml) was added and placed in a vortex 
mixer. Following 5 minutes rest at room temperature, the digested material was 
centrifuged for 5 minutes. The DNA-containing top layer was decanted into a 
fresh eppendorf taking care not to disturb the protein layer under. This was 
mixed with 0.5 ml chloroform and centrifuged for 5 minutes. The top DNA-
containing layer was further decanted again and 0.8 ml of ice cold 100% ethanol 
was added and following mixing left at -20°C for 20 minutes allowing the DNA to 
precipitate. This was centrifuged for 15 minutes, the supernatant was poured 
off, and 0.5 ml of ice cold 70% ethanol added to the DNA pellet. This was 
centrifuged again for 15 minutes, and the supernatant poured off. All 
centrifugations were at 14000 rpm at 4°C. The DNA pellet was air-dried for 25 
minutes at 55°C in a vacuum-dryer, and resuspended in 50μl pure water for 
injection. The DNA was stored at 4°C until PCR was performed for amplification. 
ST2 -/- mice have a targeted vector deletion within the St2 gene which involves 
the majority of exons 4 and 5 339. ST2 primer sequences were based on his 
published data and obtained from Sigma-Genosys. IL-4 -/- mice generated by 
targeted vector insertion transfection into embryonic cell lines 450. Constructed 
IL-4 primers were based on published data but modified using  BLAST® mus 
muscularis genome search (with assistance from Dr Derek Gilchrist) and 
synthesised by VHBio 450,451. All primers were reconstituted in Diethyl 
Pyrocarbonate (DEPC) treated water (Ambion). 
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 5’                3’ sequence 
Primer 1 TTG GCT TCT TTT AAT AGG CCC 
Primer 2 CTA TCA GGA CAT AGC GTT GGC TAC C 
Primer 3 TGT TGA AGC CAA GAG CTT ACC 
Table 2.2: ST2 oligonucleotide sequence primers for PCR 
Primers were obtained from Sigma-Genosys and diluted to 10OD with pure water and stored at      
-20°C until use.  
 5’             3’ sequence 
Primer 1 GTT GAG CAG ATG ACA TTG GGG C 
Primer 2 CTT CAA GCA TGG AGT TTT CCC 
Table 2.3: IL-4 oligonucleotide sequence primers for PCR 
Primers were obtained from VHBio and reconstituted with pure water as per volume instructed to a 
100 μM concentration. A working stock solution of 10 μM was prepared and stored at -20°C until 
use.  
Reaction buffer and sample DNA were mixed in PCR tubes. Reaction buffers for 
ST2 and IL-4 PCR are as shown in Table 2.4.  
Per well  ST2 IL-4 
10x PCR buffer  
MgCl2 (50mM)  
dNTPs (10mM)  
Taq DNA polymerase 
Pure H2O  
Primer 1  
Primer 2  
Primer 3  
 
Sample DNA 
2μl 
1μl 
0.5μl 
0.5μl 
13μl 
              0.5μl (10 OD) 
             0.5μl(10 OD) 
           1μl(10 OD) 
 
1μl 
5μl 
2.5μl 
1μl 
0.5μl 
36μl 
             1.5μl (10 μM) 
             1.5μl(10 μM) 
 
 
2μl 
Table 2.4: PCR reaction mix for ST2 and IL-4 polymerase chain reaction 
 
DNA samples from ST2 +/+, ST2 +/-, ST2 -/- , IL-4 +/+, IL-4 +/- and IL-4 -/- mice were 
used as positive controls and pure water as a negative control. PCR was 
amplified in a thermal cycler (Eppendorf) using the following protocols in Table 
2.5. 
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ST2 IL-4 
94°C 3 minutes               x1 
94°C 45 seconds  
60°C 30 seconds           x30 
72°C 90 seconds  
72°C 10 minutes             x1 
 
 
 
 
Store at 4°C until run on DNA detection gel 
94°C 2 minutes               x1 
94°C 30 seconds  
58°C 45seconds             x5 
68°C 2.5 minutes  
94°C 30 seconds  
68°C 30 seconds            x35 
68°C 30 seconds  
68°C 2.5 minutes            x1 
 
Store at 4°C until run on DNA detection gel 
Table 2.5: PCR protocol for ST2 and IL-4 
 
The PCR product was mixed with 5μl loading buffer and run on a 2% agarose 
weight/volume gel with 0.005% ethidium bromide for 30 minutes at 100 mV in 
TAE buffer, then viewed under ultraviolet (UV) light (Gel logic 200 imaging 
system) and Kodak software. A DNA sample ladder was used to estimate the size 
of the bands detected, the ladders were 50 base pair (bp) and 1 kbp 
(Invitrogen). For ST2, primers 1 and 3 amplified the 500 bp WT band with 
primers 2 and 3 amplifying the 200 bp disrupted ST2 band. For IL-4, primer 1 and 
2 gave the WT band (~120 bp) and targeted band (~1320 bp). Example gels are 
shown in Chapter 6. 
2.3 In vivo methods 
Procedures were carried under Project Licence Number 60/3119, Procedure 9, or 
Project Licence Number 60/3791, Procedure 5 in strict accordance with United 
Kingdom Home Office regulations under the Animals (Scientific Procedures) Act 
1986. RAG-/- mice were kept in filter top cages with sterilised food and water.  
2.3.1 Intranasal (i.n.) dosing 
Mice were anaesthetised by the intraperitoneal (i.p.) injection of 250 μl of 
avertin solution (1:40 dilution of avertin stock (Table 1) in PBS). Intranasal (i.n.) 
administration was performed with the animal in the upright position. Using a 
200 μl pipette, 30 μl of reagent in sterile PBS was instilled into the nostrils. The 
mice were placed in the recovery position in a warming chamber until they 
recovered consciousness, with supplemental oxygen given if required.  The 
number of challenges is described in each experimental protocol.   
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2.3.2 Intravenous (i.v.) dosing 
Mice were placed in a warming chamber at 38°C for 20 minutes prior to injection 
to induce vasodilatation. Following placement in a restrainer, intravenous (i.v.) 
access of a tail vein was obtained using a 1 ml insulin syringe and up to 200 μl 
volume of cells injected. Direct pressure was applied to the puncture site and 
mice released.  
2.3.3 Ovalbumin allergic airways inflammation model 
2.3.3.1 Rapid 12 day OVA allergic airways inflammation 
An optimised model of experimental asthma based on a published model was 
already in use within the laboratory452. AAI was induced in female BALB/c mice 
aged 6-8 weeks with senstised by i.p. injection of 100 μg chicken OVA (Grade V) 
adsorbed to 2 mg alum (Brenntag Biosector, Frederlkssund, Denmark) in sterile 
100 μl of PBS on day 1. On days 9-11, were challenged with 10 μg OVA in 30 μl by 
i.n. administration. Mice were culled on day 12 by i.p. injection of avertin 500 μl 
before exsanguination. Samples were collected and processed as detailed below. 
Dosing modifications and addition of IL-33 for some experiments are detailed 
where relevant in chapter 6.  
2.3.3.2 Long traditional 28 day OVA allergic airways inflammation model 
For some experiments, a well studied longer 28 day model of AAI was used104. 
Mice had a further identical sensitisation dose on day 14 with i.n. challenges on 
days 25, 26 and 27 mice and culled on day 28 as above.  
2.3.4 Adoptive transfer model 
CD4 T cells from WT, IL-4-/- and WT DO.11.10 mice were grown as described 
below. The cells were transferred i.v. as described above. Mice were challenged 
i.n. with daily consecutive dose of OVA or OVA peptide (ovapp) as indicated. 
Mice were culled 24 hours following final airway challenge and specimens 
collected as detailed below. 
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2.3.5 IL-33-induced airway inflammation model 
Recombinant IL-33 or PBS was instilled into the airway of WT, ST2-/-, IL-4-/- and 
RAG-/- mice as detailed above for 1-7 consecutive days. Murine (2 μg) or human 
(4 μg) IL-33 in 30 μl PBS was used as detailed in experimental protocols. Mice 
were culled at 24-172 hours and specimens collected as detailed below.  
2.3.6 Airway hyperresponsiveness measurement 
Non-invasive plethysmography was used to measure enhanced pause (Penh) as an 
indicator of airways responsiveness to broncho-provocation with 
methacholine284. Penh is a dimensionless parameter which is derived from the 
relationship between inspiratory and expiratory pressure as well as the pause 
which occurs at the end of expiration. Briefly, animals are placed in sealed 
individual chambers in a 4 chamber unit (EMMS, UK) where pressure changes are 
measured by a transducer. Following a 30 minute acclimatisation period, 
baseline measurements were recorded and mice were given nebulised increasing 
concentrations of methacholine or saline in 2 minute intervals and Penh 
continually recorded. Methacholine was prepared freshly and delivered at doses 
of 12.5 mg/ml-100 mg/ml.  An average reading for the challenge period was 
calculated using EMMS EDAQ® software.  
2.3.7 Sample collection and processing 
2.3.7.1 Serum collection 
Mice were given an i.p. terminal dose of 500 μl of avertin. Following the onset of 
full anaesthesia, the mice were killed by exsanguination. The heart was exposed 
and blood withdrawn using a 1 ml syringe attached to a 23G needle. The blood 
was stored in 1.5 ml centrifuge tubes for 2-3 hours at room temperature to allow 
clotting, before serum was separated by centrifugation at 14000 rpm at 4°C for 
30 minutes (Joan BR4i centrifuge). Serum was then collected and stored at -20°C 
until analysed.  
Chapter 2  88 
2.3.7.2 Bronchoalveolar lavage (BAL) collection 
The trachea was exposed by dissection of the superficial neck structures and 
following a small incision, it was cannulated using a 1 ml syringe with a 23 gauge 
needle sheathed in plastic tubing (0.58 mm ID, 0.78 mm OD; VWR International).  
The lungs were carefully inflated with 800 μl PBS whilst holding the needle in 
place at the insertion site by blunt forceps to provide a seal. The fluid was 
aspirated after 10 seconds and BAL fluid collected into a 1.5 ml eppendorf tube 
and kept on ice until further processing. The process was repeated with a fresh 
800 μl aliquot of PBS and the two aliquots pooled. Live cell counts were 
performed in a Neubauer haemocytometer (Weber Scientific International Ltd, 
Teddington, UK) using a 1:2 dilution with 0.4% trypan blue solution. After 
removal of cells for differential cell counting (see below) the remaining BAL 
fluid was centrifuged at 1400 rpm for 5 minutes at 4°C and the supernatant 
frozen at -20°C until further analysis.  
2.3.7.3 Cytospin preparation 
In order to determine the frequency of different cell types in the BAL, 1 x105 
cells were spun onto glass slides using a Shandon Cytospin3 (ThermoShandon, 
Runcorn, UK) at 350 rpm for 6 minutes. Slides were air dried before fixing in 
methanol at room temperature for 10 minutes. Fixed slides were stained by the 
Romanovsky method using Rapi-Diff II stain kit (Raymond A Lamb, Eastbourne, 
UK) and coverslips secured in place with Di-n-butylPhthalate in xylene (DPX) 
adhesive (BDH Laboratory Supplies, Poole, UK).  
Differential cell counts were counted at x100 magnification under oil immersion 
with macrophages, eosinophils, neutrophils and lymphocytes identified using 
standard morphological criteria. The relative frequency of each was determined 
by counting 400 consecutive cells. The number of cells/ml was calculated from 
the total cell count. Squamous epithelial cells were not included in the analysis. 
The slides were blinded and randomised before counting with selected 
experiments counted by a second observer to ensure no inter-observer error. 
Figure 2.3 shows an example of these BAL cytospin preparations at x40 
magnification.  
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Figure 2.3: Leukocytes in bronchoalveolar lavage fluid cytospin preparation 
Example cytospin preparation of BAL indicating eosinophils (E), macrophages (M), neutrophils (N), 
lymphocytes (L) and ciliated epithelial cell (EC). Magnification x40 
 
2.3.7.4 Mediastinal draining lymph node (DLN) collection 
The heart and lungs were removed en bloc from the chest cavity and the 
mediastinal lymph nodes draining the lung (DLN) from individual mice were 
removed and placed into cold wash medium.  These were placed on ice until 
further processing.  A single cell suspension was created by crushing the lymph 
nodes with a syringe plunger in wash medium gently through Nitex, a 100 μm 
nylon monofilament gauze (Cadisch, UK), and filtering again through Nitex into 
25 ml centrifuge tubes to remove debris. Cells were washed twice with 
centrifuging at 1400 rpm for 5 minutes. The cells were resuspended in 5 ml of 
CM, counted and kept on ice until required for cell culture or FACS analysis.  
2.3.7.5 Lung collection 
After removal of the heart and lung en bloc the lungs were inflated with 10% 
neutral buffered formalin (NBF) via the trachea using a 1 ml syringe and 23G 
needle sheathed with polythene tubing, as used for BAL. The trachea was then 
tied off with thread and the lungs immersed in 10% NBF for 48 hours then 
transferred to 70% alcohol. The lungs were subsequently mounted in paraffin 
blocks and stored at 4°C. 
E 
M 
L 
N 
EC 
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Where the lungs were required to be frozen, the lungs were similarly re-inflated 
with optimum cutting temperature (OCT) medium (Raymond A Lamb, UK) and 
immediately snap-frozen in liquid nitrogen and then stored at -80°C. When lungs 
were used to perform lung digests, the lung was dissected from the main bronchi 
and placed in media on ice for further preparation.  
When tracheas were taken for epithelial cell culture, the trachea and large 
airways were carefully dissected from the surrounding heart, lungs, oesophagus 
and other tissues and then placed in media on ice until further culture.  
2.3.7.6 Lung digestion 
Lungs were removed and perfused with PBS. The lungs were cut with scissors and 
then mechanically dissociated with a tissue chopper in wash medium into a 5 ml 
centrifuge tube. Four millilitres of sterile digest medium containing an enzyme 
cocktail of 200 μl of 28 Wϋnsch units/ml liberase Blendzyme 2 (Roche) and 
DNase1 250 μg/ml (Roche) in wash medium  was added and tubes placed in a 
shaking waterbath at 37°c for 1 hour. The digested material was passed through 
a 70 μM filter and CM added to stop the digestion reaction. The cells were 
centrifuged at 1900rpm for 10 minutes and the cell resuspended in 1.5 ml or red-
cell lysis buffer for 1 minute. The cells were flooded with CM and centrifuged 
again. The single cell suspension was resuspended in 5 mls of CM and counted. 
The cells were incubated in FACS buffer with EDTA and stained as per FACS 
protocol. 
2.3.7.7 Tracheal digestion 
Murine tracheal digestion was based on published methods 453. Following 
tracheal removal, the specimen was carefully processed to remove all other 
surrounding tissues, then cut longitudinally, transferred to PBS for 5 minutes and 
placed in collection media (1:1 Dulbecco’s Modified Eagle Medium (DMEM): Ham’s 
F-12, 1% pen/strep). The trachea was incubated in dissociation media [DMEM: 
Ham’s F-12, 1% pen/strep, 1.4 mg/ml pronase (Roche) and 0.1 mg/ml DNase 
(Roche)] for 60 minutes at 37°C on a rotator.  FCS (10%) was added to stop the 
digestion and tube agitated to dissociate cells. Cell suspensions were transferred 
into a 50 ml centrifuge tube and digested tracheas rinsed twice more with 15 ml 
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of media and pooled together into the centrifuge tube. Cell suspension was 
centrifuged at 300 g for 10 minutes. The supernatant was removed and cells 
resuspended in culture medium (1:1 DMEM: Ham’s F-12, 1% pen strep/5% FCS, 
120 IU/ml Insulin) (~5 ml for large Petri dish) and transfer to culture dish for 2 
hrs at 37°C to remove rapidly adherent cells. Non-adherent cells were collected 
spun again, resuspended in FACS buffer to allow cell counting. 
 
2.3.8 Histology 
Lungs in paraffin blocks were cut using a microtome into 5 μm sections onto 
histology slides or superfrost antigen charged slides (VWR) for 
immunohistochemistry and allowed to dry at 55°C for 30 minutes before being 
stored at 4°C until used for staining.  
Lungs frozen in OCT medium were removed from -80°C and kept on ice then cut 
into 6 μm sections onto superfrost slides (VWR), allowed to dry and stored at 4°C 
until used for staining.  
2.3.8.1 Lung histology-haematoxylin and eosin staining (H&E) 
Paraffin sections were stained with haematoxylin and eosin (H&E). Some of the 
H&E staining was performed by Mr. Roderick Ferrier, Department of Pathology, 
Western Infirmary, Glasgow or Veterinary Diagnostic Services, University of 
Glasgow.  Otherwise, the slides were deparaffinised and rehydrated with graded 
alcohol solutions (Xylene, 100% alcohol, 70% alcohol and distilled water). 
Following this, the slides were stained in Harris haematoxylin for 2 minutes and 
excess removed by gently washing with running water. The slides were 
counterstained with 1% eosin for approximately 2 minutes and excess washed off 
with running water. The sections were then dehydrated and covered in DPX and 
a coverslide.  
2.3.8.2 H&E scoring method 
Sections were examined blinded at x 20-100 magnification and peribronchial and 
perivascular inflammation assessed. Some experiments were also assessed by a 
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second assessor. A semi-quantitative scoring system was used to assess the 
degree of eosinophilic infiltration: 0= no eosinophils; 1= eosinophils comprise 
less than 10% of total infiltrate or total infiltrate is <20 cells; 2= eosinophils 
comprise 10%-50% total infiltrate and; 3= eosinophils comprise more than 50% 
total infiltrate.  A total of 10 fields were scored for each mouse and each field 
contained an airway and vessel in close proximity. Score were averaged for each 
mouse. Slides were photographed using an Olympus Camera. 
2.3.8.3 Periodic Acid-Schiff (PAS) staining 
PAS staining on selected experiments was performed by Veterinary Diagnositics, 
University of Glasgow. 
2.3.8.4 Lung immunohistochemistry: ST2 and IL-33 
Frozen histological sections as described above were removed from the freezer 
and slowly dried, then fixed in ice cold acetone/ethanol (75%/25%) for 10 
minutes at room temperature, washed in PBS, then dried for 30 minutes. 
Endogenous peroxidase activity was blocked using 0.5% H202/Methanol for 30 
minutes. Sections were washed in PBS twice. The sections were blocked with 
20% appropriate serum (in which the secondary antibody was raised) in PBS with 
Avidin D block (4 drops/ml) for 30 minutes. Following a PBS wash, primary 
antibody or control was added and sections incubated overnight at 4°C. The 
following day following 2 PBS washes, the sections were incubated with the 
appropriate secondary biotinylated antibody for 30 minutes followed by 2 PBS 
washes. Avidin-biotin complex (ABC) vectastain (Vector Laboratories) was 
applied for 30 minutes followed by 2 PBS washes. Immunoreactive sites were 
visualized with 3,3’-diaminobenzidine tetrahydrochloride (DAB) (Vector 
Laboratories) substrate which was applied for 1-5 minutes and washed off with 
PBS. The sections were then washed in running water and counterstained with 
Harris Haemotoxylin for 10 seconds followed by a running water wash. Finally, 
sections were dehydrated from alcohol to xylene and a coverslide mounted with 
DPX.  
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For paraffin sections, histological sections on electrostatically charged slides 
were heated in an oven for 35 minutes at 65°C and deparaffinised as before. 
Peroxidase activity was blocked as described above. Antigen retrieval was 
performed by pressure cooker method: slides were added to boiling 0.01M 
citrate buffer pH 6.0 and heated under pressure for 8 minutes. Following 
cooling, slides were washed in distilled water, then PBS and transferred to a 
staining apparatus. Non-specific binding block, addition of primary antibody and 
secondary antibody were added as described above followed by the ABC/DAB 
system for visualisation.  
For secondary antibody, biotinylated (pan-specific) anti-goat/mouse/rabbit IgG  
produced in horse was used at concentration 4 drops/5 ml. Alternatively, 
biotinylated horse anti-rat (1:200), rabbit anti-rat (1:200) and appropriate 
secondary species serum were used (all Vector Labs). 
For some paraffin sections, the ImmPRESS polymer reagent kit (Vector 
Laboratories) was used. Following blocking peroxidase activity and antigen 
retrieval as above the slides were washed in PBS and TBST buffer. Ready to use 
normal horse blocking serum (2.5%) was used to block non-specific binding and 
sections were incubated with primary antibody in 2.5% horse serum/2.5% 
appropriate species serum (in which primary antibody raised) in TBST. Following 
overnight incubation and a wash, sections were incubated for 30 minutes with 
species specific ImmPress reagent (of primary antibody) and Impact DAB applied 
before counterstaining, washing and dehydrating as before.  
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Antibody Manufacturer Source Concentration Isotype 
IL-33 Nessy-1; 
Axxora Life 
Science 
Mouse 
monoclonal 
anti-mouse 
5-10 μg/ml  IgG1κ 
IL-33 R&D Rat monoclonal 
anti-mouse 
0.8 μg/ml 
(1:600) 
IgG2a 
IL-33 R&D Goat polyclonal 
anti-mouse 
2-15 μg/ml IgG 
ST2 MD biosciences 
(Switzerland) 
(Clone DJ8) 
Rat monoclonal 
anti-mouse 
0.8-5 μg/ml 
(1:1200-1:500) 
IgG1 
ST2 Santa cruz 
Biotechnologies  
(USA) (C-20) 
Goat polyclonal 
anti-mouse 
0.4-4 μg/ml 
(1:50-1:500) 
IgG 
ST2 R&D (clone 
245707) 
Rat monoclonal 
anti-mouse 
5-10 μg/ml IgG2b 
ST2 (IL-1RL1) Atlas (Sweden) Rabbit 
polyclonal anti-
human 
0.4 μg/ml 
(1:150) 
IgG 
F4/80 Serotec 
(Oxford, UK) 
(clone CI:A3-1)  
Rat polyclonal 
anti-mouse 
1:50 IgG2b 
vWF Dako 
(Denmark) 
Rabbit 
polyclonal anti-
human (cross-
reactive with 
mouse) 
1:300 Ig fraction 
Table 2.6: Primary antibodies used in Immunhistochemistry 
 
 
2.3.8.5 Lung immunohistochemisty (vWF) scoring method 
For assessment of vessel changes in vivo, an angiogenesis index was developed. 
Paraffin sections were stained as described above with the ImmPRESS kit using 
von-willebrand’s factor (vWF) or isotype control in lungs from IL-33 or PBS i.n. 
treated mice.  Using a high powered field that included one airway and 90% lung 
tissue, 10 fields were assessed per slide. Blood vessels were identified with a 
clear structural lining positive for vWF stain. Images were acquired using 
Olympus Pro-Cell D software (Olympus). Airway and vessel perimeters were 
drawn by hand close to the parenchymal edge of epithelial or endothelial cell 
layer. Perimeter, surface area and blood vessel number were recorded. Sections 
were discounted if total area of airways on a section fell out with 2 standard 
deviations of the group mean. Measurements were also recorded independently 
by Dr M Shepherd.  
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2.3.8.6 Cell immunohistochemistry 
Normal Human Bronchial Epithelial (NHBE) cells (see below for culture methods) 
were grown on Lab-Teck 4 chamber slides (VWR) and then stained with anti-ST2 
human (Atlas) using ImmPRESS kit as described above.  
2.4 In vitro methods 
All cell culture was performed under sterile conditions and cultures were 
incubated in a humidified incubator at 37°C, supplemented with 5% carbon 
dioxide. Centrifugation was performed at 380g for 5 minutes at 4°C (Jouan CR3i 
centrifuge), unless otherwise stated. Cell counts were performed in varying 
dilutions of 0.4% trypan blue solution. Plastics for cell culture were purchased 
form Corning and Gibco unless otherwise stated. 
2.4.1 Cell culture for adoptive transfer 
Previously polarised D011.10 Th2 CD4 cells (Dr Damo Xu) (5x106 cells/ml) stored 
in liquid nitrogen CM/20% FCS/10% DMSO were used. Antigen presenting cells 
(APC) and reagents were prepared before CD4 cells were thawed and cultured.  
For APC preparation, a single cell suspension was created by crushing the spleen 
with a syringe plunger in wash medium gently through Nitex and filtering again 
through Nitex into 25 ml centrifuge tubes to remove debris. Cells were washed 
twice with centrifuging and pellet resuspended in CM. Red cell lysis solution (2 
ml) was added and after 1 minute tubes filled with wash medium and spun 
again, resuspended ready for counting.   Filtered mitomycin C (1 mg/ml) was 
added, 5μl per 106 cells, and incubated for 45 minutes. Cells were washed 3 
times in CM, resuspended and counted ready for culture with CD4 cells.  
The vials removed from liquid nitrogen were held in 37°C bath for 2-3 minutes to 
thaw, then transferred and rinsed carefully into 10 ml CM. They were spun and 
washed again and resuspended in 5 ml ready for transfer to 150cm2 culture flasks 
with 5 mls other reagents for final concentration of APC 0.5x107/ml, OVA 
peptide 1:1000 and IL-4 10 ng/ml for repolarisation. Media was supplemented 
with IL-2 (10 ng/ml) and OVA peptide (1:1000) every 2-3 days until use. Cells 
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were washed twice with sterile PBS, resuspended in PBS and counted before 
preparing required cells in 200 μl aliquots for each mouse to be injected. 
CD4+IL-5+IL-4- cells used for adoptive transfer were produced by Dr Mariola 
Kurowska-Stolarska. Briefly, murine CD4+T cells from D0.11.10 IL-4-/-mice were 
purified by negative selection (AutoMACS) and cultured with mitomycin C-
treated APC (spleens from ST2-/- mice) with OVA peptide (10 nM), and IL-2 and 
IL-33 (10 ng/ml) for 3 days then prepared for i.v. transfer. Unstimulated CD4 
cells (Th0) were used as a control. 
2.4.2 Cell culture for cytokine quantification  
Single cell DLN preparation was described above. Cells were placed in 24 well 
culture plates at a final concentration of 1x106 cells/ml and cultured with CM or 
sterile OVA at a final concentration of 1 mg/ml. For in vivo experiments without 
OVA antigen, single cell suspensions of DLN were stimulated in 24 well culture 
places with 2.5 μg/ml of plate-bound αCD3 (BD biosciences) in CM. After 72 
hours of incubation, supernatants were aspirated and stored at -20°C until 
further analysis.  
2.4.3 Cell proliferation assay 
2.4.3.1 Thymidine proliferation assay 
Cells as described in OVA-recall assay were also cultured in 96 round bottom  
well plates (200 μl per well) in triplicate for 48 hours to assess proliferation. In 
the final 8 hours of culture, cells were pulsed with 0.037MBq 3H-thymidine in 
wash medium. Cells were then harvested onto glass fibre filter paper 
(PerkinElmer, UK) using a 295-0054 Betaplate 96 well harvester (PerkinElmer). 
Radioactivity was measured using a MicroBeta TriLux scintillation counter 
(PerkinElmer). All procedures were performed according to local radiation safety 
guidelines.  
For epithelial cells, cells were cultured at a density of 1x 104 cells/well with 
indicated concentrations of IL-33.  3H-thymidine was added for the final 8 hours 
of culture. 
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2.4.3.2 MTT proliferation assay 
3,[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) colorimetric 
proliferation assay was performed as per manufacturers’ instructions (Cell 
Proliferation Kit 1, Roche). Briefly, 1x 104 cells in 200 μl of medium on a 96 well 
plate are incubated with the yellow MTT solution and the salt crystals solubilized 
and spectrophotmetrically quantified using an ELISA plate reader.  
2.4.4 Epithelial cell culture  
NHBE cell line is referred to as 16HBE in the literature and is a transformed 
bronchial epithelial cell. NHBEs were grown in CM in 75 cm2 and media was 
changed every 2-3 days with cells were passaged approximately weekly by 
Hank’s balanced salt solution (HBSS) rinsing and 1x trypsin (Gibco). For culture 
experiments, cells were seeded onto 6 well (2x105/well) or 96 well plates as 
stated. In some experiments CM was used without FCS supplementation and the 
addition of 1:100 Insulin transferring Selenium A (Gibco).  
Primary human bronchial epithelial cells (pHBE) were obtained from Promocell 
(Hiedelberg, Germany) and resuscitated according to manufacturers’ 
instructions. Cells were subcultured in 75 cm2 at recommended density and 
grown in serum-free complete growth medium (GM) consisting of growth media 
plus 1 vial of supplement mix (Bovine Pituitary Extract, Epidermal Growth 
Factor, Insulin, Hydrocortisone, Epinephrine, Triiodo-L-thyronine, Transferrin 
and Reninoic Acid) (all Promocell).  Once 80% confluent, adherent cells were 
dissociated using Detach Kit (Promocell). Some subcultured cells were 
cryopreseved using Cryo-SFM (Promocell) under manufacturers’ instructions and 
stored at -80 C. pHBE were used between passage 4 – 6 for FACS, cell culture 
experiments and transwell experiments. For transwell experiments, 1% 
pen/strep was added to the media.  
Human Umbilical Vein Endothelial cells (HUVEC) were maintained in serum and 
VEGF free endothelial cell growth medium (Promocell, Heidelberg, Germany) 
and used at passage 4. Endothelial cell Tube Formation Assay (Life Technologies, 
UK) was performed under manufacturers’ instructions by Dr Malcolm Shepherd.  
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2.4.4.1 On transwell inserts 
Methods were adapted from published studies Lauer et al and Tammi et al 454,455.  
CostarTM (Cambridge, USA) clear transwell 24.5mm culture inserts (pore size 0.4 
μM) were placed into 6-well culture dish and a thin coating of collagen basement 
membrane (BM) added. Collagen volume calculated for 5 μl/cm2 by adding 
correct weight of type 1 rat tail collagen (BD Bioscience) to acetic acid for a 
final concentration of 50 μg/ml. This was kept at room temperature overnight in 
sterile conditions and washed twice in PBS and used immediately or stored at 
4°C for up to 1 week before use. 
For polarisation, NHBE or pHBE were seeded 1 x 105/well on the collagen BM 
submerged in their appropriate media, NHBE polarisation media was 1:1 DMEM 
with high glucose: CM and for pHBE serum-free GM with 1% pen/strep and 
changed every 2 days for 5-7 days until confluence reached. At this point, the 
apical medium was removed and media was changed on basolateral side only to 
expose an air-liquid interface (ALI) for further 14 days. 
Cells were exposed to recombinant human IL-33 (0.1-100 ng/ml) in the basal 
media for 24 hours, following which supernatants were collected and stored at -
20°C for later analysis. 
2.4.4.2 On transwell inserts with native basement membrane 
ThincertTM  clear transwell  35 mm culture inserts (pore size 8.0 μM) (Greiner)  
were thin-coated with collagen BM added as above. On top of this Madin-Derby 
Canine Kidney (MDCK) cells were added (2 x 105 per transwell). MDCK cells were 
grown in DMEM in 75 cm2 culture flasks and removed when required with 
EDTA/Trypsin. Following transfer to transwells, media was changed 
approximately 3 times a week for 18-22 days. To remove the MDCK cells, sterile 
10 mM TRIS-HCL/0.1% bovine serum albumin (BSA)/0.1 mM CaCl2 pH 7.5 was 
added for for 10 minutes followed by washing with 0.5 % Nonidet with a Pasteur 
pastette. To solubilise the cells, incubation for 5 minutes in sterile 0.2% 
deoxycholate was performed for 5 minutes at 37°c followed by 2 washes and 
inserts viewed under phase contrast microscope to ensure cell removal. The BM 
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was rinsed in HBSS twice and incubated with media or could be stored at 4°C 
until required. Cells and IL-33 were added as described above.  
Transepithelial electrical resistance (TEER) was measured as an indication of 
polarisation. The apical surface was washed in HBSS and fresh HBSS added and 
electrical resistance measured by epithelial voltohmmeter (Prof Tom Evans) 
according to manufacturers’ instruction with a baseline assessed in uncoated 
transwells without cells ≤200 Ω cm2 . 
2.5 Clinical study 
2.5.1 Study protocol 
The study was a cross-sectional unblinded use of oral dexamethasone to 
determine if distinct cytokine profiles could provide mechanistic insights into 
corticosteroid (CS) insensitivity in smoking asthmatics . Study design and 
recruitment was approved by the Local Ethics Committee and patients gave 
informed written consent. All patients were recruited by staff at the Asthma 
Research Unit, University of Glasgow under the supervision of Dr Mark Spears and 
Prof Neil C Thomson. Patient demographics are described in chapter 3. Full 
design, inclusion and exclusion criteria and further information available in the 
published study by Spears et al 456. Briefly, all subjects had to demonstrate 
reversible airflow obstruction with a Forced Expiratory Volume in 1 second 
(FEV1) bronchodilator response of ≥12% (and >200 ml), Peak Expiratory Flow 
(PEF) or positive methacholine test to be eligible. Patients completed a 
questionnaire including Juniper Asthma Control Questionnaire (ACQ), and 
underwent spirometry, serum and sputum collection before and after a 2 week 
trial of oral dexamethasone.  
2.5.2 Sputum and serum sampling 
Sputum and serum collection and processing was performed by staff form the 
Asthma Research Unit and Division of Infection, Immunity and Inflammation, 
University of Glasgow as published by Spears et al 456. Briefly, a whole sputum 
sample method was used with low concentration dithiothereitol (DTT) and 
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supernatants collected and stored at -80°C until cytokine analysis. Plasma was 
collected from heparinised blood samples and similarly stored until analysis. 
Sputum and plasma sST2 and IL-33 levels were assessed by ELISA according to 
protocol in section 2.6.2 below.  
2.6 Assays and analysis 
2.6.1 Flow cytometry (FACS) 
Washed 1 x105 cell pellets in FACS tubes (BD Biosciences, UK) were resuspended 
in 50 μl FACS buffer with 1 μl of Fc block (anti-CD16/CD32, BD Biosciences) and 
incubated for 15 minutes at room temperature (RT). Cells were stained by 
adding the required amount of antibody to the tube followed by vortex mixing 
and incubation in the dark at 4°C for 30 minutes. Cells were washed with 500 μl 
FACS buffer and centrifuged before resuspension in buffer ready for analysis. 
Three μl microlitres of 7-Amino-actinomycin D (7-AAD, Via-Probe, BD 
Biosciences) was added before acquisition.  
For intracellular (IC) staining, 100 μl Cytofix/Cytoperm buffer (BD biosciences)  
was added to the cell pellet which was incubated for 20 minutes at RT followed 
by washing in 500 μl Cytoperm wash (BD biosciences) (made from stock solution 
diluted in distilled water). Cells were resuspended in 50 μl cytoperm wash and 
the required amount of antibody before being incubated at 4°C for 30 minutes. 
The cells were washed again and resuspended ready for acquisition.  
 
For DLN IC staining, DLN were stimulated with 50 ng/ml phorbol 12-myristate 13-
acetate (PMA) and 500 ng/ml ionomycin for 4 h with GolgiStop (BD biosciences) 
added during the final 3 hours. Cells were then fixed, permeabilized and 
incubated with antibody as above.  
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Antibody-
Conjugation 
Volume added or 
dilution used 
Manufacturer Isotype 
Human ST2-
FITC 
5 μl MD biosciences  Mouse IgG1 
Murine ST2-FITC 2 μl MD biosciences Rat IgG1 
Pan Cytokeratin-
PE 
1 μl Abcam Rat IgG1-PE 
CD45-PE 2 μl R&D IgG2b 
CD4-APC 1 μl BD biosciences Rat IgG2b 
c-kit-APC 2 μl BD biosciences Rat IgG2b 
Siglec F-PE 1:200 BD biosciences Rat IgG2a 
F4/80 2 μl eBioscience Rat IgG2aκ 
Gr-1-Percp/Ly5 0.8 μl BD biosciences Rat IgG2bκ 
CCR3-APC 5 μl R&D Rat IgG2a 
IL-4-PE 1:200 BD biosciences Rat IgG1 
IL-5-APC 1:200 BD biosciences Rat IgG1κ 
IFNγ-FITC 1:200 BD biosciences Rat IgG1κ 
Table 2.7: FACS antibodies 
 
Samples were analysed using a FACSCalibur flow cytometer (BD Biosciences) and 
data acquired using CellQuest software (BD Biosciences). Live cells were gated 
according to forward scatter (FSC) and side scatter (SSC) and exclusion of 7-AAD 
positive cells using unstained cells. Using sample cells, isotype staining was used 
to ensure not that less than 2% of total cells were falsely positive on any axis. 
Using a combination of single stained samples on each flurochrome with other 
flurochrome isotypes, compensation was carried out for emission overlap. All 
data analysis was carried out using the FlowJo package (Tree Star Inc., Oregon, 
USA). 
2.6.2 Cytokine immunoassays 
Enzyme linked immunosorbant assays (ELISAs) were performed for cytokine and 
chemokine quantification using paired antibodies or kits as specified in Table 2.8 
Buffers used are as detailed in Table 2.1.  
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Analyte Manufacturer Lower limit 
detection 
(pg/ml) 
IL-4 BD 40 
IL-5 BD 30 
IFN-γ BD 100 
IL-13 R&D  5 
Eotaxin/CCL11 R&D 5 
Eotaxin-2/CCL24 R&D 4 
TARC/CCL17 R&D 5 
RANTES/CCL5 R&D 5 
IL-17E R&D 62.5 
OVA-IgE BD dilutions (see 
text) 
Total IgE Bethyl Labs 3900 
Human IL-8 R&D 31.2 
Human IL-6 Invitrogen  5 
Human Eotaxin-2/CCL24 R&D 15.6 
Human MIP1α/CCL3 R&D 7.81 
Human VEGF Invitrogen 23.4 
Human IL-33 Genway 700 
Human ST2 R&D 31.2 
Table 2.8:  ELISA kits and antibody pairs  
 
ELISA Immulon 4 HBX plates (Thermo Labsystems, Franklin) were coated with 
capture antibody 50 μl/well in appropriate coating buffer and incubated 
overnight. Plates were washed three times with ELISA wash buffer then 
incubated with 200 μl/well of assay diluent buffer for 1 hour at 37°C as a 
blocking step. Following three washes samples and standards were added. An 
eleven doubling dilutions of the standard were added to obtain a standard curve 
and 2 wells were incubated with assay buffer alone as blank wells. After 
incubation for 2 hours at room temperature plates were washed five times 
before biotin-conjugated detection antibody in assay buffer was added to each 
well. After 1 hour at room temperature plates were washed three times and 
Streptavidin-horseradish peroxidase (HRP) conjugate (Extravidin, Sigma), diluted 
1:1000 with assay buffer, was added. After 30 minutes plates were washed three 
times and 100 μl/well of 3,3’,5,5’-tetramethylbenzidine (TMB) substrate (KPL, 
Gaithersburg, USA) added. Plates were incubated in the dark for up to 30 
minutes or until sufficient blue colour had developed. Optical density was read 
immediately at 630 nm on a MRX II microplate reader (Dynex Technologies, 
Worthing, UK) running Revelation (Dynex Technologies) software or Sunrise 
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absorbance plate reader machine and sample values calculated from the 
standard curves generated. Modifications to this protocol are as noted below. 
For R&D ELISAs, assay buffer and Streptavidin-HRP conjugate provided by R&D 
and diluted to 1:200 were used. In addition, the detection antibody was 
incubated for 2 hours rather than 1. The Eotaxin-2 detection antibody was 
diluted in the R&D ELISA assay buffer with the addition of 2% heat-inactivated 
normal goat serum. Following TMB substrate, the reaction stopped with addition 
of 100 μl stop buffer and read at optical density of 430nm with a 570nm 
correction filter. 
Total IgE was measured using a kit from Bethyl Laboratories (Texas, USA) using: 
coating boater 0.05 M carbonate-bicarbonate pH 9.6, wash 50 mM Tris, 0.14 M 
NaCl, 0.05% tween 20, pH 8.0, blocking solution 50 mM Tris, 0.14 M NaCl, 1% 
BSA, pH 8.0; and sample diluent  blocking solution with 0.05% tween 20.  For 
OVA-specific IgE ELISA, plates were coated with OVA 10 μg/ml in OptEIA buffer 
and incubated overnight. In the absence of any standard for OVA specific 
immunoglobulins, serial dilution curves were obtained for each sample using 
assay buffer as a diluent with an initial sample dilution of between 1:10 and 
1:40. 
For antibodies from Invitrogen the coating buffer was PBS and the sample and 
detection steps were combined, with 50 μl/well of sample or standard added to 
each well followed immediately by 25 μl/well of detection antibody in assay 
buffer followed by 2 hour incubation. 
 For the human IL-33 ELISA (Genway Biotech, CA, USA) the reagents are the 
same as for the Bethyl IgE ELISA with standard ELISA wash buffer.  
A murine IL-33 ELISA was developed as described in section 3.2.3. Both capture 
and detection antibodies were titrated at reducing concentrations measuring 
blank assay diluent wells and assay diluent wells with a concentration of 1 ng/ml 
of murine IL-33. 
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2.6.3 Multiplexed immunoassays 
Multiplexed immunoassay is a method by which multiple cytokines or other 
mediators are measured simultaneously in a small volume of fluid using latex 
microbeads with antibody covalently attached.  Biosource Multiplex kits LHC0009 
(Cytokine Human 25-Plex), LMC0006 (Cytokine Mouse 20-Plex) and LMC1031 
(RANTES Mouse Singleplex) were used according to the manufacturers’ 
instructions. All reagents and buffers were sourced from the kits. Beads were 
sonicated before addition to sample well to ensure there was no clumping. Fifty 
microlitres of incubation buffer, assay diluent and sample were added to each 
sample well. Data was acquired on a Luminex 100TM analyser (Luminex Corp., 
Texas, USA). Data was analysed using Luminex software (Luminex Corp.). 
2.7 Statistics 
Data from in vitro and in vivo experiments were usually normally distributed 
with equal variance. Therefore mean values were calculated and expressed with 
standard errors of the mean (SEM). Comparison between groups of data was 
made with unpaired Students two-sample t-test, one-way analysis of variance 
(ANOVA) or two-way ANOVA depending on the data. A p value of less than 0.05 
was considered significant. Statistical analysis was performed using Excel 
(Microsoft, Redmond, USA),  MINITAB 16 (Minitab Inc, PA, USA) and GraphPad v4 
(GraphPad, CA, USA).  
For the clinical studies, Student’s t-test or Mann-Whitney test when appropriate 
for comparisons of clinical data between smokers, ex-smokers and never smokers 
performed by Dr Mark Spears using SAS software (SAS Institute, NC, USA) and 
MINITAB (Minitab Inc.).  ST2 and IL-33 analysis was performed between groups 
using Student’s t-test or Mann-Whitney test and within groups (before/after CS) 
analysed with paired t-test and Wilcoxon U test and correlations using Pearson’s 
correlation using MINITAB (Minitab Inc.).   
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3 Expression of ST2 and IL-33 in the lung 
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3.1 Introduction and Aims 
Schmitz and colleagues reported IL-33 mRNA expression, detected by RT-PCR, 
was present at a high level in murine lung.  On a cellular level, human bronchial 
and pulmonary artery smooth muscle cells along with bronchial epithelial cells 
express significant IL-33 mRNA levels293. These findings were predated by the 
detection of protein nuclear factor-high endothelial venule HEV (NF-HEV), 
subsequently characterised as IL-33380. Accordingly, nuclear localisation of IL-33 
was predominantly detected in endothelial cells387,389. Furthermore, in an 
inflammatory setting, IL-33 mRNA was detected at higher levels in murine lung 
in allergic airways inflammation (AAI) model397. However, the presence of IL-33 
protein in the lungs at a cellular level and localisation within the expressing cell 
is unknown. 
The IL-33 receptor, ST2L is predominantly present on Th2, mast cells and 
macrophages and lung ST2 mRNA levels are increased in a murine allergic 
airways inflammation (AAI) model of asthma. Serum sST2 is also elevated 
following allergen challenge in AAI313. In humans, sST2 is being increasingly 
considered a biomarker with elevated levels shown to correlate in particular 
with acute myocardial infarction and left ventricular dysfunction 350,374. In 
asthma, increased levels of sST2 in the serum have been reported and correlate 
with severity of acute asthma exacerbations in humans, 354,355 but the potential 
of sST2 as a biomarker in this condition has not been fully explored.  
Elevated serum levels of IL-33 have been reported in allergic patients, 
specifically with a form of allergic rhinitis 428 but its presence is unknown in 
asthmatic patients. Elevated mediators in the sputum can correlate with disease 
severity 8 but the presence of sST2 or IL-33 in sputum samples of asthmatic 
patients is unknown. Furthermore as many asthmatic patients are being 
concurrently treated with anti-inflammatory corticosteroids (CS), which can 
alter concentrations of these markers 457, the potential effect of CS on sST2 and 
IL-33 in the serum and sputum is also unknown. 
The presence and distribution of ST2 and IL-33 in murine lung, including whether 
IL-33 and sST2 are directly released from the cell in mice as well as humans, will 
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now be considered. At the outset of this work, there were few commercially 
available reagents for IL-33.  The aim of this chapter is to elucidate murine 
protein expression by developing immunohistochemical and sandwich ELISA 
techniques.  Furthermore using human asthmatic sputum and plasma samples, 
the presence of sST2 and IL-33 concentrations in humans, and the effect of CS, 
will be assessed. 
3.2 Characterisation of IL-33 and ST2 expression in 
murine lungs determined by immunohistochemistry  
As published data to date has shown potent effects of exogenous recombinant IL-
33293, it was important to establish the presence of endogenous IL-33 protein in 
murine lung (in addition to endogenous mRNA expression) and characterise the 
expressing cell type.  
3.2.1 Pulmonary murine IL-33 expression  
Following on from the finding of IL-33 mRNA in murine lungs in a model of       
AAI 397, using lungs from WT PBS- and OVA-treated BALB/c mice in a 12 day AAI 
model, immunohistochemical staining was performed to assess the presence of 
IL-33. Heart and lung sections were processed en bloc in formalin and then 
paraffin embedded. At the time of performing these analyses, only one 
commercial antibody reagent for IL-33 was available. This anti-IL-33 [Nessy-1] 
(Axxora) is a mouse antibody reactive with both mouse and human tissues. A 
biotinylated secondary antibody and ABC/DAB system was used to visualise the 
binding product. Omission of primary antibody was used as a control. Despite 
optimisation strategies, no specific binding was seen using paraffin embedded 
lungs. Therefore, as an alternative, some lungs were re-inflated with OCT 
freezing medium, immediately snap frozen in liquid nitrogen and stored at -80°C 
until analysis (see chapter 2).  Figure 3.1 (A-D) shows the results of anti-IL-33 in 
frozen sections of murine lung. The architecture is not well preserved in frozen 
specimens but specific IL-33 staining appears to be present in: (1) lung 
parenchymal cells that lie around the alveolus; (2) the nucleus of cells that 
morphologically appear to be macrophages (Figure 3.1A and C).  As expected, 
endothelial vessels showed strong IL-33 expression (Figure 3.1B). To further 
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investigate that the other IL-33 expressing cell was the macrophage, double-
colour staining with anti-F4/80 antibody was attempted. In contrast to the IL-33 
antibody, anti-F4/80 staining of macrophages was only determined in the 
paraffin but not frozen section, therefore double staining to confirm 
macrophage nuclear IL-33 was not possible. However, the results from the 
paraffin sections appear to show that the corresponding cells morphologically 
are macrophages (Figure 3.1E).  
Later, with the availability of alternative commercial antibodies, IL-33 was 
identified in the paraffin-embedded tissues using a R&D rat anti-mouse IL-33 
antibody with pressurised citrated antigen retrieval (Figure 1 F-I). As well as 
expression as noted in the Nessy-1 samples, another cell population, consistent 
with epithelial cells, show lighter IL-33 staining located in the cytoplasm.  
Interestingly, although IL-33 expression was seen in the OVA-treated mice, 
similar expression was seen in the PBS mice indicating no obvious induction of IL-
33 expression. However, it can be concluded that IL-33 is present and potentially 
has a role in AAI. 
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Figure 3.1:  Mouse lung IL-33 Immunohistochemistry 
See over for legend 
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Figure 3.1:  Mouse lung IL-33 Immunohistochemistry 
(A-D) IL-33 expression using primary Nessy-1 IL-33 antibody on frozen sections of lung.  (A-C) 
OVA- and D) PBS- treated mice . A) x10 magnification (insert is isotype control x10). Lung 
macrophages (B), and vessel with endothelial cells (C). B) & C) are magnified images from A) at 
x40. D) x40 magnification (insert is isotype control x10). E) Macrophage F4/80 antibody staining 
x40. Insert is isotype control x40 in OVA-treated mouse.  (F-I)IL-33 expression using primary R&D 
anti-mouse IL-33 antibody in paraffin sections.  F) PBS- and H) OVA- treated mice x10 with insert 
isotype x10. IL-33 expression as F) and H) with magnification x40 of section indicated by 
arrowheads.  G) and I)  nuclear macrophage and cytoplasmic epithelial IL-33 
staining.(Representative images shown of n=5-10). 
3.2.2 Pulmonary murine ST2 expression 
In terms of the IL-33 receptor ST2L, similar immunohistochemical methods to IL-
33 were used to determine the expression. The primary antibody anti-ST2 
however will bind to sST2 and ST2L, so any protein expression identified could 
represent either isoform.  Three ST2 antibodies (goat anti-mouse, Santa Cruz, 
rat anti-mouse, R&D and rat anti-mouse, MD Biosciences) were tested and 
titrated with optimal results using a rat anti-mouse anti-ST2 (MD Biosciences). 
This staining was again optimally performed in the paraffin sections and shown 
in Figure 3.2. ST2 expression was identified in epithelial cells and scattered 
parenchymal cell nuclei. In addition, there was some lighter staining in 
epithelial cell cytoplasm. Results shown are from naïve mice, as no significant 
difference was noted in OVA-treated mice specimens analysed (data not shown). 
Specific staining was confirmed with positive staining in cardiac myocytes (with 
thanks to Dr Ashley Miller for providing the cardiac sections) and no expression 
was identified in ST2-/- mice confirming specificity.  
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Figure 3.2:  Murine lung ST2 immunohistochemistry 
ST2 immunohistochemistry on paraffin sections in naïve WT mouse lung stained with rat anti-
mouse ST2L in A) x10 magnification and C) x40 demonstrating scattered parenchymal cell and 
epithelial cell nuclear staining with lighter epithelial cell cytoplasmic staining. B) and D) represent 
isotype control of A) and C).  E) Positive control representing ST2 positive cardiac myocytes in 
heart muscle and F) isotype control both x40 in WT mice. G) Negative control demonstrating no 
signal in ST2-/- mouse lungs and isotype control H) both x 40. (Representative images of  n=2 for 
cardiac myocytes otherwise n=5-10). 
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3.2.3 Levels of IL-33 in mice as determined by ELISA 
Following the manufacture of a biotinylated antibody for the Nessy-1 IL-33 
antibody (Axxora UK, Nessy-1, biotin conjugated) a working direct enzyme-linked 
immunosorbent assay (ELISA) for the detection of IL-33 in murine biological 
samples related to this work was developed; including bronchoalveolar lavage 
(BAL), digested lung and serum available from a range of animal models.  In pilot 
work (data not shown), a monoclonal anti-IL-33 antibody (R&D systems UK 
catalogue MAB 3626) was chosen as the capture antibody that was the most 
sensitive in combination with the secondary biotinylated anti-IL-33 antibody.  
The optimal diluent identified was 0.1M NaHCO3 coating buffer for the capture 
antibody. In house as well as newly available commercial recombinant murine IL-
33 (R&D 3626-ML-010) were tested as ELISA standards.  Figure 3.3 shows 
optimisation of the antibody pair, choosing the concentration of reagent that 
minimises use but without losing significant IL-33 detection.   The minimum 
detectable concentration was 200 pg/ml.  
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  R&D Capture AB concentration μg/ml 
     OD 
 
 32 16 8 4 2 1 0.5 
16 0.168 0.135 0.097 0.074 0.054 0.047 0.053 
8 0.105 0.084 0.073 0.046 0.035 0.029 0.030 
4 0.079 0.069 0.052 0.034 0.026 0.020 0.023 
2 0.057 0067 0.041 0.024 0.021 0.022 0.018 
1 0.062 0.060 0.035 0.020 0.016 0.014 0.016 
0.5 0.045 0.042 0.033 0.018 0.016 0.023 0.021 
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Figure 3.3: IL-33 ELISA optimisation 
A) Chequerboard assay to optimise concentrations of capture and detection antibodies. OD=optical 
density. B) Standard curve using rmIL-33 standard (R&D) using concentrations 16 μg/ml capture 
antibody and 4 μg/ml for detection antibody. 
Following this, the presence of IL-33 in samples generated from a murine AAI 
model was assessed. Figure 3.4 shows lower levels of IL-33 were detected in the 
BAL and serum of the OVA-treated group in comparison to PBS-treated controls. 
Soluble ST2 levels were not measured but would have been useful to determine 
if high levels of sST2 could sequester IL-33 making it unavailable for detection in 
the ELISA.  These experiments were repeated in ST2-/- mice which lack all 
isoforms of ST2 (Figure 4). Concentrations of IL-33 were lower in PBS-treated 
ST2-/- mice compared to the WT PBS-treated group. In response to allergen, ST2-
/- mice had elevated serum IL-33 levels compared to the PBS-treated group 
which could theoretically be explained by lack of sST2 to sequester IL-33 but this 
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could not be confirmed.  No detectable IL-33 was measured in digested 
tracheas, oesophagus, spleens or BAL (data not shown).  
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Figure 3.4: Serum levels of IL-33 effects of allergic airways inflammation in mice  
IL-33 serum concentrations following a 14 day model of AAI in WT BALB/c mice A) and 28 day 
model of AAI in BALB/c WT and ST2-/- mice B). n=4-5 per groups. Data shown are mean ± SEM. * 
p<0.05, *** p <0.01, *** p <0.001.   
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3.3 Characterisation of sST2 and IL-33 in smoking 
asthmatics 
One of the challenges of modern medicine is having the ability to direct the 
most suitable treatments towards the most appropriate patients.  The 
measurement of biomarkers, which are proteins in blood or bodily fluids present 
in disease, can help with prognosis, assessment of disease progress, directing 
treatment and monitoring treatment effect.  Soluble ST2 is one such potential 
biomarker, predominantly studied in myocardial infarction and heart failure 374.   
Two studies measuring serum sST2 in patients with asthma have shown an 
increase in the levels during acute exacerbations 352,355. One study performed in 
adults, demonstrated this increase correlated with the severity of exacerbation 
by negatively correlating with peak expiratory flow (%PEF) and positively with 
partial pressure carbon dioxide in the blood (PaC02) 355. A second study in 
children however did not demonstrate a correlation with severity 352.  Asthmatics 
who smoke have an altered cytokine profile and relative CS sensitivity 458. It is 
unknown what effect smoking, if any, has on sST2/IL-33.  Local research interest 
and expertise in the area of smoking and asthma led to the development of a 
sub-study to investigate concentrations of sST2 and IL-33 in this patient 
population; and assess the effects of smoking and CS on these levels.   
3.3.1 Study design 
The study design and methods are more fully described in Chapter 2 (section 
2.5). Three groups of adult patients with stable asthma were recruited: current 
smokers, ex-smokers or never smokers. Patients were recruited from hospital 
outpatient clinics and general practice. Fifty-three patients with asthma agreed 
to participate. Eligibility for the study required demonstration of reversible 
airflow obstruction (FEV1 response to β2 agonist ≥12 %, PEF lability or a positive 
methacholine challenge test). Patients took two weeks of oral dexamethasone (6 
mg/1.74 m2 equivalent to 40 mg/day prednisolone. Induced sputum and plasma 
were obtained before and after oral dexamethasone treatment.  Medication 
history including ICS dose and compliance was recorded as well as asthma 
control questionnaire (ACQ) scores were determined at each visit. Sputum 
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differential cell counts were performed by a whole sputum sample method and 
sputum supernatants collected and stored at -80°C until further analysis459. 
Plasma was collected from processed heparinised blood samples stored at -80°C 
until further analysis. 
3.3.2 Patient demographics 
Fifty-three patients participated with 22 smokers, 10 ex-smokers and 21 never 
smokers with asthma. The patients were reasonably well matched although the 
smoker and ex-smoker groups were prescribed higher daily ICS doses and had 
higher ACQ scores. Table 3.1 summarises the baseline demographics of the 
participants. 
  
Smokers with 
asthma 
(n=22) 
Ex-smokers with 
asthma 
(n=10) 
Never Smokers 
with asthma 
(n=21) 
Age  
(yrs) 
46.6 
(6.7) 
49.8 
(9.0) 
42.5 
(10.0) 
Sex (F:M) 12:10 5:5 11:10 
Asthma Duration 
(yrs) 
22.1 
(15.9) 
24.6 
(15.9) 
28.6 
(15.0) 
Pack years 27.6 (15.7) 
28.5 
(15.9) 0 
Inhaled steroid 
(mcg/day) 
beclomethasone 
equivalent 
   1046 * 
(611) 
1280 * 
(551) 
679 
(419) 
ACQ Score 
(0 to 6)   
   2.2 * 
(0.9) 
2.3 
(0.7) 
1.5 
(0.8) 
Pre BD FEV1  
(% predicted) 
73.6 
(18.5) 
79.7 
(24.1) 
73.3 
(15.3) 
Pre BD PEF  
(% predicted) 
81.7 
(20.8) 
85.4 
(24.7) 
85.8 
(19.1) 
Sputum esonophils 
(%) median (IQR) 0.4 (0,10) 1.0 (0.1,5) 0.3 (0,2) 
Sputum neutrophils 
(%) median (IQR) 34 (24,56) 37 (22,63) 24 (10.5,41) 
Table 3.1: Baseline study participant demographics 
Data presented as mean (SD). *; p<0.05. p values are compared to non-smokers.  Abbreviations: 
ACQ; asthma control questionnaire, BD; bronchodilator, mcg; microgram, FEV1; forced expiratory 
volume in 1 second, IQR; interquartile range, PEF; peak expiratory flow.   
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3.3.3 Levels of plasma sST2 are similar between groups 
Human plasma samples were defrosted and sST2 concentration quantified using 
a human IL-1 R4/ST2 ELISA (R&D Systems, catalogue DY523). The lower limit of 
detection was 32 pg/ml 374. All measurements were performed in parallel in one 
experimental run with sample duplicates. No significant differences were seen in 
baseline pre-oral corticosteroid (pre-steroid) sST2 levels between groups (never 
smokers v ex-smokers p=0.648; never smokers v smokers p=0.120; ex-smokers v 
smokers p=0.056) (Figure 3.5). Baseline sST2 levels did not correlate with either 
lung function, FEV1 or PEF, or symptoms with ACQ score (data not shown). 
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Figure 3.5: Baseline plasma sST2 in never smokers, ex- smokers and smokers with asthma; 
between group comparisons 
Levels of sST2 (pg/ml) were determined in the plasma by ELISA. Data are presented as individual 
patient measurements. No significant differences between group medians using Mann Whitney U 
test with p<0.05 considered significant.  
 
Normal controls were not included in the primary study design, as the main aim       
was to compare the effects of smoking on cytokine profiles in asthmatics. 
Therefore, in a separate pilot study comparison to ascertain if any difference 
seen could be explained by having asthma, 14 individuals without asthma 
‘normals’ were recruited for baseline sST2 plasma analysis. The only baseline 
demographic available on the ‘normal’ subjects is age with a range of 25-48 
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years. Normals did not have asthma and were never smokers.  No differences 
were seen between median sST2 in normals compared to: never smokers, 
p=0.96; ex-smokers 0.6318 or; smokers p=0.0929 (data not shown). A trend of 
the closest association with never smokers with asthma and biggest difference 
with smokers with asthma was apparent but in context of exploratory data, 
likely limited by sample size, could not be confirmed.  
3.3.4 Plasma sST2 levels are elevated following steroid treatment 
Following a 2 week course of oral CS treatment, plasma sST2 was re-assessed. 
The difference between sST2 pre- and post-steroid within each group of patients 
was statistically significant (Figure 3.6).  
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Figure 3.6: sST2 post-dexamethasone treatment; within-group comparison 
Levels of sST2 (pg/ml) were determined in the plasma by ELISA. Single data points in each group 
are displayed. Paired t-test (Wilcoxon signed rank test) was performed between pre-steroid and 
post-steroid within each group. p<0.05 was considered significant. 
There was no significant difference in post-steroid sST2 levels between the 
groups (t-test of difference; never smoker v ex-smoker p=0.169, never smoker v 
smoker p=0.597 and ex-smoker v smoker p=0.122). Furthermore, no significant 
difference was identified in the magnitude of group pre- to post-steroid 
difference between groups  (Mann-Whitney test of differences; never smoker v 
ex-smoker p=0.2724, never smoker v smoker p=0.6923 and ex-smoker v smoker 
p=0.0656) (Figure 3.7).  Correlations with increased plasma ST2 levels were 
determined in each group for post-steroid sST2 as well as difference in sST2 pre- 
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and post-steroid. No correlations between sST2 and FEV1 change in FEV1, PEF or 
ACQ scores was found in any of the groups. The only correlation identified with 
respect to difference in sST2 was in the never smoker groups with ACQ score 
(log-transformed sST2, Pearson’s correlation r=0.731, p=0.007). Two never 
smoking patients failed to provide follow-up samples therefore were excluded 
from post-steroid or difference in sST2 analysis with a new group size n=19. 
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Figure 3.7: Difference between pre- and post-steroid sST2; between group comparisons 
Difference in pre- and post-steroid levels of sST2 was calculated for each individual and 
differences plotted for each group according to smoking status. Mann-Whitney U test was 
performed on the median difference (open cross circle) between groups. No significant differences 
were shown. Significance was determined if p<0.05.  
 
3.3.5 Plasma IL-33 levels are unaffected by smoking status or 
steroid treatment 
Following the measurement of sST2 levels, the levels of IL-33 in plasma were 
determined. At the point of experiment design, only limited data existed 
demonstrating IL-33 levels could be measured in biological samples. Two 
published reports showed presence of IL-33 in atopic patients with a form of 
allergic rhinitis 428 and in atopic individuals with anaphylaxis 460 (retracted 2012).  
The former study used an in-house ELISA constructed from locally manufactured 
antibodies and the latter using commercial IL-33 ELISA (Centaur or Genway 
biotech, San Diego, USA catalogue no 40-288-23146) which was therefore chosen 
for use in this work. The manufacturer minimum detectable IL-33 is 0.7ng/ml. 
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Recovery was determined by spiking recombinant IL-33 into normal plasma, 
serum and cell culture media (not shown). 
Previously processed specimens stored at -80°C were defrosted as before and Il-
33 levels measured in one experimental run. Table 2 summaries the baseline IL-
33 levels. There was a wide range of measured IL-33 in all patients but the 
majority fell below the manufacturer minimal detectable level (0.7 ng/ml). 
Three, 1 and 2 patients had plasma levels above 0.7 ng/ml in the neversmoking, 
ex-smoking and smoking groups respectively. Baseline IL-33 was also measured 
on the group of 14 normals as previously described. No differences were seen 
between the average values of these individuals and study participants (Table 
3.2). 
 Median IL-33 
(pg/ml) 
IQ range (pg/ml) 
 
Maximum IL-33 
(pg/ml) 
Normal never 
smoker (n=14) 
48 0-108 982 
Never-smoker 
with asthma 
(n=21) 
40 0-257 2635 
Ex-smoker with 
asthma (n=10) 
45 5-312 1508 
Smoker with 
asthma (n=22) 
28.3 0-316 1116 
Table 3.2: Baseline plasma IL-33 concentration in stable asthmatics 
 
 
Comparison of baseline pre-steroid IL-33 levels did not show any difference 
between the group medians (Figure 3.7A). Again, following steroid treatment, no 
difference between median levels in each of the groups was seen (Figure 3.7). 
Within-group comparison did not attribute any change in IL-33 to steroid 
treatment (non-smokers p=0.191; ex-smokers p=0.793; smokers p=0.808). 
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Figure 3.8 Plasma IL-33 pre- and post-steroid in all groups 
IL-33 concentrations (pg/ml) as measured by ELISA in non-smokers, ex-smoker and smokers pre- 
and post- steroid treatment. No significant differences were seen in baseline or post-steroid median 
group levels assessed by Mann-Whitney U test.  Within-group comparison using paired t test did 
not find any difference in levels related to steroid treatment. p <0.05 was considered significant. 
There was no difference between the groups comparing the ratio of baseline ST2 
to IL-33 or post-dexamethasone ST2 to IL-33 levels (not shown).  
3.3.6 Levels of sST2 and IL-33 in sputum 
The same ELISA kits and protocols as described for plasma samples were used to 
go on to measure the levels of sST2 and IL-33 in the induced sputum specimens.  
Levels of sST2 in the sputum of all participants were very low, around 15 pg/ml 
and no change was identified with steroid treatment (data not shown). 
Furthermore, there was no detectable IL-33 in the sputum pre- or post- steroid 
so no further assessments could be performed (data not shown).  
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3.4 Conclusions 
This set of experiments aimed to examine the expression of ST2 and IL-33 in 
murine and human samples. IL-33 protein was detected in murine lungs by 
immunohistochemisty. Endothelial cell IL-33 expression in murine lungs is 
consistent with other reports of vascular expression 387,389. New findings 
presented here show the cellular distribution appears to be strongly expressed in 
nucleus of parenchymal inflammatory cells, most likely macrophages, and in the 
cytoplasm of epithelial cells. As the antigenic content is generally better 
preserved in snap frozen sections, the finding that the Nessy-1 IL-33 antibody 
was not effective in paraffin sections is consistent with current understanding 
461. The R&D antibody subsequently worked well in paraffin sections with 
enhanced antigen retrieval techniques. The R&D antibody also avoided 
specificity problems caused by using the Nessy-1 mouse antibody on mouse tissue 
as this antibody was raised in rat. As the morphology is improved by using this 
methodology, enhanced definition of IL-33 staining was appreciated. It should be 
noted that successful use of anti-IL-33 Nessy-1 in paraffin samples has now been 
described by others in mice 389 and humans 399. However, using specimens 
processing techniques in our laboratory, optimal antibody efficiency in frozen 
and paraffin sections was achieved with Nessy-1 and R&D antibodies 
respectively.  
IL-33 mRNA is expressed predominantly in non-haematopoietic cells and in 
restricted inflammatory cell populations including macrophages 293. However, 
the finding of strong expression of IL-33 in a nuclear location in murine 
parenchymal macrophages is novel and of interest as it suggests important 
function in these cells in IL-33 dependent effects in the lung. IL-33 has been now 
shown to bind NF-κB directly therefore reducing its ability to turn on gene 
transcription suggesting a predominantly regulatory role in these cells 418. 
Recently, very similar results to these presented in this thesis have been 
published, showing IL-33 expression in inflammatory, epithelial and endothelial 
cells in OVA treated mice with identical paraffin section methods 462. Epithelial 
cell IL-33 expression as determined by immunofluorescence and anti-IL-33 
antibody (R&D), has been confirmed in AAI and control mice 463. Although the 
form of IL-33 detected in cytoplasm of epithelial cells is unclear, its presence is 
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in keeping with a translated protein available to be released either by necrosis 
or secretion. As extracellular release from epithelial cells has been shown, IL-33 
is now considered in the category of epithelial derived cytokine akin to IL-25 and 
TSLP 186,246. In vitro, co-culture of epithelial cells with a gastrointestinal 
nematode leads to necrosis and release of full-length IL-33 464. In the lungs, 
extracellular IL-33 is detected in BAL following influenza infection in a murine 
model 465 and 2 hours following flagellin challenge 466. Both findings would be in 
keeping with epithelial cell damage; IL-33 was also detected in vitro in the 
supernatant from the influenza infected murine respiratory epithelial cells (MLE-
15 cell line) 465. Secretion of full-length nuclear IL-33 from intact undamaged 
bronchial epithelial cells (NHBE) is also described, induced by a fungal extract 
Alternaria, and dependent on intracellular calcium concentration by ATP 467. IL-
33 secretion from human AEC is enhanced by IL-1β, TNFα and IFNγ 468. IL-33 is 
released from primary cells in tracheal murine cells and primary human NBEC 
cells in response to HDM allergen 469.  
Human tissue was not examined here for IL-33 expression but its presence has 
now been clearly demonstrated by others. In asthma, lung IL-33 mRNA was 
elevated in endobronchial biopsies of moderate and severe asthmatics but not in 
those with mild disease, compared to healthy controls. In terms of cellular 
expression, the same investigators demonstrated IL-33 in epithelial and 
endothelial cells in both the healthy and asthmatic samples, similar to murine 
expression results presented here470, but they also identified expression in 
airway smooth muscle (ASM) cells, a feature only apparent in the asthmatic 
patients 399. ASM changes in murine models of AAI are often not a reproducible 
feature of human asthma and hence these changes may not been seen in 
samples used here134. Epithelial cell staining was found in the nucleus along with 
the cytoplasm and increased staining intensity was measured in subjects with 
severe asthma compared to healthy controls but not compared to other 
asthmatics. The human studies did not describe in IL-33 positivity in 
parenchymal inflammatory cells or macrophages;  this could be a finding 
restricted to murine lung.   
This demonstration of IL-33 expression in murine lung is consistent with the 
finding of IL-33 expression at other comparable mucosal surfaces such as the gut 
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and skin in humans. In psoriatic skin biopsies, IL-33 immunohistochemistry, also 
using anti-IL-33 Nessy-1 in frozen sections, was associated with blood vessels and 
inflammatory cells, and more strongly in affected than unaffected skin sites 445. 
IL-33 and ST2 expression is also seen in the gut mucosa. IL-33 was detected in 
the nucleus and cytoplasm of the intestinal epithelial cell, the lamina propia 
mononuclear cells of normal controls and in diseased mucosa with varying 
intensity with the highest expression was in ulcerative colitis biopsies 406. This 
study in the gut utilised an anti-human IL-33 IgG with results similar to those 
described in murine paraffin staining results presented in this chapter. 
Expression clearly does not assume presence of inflammation as nuclear IL-33 
can act as a transcriptional regulator. Further studies show IL-33 expression is 
present in converged endothelial cells but lost in those which are dividing 
including tumour cells, suggests control of endothelial cell activation 388. 
Whether nuclear epithelial IL-33 plays some role in regulating division in the 
murine lung is unclear but a further study in the gut identifies IL-33 
redistribution in intestinal epithelial cells; from cytoplasmic expression in 
healthy tissue to strong nuclear expression in diseased tissue suggests this is 
possible471.  
Results here show pulmonary ST2 protein staining was predominantly identified 
in unstimulated epithelial cells. Previously, ST2L mRNA expression was first 
noted to be weakly inducible in a murine mammary epithelial cell line whereas 
sST2 was expressed constitutively at low levels but strongly inducible 318. A 
subsequent study found inducible sST2 in alveolar (A549) and bronchial (NHBE) 
cells, with no baseline ST2L expression in either cell type identified but it was 
weakly inducible in the NHBEs 306. Another study showed sST2 mRNA expression 
is inducible in the A549 cells by IL-1β plus IL-4; however, it was not released 
extracellularly as determined by ELISA 314.  Data presented here shows 
constitutive ST2 expression however the isoform cannot be determined; 
experiments in Chapter 5 will further examine ST2L expression in epithelial 
cells. Since the presented experiments were performed, further published 
studies show sST2 release, with low level sST2 and ST2L expression in epithelial 
cells during growth phase 320 or sST2 expression in primary alveolar and bronchial 
epithelial cells with high sST2 production in the alveolar cells 316. In comparison, 
ST2 is also present at other mucosal epithelial surfaces. In human colon biopsies, 
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ST2 is expressed in epithelial cells but in contrast to IL-33 expression it is 
specifically decreased in patients with ulcerative colitis. The isoform identified 
was ST2L by mRNA, which could indicate ST2L down regulation in the presence 
of chronic disease; both circulating IL-33 and sST2 levels were elevated in these 
patients suggesting this is the case 406. Another similar study shows similar 
dysregulated sST2/ST2L expression in the human gut but this not seen 
consistently in all the examined bowel and in this case was predominantly 
explained by increased sST2 production 471. ST2 is also described in parenchymal 
inflammatory cells, most likely macrophages, in keeping with these known ST2 
expressing cells 306. 
To confirm these findings presented here, follow up work would include double 
staining with epithelial cell markers (Cytokeratin) and as well as F4/80 with IL-
33 in the paraffin sections. Furthermore, ST2 and IL-33 co-staining would be 
valuable and this work has already been completed in collaboration with another 
investigator in our laboratory (data not presented here) 472. Alternatively, FACS 
using individual cell expression markers combined with ST2 and IL-33 antibodies, 
including intracellular staining techniques, can now be undertaken. 
Unexpectedly, levels of IL-33 measured in sera of mice with AAI were lower than 
in the control mice. The possibility that sST2 sequestered IL-33, thus making it 
undetectable is supported by a rise in IL-33 in sera of OVA-treated ST2-/- mice 
397. However, no corresponding sST2 measurements were performed here to 
confirm these findings, due to the lack of an available ELISA. Furthermore, as 
ST2-/- mice can have diminished inflammatory responses in this OVA-model of AAI 
compared to control WT mice (see chapter 6) this could affect interpretation of 
these results. However the experiment examined here showed no significant 
differences in airway inflammation between WT and ST2-/- mice following a long 
(28 day) model. A further significant limitation of this data is that it was 
obtained from an ELISA system developed in house and should be repeated with 
one of the multiple mIL-33 kits now available commercially. Murine IL-33 
detection by ELISA has been demonstrated in multiple cell cultures and systems 
464,467-469,473 although the ELISA used is not stated nor absolute values measured 
in the former and using duoset R&D in the later; the presence in serum was not 
reported. IL-33 was detected in digested lung tissue 24 hours and 7 days 
following final AAI challenge in C57BL/6 and BALB/c mice respectively 282. This 
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could be explained by the view that IL-33 peaks in the lung at the peak of 
inflammation in C57BL/6 mice but that in BALB/c mice IL-33 is associated with 
persisting AHR demonstrated in these mice 1 week following challenge. IL-33 
detection was not reported in the serum but these findings suggest IL-33 is 
elevated in AAI, in contrast to a reduction demonstrated in data presented here. 
Despite a different compartment analysed and although sST2 was not measured 
it could be assumed that if sST2 were to be sequestering IL-33, it could also be 
doing so in these published studies. Observational findings by the thesis author 
are consistent with the report of higher levels of IL-33 in C57BL/6 mice 24 hours 
following airway challenge, and suggest the measurement interval for correct 
peak levels interpretation in BALB/c might need to be extended.  A further study 
in C57BL/6 mice is in agreement with this finding showing increased lung IL-33 
levels in OVA treated mice compared to control mice with a corresponding trend 
to increased sST2 levels. A parallel experiment using a house dust mite (HDM) 
allergen protocol showed increased IL-33 and sST2 levels in the treated group 
compared to controls 462. 
Corticosteroids are effective in reducing eosinophilic inflammation, a range of 
inflammatory cytokines and symptoms in asthmatics. Not all patients have these 
beneficial effects and those who smoke cigarettes are recognised as a group that 
modulate the response to CS in asthma 474. Therefore as part of a wider study 
investigating altered plasma and sputum cytokine profiles in smokers compared 
to never smokers with asthma, the levels of sST2 and IL-33 in plasma were 
determined to investigate if any associations exist. 
Data presented here from a clinical study is exploratory and therefore 
limitations apply. No primary endpoints were identified and numbers recruited 
were not powered to necessarily detect significant differences between groups; 
the expected difference was unknown. Full age, sex and smoking matched 
controls were not recruited and the small number of controls used cannot be 
considered an adequate control group. Plasma and sputum levels of sST2 and IL-
33 were measured in this study.  Numerous previous studies of sST2 levels have 
reported measurements predominantly in serum. However, analysis in plasma 
samples has also been reported and furthermore, long term stability of up to 18 
months in plasma samples stored at -80°C was shown validating the results 
presented here 475. Personal, unpublished observations based on performing 
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ELISA in serum and plasma samples from renal dialysis, post-MI and pulmonary 
hypertension patient cohorts by the author, detect no appreciable difficulties or 
discrepancies in performing the sST2 assay on plasma or serum samples. For IL-
33, plasma detection has been identified by others 476. 
sST2 and IL-33 levels were low or undetectable in the induced sputum samples. 
Cytokines have been detected in induced sputum and correlate with clinical 
features 38,51,60. However, there are criticisms of measuring cytokines in sputum 
supernatant, predominantly due to sputum processing technique, in particular 
the use of the reducing mucolytic agent dithiothreitol (DTT). Use of DTT results 
in the reduced detectable concentrations of some cytokines and the potential 
effect on this on sST2 and IL-33 levels was unknown 477.  Varieties of laborious 
sputum processing techniques can be employed and as such a lack of consistency 
in published data exists. New standardised filters and kits could potentially 
improve consistency if widely employed 478. The only report of sST2 and IL-33 
detectable in sputum was recently published and identifies their presence in 
induced sputum from children processed with the DTT technique suggesting this 
processing technique may not impede detection. The ELISA used were the 
BioPorto Diagnostic, Denmark and GenWay biotech, California, USA respectively. 
These investigators looked at 37 patients with mild to moderate asthma and 
found both sST2 and IL-33 in sputum samples were higher in asthmatics than 
healthy controls 479. These results are not in keeping with the findings in results 
presented here which also measured activity in non-severe asthmatics. Despite 
the lack of normal controls measured in our data, no appreciable levels were 
seen in the asthmatics assessed. This difference could be explained by technical 
issues including dilution or that there are indeed no appreciable levels in this 
adult cohort.  
Since the construction of an ELISA to determine human sST2 protein, levels in 
the sera have been assessed in many conditions (chapter 1.2.4.1) 354. When 
considering sST2 in plasma levels in this study, the main finding of the data 
presented here is that despite small patient numbers, there was a clear 
association of increased sST2 levels with oral CS treatment.  Smoking does not 
appear to have a significant effect of sST2 at baseline or influence this CS-
related increase. Based on this presented data, sST2 levels do not correlate to 
clinical parameters measured therefore sST2 is unlikely to be useful in reflecting 
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disease process or use as a biomarker in this cohort of stable moderate patients 
or reflect altered cytokine profile of smoking status. 
It must be noted that the patients taking oral CS in this study are not steroid 
naïve. All patients were already taking inhaled CS and this was not 100% 
matched between the groups with the smokers having the highest inhaled CS 
usage. No statistical correction was employed for this in data interpretation. 
Smokers have higher symptom scores 480 and data presented here is in agreement 
with the ACQ scores higher in smokers and ex-smokers compared to non-smokers 
which explains the higher steroid usage amongst this group. Despite this 
however, as no inter-group differences were measured and an increased sST2 
response to oral CS steroid was seen in all groups, this is unlikely to affect the 
results presented. Furthermore the smokers with higher inhaled CS had a trend 
to lowest baseline sST2 compared to other groups and normal controls and so the 
response to oral CS was inversely related to this association and strongest in the 
smokers, thus it is unlikely to have been influenced by inhaled CS dose.  
It is not clear what the mechanistic cause is for the association of CS with raised 
sST2 levels.  Although many studies have demonstrated sST2 correlating with 
clinical measures as a biomarker, less is clear about the direct role for sST2 in 
pathogenesis.  Soluble ST2 has been shown to be directly released by cells 
undergoing biomechanical stress in in vitro models 394.  Clinically, diastolic load 
appears to modulate ST2 production where patients with isolated diastolic heart 
failure (elevated left ventricular end diastolic pressure (LV EDP)) and normal LV 
systolic function with raised sST2 compared to controls. However despite this, 
the source of the sST2 was apparently extra-myocardial 481. In patients with a 
form of nephrotic syndrome, sST2 was a marker of recurrence after 
transplantation but neither in vitro nor in vivo studies identified an actual role 
in kidney injury 482. The mechanism of action of sST2 is postulated to be via 
ability to bind to IL-33 preventing its binding to ST2L 397.   If in the asthmatics 
cohort sST2 is truly raised without a rise if IL-33 it could indicate a separate non-
IL-33 pathway stimulated by steroids; the cellular source of sST2 production in 
this circumstance is unclear.  
The association of sST2 and oral CS must be taken in account when we consider 
sST2 as a biomarker, particularly in the context of acute exacerbations of 
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asthma. Many patients may well have received oral CS in primary care before a 
measurement is taken in hospital. This could significantly alter the 
interpretation of sST2 in this context. Previous studies have shown sST2 levels 
are elevated in acute asthma 352,355. A study of 56 asthmatics showed a 
difference in levels of sST2 between moderate asthmatics with persistent 
symptoms compared to controls. No difference was seen in intermittent, mild or 
severe persistent cases compared to controls with 33% and 57% of moderate and 
severe groups respectively taking oral corticosteroids. Thirty of the patients had 
an exacerbation during the study and a strongly significant increase in sST2 was 
shown in these patients. It is possible therefore this elevation could reflect a 
response to an oral steroid ‘boost’. However, this would not necessarily explain 
other clinical correlations of %PEF and PaCO2 reflecting the severity of the 
exacerbation with sST2, as all patients would be expected to have a similar 
steroid boost 355.  In the second study performed in children, steroid doses are 
not recorded but sST2 was measured acutely and in convalescence, most likely 
after steroid treatment. In these patients levels of sST2 are lower in the 
convalescence period whilst patients are taking steroids which would be contrary 
to the findings in presented here 352. In the children where the presence of atopy 
was assessed sST2 levels were elevated but it is unclear if atopy or indeed age is 
relevant to the interpretation of sST2 levels 483. The data presented here would 
suggest caution in interpreting sST2 levels in asthma as concomitant steroid, 
which will be common in these patients, may influence these. Further 
information, particularly the effect of oral CS in normal controls would be 
essential as dissecting oral CS from an exacerbation effect will be difficult unless 
pre-steroid samples at time of exacerbation are assessed for clarification. 
Despite these considerations, sST2 in unselected group of dyspnoeic patients is 
accurate in predicting mortality up to 4 years where steroid use and proportion 
patients with HF or asthma/COPD is unknown 361. 
In the study presented, levels of IL-33 in the plasma were generally low with a 
small number of high IL-33 level individuals present in all groups. There was no 
association with smoking status or steroid treatment. Several explanations for 
these findings can be considered. Firstly, the concentrations measured are an 
accurate reflection of IL-33 in this cohort of patients. Considering these are 
stable, non-exacerbating and non-severe asthmatics, we could expect that levels 
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of inflammation would be low and thus as IL-33 is pro-inflammatory, could well 
be at low or undetectable levels. In comparison to IL-1, a member of the same 
super family as IL-33, levels of IL-1α are present in high amounts constitutively 
in epidermal surfaces but not readily measured in plasma or serum 484 and its 
antagonist IL-1Ra is produced in 10- to 100-fold excess 485. This suggests tight 
regulation of this potent cytokine and increased concentrations are likely to be 
present locally rather than systemically, an explanation that could also apply to 
IL-33.  
If sST2 only acts as a decoy receptor, the detection of levels of sST2 in the 
serum does suggest that IL-33 could be detectable. Therefore another 
explanation for the levels detected is that the detection system is not 
sufficiently sensitive at measuring these lower levels.  The ELISA kit used has an 
apparent high minimally detective IL-33 level of 700 pg/ml. Although it was 
possible to titrate this downwards in our laboratory to a detection level of 400-
500 pg/ml, this is not validated by the manufacturer. In comparison to the other 
published study available at the time, levels of IL-33 were measured in controls, 
infectious rhinitis and allergic rhinitis patients by an in-house ELISA with a lower 
limit of detection 30 pg/ml 428. The profile of measurements is similar in this 
published study to that presented here whereby the majority of patients had 
very low or undetectable levels and those with elevated levels were 
predominantly under 1000 pg/ml. Interestingly, in this population there was a 
similar picture of outliers with nanogram levels, the highest 19 ng/ml in a 
control group individual 428.  A subsequent publication using the same ELISA as in 
the data presented here, similarly found most patients had a concentration of 
IL-33 beneath the detection level in keeping findings here 486. The patients in 
that study had systemic lupus erythematosus (SLE) and although cannot be 
considered directly comparable, this cohort had elevated sST2 which correlated 
with disease activity. In this group, 3/70 patients and 2/28 age and sex matched 
controls had detectable IL-33 486.  
Following the undertaking of this work, several other manufacturers have 
developed improved human IL-33 ELISA kits and subsequently reports of these 
assays in detecting human IL-33 have been published. Using a R&D systems 
human IL-33 detection assay, studies have shown elevated serum IL-33 in 
patients following MI 487 and in those with acute phase SLE or RA patients using a 
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Peprotech kit 488. The lower level of detection in these assays are 23.4 pg/ml 
and 32 pg/ml respectively with participant measurements averaged 150-200 
pg/ml or 500 pg/ml in the later study. Beltran et al used an ELISA with a low 
limit of detection (5 pg/ml) and measured very low serum levels of IL-33, 
maximum 15pg/ml (Apotech range 0-500pg/ml) was detected with some 
differences determined between controls and those with CD and UC 471. These 
patients had IL-33 expression demonstrated in biopsies as discussed previously.  
Taken together with the results presented here, serum/plasma IL-33 is detected 
in patients with asthma but there is no correlation with disease. 
Recommendations for further work would be a controlled study including 
patients with increased severity with age-matched controls analysed by an assay 
system with lower detection limits. As IL-33 could be a poor marker of stable 
disease, exacerbating patients should be included. Also with increased numbers, 
more information about correlation of the sub-group of very high responders 
could be obtained. A subsequent small study has shown no change in serum IL-33 
between control and a group of asthmatics. However subgroup analysis shows 
characteristics associated with increased levels including IgE, current treatment 
and interestingly smoking 489. However, two just published studies show 
increased IL-33 in serum of asthmatics with Raeiszadeh et al recording mean 
concentrations of 79.10 ± 20.62 pg/ml IL-33 compared to controls 0.51 ± 0.26 in 
pg/ml (RayBiotech, Norcross, GA ,catalogue ELH-Il-33-001, sensitivity 2 
pg/ml)490. Guo et al measured higher levels using an alternate R&D assay kit 
with IL-33 903.62 ± 523.78 pg/ml and controls 158.1 ± 81.74 pg/ml (human IL-33 
quantikine ELISA kit R&D systems, sensitivity 1.65pg/ml, assay arrange 6.25-400 
pg/ml). Furthermore, this cohort included mild, moderate and severe asthmatics 
and IL-33 correlated with FEV1 and severity 491. Finally, another group of patients 
who have pulmonary eosinophilia but not asthma show increased IL-33 plasma 
levels compared to controls but correlation with disease activity was not clearly 
found 492.  
In conclusion, plasma sST2 is increased by oral CS in asthmatic patients. It is 
unclear if this finding can be extrapolated to other conditions or to control 
individuals. Although the mechanism for this is unclear, it requires further 
investigation and suggests important implications into interpreting sST2 in many 
other inflammatory conditions where use of CS is commonplace. Plasma IL-33 
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levels were not significantly elevated in this cohort of patients but limitations 
based on detection system and subsequent studies suggest serum/plasma IL-33 
may be related to asthma severity and this suggests value in further studies to 
determine its validity as a biomarker. Assessment of different forms of IL-33 
with asthma phenotypes could enhance clinical correlations. 
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4.1 Introduction and Aims 
Schmitz et al administered IL-33 intraperitoneally to C57BL/6 mice, which 
resulted in eosinophilic peritoneal inflammation and systemic Th2 or type-2 
inflammation 293. Investigations in our laboratory subsequently demonstrated 
that IL-33 given to BALB/c mice via the i.n. route resulted in a similar potent 
local Th2 response demonstrated by eosinophilia and cytokine release in the 
bronchoalveolar lavage fluid (Kewin PK, 2007, PhD thesis, University of 
Glasgow). 
ST2L, the cell bound receptor for IL-33, is present on Th2 cells and mast cells, 
both of which are influential cells in the pathogenesis of asthma304 317. In chapter 
3, evidence of additional cellular ST2 and IL-33 expression in the murine lung 
demonstrates cell types capable of producing and responding to IL-33. Taken 
together, this demonstrates that the ST2/IL-33 axis is present in the lung and 
therefore IL-33 can potentially modulate Th2 and innate cells, suggesting a role 
for this cytokine in asthma.  
Experiments in this chapter aim to extend the knowledge of the direct response 
to IL-33 in the lungs.  The hypothesis that IL-33 drives a potent Th2 type 
response in the lungs via the activation of ST2L, in particular on Th2 cells of the 
adaptive immune system which are essential for development of this phenotype, 
will be tested.   
Firstly, to further investigate this response of IL-33 in the airway, the cell types 
involved will be characterised and the dynamics of inflammatory mediators in 
this response examined in more detail. Secondly, using this information, the 
detailed contribution of select relevant mediators will be investigated. Thirdly, 
the role of the adaptive immune system using RAG-/- mice, which completely 
lack T and B cells, will be elucidated together with the assessment of whether 
IL-33 in absence of antigen can generate other key features of asthma, in 
particular AHR. 
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4.2 The effect of intranasal IL-33 on airways inflammation 
In the first instance, the aim was to confirm earlier laboratory findings that 
direct intranasal application of IL-33 to the murine airway resulted in a Th2 type 
inflammatory profile.  Schmitz et al used a dose of 4 μg human IL-33 
intraperitoneally but experiments in our laboratory using T cells in vitro (M 
Kurowska-Stolarska, unpublished data) demonstrate an approximately equivalent 
inflammatory response using 2 μg recombinant murine IL-33, which was 
generated in our laboratory 424.  Based on the Schmitz data and pilot 
experiments done by others in our group, an initial dosage schedule of 7 days 
was chosen. In some subsequent experiments, where recombinant murine IL-33 
was not available due to technical problems, recombinant human IL-33 (hIL-33) 
was used and this is acknowledged in the relevant figure legends.  
4.2.1 Intranasal IL-33 initiates cellular Th2 inflammation profile 
Recombinant murine IL-33 (2 μg) or phosphate buffered saline (PBS) was 
administered i.n. for 7 consecutive days to BALB/c mice.  Twenty four hours 
after the final dose, the mice were culled, bronchoalveolar fluid and lungs 
collected and cellular profile analysed. 
Administration of IL-33 to the airways resulted in a massive influx of cells 
measuring 18.32 x 105 cells/ml compared to 1.08 x 105 cells/ml in control mice 
given PBS (Figure 4.1A).  The numbers of all cell types increased but eosinophils 
were the dominant cellular population at 13.48 x 105 cells/ml (73.5%) (Figure 
4.1B).  Macrophages (19.1%) and neutrophils (7.3%) were the other most 
abundant immune cells identified. Th2 cytokines in the BAL were increased with 
IL-5 shown in Figure 4.1C. 
Similarly, histological examination of the lungs show extensive eosinophilic 
inflammation, predominantly in the peri-vascular but also peri-bronchial areas in 
the lungs treated with IL-33 (Figures 4.2A and 4.2B).  
These data confirm that IL-33 administered directly to the airways causes a 
potent Th2 innate inflammatory response. 
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Figure 4.1: Intranasal IL-33 increases BAL cell counts and IL-5 
BALB/c wildtype mice were given PBS or 2 μg IL-33 intranasally for 7 days. Mice were culled on 
day 8 and BAL collected. Total and differential BAL cell counts were performed and cytokine levels 
measured by ELISA. Data shown as mean +/- SEM, n=5-9 per group. *p<0.05 compared to the 
PBS group. Data representative of at least 3 experiments. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: Intranasal IL-33 induces eosinophilic lung inflammation            
Lungs from experiments in Figure 4.1 were fixed in formalin and stained with H&E. A) PBS treated 
mice x 40 magnification. (B-C) IL-33 treated mice with severe eosinophil peri-bronchial and peri-
vascular inflammation shown x10 magnification B) and x40 C) Representative histological sections 
shown (n=5-9 per group). 
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4.2.2 IL-33 increases Th2 cellular inflammation in the lungs 
BAL fluid sampling is thought to reflect the degree and type of inflammation 
within and around the bronchoalveolar lumen and deeper alveolar compartments 
80. Given the now well demonstrated findings of IL-33-driven cellular 
inflammation in the airway, the cellular contents of the lung were further 
investigated.  Simultaneous evaluation of multiple cell types in the lungs and 
BAL provides a fuller evaluation of the cellular infiltrate including cells 
embedded in the tissue, as well as opportunity to assess lung tissue cells.  
Furthermore, using the technique of lung digestion, a large number of cells are 
obtained in suspension which is necessary for FACS analysis, overcoming a 
limitation of low cell numbers of performing FACS analysis on BAL fluid, in 
particular on control or naïve mice. Lung digestion methods were based on 
published methods and using pilot studies modified for use in our laboratory 
493,494. These methods are more fully described in chapter 2. 
In order to characterise which cells are capable of responding to IL-33, the level 
of cell surface ST2 expression in whole lung preparations from control mice was 
ascertained.  The specificity of the chosen ST2 antibody (FITC-conjugated anti-
T1/ST2, DJ8, MD Biosciences, UK) was tested in pilot studies on high ST2 
expressing mast cell lines293 and has been previously used on mast cells495. 
Following digestion of the lungs, a single cell suspension was stained for ST2 or 
with isotype control. In the PBS treated lungs, 29.1 % ( ±1.9 %) cells expressed 
ST2 whilst in the IL-33 treatment group, the percentage rose significantly to 
55.4% (± 2.8%), indicating an influx of these cells or up regulation of ST2 on 
resident cells (Figure 4.3).  
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Figure 4.3: Intranasal IL-33 increases total lung cellular ST2 expression  
BALB/c WT mice were given PBS or 2 μg IL-33 intranasally for 7 days. Lungs from individual mice 
were isolated, digested and single cell suspensions obtained. Cells were gated following exclusion 
of dead cells (7-AAD). Cell surface was stained with FITC-ST2 or FITC-IgG antibodies.   Scatter 
dot plot of viable cells and histogram of ST2 expression in PBS A) and IL-33 B) treated mice.  Data 
shown representative of 3 separate experiments. n=5 per group. 
In mice, cellular expression of ST2 was originally described in fibroblasts, 
subsequently ST2L expression was demonstrated on Th2 lymphocytes 304, mast 
cells 305 and macrophages 306,346. 
In order to further study which cell subpopulations demonstrate ST2L expression 
in PBS treated lungs seen here and to assess to what extent these populations 
are influenced by IL-33 administration, cell specific surface antibody staining on 
the digested lung cell population was performed.  Figure 4.4 shows FACS cell 
surface staining for individual cell types plotted against ST2 expression.  F4/80 is 
a well characterised marker for mature mouse macrophages and using this, 
6.32% of the total population were identified as macrophages and 70% (4.43% 
overall population) of this group co-expressed ST2.  In mice treated with IL-33, 
29% 
55% 
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overall the macrophage population increased to 23.65%, 54% of which were 
ST2+ve (12.83% overall population).   
ST2 is a stable selective cell marker on CD4+Th2 cells but not CD4+Th1 cells 304. 
Approximately 10% of cells in PBS treated lungs expressed CD4 but unsurprisingly 
in non-inflamed lung, less than 1% co-expressed ST2. In IL-33-treated lungs, the 
proportion of CD4+ST2+ cells increased to 4.13% indicating IL-33 influences the 
adaptive immune response directly by driving differentiation or recruitment of 
Th2 cells ST2+ve cells.  Although studies in ST2-/- mice show ST2 is not essential 
for Th2 differentiation 338,339, in vitro analysis in our laboratory shows IL-33 can 
induce differentiation of IL-5+IL-4-CD4+ cells from naïve CD4+Th cells 
independently of factors typical for Th2 differentiation, namely  IL-4, STAT-6 
and GATA-3 496. 
Mast cells highly express ST2, with mature mast cells identified by the presence 
of SCF receptor (c-kit) 305.  IL-33 treatment increased the population of mast 
cells in the lung to 2.32% compared to a 0.22% in PBS-treated mice. Ideally, mast 
cell identity should be confirmed with further co-staining with FCεRIα and the 
gating strategy used optimised.  
Neutrophils were identified as a population of high Gr-1 (Grhi) expressing cells in 
Figure 4.4D. There was no change in proportion of neutrophils between PBS and 
IL-33 treated lungs, at approximately 7-9%. Other granulocytes can express Gr-1, 
in particular eosinophils which are of interest in these experiments. However, 
Gr-1 is expressed at a lower level (Gr-1med) in eosinophils 497. Thus eosinophils 
probably represent the Gr-1med population seen here and these cell populations 
were further discriminated from each other by using scatter parameters (data 
not shown). 
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Figure 4.4:  Lungs treated with IL-33 demonstrate an increased proportion of ST2+ve cells 
The surface expression of A) F/480, B) c-kit, C) Gr-1 and D) CD4+ versus ST2 on single cell 
suspensions of whole lung digests in mice treated with intranasal PBS or IL-33 were analysed. 
FACS plots were gated on live cells, with 7-AAD positive dead cells excluded from the analysis. 
Numbers indicate percentage of cells in each quadrant. FACS plots are of individual mice 
representative of 3 independent experiments.  
Eosinophils were identified using the cell surface marker Siglec-F 498 or CCR3 
antibody (Figure 4.5). Eosinophils were not seen in the PBS treated lungs.  
Technical problems with the Siglec F antibody (or unavailability of alternate 
flurophore from the ST2 antibody) meant difficulties obtaining ST2 and Siglec F 
co-expression data. A population of Siglec-Fhi eosinophils appeared to co-express 
ST2 at low levels in IL-33 treated mice. Siglec-F is also expressed on alveolar 
macrophages499 and so the second population of Siglec-Fmed cells were eliminated 
A 
B 
C 
D 
Chapter 4  142 
with negative gating for F4/80 to exclude macrophages, and the remaining cells 
had morphological characteristics of eosinophils on SSC analysis. Direct 
microscopy of the digested cell suspension, stained by Romanovsky method, 
shows eosinophils, macrophages, neutrophils and epithelial cells in the IL-33 
treated group confirming the identity of the cells (Figure 4.5).  
Small numbers of B cells (CD19+) were identified in the lung digests but numbers 
were similar in both groups (1.8% vs. 2.2%) (data not shown). 
These data show a range of immune cells expressing ST2 that are capable of 
initially responding to IL-33. Immune cells not assessed include DC, NK, iNKT, 
NKT and recently described ILCs. However, these cells are unlikely to be present 
in sufficient numbers to account for the total remaining proportion of ST2+ve 
cells seen in Figure 4.3.  The other unidentified cells were larger on FSC and 
therefore, reasonable to assume are predominantly structural cells, which could 
include epithelial cells, smooth muscle cells, endothelial cells or fibroblasts. 
Epithelial cells in particular are well placed to encounter IL-33 initially, and as 
such efforts to assess epithelial and endothelial cells in the response to IL-33 are 
further described in chapter 6.  
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Figure 4.5: Eosinophils population in lung digest of PBS and IL-33 treated mice 
A) The surface expression Siglec-F, F/480 and  ST2 on single cell suspensions of whole lung 
digests in mice treated with intranasal PBS or IL-33  was analysed by FACS. FACS plots were 
gated on live cells, with 7-AAD positive dead cells excluded from the analysis. FACS plots are of 
individual mice representative n=3. B) Light microscopy of IL-33 treated lung digest showing 
macrophages (m), neutrophils (n) and eosinophils (e) stained with Romanovsky method x20 
magnification.   
 
4.2.3 Dynamics of the response to IN IL-33 
Cytokines, chemokines and their networks are implicated in orchestrating the 
innate and adaptive immune responses that drive asthma1.   To further define 
the biological response of the cytokine IL-33 and how it may relate to asthma, a 
set of experiments to assess the dynamics of cytokine and chemokine profiles 
using multiple doses of IL-33 were designed.  The choice was made to perform 
these studies on mice on the C57BL/6 background as the subsequent aim is to 
use RAG-/- mice (C57BL/6 background), to assess the contribution of T cells to 
the IL-33 response.  The 8 day experimental protocol detailed in Figure 4.6 
shows mice were given daily dose of IL-33 for between 0 and 7 days, and samples 
obtained for analysis 24 hours following the final dose.  These were analysed 
with particular interest in cell count, cytokine and chemokine profile. 
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Figure 4.6: Experimental protocol to study dynamics of the response to Intranasal IL-33 
C57BL/6 mice received between 0 and up to 7 once daily doses of 2 μg of recombinant murine IL-
33 via the i.n. route. Mice were culled 24 hours following each dose and BAL, lung and serum 
samples obtained. 
Total cell counts in the BAL were very low when measured following 0-2 doses. 
Numbers began to increase following the administration of the 3rd dose (5.16 x 
105 cells/ml) and continued to increase following each subsequent dose to 
maximal level of 49.53 x 105 cells/ml following administration of the 7th dose 
(Figure 4.7A).  All cell populations increased in number over the time course as 
shown in Figure 4.7B.  Macrophages were the most dominant cell type initially 
and up to following dose 5. Numbers increased steadily from a mean of 1.4 x 105 
cells/ml to a mean of 9.48 x 105 cells/ml following the 7th dose.  Eosinophils, 
neutrophils and lymphocytes, were initially completely absent from the BAL, 
appearing in small numbers only following the 3rd dose.  Eosinophil numbers then 
increased exponentially to become the dominant cell type in the BAL by dose 5 
at 6.43 x 105 cells/ml (40.2%) and following 7 doses measured 31.52 x 105 
cells/ml (59.3%)(Figure 4.7C). 
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Figure 4.7: Successive doses of IL-33 lead to predominantly increasing eosinophil  
  numbers in BAL 
Mice were administered IL-33 as per Figure 4.6. A) Total BAL cell count, B) Differential cell count 
and C) Differential cell percentage. Results are the mean of each group of mice +/- SEM. n= 4-5. 
One way ANOVA for the effect of repeated IL-33 dosing on macrophages p<0.001, eosinophils 
p<0.001 and lymphocytes p<0.001 in B). 
In order to ascertain if the histological characteristics of this time course were 
comparable to airway inflammation, the lungs were collected and cellular 
infiltration assessed on H&E staining on paraffin embedded sections. Compared 
to control PBS treated mice, IL-33 treated lungs showed a clear predominantly 
eosinophilic infiltration in the peri-bronchial and peri-vascular regions. This was 
first noted by dose 2 where a few eosinophils are seen, preceding the first 
appearance in the BAL by 1 dose/24 hours. By dose 3, when eosinophils are 
appearing the BAL, severe histological eosinophilia has occurred with maximal 
infiltration (by scoring technique) by dose 6.  Increasing architecture distortion 
with epithelial hyperplasia and shedding occurs following dose 3 (Figure 4.8).    
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Figure 4.8: Intranasal IL-33 induces eosinophilic inflammation in the lung 
Lungs were administered IL-33 as per Figure 4.6. Lungs were fixed in formalin and stained with 
H&E. Sections were scored according to previously described parameters. Zero dose=score 0, 1 
dose=score 0, 2 doses=score 1, 3 doses=score 2, 4 doses=score 2, 5 doses=2, 6 doses=score 3, 
7 doses=score 3. Panels shown are representative sections following each dose of IL-33. Scale 
bars represent 50μm.  
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A wide range of cytokines and chemokines were detected in the BAL.  IL-13 was 
the cytokine detected at the highest concentration. There were no or very low 
levels of IL-13 present after doses 0-2. It appeared in significant amounts 
following 3 doses and peaked following 4 doses at (777 pg/ml); thereafter levels 
fell with further dosing (Figure 4.9A).  Other Th2 cytokines, IL-5 and IL-4 
followed a similar pattern with peak levels following dose 4 and dose 3 
respectively (Figure 4.9A).  Levels of IL-12 and IP-10 also rose to peak levels on 
day 4 and 3 respectively (Figure 4.9B and C).  Concentrations of IL-2, KC and 
MCP-1 rose a small but significant amount, peaking at dose 3 (Figure 4.9B and 
C).  
Alternative patterns of mediator production in response to IL-33 were also 
demonstrated.  Interleukin-17 levels rose from zero to a peak of 205 pg/ml 
following 5 doses (Figure 4.9B) and VEGF showed a rapid response by peaking on 
day 1 with just one dose of IL-33 then levels declined with repeated IL-33 dosing 
(Figure 4.9C).  Eotaxin/CCL11 and eotaxin-2/CCL24 levels rose sharply following 
3 doses to a peak concentration of 281 pg/ml at day 4 and 820 pg/ml at dose 3 
respectively (Figure 4.9D).  Levels however remained raised with repeated 
dosing suggesting a role in the continued eosinophil accumulation (Figure 4.7B). 
Concentrations of MIP1α, GMCSF, IL-6, IFNγ showed trends of a pattern similar 
to IL-13 but levels were low (<50 pg/ml).  Levels of FGF, IL-1α, TSLP, IL-10, IL1-
β, RANTES (CCL-5) and MIG were zero or low (data not shown).  
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Figure 4.9:  BAL cytokine and chemokine profile during repeated intranasal IL-33 
administration 
IL-33 was administered as per the protocol in Figure 4.6.  Analysis was performed by multiplex 
immunoassay or ELISA. Results shown are group mean, n=4-5. One way ANOVA for the effect of 
repeated IL-33 dosing on BAL IL-4 p<0.01, IL-5 p<0.01, IL-13 p<0.01, IL-2 p<0.05, IL-12 p<0.001, 
IL-17 p<0.01, VEGF p<0.0001, KC p<0.01, MCP-1 p< 0.01, IP-10 p<0.001, Eotaxin-1 p<0.0001 
and Eotaxin-2 p<0.0001. 
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Within the serum, the most notable cytokine profile was that of IL-13; the 
concentration of this began to rise following dose 3, and then steadily increased 
to a peak following 7 doses at 614 pg/ml (Figure 4.10A).  Concentrations of IL-5 
in the serum mirrored that of the BAL peaking following the 3rd dose (Figure 
4.10B).  IL-4 levels were low and did not significantly alter throughout (Figure 
4.10B).  Other results include: IP-10 which rose following 7 doses; and FGF 
whose levels were elevated throughout but with no discernable pattern (Figure 
4.10C).  Levels of IL-2, IL-10, IL-12, IFNγ, IL-1β, IL-6, GMCSF, IL-17, KC, VEGF, 
IL-1α, MCP-1, MIP1α, RANTES and MIG were below the limit of detection for the 
assay or zero. 
These data show that repeated serial intranasal dosing of IL-33 results in 
eosinophilic inflammation within the BAL after 3 doses and is associated with 
release of multiple inflammatory mediators, in particular Th2 cytokines and 
eotaxins. 
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Figure 4.10:  Serum cytokine and chemokine profile during repeated intranasal IL-33 
administration 
IL-33 was administered as per protocol in Figure 4.6.  Cytokine and chemokine analysis was 
performed by multiplex immunoassay or ELISA.  A) IL-13. B) IL-4 and IL-5. C) FGF and IP-10. 
Results shown are group mean, n=4-5. One way ANOVA for the effect of repeated IL-33 dosing on 
BAL IL-13 p<0.01, IL-4 p=ns, IL-5 p<0.05, FGF p=ns, IP-10 p<0.05. 
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4.2.4 Dynamics following intranasal IL-33 administration 
Having shown inflammation following administration of 7 days of IL-33 in BALB/c 
and C57BL/6 mice, the aim was to further assess the response to IL-33, in 
particular the contribution of the adaptive immune response.  It was important 
to refine the experimental protocol whilst minimising animal requirements, 
excessive inflammation, experimental duration and reagent use.  
BAL cellular inflammation continues to escalate with repeated IL-33 dosing and 
after 4 doses of IL-33; inflammation is established in C57BL/6 mice.  In the 
experimental protocol in Figure 4.6, animal sacrifice and sample retrieval was 
performed 24 hours following the final dose in each group, which is standard 
protocol in airway challenge models 500. It is not clear whether inflammation will 
continue without ongoing ST2 receptor stimulus over time. Therefore an 
experiment to study changes in the BAL and serum following cessation of IL-33 
application choosing time points over 8 days following the final dose was 
designed. A total of 4 doses were chosen, reflective of a moderate degree of 
inflammation comparable to that seen in asthma models(Figure 4.11) 282.    
Results are shown in Figure 4.12. Following the administration of 4 daily doses of 
IL-33, total cell counts in the BAL continued to rise before peaking at 4 days 
after the final dose at 35.8 x105 cells/ml before gradually declining over time.  
Eosinophil counts followed a similar pattern, peaking at day 4 post dose at 24.5 x 
105 cells/ml.  Macrophages numbers peaked earlier at day 2 measuring 7.73 x 105 
cells/ml. Despite this, the rising eosinophil numbers replaced macrophages as 
the predominant cell type in the BAL at day 2.  Eosinophils remained the 
dominant cell type until the final recorded sample at day 8 where eosinophils 
and macrophages each comprised more than 49% of the population.  This 
indicates that even 8 days following a series of IL-33 doses there is still 
significant eosinophilic inflammation.  
Within the BAL, unsurprisingly elevated levels of most cytokines significantly fell 
away in the days following the final dose.  IL-13, IL-5 and IL-4 peaked on day 1 
(Figure 4.13A) along with IL-2, IL-12 and KC (data not shown).  IL-10, IFN-γ and 
IL-17 levels peaked on day 2 (Figure 4.13B). Eotaxin/CCL11 and eotaxin-2/CCL24 
levels reduced much more slowly over time and remained significantly elevated 
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for several days (Figure 4.13C). IL-1β, IL-6, GMCSF, TNF-α, FGF, IL-1α, MCP-1, 
MIP1α, RANTES IP-10 and MIG were low (<50 pg/ml) or zero (data not shown). 
IL-13 was the predominant cytokine in the serum.  Levels of IL-13 and also IL-5 
peaked one day following the last administration of IL-33 before gradually 
reducing (Figure 4.14A).  IL-4 concentrations were low.  Concentrations of both 
chemokines KC and IP-10 appeared to increase up to 8 days post final dose 
although overall levels of these remained low (Figure 4.14B).  IL-6, IL-12 and 
TNF-α levels were unchanged and those of IL-2, IL-10, IFN-γ, IL-1β, GMCSF, IL-
17, VEGF, FGF, IL-1α, MCP-1, MIP1α, RANTES and MIG were low (<50 pg/ml) or 
zero (data not shown). 
These data indicate IL-33 driven inflammation continues to accumulate following 
removal of receptor stimulation. 
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Figure 4.11:  Experimental protocol to study dynamics following Intranasal IL-33 
administration 
C57BL/6 mice received between 4 once daily doses of 2 μg of IL-33 via the intranasal route. Mice 
were culled between 1 and 8 days following the delivery of the final dose and BAL and serum 
samples obtained. 
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Figure 4.12: BAL eosinophils peak 4 days following 4 daily intranasal IL-33  
Mice were administered IL-33 as per Figure 4.11 and BAL cellular composition measured A) Total 
BAL cell count and B) Differential cell count. Results are the mean of each group of mice ± SEM. 
n= 4-5. One way ANOVA for the effect of IL-33 on BAL cellular composition over time: total cell 
count p<0.0001, macrophages p=ns, eosinophils p< 0.0001 and neutrophils p=ns.  ns= not 
significant. 
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Figure 4.13:  BAL cytokine and chemokine profile following intranasal IL-33  
IL-33 was administered as per the protocol in Figure 4.11.  Analysis was performed by multiplex 
immunoassay or ELISA. A) BAL IL-4, IL-5 and IL-13. B) BAL IL-10, IFNγ and IL-17. C) BAL 
eotaxin/CCL11 and eotaxin-2/CCL24. Results shown are group mean, n=4-5. One way ANOVA for 
the effect following IL-33 dosing on BAL IL-4 p<0.01, IL-5 p=0.01, IL-13 p=0.01, IL-10 p<0.01, IFNγ 
p=0.05, IL-17 p<0.05, Eotaxin-1 p<0.0001 and Eotaxin-2 p<0.0001. 
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Figure 4.14: Serum cytokine and chemokine profile following intranasal IL-33 
IL-33 was administered as per the protocol in Figure 4.11.  Analysis was performed by multiplex 
immunoassay or ELISA. A) Serum IL-4, IL-5 and IL-13. B) Serum KC and IP-10.  Results shown 
are group mean, n=4-5. One way ANOVA for the effect following IL-33 dosing on serum IL-4 p=ns, 
IL-5 p<0.01, IL-13 p<0.001, KC p<0.05 and IP-10 p<0.05. 
 
4.2.5  Protocol for IL-33 induced inflammation in C57BL/6 mice 
Using the data detailed in the experiments above, an experimental protocol to 
use in C57BL/6 mice to accommodate the analytes of interest was chosen. As 
BAL inflammation continues to increase up to 4 days following IL-33 dosing, a 
time point of 3 days was chosen to reflect the mid-point in the rise of 
eosinophilic inflammation; this would allow sufficient inflammation to study the 
influence of inhibitors, but not at peak levels which may be affected by 
exacerbating parameters. Furthermore, as 3 days post dose as the eosinophilic 
inflammation was still high at 27.4 x 105 cells/ml, the number of challenges was 
B 
A 
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reduced from 4 to 3 aiming for inflammation levels in keeping with current 
asthma protocols. The protocol is shown is Figure 4.15A. As expected, a 
predominant moderate eosinophilic inflammation was induced in the BAL as 
shown in Figure 4.15B.   
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Figure 4.15: Final experimental protocol for intranasal IL-33 in C57BL/6 mice 
A) 2 μg of recombinant murine IL-33 was administered daily for 3 days and mice culled following a 
further 3 days on day 6. B) Total and differential cell counts in the BAL were performed.  Results 
are mean ±SEM. n= 5. 
 
4.2.6 The response to intranasal IL-33 activity is dependent on 
ST2 expression 
IL-33 binds to ST2 and forms a receptor complex with IL-1RAP 293,416; with the 
crystal structure of IL-33/ST2 binding recently solved 501. This complex activates 
a range of signalling proteins including NF-κB 293. To confirm the effects of i.n. 
IL-33 that are described above are dependent on ST2 expression, the 
experimental protocol in Figure 4.15A was repeated in ST2-/- mice.  The 
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available ST2-/- mice in the laboratory were on a BALB/c mouse strain genetic 
background so this protocol was also performed in WT BALB/c mice as a control.  
As expected, IL-33 generated an increase in total cell count in WT but not in 
ST2-/- mice (Figure 4.16A).  In particular, no eosinophils were found in the 
knockout group (Figure 4.16B).  Of interest, the BALB/c mice generated a more 
modest level of inflammation in the BAL using this protocol compared to the 
C57BL/6 mice, indicating a strain difference in the responses to IL-33 (Figure 
4.16 A and B).   
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Figure 4.16:  IL-33-induced BAL inflammation is ST2 specific  
WT (BALB/c) , ST2-/- (BALB/c) or WT (C57BL/6) mice were given 2 μg of recombinant murine IL-
33 or PBS as per protocol in Figure 4.15.  A) Total and B) differential cell counts were performed in 
the BAL.  Results shown are mean ± SEM. n=5. **p<0.01, ***p<0.001.  
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4.3 The adaptive immune system is not required for 
intranasal IL-33 induced inflammation 
Asthma in humans and AAI in mice has long been seen as predominantly Th2-
mediated inflammation 20-22,24. In response to i.n. IL-33, a predominantly Th2-
type inflammatory profile of eosinophilia and inflammatory mediators is seen in 
the airway and lungs in vivo.   Furthermore, an increased population of CD4+ 
ST2+ Th2 cells in lung has been demonstrated (Figure 4.4). Despite an absence of 
antigen priming in this particular model, this suggests that Th2 cells could be 
involved; either being directly activated by IL-33 or indirectly by the cytokine 
cascade generated in response to IL-33.  To further consider the role of Th2 
cells, mice deficient in the adaptive immune system can be utilised.  Pilot 
experiments in SCID mice, which lack T and B lymphocytes due to a defect in 
VDJ recombination of antigen receptors 502, demonstrated a trend of reduced 
inflammatory profile in comparison to WT BALB/c mice (data not shown).  Some 
SCID mice are considered “leaky” (in particular those on BALB/c and C57BL/6 
backgrounds) 503(www.jax.org/strain/001803 or 001913) and therefore not 
completely deficient in all lymphocyte subsets 504. Therefore it was decided to 
perform the attenuated experimental protocol above (Figure 4.15A) in RAG1-/- 
mice on a C57BL/6 background which are completely deficient in T, B and NKT 
cells 505,506. 
When IL-33 was administered intranasally to C57BL/6 and RAG-/- mice, the 
complete deficiency of the adaptive immune system did not have any influence 
on the ability to mount a robust inflammatory response to IL-33.  In fact, there 
was a suggestion that the cellular inflammation was worse in the BAL and lungs 
of the RAG-/- mice, but this did not reach statistical significance in all 
experiments.  Figure 4.17 shows similar total cell counts in both groups and a 
trend towards increased proportion of eosinophils in RAG-/-.   The cytokine 
response within the BAL was lower in the RAG-/- group when compared to the WT 
group suggesting that CD4 Th2 cells may contribute to cytokine production 
(Figure 4.17B).  The levels of analytes were generally low in the serum and no 
differences between the groups were identified (data not shown).   
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Figure 4.17: The adaptive immune system is not necessary for the generation of airway 
inflammation in response to intranasal IL-33 
Intranasal IL-33 was administered to wildtype C57BL/6 or RAG-/- mice as per Figure 4.15A. A) Total 
and differential cell counts and B) Cytokine and chemokine analysis was performed on the BAL.  
Results shown are the mean of each group of mice ± SEM. n=8. Results are representative of 
several experiments. 
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Figure 4.18 shows a trend towards worse parenchymal eosinophilic inflammation 
in the RAG-/- mice.  
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Figure 4.18: The adaptive immune system is not necessary for the generation of lung 
inflammation in response to intranasal IL-33.    
Intranasal IL-33 was administered to wildtype C57BL/6 or RAG-/- mice as per Figure 4.15A. Lungs 
were fixed in formalin and stained with H&E for eosinophil assessment. A) Representative sections 
shown at x10 and x40 magnification. B) Eosinophil score assessed as previously described.  n=5 
per group. t-test p value shown. 
In summary, these data show that IL-33 causes a Th2-innate response for which 
the Th2 cells and adaptive immune system are not an essential component.  
Some data further indicates the cellular inflammation could be worse in mice 
with no effective adaptive immune system.   
B) 
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4.4 IL-4 is not required for the response to intranasal    
IL-33 in mice 
Cytokines, in particular IL-4, IL-5 and IL-13, are key in driving Th2-mediated 
inflammation in asthma and AAI 44,54,68. When IL-4 or IL-13 is given alone 
intranasally to mice, they can replicate some of the features of asthma 45,54. Th2 
cells are important sources of these cytokines but other sources include NKT 
cells, eosinophils, MC and ILCs.  Results described in this thesis similarly show IL-
33 alone drives innate-type pathology with features of asthma. Furthermore, it 
is clear that inflammation is not exerted by a direct action of Th2 cells, although 
they may contribute to cytokine production indirectly.  In considering the 
cytokine hierarchy, analysis of the time course above (Figure 4.9), shows IL-33 
drives IL-5 and IL-13 release but limited IL-4, suggesting this latter cytokine is 
not involved in IL-33 directed effector pathology. However, IL-4 protein can be 
difficult to measure in BAL and levels are often low 35.  To further elucidate the 
role of IL-4 and ascertain if is redundant in IL-33 mediated inflammation, 
experiments were performed in IL-4-/-mice.  For consistency the protocol in 
Figure 4.15A was followed; however, the IL-4-/-mice are on a BALB/c 
background. 
When IL-33 was administered intranasally to WT and IL-4-/- BALB/c mice, the 
absence of IL-4 had no impact on the total or eosinophil cell count in the 
bronchoalveolar lavage (Figure 4.19 A and B) or lung (Figure 4.19 C and D). With 
regard to cytokines and chemokines in the BAL and serum, no differences were 
identified between the groups. No IL-4 was measured in any compartment in the 
IL-4-/- mice (data not shown).  
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Figure 4.19:  IL-4 is not necessary for the generation of IL-33 induced airway and lung 
inflammation  
Intranasal IL-33 was administered to wildtype BALB/c or IL-4-/- mice as per Figure 4.15A. A) Total 
and B) differential cell counts were performed on the BAL, C) Eosinophil score assessed as 
previously described on lungs fixed in formalin and stained with H&E. D) Representative histology 
sections x40 magnification.  Results shown are the mean of each group of mice +/- SEM. n=5-7 per 
group. Data are representative of 3 experiments.  
A) B) 
C) 
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This confirms IL-4 is not critical for the generation of responses to IL-33.  
Duplicate experiments in IL-5 and IL-13 mice may yield further information in 
cytokine hierarchy.  
4.5 IL-33 mediated eosinophilic inflammation is partially 
eotaxin dependent 
From experiments detailed above (Figures 4.9 and 4.13), a number of secondary 
mediators were produced in particular IL-5, IL-13, eotaxin/CCL11 and eotaxin-
2/CCL24 and mediate IL-33-induced inflammation.  Further understanding of the 
role of these secondary mediators and the identification of cell types releasing 
them is warranted.   The development of BAL eosinophilia coincided with the 
appearance of BAL eotaxin/CCL11 and eotaxin-2/CCL24 and the strikingly 
sustained release of these eotaxins resulted in continued eosinophil recruitment 
for many days following IL-33 administration.  To further investigate the role of 
eotaxins, the use of CCL11 and CCL24 neutralising antibodies in the 
experimental protocol of IL-33-induced airways inflammation was chosen (Figure 
4.15A).  These antibodies were chosen following pilot studies testing siRNA and a 
range of neutralising antibodies. As described in Figure 4.12, inflammation 
continues to rise following IL-33 exposure and eotaxin levels remain elevated 
(Figure 4.13), therefore antibody was administered for a further 3 days as shown 
in Figure 4.20A. 
Co-administration of anti-eotaxin antibodies resulted in a reduction in IL-33-
mediated airway and tissue inflammation when compared to control mice 
treated with control IgG.  Specifically, anti-CCL11 caused a significant reduction 
in the total cell count by reducing both the eosinophil as well as macrophage 
cell count by 90% and 50% respectively (Figure 4.20 B-D).  Anti-CCL24 
administration had no significant effect on the total or macrophage cell count 
but resulted in an 80% reduction in the number of eosinophils in the BAL 
indicating some functional redundancy between the eotaxins (Figure 4.20 B-D).  
Cytokine analysis revealed reduced levels of BAL IL-5 in mice receiving either 
neutralising antibody (Figure 4.20E).  No changes were seen in serum IL-5 levels 
and levels of IL-4 and IL-13 in BAL or serum were very low or undetectable (data 
not shown).  Overall the levels of cytokines were low in this model compared to 
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previous experiments in keeping with a proportionately less intense 
inflammatory response.  This protocol was developed in the C57BL/6 strain 
rather than BALB/c mice used here, which although Th2 biased, do not to 
develop as severe inflammation with the same dose of IL-33 as described in 
Figure 4.15 above. 
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Figure 4.20: CCL11 and CCL24 mediate IL-33 induced airway inflammation 
BALB/c mice received 4μg hIL-33 for 3 days.  Mice additionally received neutralising anti-CCL11, 
anti-CCL24 or control antibody intranasally for 5 consecutive days (A). Total B) and differential cell 
counts (C-D) were performed on the BAL. IL-5 was measured in the BAL by ELISA (E). Results 
A 
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shown are the mean of each group of mice ±SEM. n=5 per group. Data are representative of 2 
experiments. ns p= not significant, *p<0.05, **p<0.01 of IgG versus antibody treated mice. 
Anti-CCL24 reduced and anti-CCL11 reduced tissue eosinophilia, the latter not 
reaching statistical significance (Figure 4.21). 
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Figure 4.21: CCL11 and CCL24 mediate IL-33 induced lung inflammation 
Lungs were harvested and histology score performed as previously described.  Results shown are 
the mean of each group of mice +/- SEM. n=5 per group. H&E panels are representative of each 
group x40 magnification. Data are representative of 2 experiments. ns p= not significant, *p<0.05, 
of IgG versus antibody treated mice. 
 
4.6  The effect of IL-33 on airway hyperresponsiveness 
IL-33 generates lung and tissue eosinophilia, goblet cell hyperplasia, and 
inflammatory mediator changes that are in keeping with features of allergic 
asthma.   At the outset of this work, it was not know whether IL-33 alone could 
replicate other features of asthma, in particular the defining feature of airflow 
obstruction caused by AHR.   By using neutralising antibodies or direct 
application of cytokine; studies in mice show AHR in allergic airways disease can 
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predominantly be attributed to the actions of IL-13 54. IL-13 is one of the 
predominant cytokine outputs of IL-33 induced inflammation so it seemed 
plausible that it could be the mechanism of AHR demonstrated. Enhanced pause 
(Penh), a non-invasive method of whole body plethysmography, was used to 
measure AHR 284.  
4.6.1 Three doses of IL-33 is insufficient to generate AHR in mice 
Firstly, the presence of AHR in C57BL/6 mice treated using the attenuated 3 day 
IL-33 protocol (Figure 4.15A) described above was assessed.  No difference was 
seen in response to increasing concentrations of nebulised methacholine 
between the PBS and IL-33 treated groups of mice (Figure 4.22A).   
It is well known that differences in inflammation as well as AHR exist between 
strains of mice often used in asthma models 287,507,508. Therefore AHR in mice on 
the BALB/c background, which typically have greater levels of reactivity to 
methacholine than C57BL/6 mice, was assessed 287. 
BALB/c mice treated with IL-33 showed a trend towards induction of AHR at 50 
mg/ml of methacholine in comparison to PBS controls.  There was no difference 
seen in AHR between PBS-treated WT BALB/c mice and ST2-/- BALB/c mice 
(Figure 4.22B).   
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Figure 4.22: 3 doses of intranasal IL-33 does not induce AHR in mice 
Mice were treated with intranasal IL-33 or PBS as per protocol in Figure 4.13A.  On day 6, mice 
were exposed to increasing concentrations of methacholine and Penh measured in A) C57Bl/6 and 
B) BALB/c mice.  Results are mean of each group of mice ± SEM. n=4-5.   
4.6.2 Seven doses of IL-33 induces AHR in BALB/c but not 
C57BL/6 mice 
There is an apparent dichotomy in mouse strain between airway eosinophilia and 
AHR. The aim of these experiments is to assess the contribution of the adaptive 
immune system to IL-33-induced effects including AHR using the RAG-/- mice on 
C57BL/6 background; therefore the ability to generate AHR in WT C57BL/6 mice 
was explored.  Based on results in Figure 4.20, AHR was assessed in a protocol of 
maximal inflammation using 7 consecutive daily doses of IL-33 as in Figure 4.1.  
These assessments were also performed in BALB/c mice to confirm the trend 
identified in Figure 4.22, and sample size was increased based on those 
observations. 
B 
A 
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The Penh assessment was undertaken 24 hours following the last dose of IL-33 in 
line with standard airway assessment protocol, rather than after 72 hours due to 
the possibility that these mice could recover from any generated AHR 500.  
Results are shown in Figure 4.23. BALB/c mice demonstrated a robust AHR in 
response to intranasal IL-33 confirming the earlier interpretation.  However, IL-
33 treated C57BL/6 mice did not show increased Penh measurements in response 
to increasing doses of methacholine compared to PBS treated mice.  This is 
despite a very significant level of airway inflammation (Figure 4.23C), 
confirming the dichotomy of AHR and eosinophilia in these mice.  At 7 days there 
was no significant difference between the strains of mice and level of airway 
inflammation, suggesting that the BALB/c mice had overcame the earlier 
reduction seen in Figure 4.16 by continued treatment, and both strains of mice 
reached a maximal tolerable inflammation.   
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Figure 4.23: 7 doses of IL-33 induces AHR in BALB/c but not C57BL/6 mice despite maximal 
airway inflammation 
Mice were treated with intranasal IL-33 or PBS or as per protocol in Figure 4.1.  On day 8, mice 
were exposed to increasing concentrations of methacholine and Penh measured in A) C57BL/6 
mice and B) BALB/c with an additional OVA-induced AAI (asthma) control group.  Results are 
mean of each group of mice +/- SEM. n=8-12.  Two way ANOVA BALB/c PBS vs IL-33 p<0.001. 
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4.6.3 Rapid assessment of AHR in C57Bl/6 mice following IL-33 
challenge 
C57BL/6 mice do not develop IL-33-induced AHR as measured by Penh following 
final airway challenge.  This study protocol was designed to measure eosinophilic 
inflammation; despite maximal inflammation and standard assessment (24 hours) 
AHR was not found although it was demonstrated concurrently in BALB/c mice.  
Bronchial hyperresponsiveness and eosinophilic inflammation are distinct 
features and it is known that there are differences in inflammatory and AHR 
features between these two strains of mice 287.  C57BL/6 mice can develop AHR 
but it does not persist in comparison to BALB/c mice in AAI models 282. 
Therefore, it seemed possible that the time point of Penh measurement was 
incorrect in this model; thus it was hypothesised in direct innate IL-33 
inflammation, the appropriate time point would be shorter.  Studies have 
measured changes in respiratory dynamics from 15 minute following a toxic 
challenge 509. Experiments to measure Penh were performed 1.5 hours after each 
of 3 sequential doses of IL-33.  This time point was chosen to allow the mice to 
fully recover from the anaesthetic and intranasal dosing 510. 
These results show that measuring Penh 1.5 hours after 1, 2 or 3 daily doses of 
IL-33 in C57BL/6 mice and at increased doses of methacholine, did not elucidate 
any IL-33 generated AHR (Figure 4.24).   
Since AHR was not generated in C57BL/6 mice, the background on which the 
RAG-/- mice were available, it was not possible to assess the importance of the 
adaptive immune response in IL-33-induced AHR. This could be the subject of 
further work using RAG2-/- on the BALB/c background. 
 
Chapter 4  171 
0 25 50 75 100
0
2
4
6
8
10
12
14
16
18 1 dose IL-33
Metacholine mg/ml
Pe
nh
0 25 50 75 100
0
2
4
6
8
10
12
14
16
18 2 doses IL-33
Metacholine mg/ml
Pe
nh
0 25 50 75 100
0
2
4
6
8
10
12
14
16
18 3 doses IL-33
Metacholine mg/ml
Pe
nh
C57BL/6 PBS
C57BL/6 IL-33
 
Figure 4.24: IL-33 does not induce AHR in C57BL/6 mice with short measurement protocol 
Mice were treated with intranasal 2 μg IL-33 or PBS for 1, 2 or 3 days.  On day 6, mice were 
exposed to increasing concentrations of methacholine and Penh measured 1.5hr after final airway 
challenge.  Results are mean of each group of mice ±- SEM. n=5.  2 way ANOVA not statistically 
significant. 
4.7 Conclusions 
The data presented in this chapter clearly demonstrates  profound inflammatory 
effect of intranasal IL-33 on the airway and lung parenchyma, features that are 
in common with allergic asthma. The predominant cell type in the 
bronchoalveolar lavage was the eosinophil in keeping with the now well 
established characteristic effect systemic of IL-33 as shown initially by Schmitz 
in the peritoneum 293, and subsequently in the lungs by our group and others 
335,496.  A rise in numbers of other innate inflammatory cells was also shown.  
Further examination of the cellular content of the BAL fluid from these 
experiments by FACS (by Dr Mariola-Kurowska-Stolarska) correlated with the 
differential cell counts classified by morphological characteristics on cytological 
staining by the Romanovsky method demonstrating the validity of this technique 
281. More detailed studies on effect of IL-33 on eosinophils, macrophages and 
neutrophils within the lungs have been undertaken 311,496,511. 
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Within the lung itself, marked eosinophilia is further demonstrated histologically 
and is of a predominantly peri-vascular and peri-bronchial pattern consistent 
with published findings 335,422,496. The lung cellular composition analysed by FACS 
identified a mixed population of resident ST2+ve cells capable to respond to 
directly to IL-33.  Subpopulations were identified as macrophages, mast cells 
and Th2 cells as might be expected from the ST2 receptor protein expression 
profile previously described. Other populations of ST2+ve cells probably included 
eosinophils, B cells, and neutrophils. Other unidentified cells ST2+ve cells were 
found that are capable of responding to IL-33 directly.  Possibilities include 
structural cells, DC, NK cells and others.  This group will also include type-2 
ILC2, the recently described novel populations of IL-33 responsive non-T, non-B 
lymphoid cells including NHC, nuocytes and Ih2 cells 157-159.  Structural cells are 
ideally positioned to respond initially to IL-33 if released as an alarmin by 
necrotic cells. ST2 mRNA is present in murine fibroblasts 291,412, epithelial cells 
318 and human endothelial cells 320,321,413. The possibility that epithelial cells 
might drive the initial response to IL-33 is further investigated in chapter 5.  
IL-33 recruits or drives proliferation of ST2+ve cells in the lungs in particular 
macrophages, CD4+ cells, mast cells and probably eosinophils and neutrophils. 
These results indicate IL-33 can directly, without antigen, activate the adaptive 
as well as innate immune system. The granulocyte results presented here should 
be repeated with more robust cell surface combined CCR3/SiglecF staining311. 
Cherry et al showed eosinophils but not neutrophils express ST2 after activation 
309. Other members of our group have now definitively demonstrated ST2 
expression at low levels on eosinophils 311 and neutrophils 312, significantly 
upregulated by IL-33. 
In order to further investigate how IL-33 may bring about this inflammatory 
profile directly, a series of experiments to look in detail at the cellular 
accumulation while measuring the cytokine and chemokine levels at a large 
number of time points was performed. IL-33 induces sustained airway 
eosinophilia in vivo but eosinophils are actually not detected until 24 hours 
following the 3rd dose of IL-33.  Unstimulated eosinophils express low levels ST2 
and studies show IL-33 can promote eosinophilia by directly stimulating bone 
marrow progenitors in an IL-5 dependent manner311, but the delay in their 
appearance in the BAL suggests a more indirect effect in vivo.  When mature 
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eosinophils appear in the airway, expressing higher levels of ST2L, they can 
perpetuate IL-33 driven inflammation directly311. Eosinophil recruitment into 
injured tissue is regulated by different cytokines and chemokines including IL-3, 
IL-4, IL-5, IL-13, GM-CSF, and chemokines eotaxin/CCL11 and RANTES512. IL-5 is 
probably the most specific and affects function, differentiation, proliferation, 
recruitment and survival and as such has been extensively investigated, including 
blocking antibodies and clinical trials discussed in chapter 1. Data here show IL-5 
was not significantly present in BAL until 24 hours after the eosinophils, 
suggesting that IL-33 driven eosinophilia is not, at least not initially, driven by 
IL-5. Eosinophils themselves are a source of IL-5 and once recruited may further 
enhance eosinophilia in an autocrine and paracrine manner.  Another cytokine 
noted in significant amount in the BAL and also the serum of IL-33 treated mice 
was IL-13.  Similar to IL-5, IL-13 did not appear until after eosinophilia in the 
BAL.  IL-13 induces goblet hyperplasia and mucus secretion when applied 
directly to the airway 53.  These changes were apparent in lung histological 
sections shown here and therefore most likely explained by IL-33 induced IL-13 
production. Others have shown systemic IL-33 causes similar lung changes in WT 
but not in IL-13-/- mice, corroborating endogenous IL-13 is the mechanism of this 
feature 422. Consistent with this, blocking IL-13 in the i.n. IL-33 model with 
neutralising antibodies reduced eosinophilic AI confirming a role for IL-13 in IL-
33-mediated effects 513. 
The potential effects of innate IL-33 have been further investigated in transgenic 
mice overexpressing IL-33 and in IL-33-/- mice. In the transgenic mice, cleaved 
mature 18kDa protein was released into the lung (BAL) and the mice developed 
spontaneous airway inflammation, mucus hypersecretion and cytokine 
production mirroring exogenous IL-33 treatment 514. IL-33 deficient mice did not 
show any phenotypic abnormalities as result of the loss of endogenous IL-33. 
However, in response to protease allergen in non-sensitised mice, IL-33 
deficiency resulted in attenuated type-2 responses which was not seen in WT or 
RAG-/- mice in agreement with a role of IL-33 in innate responses 515. 
Eotaxins potently recruit eosinophils. The profile of BAL eotaxin/CCL11 and 
eotaxin-2/CCL24 production correlated with eosinophilia detected after the 3rd 
IL-33 dose. This is in agreement with a known synergistic role for eotaxins and 
airway eosinophilia 516. Eotaxin-1 and -2 also synergise with IL-5 and IL-13 in 
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eosinophil recruitment 516-518. This suggests these chemokines are important in 
mediating initial IL-33 driven recruitment of eosinophils to the airway and lung, 
in keeping with the respective dominant function of eotaxin-2 and eotaxin 56,516. 
Thus, the possibility of abrogating the effect of IL-33 by using eotaxin 
neutralising antibodies was explored.  Data here show both eotaxin and eotaxin-
2 are partially responsible for this inflammation.  To further explore this 
mechanism, it is useful to consider which cellular source may be responding to 
IL-33 directly or indirectly to produce the eotaxins.  Eotaxin-2/CCL24 sources in 
the lungs are resident macrophages, endothelial cells and epithelial cells519. As 
macrophages are resident and accumulate in the BAL immediately following IL-
33 administration, they are a candidate of producing eotaxin-2 in direct 
response to IL-33. Indeed, a sub-population, the alternatively activated 
macrophages (AAM or M2 or M(IL-4)) which play an important role in type 2 
immunity and are induced by IL-4, IL-13 or IL-21 on stimulation produce of 
eotaxin-2 and TARC 109,520. Work within our group shows that IL-33 can also 
enhance polarisation of M2 macrophages. Moreover, in vitro and in vivo 
depletion of alveolar macrophages results in attenuated IL-33 induced airway 
inflammation 513. IL-33 induction of M2 macrophages has been reported by 
others521 and is shown to be involved in reduced obesity 436, suppressing  murine 
encephalitis and autoimmune uveitis models 449,522 as well as promoting lung 
fibrosis 523.  IL-4 does not appear to be important in development of M2 
macrophages in IL-33-driven inflammation in vitro or in vivo and that IL-13 is the 
predominant IL-4Rα stimulus 513. CD4 Th2 cells, mast cells and type-2 ILCs are 
candidate sources for IL-13 in the airways 58,293,496,524,525 with studies suggesting 
the ILCs an essential source of initial IL-13 335,526-528.   
Sources of eotaxin/CCL11 production in the lung include structural cells; smooth 
muscle, bronchial epithelial cells, vascular endothelial cells and fibroblasts 
67,196,230 as well as immune cells; macrophages, eosinophils T-cells 529.  CCL11 
was not released from the M2 macrophages on IL-33 stimulation 513 and there is 
no description of IL-33 driven CCL11 production from isolated T cells.  Although 
IL-33 up regulates the eotaxin receptor, CCR3, on eosinophils it does not 
enhance their eotaxin production 311.  In relation to structural cells, the response 
of epithelial cells to IL-33 is further considered in chapter 5. To date, IL-33 
driven CCL11 production from endothelial cells is not described. In vitro, it has 
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now been demonstrated fibroblasts can produce CCL11 in response to IL-33 
which is enhanced by IL-13 suggesting these cells could be the source of eotaxin 
in this model 530. Levels of eotaxins remained significantly many elevated days 
following last exposure to IL-33 in keeping with a sustained local source. 
Neutrophils which can acquire CCR3 expression, could be recruited by this 
mechanism 531. It is not clear if the source(s) of IL-33-driven eotaxin is direct or 
via type 2 cytokine production such as IL-4/13 which are known to regulate 
eotaxin production via a stat-6 pathway 226. A cascade of mediator production is 
initiated by IL-33 so it is perhaps unsurprising that single chemokine blockade 
would fail to ‘switch-off’ the inflammatory response and suggests these are 
downstream mediators.   
A small but significant amount of MCP-1 was measured in the BAL that peaked on 
day 4. In response to IL-33, mast cells have been shown to produce MCP-1 which 
primarily recruits monocytes 419. IP-10 (CXCL10) is involved in the 
chemoattraction of macrophages and T cells. Surprisingly, in these studies MIP-
1α was not measured in the BAL of IL-33 treated mice.  This has been shown to 
be present in the BAL after IL-33 treatment by others in our group (Kewin PK, 
2007, PhD Thesis, University of Glasgow, and  Mirchandani AS, 2012, PhD Thesis, 
University of Glasgow, 2012) and by myself in similar experiments; the 
difference perhaps explained by a technical issue or mouse strain.    
The long established finding that ST2 as a selective marker for CD4 T cells has 
lead to an association with allergic airways disease. In vitro polarised murine 
Th2 cells produced IL-5 and IL-13 in response to IL-33 293. Smithgall and 
colleagues went on to show this in antigen- dependent and -independent routes 
in humans cells from allergic donors 326.  Surprisingly, they were not the source 
of abundant levels of BAL IL-5 and IL-13 in this model of AI. Data presented here 
shows that following IL-33 treatment a significant expansion in the population of 
CD4 cells was seen within the lung.  Using RAG-/- mice, data here demonstrate 
that Th2 cells and furthermore, all lymphoid cells of the adaptive immune 
system, are not essential for IL-33 induced airway inflammation experimentally 
and hence this model must be dependent on the innate immune system. These 
findings were corroborated by subsequently published work by Kondo and 
colleagues although a different genetic background strain of RAG-/- was used 
422,527. The possible worsening of inflammation in the mice used in data 
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presented here actually suggests a loss of regulation provided by the adaptive 
immune response which is supported by subsequent studies 515.  As well as T 
cells,  RAG-/-  mice are also deficient in B and NKT cells and the effect of IL-33 
on other potentially protective pathways in these cells could result in a net 
worsening of inflammation. Evidence from a cardiac transplant model shows IL-
33 can promote development of a population of CD4+Foxp3+ regulatory T cells 
(Tregs)532. Although indicating an immunoregulatory role for IL-33, these studies 
are performed in the disease context where IL-33 is disease-protective, and thus 
extrapolation to Th2-type diseases is made with caution, however Tregs are 
known to be involved in resolution of lung injury in mice 533.   
Similarities to the innate mechanism of action of IL-33 must be drawn with IL-25, 
another epithelial cell derived cytokine. IL-25 induces a type-2 cellular, antibody 
and cytokine response including IL-4 production. Like IL-33 this effect is not 
dependent on the adaptive immune response and RAG-/- mice also display worse 
inflammation with IL-25 treatment. Furthermore, the source of IL-5/13 in this 
model is dependent on a lineage negative population in vivo 161. 
CD4 Th2 cells are not critical for IL-33-induced AI, but there is evidence IL-33 
has an enhancing role in CD4 responses.  Interleukin-33 upregulates the 
inflammatory potential of human Th2 cultures 534 and IL-33 stimulated ILC cells 
can enhance CD4 T cell Th2 cytokines in vitro and host CD4 T cell responses to 
antigen in the lungs in vivo 535. In this way, IL-33 may act to exacerbate already 
present effector CD4 Th2 cell population in established disease states.  
Candidates for innate cells that produce IL-33 driven type 2 cytokines in this 
model include: mast cells which secrete IL-13 but also IL-5 330,419; basophils 
secreting IL-4, IL-13 and IL-5 326; and eosinophils secreting IL-13 311.  Also, ILCs 
have been identified as an abundant source of IL-5 as well as IL-13 in IL-33 
enhanced antigen or innate airways inflammation 58,335,526. Furthermore, ILC are 
essential in viral exacerbation caused by influenza virus in complete absence of 
adaptive immunity, which is important if transferable to human studies 
explaining mechanisms of how viral infections exacerbate asthma 408.  
IL-4 is important in Th2 differentiation and B cells isotype class switching to 
produce Th2 associated antibodies IgG1 and IgE in asthma 42.  Schmitz and 
colleagues treated in vitro IL-4 polarised Th2 cells with IL-33 which produced IL-
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5 and IL-13 without a change in the already high concentrations of IL-4. In vivo, 
IL-33 treated mice developed systemic Th2 type inflammation with increased 
levels of IgE 293. While this IgE finding could by related to increased IL-4 
production, IL-4 was not detected in the serum, although increased levels of IL-4 
mRNA were measured.  Intriguingly, in the time course experiments presented 
here, only insignificant amounts of IL-4 were measured in the BAL in response to 
IL-33.  However, IL-4 can be difficult to measure in this compartment35,287. Using 
IL-4-/-mice, data here show for the first time that the Th2 cytokine IL-4 is not 
essential for the development of innate IL-33 Th2/type-2 responses in vivo.  As 
discussed, the adaptive immune response is not essential for the innate response 
triggered by IL-33 so an IL-4 independent mechanism is in keeping with this.  
Also in keeping with this data is the discovery that IL-33-mediated effector 
responses in the lungs are dependent on ILCs and this occurs in part via their 
production of IL-5 and IL-13 but not IL-4 335. In the context of allergic airways 
disease the generation of T cell and antibody responses at sensitisation in vivo, 
the mechanism of action of IL-33 could vary. Extension of the work of this thesis 
in our laboratory shows in vitro IL-33 can polarise a subset of CD4 T cells 
(antigen driven) cells to IL-5/13 producing CD4 T cells in the absence of IL-4 496. 
Furthermore, IL-33 exacerbates AAI, independent of IL-4 (further discussed in 
chapter 6) 496. A requirement for IL-4 is described for IL-33 mediated mast cell 
degranulation and IgE amplification 536. In addition, in an innate acute colitis 
model that is associated with type-2 cytokine dysregulation, IL-33 exacerbated 
disease in an IL-4 dependent manner 447. CXCL10/IP-10, VEGF and IL-17 were 
also increased in this colitis model similar to results in the AI model here but not 
in agreement with elevated CXCL9/MIG, IL-6 and IL-4 in the colitis model.  In 
contrast, IL-33 enhanced cutaneous fibrosis was found to be IL-4 independent 
537. In IL-33-induced eosinophil activation, IL-4 independent and dependent 
mechanisms are both described indicating the mechanisms for IL-33-mediated 
responses are multiple and dependent on environmental situation and 
surrounding milieu 538.   
In the innate IL-33 AI model, despite the preponderance for BALB/c mice to have 
biased Th2 responses, inflammatory responses were exaggerated in the 
classically Th1 biased C57BL/6 strain at lower doses of IL-33. The effect of IL-33 
was found to be ST2 specific. There is evidence from asthma models that 
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eosinophilic and neutrophilic cellular inflammation is higher in C57BL/6 mice 
correlating with higher eotaxin-1 levels 287.  The findings presented in this thesis 
have since been replicated by a study which showed significant differences 
between inflammation in innate IL-33 AI following 3 days administration in 
BALB/c and C57BL/6 mice 515. However data presented here also show that at 
higher doses of IL-33 with maximal inflammation, no difference seen between 
the mice strains in relation to cellular inflammation but IL-33 induced AHR was 
still dichotomous.   These observations confirm differences exist between strains 
and this must be borne in mind when interpreting data from such models.   
AHR is a cardinal feature of asthma and as IL-33 induces IL-13 production which 
is important for AHR development 53, it seemed plausible that IL-33 could also 
drive this feature.  It has been demonstrated here that IL-33 does induce AHR in 
BALB/c mice.  This is a novel finding and has subsequently been corroborated by 
other groups where it was associated with increased IL-13 lung mRNA 422,527. The 
mechanism of IL-33 induced IL-13 dependent AHR could be verified in IL-13-/- 
mice. The data here show that dosing and assessment protocols as well as mouse 
strain influence this IL-33 driven effect.  AHR was demonstrated only at highest 
levels of methacholine in BALB/c mice treated in shorter 3 day protocol despite 
significant inflammation (or peaking) at this time.  This could in part be 
explained by the chosen protocol, where a delay of 72 hours following final 
administration to time of assessment could allow the time of maximal AHR to be 
missed.  Although evidence from asthma models shows AHR persists at least up 
to 7 days or weeks following final aerosolised antigen challenge in BALB/c mice 
the profile in non-antigen sensitised mice could be different 273,282.  
Measurement of AHR 24 hours following a maximal inflammation 7 day protocol 
more robustly demonstrated AHR in these mice compared to those treated with 
PBS, at all concentrations of methacholine. It is recognised that there is 
dichotomy between eosinophilia and AHR and that the most commonly used 
mouse strains in these asthma studies, differ in their generation of these 
features 282,287.  BALB/c mice have significantly greater airways responses to 
inspired methacholine compared to C57BL/6 mice and that appears to be 
replicated in the data here.  Despite adjustments in protocol timing, it was not 
possible to generate AHR in the C57BL/6 mice.  It is not clear whether IL-33 
simply does not cause AHR in these mice or whether the protocol or assessment 
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method was not appropriate for detecting it. One study reported in abstract 
publication only suggests high dose IL-33 could induce AHR in C57BL/6 mice 
measured by invasive techniques539. Appreciation of these apparent strain 
differences may reflect different phenotypes in the response to IL-33 and further 
study could inform asthma clinical phenotypes.  
It was not possible to go on to assess the contribution of CD4 T cells to AHR as 
the RAG-/-available were on the C57BL/6 background.  Using RAG2-/- mice on a 
BALB/c background, others have shown AHR like eosinophilia, was more severe 
in the RAG2-/- suggesting a loss of regulation by adaptive immune response in the 
direct response to IL-33 422. A further important study confirmed the induction of 
AHR in these mice and the mechanism in this innate context was via NKT and NH 
(ILC) cell production of IL-13 527. In the context of AAI, maintenance of AHR, 
measured invasively, was shown to be dependent on the IL-33/ST2 pathway via 
Th2 cells in BALB/c and but not C57BL/6 mice suggesting different mechanisms 
whereby IL-33 can mediate AHR 282. 
Whilst the conclusions regarding possible different phenotypes in IL-33 induced 
AHR are interesting, it should be appreciated that there are some limitations on 
the use of Penh as a measurement of AHR and hence interpretation of results 
using it.   Enhanced pause is a dimensionless index that reflects change of 
amplitude of pressure waveform and expiratory time and thus has been criticised 
as a derived parameter not reflecting real respiratory function 285. Gold standard 
whole body plethysmography assessment would be necessary to confirm the 
findings presented here in relation to AHR in mice.  However, regarding AHR in 
mice models in general, as mice do not exhibit spontaneous airway 
hyperresponsiveness any extrapolations to the role of IL-33 in AHR in asthma 
must be guarded.   
In conclusion, data in this chapter demonstrate that IL-33 applied directly to the 
airway in the absence of antigen, acts in a ST2-dependent manner to induce 
eosinophilia and AHR.  This is associated with increased production of type-2 
cytokines and chemokines.  In particular, eotaxins CCL11 and CCL24 are found to 
be partially responsible for the IL-33 driven response but the cytokine IL-4 is not 
required.  Furthermore, this response is not dependent on lymphoid cells 
although they may enhance the response which suggests innate cells play a more 
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crucial role. This finding may help to explain non-allergic forms of asthma that 
develop independently of Th2 cells. 
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5 The role of ST2/IL-33 on epithelial cells 
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5.1 Introduction and Aims 
Asthma is classically considered as a Th2 inflammatory and overactive allergic 
antibody response.  Whilst undoubtedly important in the pathogenesis of 
asthma, trials targeting this pathway have been underwhelming aside from anti-
IgE therapy which has been beneficial in a select group of patients. This 
heterogeneous response has led to the understanding that there are multiple 
asthmatic phenotypes with distinct pathological mechanisms and to 
consideration of the contribution of other pathways, in particular structural cells 
540.  Epithelial cells (ECs) at the airway mucosal surface are the first line of 
defence and this barrier is impaired in asthma 185. They are partly, responsible 
for early non-specific innate immunity and release early danger signals such as 
HMGB-1 541. ECs also induce Th2 adaptive immunity by a variety of mechanisms 
188. Genetic studies identify links between aberrant epithelial genes and asthma 
542. Dysregulation of the repair process in asthma leads to sustained 
inflammation and subsequent remodelling. ECs have a role in promoting this by 
acquiring mesenchymal characteristics (epithelial-mesenchymal transition or 
EMT), releasing inflammatory mediators and promoting angiogenesis 175. 
Results in chapter 4 show that within the lung, there is a population of non-
immune cells expressing ST2L, capable of responding to IL-33; the number of 
which increased substantially after IL-33 treatment.  In the absence of pre-
existing inflammation, it seems plausible that other unidentified ST2+ve cells are 
the initial responder to IL-33 and resident ECs are a potential candidate.  Weak 
ST2L mRNA expression has been shown in stimulated epithelial cells and soluble 
ST2 mRNA in both unstimulated and stimulated cells 306,314. In chapter 3 the 
presence of ST2 protein was demonstrated within ECs, predominantly within in 
the nucleus. Furthermore, IL-33 induced inflammation is partially dependent on 
eotaxin and the cellular source of this is unknown; ECs may be a possible source. 
Therefore, it is hypothesised that airway ECs express ST2L and trigger IL-33 
driven inflammation and remodelling by releasing cytokines and chemokines 
including eotaxin.   Experiments in this chapter aim to identify the presence of 
ST2L on ECs and to study the effect of IL-33 on these cells in vitro and in vivo. 
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Using this information, downstream effects on remodelling in airway models 
both in vivo and in vitro will be examined. 
5.2 ST2 expression on airway epithelial cells 
Before attempting to establish primary or differentiated cell cultures, the 
expression of extracellular ST2L using a human bronchial epithelial cell line 
(HBEC), subsequently referred to as normal human bronchial epithelial (NHBE) 
cells was examined. These are immortalised cells originally derived from donor 
airways (gifted by Dr C McSharry, Glasgow, UK). 
5.2.1 Bronchial epithelial cells express ST2L 
Following on from the description of ST2 expression in the lungs in chapter 3, 
ST2 expression was assessed in the NHBE cells. Cells were grown in 4 chamber 
culture slides and ST2 expression performed using anti-ST2 antibody (Atlas) using 
the ImmPRESS (Vector) kit staining system. Figure 5.1 shows spindle shaped 
epithelial cells with predominant cytoplasmic ST2 staining in growing cells 
(Figure 5.1 A-B). No obvious difference was seen in ST2 expression in cells grown 
in culture medium supplemented with IL-33 (10-100 ng/ml)(Figure 5.1 C-D).  
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Figure 5.1: ST2 expression in NHBE cells  
NHBE grown on culture slides and stained with anti-ST2 antibody (Atlas) or isotype.  Panels (A-D) 
show ST2 staining in  cells grown in culture medium (A-B) and medium supplemented with IL-33 
100 ng/ml C) and D). Isotype control in E) x10 and F) x40 magnification.A), C), E)x10 C) and B), 
D), F) x40 magnification D).  
NHBE cell ST2 expression was further analysed by FACS. Cells were grown in 
media in 75cm2 flat bottomed culture flasks and analysed when 70-80% 
confluent. Figure 5.2B demonstrates that 12-28 % of NHBE cells are ST2+ve 
(13.45 ±1.12, mean ± sem). Cytokeratin (CK) filaments are cytoplasmic skeletal 
structures found specifically in ECs 543. Cytokeratin expression on NHBE was 
assessed with anti-pan Cytokeratin antibody (abcam, ab42460). CK expression in 
the NHBE cells was 98% positive with variation in expression intensity (Figure 
5.2C). Following on, co-staining of CK and ST2 was attempted but proved 
technically difficult with ST2 surface expression affected by intracellular 
staining methods undertaken to assess CK expression. To validate ST2 staining, 
ST2 expression was also assessed on a human mast cell line, HMC-1, an 
+ IL-33 
No IL-33 
Isotype 
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immortalised cell line known to highly express ST2.  ST2 expression was verified 
as demonstrated in Figure 5.2D.   
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Figure 5.2: Normal human bronchial epithelial cells express ST2 
NHBE were cultured, collected and stained with ST2 (unshaded) or Istoype (shaded) antibody.  A) 
Live (7-AAD-ve) NHBE were gated on FSChi and SSCmed parameters. B) ST2 expression in selected 
live NHBE cells C) Intracellular cytokeratin (CK) NHBE staining following cell fix and 
permeabilsation. Panels A)-C) are representative of at least 3 experiments D) HMC-1 mast cells 
surface ST2 expression ST2 (unshaded) or Istoype (shaded). Panel representative of duplicate 
samples from one experiment. Isotype gate <2%. 
5.2.2 NHBE ST2L expression is unaffected by IL-33 treatment 
To assess the effect of IL-33 on ST2 expression in these cells, NHBEs were 
cultured at 60-70% confluence with added IL-33 for 24 hours when ST2 
expression was assessed. IL-33 did not appear to affect the proportion of ST2+ve 
cells (Figure 5.3).  
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Figure 5.3:  NHBE cell ST2 expression is unaffected by IL-33 treatment 
NHBE were grown 6 well tissue culture plates. When 60-70% confluency was reached, hIL-33 (0.1-
1000ng m/l) was added for 24 hours.  Cells were enzymatically disrupted and stained for ST2 
expression as Figure 5.2. Panels represent NHBE ST2 expression at increasing concentrations IL-
33 noted.Red=Isotype, green=ST2. 
5.2.3 Primary murine tracheal epithelial cells express ST2L 
Following on from the studies above, it was important to assess the ST2 
expression in more physiologically appropriate primary airway ECs.  Optimally, 
ex vivo human material is used to evaluate ECs 544. However, as human tissue 
was not directly available, the decision was made to isolate murine airway ECs.  
Successful culture techniques of these cells are difficult to establish. Using  
methodology by Davidson et al,  cells were isolated from digested tracheas of 
BALB/c mice and cultured as described in more detail in chapter 2 453.  When 
analysed for CK staining this cell population reveal a sub-population of CK+ve ECs 
(Figure 5.4).  
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Figure 5.4: Isolation of murine tracheal epithelial cells 
Murine tracheas were removed and incubated ex vivo in dissociation media for 60 minutes. The 
cell suspension was rested in Petri dishes to remove more adherent cells. The suspension was 
then washed, resuspended in FACS medium, counted and stained with Isotype A) or B) CK-PE 
antibody. The number of epithelial cells was determined by expression of intracellular CK.  
Further analysis by surface ST2 staining appears to show that approximately 24% 
of ECs are ST2+ve  (Figure 5.5) . 
Unfortunately the yield was approximately 1 x105 cells per mouse, 50% of the 
published yield. Although the technique could potentially be further optimised, 
for culture purposes, the decision was taken to purchase and use primary human 
ECs.  
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Figure 5.5: The expression of ST2L in primary murine tracheal epithelial cells  
Murine tracheas were removed and cells dissociated ex vivo. (A-B) Using SSC and FSC 
parameters A) and CK staining B), EC were gated. C) The level of ST2 expression on the CK+ve 
cells, ST2  (unshaded) or isotype antibody (shaded). Isotype gate <2%. 
 
5.2.4 Primary human bronchial epithelial cells express ST2L 
Commercially available primary human bronchial epithelial cells (pHBE) 
(Promocell, Germany) were subsequently assessed for ST2L expression. Similar 
to the primary murine cells, these are isolated from donor airway epithelial 
tissue taken from above the bifurcation of the lungs. 19.6% of pHBE cells had 
detectable surface ST2 (Figure 5.6). 
C 
B A 
Chapter 5  189 
                 
m=19.5%C
ou
nt
ST2
C
ou
nt
 
Figure 5.6: The expression of ST2 on primary human bronchial epithelial cells 
Primary human bronchial epithelial cells were labelled with human ST2 (unshaded) or isotype 
antibody (shaded) and expression analysed by FACS. Representative FACS plot of n=2 
experiments. ST2 percentage expression 19.5 +/- 2.9. 
These data confirm the presence of ST2L on murine and human bronchial and 
lung epithelial cells.  
5.3 The effect of IL-33 on epithelial cells 
Having established epithelial cells express ST2L, the effect of IL-33 on cultured 
epithelial cells and on differentiated cells at an air-fluid interface, an in vitro 
airway model, was determined. 
5.3.1 IL-33 induces cytokine and chemokine production from 
NHBE cells 
ECs can initiate and perpetuate innate and adaptive immune responses by 
adhesive interactions, expression of cell surface receptors but also by selective 
release of chemokines. Epithelial-derived cytokines are not as clearly discerned 
but some novel examples TSLP and IL-25, are implicated in the pathogenesis of 
asthma 244,252,256.  To assess the contribution of epithelial cells to IL-33 induced 
inflammation in the airway, firstly NHBE IL-33-stimulated chemokine and 
cytokine production was assessed. NHBE were harvested when they reached 70% 
confluence and stimulated in 6-well culture plates with increasing 
concentrations of IL-33. Supernatants were collected 24 hours later and 
subsequently ELISA or multiplexed immunoassay was performed. Concentrations 
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of commonly produced epithelial chemokines (IL-8, MIP1α/CCL3, MCP-1/CCL2 
and RANTES/CCL5) and cytokines (IL-6, IL-1β and TNFα) were analysed. Given 
the eosinophilic profile of IL-33 in vivo described in chapter 4, eotaxins, Th2 and 
Th1 cytokines along with growth factors were also measured.   
Production of IL-8 (CXCL8) is an important function of epithelial cells recruiting 
inflammatory neutrophils.  Upon stimulation with IL-33 the NHBE cells produced 
significantly increased levels of IL-8 (Figure 5.7).  
Eotaxin was partially responsible for the IL-33 driven eosinophil recruitment as 
demonstrated in chapter 4. A very low baseline level of eotaxin was detected in 
NHBEs culture supernatants but there was no change in the eotaxin 
concentration with IL-33 treatment (Figure 5.7).  Eotaxin-2 levels were also 
assessed in the supernatants by ELISA and none was detected (data not shown). 
Other IL-33 driven chemokines produced, with the ability to direct movements of 
various cell populations include MCP-1/CCL2 and RANTES/CCL5 as well as 
MIP1α/CCL3, MIP1β and IP-10 at lower but significant amounts (Figure 5.7).  
These results show epithelial cells can attract a number of immune cells in 
particular neurophils, monocytes/macrophages and T cells in response to IL-33. 
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Figure 5.7: See over for legend 
 
Chapter 5  192 
Figure 5.7: NHBEs produce chemokines in response to IL-33 
NHBE were cultured until 70% confluent then cultured in 6 well tissue culture plates for 24 hours 
with increasing doses of recombinant hIL-33 (axxora). Culture supernatants were collected and 
cytokine and chemokine profile assessed on multiplex or elisa. Results shown are mean of 
technical duplicates (± SD) analysis wells from the same experiment. One way anova for the effect 
IL-33 on IL-8 p<0.001; eotaxin p=ns; MCP-1 p<0.01; RANTES p=0.01; MIP-1α p<0.01; MIP-1β 
p<0.01; IP-10 p<0.001. Results are representative of 2 or more experiments. p=non-significant. 
Of the pro-inflammatory cytokines measured, IL-6 and TNFα results are shown in 
Figure 5.8. Production of IL-6 from ECs was increased with IL-33 treatment. 
TNFα was produced in small amounts but this was unaffected by IL-33. The anti-
inflammatory Interleukin-1 receptor antagonist (IL-1RA), was produced in 
significant amounts by the ECs but this was unchanged with IL-33 treatment and 
no IL-1β was detected in the supernatant (data not shown). 
IL-12p40/p70 production was induced by IL-33 but IFNγ or other type 1 cytokines 
were not produced. NHBE cells produce increased levels of IL-2R (Figure 5.8) 
however no IL-2 was detected in the supernatants following IL-33 treatment 
(data not shown). Soluble IL-2R is elevated in patients with epithelial cell 
tumours but the clinical significance is unclear 545.   
With regard to type-2 cytokines, an increase in IL-4 production was observed but 
this was at low levels (Figure 5.8).  Neither IL-5 nor IL-13 were produced (data 
not shown). 
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Figure 5.8: NHBEs produce cytokines in response to IL-33 
NHBE were cultured with IL-33 as described. Culture supernatants were collected and cytokine 
profile assessed on multiplex immunoassay or ELISA. Results shown are mean of technical 
duplicates ± SD from the same experiment. One way anova for the effect IL-33 on IL-6 p<0.01; IL-
1RA p=ns; IL-2R p<0.05; IL-4 p<0.01. Results are representative of 2 or more experiments. p=non-
significant. 
Epithelial cells also produce a range of growth factors.  Of those measured, 
vascular endothelial growth factor (VEGF), a potent angiogenesis stimulant was 
induced with IL-33 treatment. Cytokine growth factors GCSF and GMCSF were 
produced in small amounts with the change in GCSF in response to IL-33 reaching 
statistical significance. Basic fibroblast growth factor (or FGF-β) which promotes 
fibroblast proliferation and angiogenesis was also released (Figure 5.9).  
Mediators produced by epithelial cells showing some increases but at low levels 
are MIG, IFNα, HGF and IL-17. Other cytokines and chemokines measured by 
multiplex assay or ELISA and not induced by IL-33 in epithelial cells are IL-7, IL-
10, IL-15 and EGF (data not shown). 
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Figure 5.9: NHBEs produce growth factors in response to IL-33 
NHBE were cultured with IL-33 as described. Culture supernatants were collected and cytokine 
profile assessed on multiplex or elisa. Results shown are mean of technical duplicates (± SD) from 
the same experiment. One way ANOVA for the effect IL-33 on VEGF p<0.01; G-CSF p<0.001; GM-
CSF p=ns; FGFβ p<0.001. Results are representative of 2 or more experiments. ns=non-
significant.  
5.3.2 IL-33 induces dose dependent production of IL-8 and VEGF 
from NHBE cells 
To further investigate the IL-33 induced IL-8 and VEGF production, dose response 
experiments were performed. From screening immunoassays and ELISA, an 
increase in mediator secretion appeared to occur at 10 ng/ml IL-33 and possibly 
inhibited at higher concentrations of 100ng n/ml and 1000ng/ml (1000ng/ml 
data not shown). To determine an optimal dose for IL-33 treatment a more 
detailed dose response was characterised by using 0.01-100 ng/ml IL-33 with IL-8 
and VEGF concentrations measured by ELISA after 24 hours IL-33 treatment. A 
dose response seen in Figure 5.10 was obtained for IL-8 and VEGF with 10ng/ml 
and 100 ng/ml respectively the optimal concentrations reflecting different 
dynamics of release.  
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Next, the effect of corticosteroids on this response was determined. Further 
groups of cells were treated with 10 ng/ml of IL-33 with or without the potent 
steroid dexamethasone.  The release of IL-8 was inhibited by the co-
administration of dexamethasone. However, the release of VEGF was unaffected 
by the addition of dexamethasone demonstrating distinct regulation in IL-33 
induced mediators induced in epithelial cells. 
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Figure 5.10:  IL-8 and VEGF production by NHBE cells is dose dependent and differentially 
corticosteroid sensitive  
NHBE cells were cultured as before and cells treated with increasing concentrations of IL-33. After 
24 hours culture supernatants were removed and IL-8 and VEGF assessed by ELISA. A) Dose 
response graphs of A) IL-8 and B) VEGF. C) Further culture wells were treated with IL-33 10ng/ml 
with or without Dexamethasone (100nM) (Dex). Results shown are mean ± SD for 2-10 culture 
replicates. *p<0.05, **p<0.01,*** p<0.001 for IL-33 vs control in A and B or otherwise as shown. 
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5.3.3 The effect of IL-1β,TNFα and IFN γ on IL-33 induced 
cytokine release from NHBE cells 
The above data demonstrate a range of mediators produced from epithelial cells 
in response to IL-33 treatment.  In the EC microenvironment common inducers of 
cytokine responses from ECs are the pro-inflammatory cytokines IL-1β, TNFα and 
IFNγ. In combination these cytokines or “cytomix” is often used experimentally 
to replicate this environment 546. Therefore, a set of experiments was performed 
to assess whether IL-33 would have any additive effect on that of cytomix on the 
EC production of IL-8 and VEGF.  It would be expected that cytomix would 
induce release of IL-6 so this was also measured.  
NHBE were plated out in 24 well culture plates and different combinations of IL-
1β, TNFα and IFNγ as well as IL-33 added to the culture wells.  The 
concentrations of IL-1β, TNFα and IFNγ used were based on published 
experiments with a final concentration of 10 ng/ml in combination with 10 
ng/ml of IL-33 as determined by the preceding data 546.  
Results are shown in Figure 5.10. When reagents were added individually, 
concentrations of IL-6 and IL-8 in the supernatants increased most potently with 
IL-1β or TNF-α.  In comparison with IL-33 alone, they induced an approximate 7 
fold or 20 fold increases in IL-6 and IL-8 production respectively.  The 
combination of IL-1β and TNFα appeared most synergistic, with IFN-γ not 
enhancing the IL-1β or TNF-α driven production. However, the cytomix 
combination was the most potent.   IL-33 appeared to have synergistic effect on 
most combinations but the magnitude of this effect was small.   
In contrast, VEGF production was only strongly enhanced when IL-33 added to 
cytomix. This suggests adding IL-33 into a pro-inflammatory milleu can influence 
EC-induced angiogenesis potential.  
These data indicate that the surrounding environment and presence of other 
mediators will have implications on the effect of IL-33 on ECs in vivo.  
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Figure 5.11: IL-33 induces synergistic cytokine and chemokine production with IFNγ, IL-1β 
and TNFα in NHBE cells 
NHBE cells were cultured on 24 well plates and cells treated with fresh media containing 
combinations of IFNγ, IL-1β, TNFα and IL-33 all at 10 ng/ml as annotated in graph.  After 24 hours 
culture supernatants were removed and IL-6, IL-8 and VEGF concentrations assessed by ELISA. 
Results shown are of single culture wells.  
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5.3.4 IL-33 does not induce NHBE proliferation in vitro 
Having shown IL-33 enhances chemokine and cytokine production from NHBE 
cells, in order to assess whether this could be explained by an increase in cell 
number, cellular proliferation was assessed. NHBE were cultured with IL-33 for 
24 or 48 hours and a further group grown in serum free media for 24 hours 
before IL-33 added to encourage a quiescent state. Proliferation was assessed by 
the colorimetric assay MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) and was unaffected under the various conditions with IL-33 treatment 
(Figure 5.12A). This was confirmed by measuring 3H thymidine uptake which was 
unchanged in cells treated with IL-33 for 24 hours compared to control (Figure 
5.12B). 
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Figure 5.12: Proliferation of NHBE cells is unaffected by IL-33 treatment 
Cells were grown in media with increasing concentrations of IL-33 for 24 hours or 48 hours and a 
further group of cells were kept in serum free media for the 24 hours preceding IL-33 treatment. 
Proliferation was measured by colorimetric assay, MTT following manufacturers instructions and A) 
or B) by 3H Thymidine incorporation (for last 8 hours of culture) in the 24 hour treatment group. 
Results are counts +/- mean of triplicate wells. One way anova for the effect of IL-33 on 
proliferation p=non-significant. Representative of 3 experiments.  
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5.3.5 The effect of IL-33 on primary human epithelial cells 
Having determined the ability of IL-33 to induce cytokine production in NHBE 
cells, the effect on pHBE was assessed. The effects on the cells of epithelial 
stimulant cytomix, was also determined. Direct microscopy of growing pHBE 
cells is seen in Figure 5.13. 
 
 
 
 
 
 
 
Figure 5.13:   Morphology of primary human bronchial epithelial cells 
pHBE grown per manufacturers instructions on 75 cm2 culture flasks. Cells viewed x10 A) and x20 
B) magnification by light microscopy. C) Phase contrast microscopy x20 magnification. Non-
confluent monolayer of primary epithelial cells demonstrating spindle shape and early cobblestone 
morphology. 
These cells were treated in vitro with IL-33 or in combination with cytotmix (IL-
1β, TNFα and IFNγ, all 10 ng/ml).   As anticipated, in agreement the with NHBE 
data, IL-33 significantly induced the production of IL-8 from the pHBEs in a dose 
dependent manner after 24 hour culture (Figure 5.14B).   A further set of 
experiments were undertaken co-treating the pHBE with cytomix and IL-33, with 
cell culture supernatants taken at 6, 12, 24 and 48 hours to determine any time 
dependent effect. Cytomix stimulated the cells to produce large quantities of IL-
8.  Like the NHBE, IL-33 appeared to be synergistic with the cyotmix over time 
but overall the magnitude of the effect of IL-33 was less than cytomix 
stimulation (Figure 5.14B). A similar pattern was seen with IL-6 (data not 
shown). 
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VEGF production from the pHBEs was similarly dose dependent. In contrast to 
the NHBE, these cells produced a substantial quantity of VEGF in response to the 
cytomix.  This was enhanced by IL-33 by 24 hours (Figure 5.14C) (6,12 hour data 
not shown). 
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Figure 5.14: IL-8 and VEGF are released by primary bronchial epithelial cells in a dose 
dependent manner and enhanced by cytomix 
Primary HBE were cultured as previously described and plated onto 12 well tissue culture plates 
(density 10,000/well) for 12, 24 or 48 hours with increasing concentrations of IL-33.  Some wells 
had co-treatment with cytomix (IFNγ, IL-1β, TNFα at 10ng/ml) and supernatants were analysed for 
IL-8 and VEGF concentrations by ELISA.  A) Dose response curve IL-8 B) Time course IL-8 C) 24 
hours dose response VEGF. Results shown are mean of duplicate experimental wells +/- SD 
except for cytomix experiments where results are single samples. One way ANOVA for effect of IL-
33 on IL-8 p <0.05; and on VEGF p<0.05.   
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The epithelium can trigger innate responses by recognising PAMPS through the 
TLRs185. Polyinosinic-polycytidylic (poly(I:C)) is a synthetic analogue of double 
stranded RNA (dsRNA), a molecular pattern shown associated with viral infection 
and recognised by TLR3. TLR3 activation is a mechanism through which viral 
infections contribute to exacerbations of asthma 547. To directly compare the 
effects or TLR3 and ST2 activation in vitro, pHBE cells were treated with IL-33 or 
Poly (I:C). Poly (I:C) induced stimulation of IL-8, IL-6 (and MIP1α) and had a far 
greater effect than IL-33 on the pHBEs.  VEGF levels were comparable further 
suggesting the most important output from epithelial cells in response to IL-33 is 
VEGF. 
 
                             
0
1000
2000
3000
4000
5000
6000
7000
cm Poly(I:C) IL-33
pg
/m
l
IL-8
IL-6
VEGF
 **
*
*
*
 **
*
*
 
Figure 5.15: Primary epithelial cell cytokine and chemokine production is greater with TLR3 
than ST2 stimulation  
Primary NHBE were cultured as previously described and plated onto 12 well tissue culture plates 
(density 10,000/well).  Cells were treated with Poly (I:C) (10μg/ml) or IL-33 (10ng/ml ) for 24 hours. 
Supernatants were analysed for IL-8, IL-6 and VEGF concentrations by ELISA.  Results shown are 
mean of triplicate experimental wells +/- SD. cm=complete media. *p <0.05, **p<0.01. 
 
5.3.6 The effect of IL-33 on polarised epithelial cells 
In vivo, the epithelium is composed of differentiated epithelial cells, ciliated or 
non ciliated (secretory and basal) cells separated from underlying mesenchymal 
cells by a basement membrane (BM). BM’s are made of type IV collagen and 
other materials 548. Cells are arranged in a pseudostratified manner with all cells 
in contact with the BM but only some reaching the luminal surface. Having 
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characterised the effect of IL-33 on epithelial cell lines and pHBE cells, in order 
to further investigate the role of IL-33, it was important to use a system that 
could better mimic the characteristics of these in vivo differentiated epithelial 
cells 549,550. For in vitro models, differentiation is commonly achieved by growing 
the cell cultures at an air-liquid interface (ALI) 549. Cells are usually grown on a 
permeable membrane of tissue culture inserts with collagen support, allowing 
the generation of apical and basal layers.   
Without regular access to donor primary human cells, the aim was to develop 
primary culture from mouse tracheal cells based on a novel method growing 
murine airway ECs on a native basement membrane 454. The basal membrane is 
generated by Madin-Darby canine kidney (MDCK) cells 455  and contains normal 
components of an epithelial basal lamina including type IV collagen 551 and as 
such more representative of the in vivo state. These methods are more fully 
described in chapter 2. However, in pilot experiments a large number of mice 
were required to obtain a significant amount of cells (see above). Therefore, the 
decision was taken to extend these methods to use the NHBE cells in the same 
native BM model.  
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Figure 5.16: Generating an in vitro model of differentiated respiratory epithelium 
Transwell tissue culture inserts (0.4μm or  8 μm) with collagen on apical surface were placed in 6 
well culture plates. Collagen BM is collagen-only basement membrane on 0.4 μm culture inserts. 
Native BM was formed by applying Madin-Darby canine kidney (MDCK) cells to the apical surface 
of the collagen gel on 8μm transwells for 3 weeks when the cells were removed by osmotic and 
detergent lysis. NHBE were grown in submerged culture on the collagen BM or native BM until 
confluence was reached after which they were exposed to an air-liquid interface for differentiation.  
Electron microscopy (EM) assessment of the airway epithelial cell morphology is 
the gold standard for confirmation of a ciliated, pseudostratified epithelium 455. 
Other features of differentiation include the development of stable 
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transepithelial electrical resistance (TEER) reflective of development of tight 
junctions and so without EM, the TEER was used to confirm differentiation in 
these cultures 552 (Figure 5.16). The morphology of the cells on the native BM is 
shown in Figure 5.17. 
 
 
 
 
 
 
Figure 5.17: Morphology of NHBE on native collagen/MDCK derived BM 
Phase contrast image of transwell culture inserts with and without cells at ALI on the surface. 
Sheets of tightly packed epithelial cells are seen with a cobblestone appearance. Magnificaion x 
20. TEER measured on the transwell 140-150 (Ω.cm2) 
To assess whether these differentiated cells had similar angiogenic profile of 
mediator production as NHBE and primary cells, IL-33 was added to the basal 
surface culture medium. Cells grown on collagen only BM showed small increases 
in production of IL-6, IL-8 and VEGF at low levels of IL-33 stimulation (Figure 
5.18A).  Higher concentrations of IL-33 (≥100 ng/ml) were possibly inhibitory 
(data not shown).  There was no significant production of eotaxin, MIP-1α or IL-
17 (data not shown). Cells grown on the native BM produced increased VEGF 
higher concentrations of IL-33. In contrast, IL-6 and IL-8 production did not 
increase with IL-33 treatment (Figure 5.18B).  
The results in this section represent preliminary data because of time 
constraints on this project further experimentation was not possible. A number 
of limitations were encountered; the technique is novel so further work required 
to optimise and validate it; the development of each in vitro culture system 
takes several weeks (3-6); inter-experiment comparison was difficult with varied 
levels of mediator production and the reasons for this are unclear.  However, it 
does seem that VEGF is reproducibly produced from differentiated epithelial 
cells in response to IL-33. Further work includes consolidating the technique and 
performing a scanning EM to identify ciliated cells as well as optimising IL-33 
concentrations and treatment duration. Following this, using primary cells a 
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robust, differentiated model to fully elucidate the effects of IL-33 on airway 
epithelial cells can be used.  Subsequently, this could be modified with ‘diseased 
cells’ and cells transfected with virus to mimic in vivo states.  
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Figure 5.18: Cytokine and chemokine production from differentiated NHBE cells 
NHBE were grown on either A) on collagen gels 0.4μm transwell inserts (collagen only BM) or on 
B) a MDCK derived membrane deposited on collagen gel on 8μm transwell inserts (native BM) 
When cells reached confluence, they were exposed to an air-liquid interface for differentiation. 7 
days later increasing concentrations of IL-33 were added to the culture medium and 24 hours later 
supernatants collected and concentration of mediators measured by ELISA. Results shown are 
mean +/- SD of 2 independent experiments in A) and representative of 3 independent experiments 
in B). 
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5.4 IL-33 induces angiogenesis and vascular remodelling 
in the lung 
In chapter 4, following exogenous treatment of mice airways with IL-33, an 
increase in the production of the pro-angiogenic factors VEGF and KC was seen 
within 24 hours, suggesting resident cells were responsible. One type of resident 
cell, the epithelial cell expresses ST2L and moreover, IL-33 drives production of 
VEGF and IL-8 from these cells.  Hence to further investigate the effect of these 
IL-33 promoted pro-angiogenic factors, evidence of a subsequent angiogenesis 
and remodelling effect was sought in vivo.   
5.4.1 IL-33 increases endothelial cells in lung 
Angiogenesis is the growth of new blood vessels from existing ones and 
remodelling involves structural changes in the vessels with the formation of new 
ones 553.  Features of pulmonary vascular remodelling include changes in all 
layers of the vessel wall with fibroblasts, smooth muscle cells as well as 
endothelial cell proliferation involved 554.  VEGF is an endothelial-specific 
mitogen and involved in angiogenesis 206. Therefore to ascertain if IL-33 might 
result in endothelial cell changes through VEGF or other mechanisms, whole lung 
digests from mice treated with IL-33 were analysed for the presence of CD31+ve 
cells, a marker for endothelial cells. 
Figure 5.19 shows lungs treated with IL-33 have increased numbers of 
endothelial cells. To ascertain if like epithelial cells, endothelial cells can 
respond directly to IL-33 and amplify the response among structural cells, co-
expression of ST2 should be measured. Unfortunately, the available CD31 
antibody was labelled with the same fluorochrome as the only ST2 FACS antibody 
so a direct or indirect effect could not be determined.  
Chapter 5  207 
  
C
ou
nt
CD31
m=53.65%
C
ou
nt
 
Figure 5.19: IL-33 increases endothelial cells in the lung  
BALB/c mice were given PBS or 2 μg IL-33 or PBS intranasally for 7 days. Lungs from individual 
mice were collected, digested and single cell suspensions prepared as previously described.    
Cells were stained with CD31 or isotype antibodies.   A histogram of CD31 expression is shown. 
Filled histogram isotype control and unfilled CD31 expression in PBS (green line) and IL-33 (red 
line) treated mice. Data shown is representative plot.   CD31 expression in PBS treated mice 4% 
and in IL-33 treated mice 53.65 %.  
 
5.4.2 IL-33 increases in vascular remodelling in lungs 
Next, the ability for IL-33 induced BAL VEGF and KC to lead to vascular 
remodelling in the lungs was assessed.  Using the i.n. IL-33 model (Figure 4.1-2) 
lungs of individual mice were fixed in formalin and then histological sections 
stained for von Willebrand factor (vWF) using immunohistochemical methods. 
VWF is made within endothelial cells which line vessels and is crucial in the 
formation of blood clots. An angiogenic index was developed for assessment: the 
numbers of vessels were identified by the presence of a clear structural lining 
and positive staining for vWF; 10 fields that included both airway and vessel 
were then assessed per slide  and index calculated using imaging software (see 
methods chapter 2).  Two blinded assessors quantified the changes.  
IL-33 treated lungs had significantly increased number of blood vessels identified 
by vWF staining. (Figure 5.20 A-D). This increase in blood vessels resulted in a 
trend of increased in percentage lung area covered by vessel but this did not 
reach statistical significance. 
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Figure 5.20: IL-33 drives vascular remodelling in the lung 
In mice treated with intranasal IL-33, lungs removed were fixed and stained with vWF. 
Representative sections are shown in A) PBS and B) IL-33 treated lungs. The sections were 
analysed for C) vessel number and D) vessel area as a percentage of overall area.  Results shown 
are mean each group +/-SEM, n= per group. Arrowheads represent vessels.  *p<0.05. 
The increase in vascular remodelling driven by IL-33 is hypothesised to be 
mediated by the release of VEGF from the ECs.  To conclusively demonstrate 
this, neutralisation of the growth factor with resultant inhibition of angiogenesis 
is required. Using the conditioned media from experiments in Figure 5.10, 
human endothelial cells (HUVEC) formed tubule with increased branching points 
in an in vitro angiogenesis assay. This effect was eliminated when the 
conditioned media was pre-incubated with VEGF neutralising antibody (assay 
performed by Dr M Shepherd) (Figure 5.21). 
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 Figure 5.21: IL-33 treated NHBE promote VEGF dependent angiogenesis 
Endothelial cells grown on collagen plugs in culture medium enriched with 50% NHBE conditioned 
medium (CM) A) or IL-33 treated NHBE conditioned medium (IL-33) B). Some medium was pre-
treated with anti-VEGFantibody before addition to endothelial cells C). Branchpoint frequency D) 
and tubule number E) were assessed.  
5.5 Conclusions 
The work presented in this chapter aims to address the role of ST2 on airway 
epithelial cells and endothelial cells.  In summary, ST2L is present on airway 
epithelial cells and that its activation by IL-33 leads to release of inflammatory 
and pro-angiogenic mediators which in turn drive vascular remodelling in the 
lung.  
The cell(s) initially responsive to IL-33 in the airway is not clearly elucidated. In 
chapter 4, a significant number of unidentified resident cell ST2+ve cells were 
found in healthy lungs. 
Activated epithelial cells weakly express ST2L mRNA 306.  ST2 protein by 
immunohistochemical analysis has been demonstrated in chapter 3. The 
abundance or expression of membrane bound ST2 or its function on airway 
epithelial cells was not known. These data clearly shows that resident epithelial 
cells in healthy lungs, epithelial cell lines and primary airway epithelial cells 
express surface ST2L capable of responding to IL-33 in vivo. More recently, ST2 
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mRNA and protein expression has been verified in airway ECs 320,555 and also 
endothelial cells but not other resident tissue cells, rested fibroblasts or smooth 
muscle cells 320. Data here show the presence of IL-33 did not affect the 
expression level of ST2 on EC in in vitro experiments.  Subsequent to this work, 
others have shown different factors may influence ST2 expression on ECs with IL-
4 enhancing expression of ST2 in NHBEs at a mRNA and protein level 320. More 
recently, morphology of ECs found to be unaltered in IL-33 treatment and ST2 
expression was enhanced by IL-13 in differentiated goblet cells but not ciliated 
cells 556.  
The role, if any, of ST2 in the development in epithelial cells has not been 
considered here but is not known to be involved in the development of Th2 or 
mast cells338. ST2 forms a receptor complex with IL-1RAcP with NFκB and MAPK 
signalling induced by IL-33. The signalling pathways in ECs was not specifically 
addressed here but others have shown IL-33 induces ERK, JNK but not p38 
phosphorylation in NHBEs 320,555 and collaborative data from our laboratory using 
cells generated from experiments presented here agree with this data 
(Mirchandani A, unpublished results).  
The effector function of IL-33/ST2 on epithelial cells was considered and when 
treated with IL-33 in vitro, EC produced a range of pro-inflammatory and pro-
angiogenic mediators were produced including IL-8, IL-6, and VEGF. Interleukin-8 
was released from NHBEs and pHBEs. This was dose dependent at physiological 
concentrations of IL-33 and inhibited by CS in agreement with later published 
studies 320. IL-8 (CXCL8) is a neutrophil chemotactic factor and is an important 
mediator in the acute innate immune response, often secreted by cells following 
TLR activation. It also triggers phagocytosis and is also a potent promoter of 
angiogenesis 557. As described, asthma phenotypes include those with a 
neutrophilic predominance but it is unclear if IL-33 role has a role in this less 
well investigated phenotype. Concentrations of other CXCL family neutrophil 
attractants; epithelial neutrophil attaractant-78 (ENA-78)/CXCL5, GROα/CXCL1, 
and GROβ/CXCL2 were not measured but would be useful to investigate the role 
of IL-33 in neutrophil recruitment.  
In chapter 4, eotaxin/CCL11 was identified as partially responsible for the IL-33 
driven eosinophil recruitment; ECs are hypothesised as the source.  However, 
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little or no eotaxin was measured in the samples from any of the cell types 
measured here.  It is possible a second co-stimulus is required for eotaxin 
release in vivo. In concordance, TNFα induces eotaxin production from ECs, 
which is further enhanced by Th2 cyotkines 558. However, it is most likely that 
ECs are not the main source of eotaxin in IL-33 driven eosinophilia.  Potential 
candidates are fully considered in chapter 4 with fibroblasts the most likely 
source 530. In keeping with the view that ECs have the capacity to recruit 
immune cells in response to a danger or inflammatory signal, IL-33 induces the 
release of MCP-1, RANTES, MIP1α and MIP1β, predominantly attracting 
monocytes, T cells and eosinophils.  
IL-6 production from epithelial cells was enhanced by IL-33. IL-6 is pleiotropic 
cytokine and as an anti-inflammatory cytokine it inhibits TNF-α and IL-1 while 
activating IL-1Ra and IL-10 559.  Interestingly, as IL-6 can regulate CD4 T cell 
responses, promoting IL-4 production during Th2 differentiation and inhibiting 
Th1 differentiation, it could be a further mechanism of IL-33 mediated Th2 
responses 221. 
With regard to Th2 cytokines, only low levels of IL-4 were produced indicating 
EC are not a significant source of IL-5 and IL-13 measured in vivo in response to 
IL-33.  ECs can produce Th2 cytokines but are more likely to influence mast cell 
or T cell production of these cytokines by the release of secondary mediators. 
IL-12 was produced, promoting Th1 and antagonising Th2 differentiation but 
other type-1 cytokines such as IFNγ were not produced. Inducible IL-12 
production from ECls has been reported in response to viral infection. 
Interleukin-12 also promotes anti-angiogenic activity directly and by promoting 
anti-angiogenic factor IP-10, which was produced here at a low concentration in 
NHBEs 560. This suggests some homeostatic anti-Th2 or anti-angiogenic activity. 
The surrounding microenvironment in which these mediators are produced is 
important in determining whether levels produced translate to a clear effect in 
vivo.   Cytokine growth factors G-CSF and GM-CSF release are often stimulated 
from epithelial cells by bacterial endotoxins or IL-17 561,562. These growth factors 
increase bone marrow stem cell release and neutrophil and eosinophil survival 
512,563. GM-CSF can also act as a true chemotaxin for eosinophils at higher 
concentrations 564. Hence, EC could contribute to IL-33-induced eosinophilia. 
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Basic fibroblast growth factor (bFGF) is a strong mitogen for fibroblasts at low 
concentrations and a chemoattractant at high concentrations. Proliferation of 
lung fibroblasts has been shown to play a role in the induction of airway 
remodelling565. In the asthmatic airways EMT contributes to fibroblast population 
and a population of sub-epithelial myofibroblasts accumulates 566. The role of IL-
33 induced bFGF from ECs could contribute to this pathology but requires further 
investigation. Latest studies suggests IL-33 can directly promote remodelling via 
fibroblast production of collagen and firbronection 491. At another mucosal 
surface, the skin, IL-33 promotes fibrosis in an IL-13 dependent manner with up-
regulation of genes involved in ECM formation including collagens and MMPs 537. 
Of particular note, the production of VEGF from epithelial cells was found 
consistently through the cell lines, primary cells and polarised airway model. 
VEGF has been detected in tissue and samples from asthmatics and is related to 
severity 205,567. VEGF is a multifunctional angiogenic regulator that contributes to 
asthma pathology predominantly by angiogenesis but also stimulates epithelial 
cell proliferation and endothelial cell survival 568. VEGF promotes vascular 
permeability and so the early rise in VEGF in vivo in response to IL-33 shown in 
chapter 4 will also promote plasma leakage and inflammation. Angiogenesis 
occurs acutely with allergen challenge 569 and in an allergen environment, IL-33 
driven VEGF could potentially contribute to this. Other VEGF producing cells 
include macrophages and mast cells but neither appear to produce VEGF in 
response to IL-33 directly but rather it augments release in the case of mast 
cells 445,570. IL-33 enhanced VEGF production in vivo is seen in a colitis model in 
mice 447.The secreting cells are not identified but given a similar mucosal 
surface, the EC is a candidate. Beyond the vasculature, VEGF has further 
functions including Th2 inflammation which will also be enhanced by IL-33 
induced VEGF 206.  
The observation that VEGF production is uninhibited by CS is significant, 
suggesting any clinically driven IL-33-induced VEGF-mediated angiogenesis would 
continue unchecked regardless of a diminished inflammatory response. This 
finding of CS insensitivity here goes against published studies of diminished VEGF 
production with CS 571. IL-33 expression on airway smooth muscle cells has also 
been shown to be resistant to CS, therefore IL-33 release and effector function 
could be beyond the scope of current asthma treatments 399.   
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To mimic proinflammatory conditions, NHBEs or pHBEs were also exposed to a 
cytomix (TNFα, IFNγ and IL-1β) or poly(I:C) to mimic viral infection. As would be 
expected, IL-8 and IL-6 production were increased under these conditions and 
although this was enhanced by IL-33 the amplification of these cytomix factors 
outweighed that of IL-33. Release of VEGF was noticeably increased when cells 
were treated with IL-33 alongside cytomix and the amount produced in response 
to poly (I:C) was only modestly more than with IL-33.  This suggests VEGF may be 
a more specific IL-33 driven response. Interestingly, with similar stimulation 
release of sST2 but not IL-33 has been detected from primary human cells 316. 
In contrast to the data presented here, subsequent similar results published 
describe only IL-8 being produced from primary NHBEs from 2 donors.  There was 
no IL-6, IL-4, MCP-1, IP-10, IL-12 and in agreement with data here no IL-5, IL-10, 
IL-13, TNFα, IL-1β 320. Other growth or angiogenic factors were not measured.  
Results from different donors may vary but these published results are more in 
keeping with the results presented here from the polarised cells.  
A number of EC cell types were used in these experiments looking at ST2 
expression and IL-33 mediated effects and so a number of limitations need to be 
considered. The majority of experiments were performed in a NHBE cell line, 
originally from a primary donor, subsequently immortalised. A range of EC 
techniques are described and successfully performed in HBECs 572. Although cell 
lines provide a useful tool readily accessible for investigation they may have 
undergone significant changes to avoid senescence which could affect biology. 
Other cell lines should be used in repeat experiments for comparison including 
BEAS-2B and the alveolar epithelial cells A549. 
The murine cells used for ST2 expression were tracheal rather than bronchial in 
origin. One study in humans showed a high level of similarity between cells of 
tracheal and bronchial origin within and between different human donors in a 
genome-wide expression profile comparison 550. Although a good potential source 
of primary cells, the main limitation found using the murine tracheal cells is in 
the number of cells produced. Although there is scope to optimise this protocol, 
to overcome this problem an alternative technique could be to use the murine 
nasal septum, which has been shown to be a good source of murine respiratory 
epithelium 573. FACS analysis of CK (intracellular) and ST2 (surface) was 
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consistently difficult to interpret when combined despite straightforward single 
antibody analysis. ST2 binds non-specifically to dead cells and despite 
appropriate washes and exclusion for these, this may affect interpretation. 
Identification of ECs from whole lung digests has subsequently been identified 
using a robust gating strategy of FSChiSSCmed, EpCAM+ (epithelial cell adhesion 
molecule), CD45- and MHCII- 574. Alternate markers of EC including MUC5AC 
(goblet cells) 575, acetylated α-tublin 556 and E-cadherin 576 could be attempted 
by FACS or using immunohistochemistry techniques.  
In an attempt to imitate the in vivo polarised nature of epithelial cells, an in 
vitro culture differentiated culture system was established. Compared to in vivo 
studies these models have advantages of flexibility, controlled experimental 
conditions, and opportunity for intervention. Overall the mediator output from 
these cells appeared more muted, with VEGF being the most reproducible 
mediator.  High baseline levels of IL-8 in these cells meant any additional effects 
generated by IL-33 was hard to distinguish.  Recently, using a system of collagen 
only BM and differentiated NHBE (primary donor), Tanabe et al also found no IL-
33 mediated increase in IL-8. However, differentiated EC subtype goblet cell, 
achieved by supplementing media with IL-13, did secrete apical IL-8 via a ST2-
ERK pathway 556.  
Because of the limitations in availability of primary cells, NHBEs were used in 
establishing the system. Some cells lines are reported to differentiate and 
develop tight junctions less well than primary cells, which could explain some of 
the findings 577. Using commercial primary cells is unlikely to eliminate this 
limitation as donor-to-donor variability in development of differentiation exists 
577. Primary murine respiratory epithelial cells from the nasal septum from 
inbred mouse strain grown on a native BM could provide a novel solution to this 
variability, using this alongside primary human cultures when available for 
comparison.  It is also important to consider the EC in asthma as its inherent 
dysfunctional nature could respond differently to IL-33. A fully validated culture 
system such as that described will be invaluable in studying more fully the 
effects of IL-33 on epithelial cells function. This requires confirm of 
differentiation where EM to identify cilia, secretion of mucus and development 
tight junctions or zona occludens demonstrated by stable transepithelial 
resistance or immunoflourescene for zo-1 could be used.  
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In asthma, there is an increase in airway vessel number and size 578.  The number 
of endothelial progenitor cells (EPCs) correlates with an increase in vessel 
number 579. The generation of new vessels is suggested to cause swelling and 
stiffening of the airway wall and hence affect airflow obstruction as well as 
remodelling effects. IL-33 drives the production of VEGF from epithelial cells, 
therefore its role in angiogenesis in the airway and considering features 
comparable to asthma were investigated. The number of endothelial cells in the 
lung was increased in the lungs of mice treated with IL-33. It was not possible to 
say whether this increase was created by proliferation of resident cells or influx 
of EPC recruited directly or indirectly. Recruitment of EPCs appears to be 
dependent on IL-8 and IL-8 receptor (CXCR2) knockout attenuates bronchial 
angiogenesis in pulmonary ischaemia 580. In support of this, data here shows IL-
33 induces IL-8 as well as other angiogenic factors RANTES, FGF, MCP-1 in 
response to IL-33 581. Along with VEGF these factors aid promotion of an 
angiogenic switch akin to asthma 579. In humans, ST2 mRNA expression has been 
described in endothelial cells and is proliferation dependent (in HUVECs) thus IL-
33 could also exert a direct effect 306,315,320,582.  Endothelial cells secrete IL-8 and 
IL-6 in response to IL-33, a further source of these mediators in vivo 582. The 
direct effects of IL-33 on endothelial cells were further investigated by Choi et 
al. They showed the number of CD31+ cells in tissue, by immunofluoresence, 
were increased by IL-33 treatment with endothelial cell chemotaxis and 
proliferation also enhanced. These findings were dependent on IL-33 and 
appeared to be mediated by nitric oxide (NO) production in the endothelial cells 
413.  
Angiogenesis is a pathologic component of asthmatic airway vascular remodelling 
and also occurs acutely with allergen challenge 569. This correlates with the 
finding in chapter 4 of increase in BAL VEGF within 24 hours of airway challenge. 
The effect of IL-33 on remodelling was ascertained using an in vivo model. There 
was a significant increase in the number of VWF positive blood vessels following 
exposure to IL-33. The mechanism appeared to be via the release of VEGF as in 
vitro VEGF blockade resulted in reduction of microtubule vessel formation.  
Extending this work by measuring VEGF, KC and GRO-β /CXCL2 levels in lung 
homogenate and in vivo blockade of VEGF to confirm this mechanism would be 
of value. 
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Further work examining other aspects of remodelling would be of interest 
including: identification of collagen (Sirius red) and quantification of total 
collagen in lung tissue;  identification of peri-bronchial smooth muscle thickness 
(α-smooth muscle actin); identification of proliferating mesenchymal cells (p-
anca) and assessment of mucin producing goblet cells (PAS). In addition, 
examining any differential effects in a chronic asthma model such as that using 
HDM which does not show resolution of remodelling, by assessing the effect of a 
neutralising antibody to IL-33 74. Impaired barrier function along with delayed 
wound healing in the gut in response to IL-33 has been described and this could 
also be the case in the airway 583. Regulation of adhesion molecules, particularly 
VCAM-1 ICAM-1 and e-selectin should be assessed.    
IL-33 was originally described as a nuclear factor and acts as a repressor of gene 
transcription. Nuclear IL-33 is present in EC 584 but, our studies also reveal 
further cytoplasmic AEC IL-33 (chapter 3). Dispersal of cytoplasmic proteins upon 
cell death or active secretion could release IL-33 into the lumen.  Much research 
focus has been on the release of IL-33 from epithelial cell as a main source of IL-
33 in the airway 186,469 and its relationship with other epithelial derived cytokines 
including IL-25 and TSLP 185. IL-33 appears to be the most upstream 585. Data 
presented here now show in addition EC are also capable of responding to IL-33 
in a paracrine and autocrine fashion. 
In summary, the airway epithelium is now appreciated as an ‘epimmunome’, a 
key cell in triggering and perpetuating innate and adaptive immunity 586. EC 
release IL-33 and initiate Th2 inflammation and furthermore, express ST2L, 
responding to IL-33 in releasing mediators perpetuating inflammation and acting 
as a bridge between innate and adaptive immune systems. Details of interplay 
between ECs and immune cells are not yet fully understood. Improved culture 
models, cell specific genetically-modified mice and analysis of human biopsies 
should inform potential mechanisms. The airway epithelium is central in driving 
pathological changes in remodelling the asthmatic lung. Data presented here 
shows that in addition to initiation of effector type-2 responses, IL-33 also drives 
angiogenesis and vascular remodelling that typifies chronic asthma. Treatments 
for the associated airway remodelling in asthma are lacking and thus 
identification of molecules underlying this is a priority.
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6 The role of ST2 and IL-33 in adaptive airway 
inflammation 
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6.1 Introduction and Aims 
From the data described in chapter 4, it can be seen that innate cells in the 
airway produce type-2 cytokines IL-5 and IL-13 but not IL-4, in direct response to 
the cytokine IL-33.  This results in features which replicate murine AAI and 
human asthma. Th2/type-2 cytokines play a crucial role in allergic airways 
disease and can also be produced by CD4 Th2 cells in a well studied mechanism 
1,20. The generation of allergen sensitisation is dependent on IL-4; IL-4 regulates 
the commitment of T cells to this phenotype and the development of allergen-
specific immunoglobulins 42. However, there is also evidence for IL-4 
independent sensitisation pathways in asthma 46. IL-33 stimulates Th2 cells to 
produce IL-5 and IL-13 but not IL-4 293,422 and in vivo, IL-33 exacerbates the 
effector response in murine model of AAI (Kewin PK, 2007, PhD Thesis, 
University of Glasgow).  Taken together, a role for IL-33 in the adaptive immune 
responses in allergic airways disease is proposed. 
A role for ST2 in asthma and AAI has been considered given its expression on Th2 
and mast cells, both of which are important in the generation and persistence of 
human and murine asthma 19,40. Previously, it had been demonstrated that ST2-/- 
mice develop attenuated inflammation in selected models of AAI 344,496 and 
application of soluble ST2 may be also beneficial in this model 341.   
To further assess the role of IL-33/ST2 in the generation of adaptive Th2 
responses and in particular the contribution of IL-4, the allergen sensitisation 
phase in a murine model of allergic airways disease will be studied using WT, IL-
4-/- and ST2-/- mice. 
6.2 IL-33 at allergen sensitisation 
6.2.1 Choosing a model to study the effects of IL-33 at allergen 
sensitisation  
There are a number of different techniques used to model asthma in 
experimental settings.  The most widely used approaches are: allergen 
sensitisation with an adjuvant to boost responses followed by allergen challenge; 
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transfer of allergen-specific lymphocytes; transient gene transfer; viral 
infection; and using transgenic mice 500. 
6.2.1.1 Adoptive transfer 
To study the effects of IL-33 at sensitisation, the adoptive transfer of allergen-
specific lymphocytes was chosen. It has the advantages of being able to control 
and adjust sensitisation and challenge conditions separately as well as the ability 
to study the transferred lymphocytes using different mouse genotype-specific 
FACS markers. 
TCR transgenic mice CD4 D011.10 cells express major histocompatibility (MHC) 
class II restricted TCR specific for a peptide derived from ovalbumin (OVA), OVA 
peptide (ovapp). Cells from these mice were stimulated in vitro towards a Th2 
phenotype in the presence of skewing cytokines and transferred to naïve WT 
mice as in Figure 6.1A.  These cells maintain their characteristics after being 
injected and express the cell marker KJ-126.  In pilot experiments (data not 
shown) cells or PBS were given i.v. followed by 3 i.n. OVApp or PBS challenges. 
No response was seen in the PBS group so these controls were not routinely 
repeated in subsequent experiments. Furthermore, the transfer of 0.5 x106 or 1 
x106 cells in mice challenged with OVApp developed a small amount of 
eosinophilia so optimal dose experiments were completed as in Figure 6.1. 
Results in Figure 6.1B and C indicate 2 x106 cells are sufficient to generate 
airways inflammation. A further dose response is seen with the transfer of 5 x106 
cells however, 2x106 cells was chosen for further experiments to minimise 
resources required to generate cell production. Transfer was confirmed by 
presence of KJ 126+CD4+ D011.10 cells in the BAL by FACS analysis (by Dr 
Kurowksa-Stolarska, data not shown). 
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Figure 6.1: Testing adoptive transfer model using OVA specific T cells 
A) WT mice were challenged i.n. with 10μg of ova peptide (OVApp) on 3 consecutive days 
following transfer of 0, 2 or 5 x106 DO11.10 CD4 Th2 cells. Cells were grown in vitro as described 
in chapter 2. B)  Total cell counts and C) eosinophils counts in the BAL. Group size n=2-4, (p * 
<0.05, p*** <0.001). Representative of 2 experiments. 
Following on from the adoptive transfer of the Th2 cells, IL-5 and IL-13 
producing CD4+ T cells were transferred i.v. to naïve mice as per Figure 6.1A 
(generated by Dr M Kurowska-Stolarska). These IL-33 stimulated cells develop in 
the absence of IL-4 496.  Following subsequent allergen challenge, low levels of 
AAI were detected in the BAL by the presence of eosinophilia (Figure 6.2B). 
Mediators in BAL and serum were at very low levels (data not shown).  The 
amount of AAI was low and it was deemed insufficient to easily detect 
differences between the groups. In addition, problems generating and 
transferring large numbers of cells consistently to WT mice occurred. Thus, the 
decision was taken to assess endogenously generated cells using the more 
conventional antigen sensitisation and challenge ‘asthma model’.  
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Figure 6.2: Testing adoptive transfer model using OVA specific T cells  
WT were challenged with 10μg of ova pp on 3 consecutive days following transfer of 2 x106 
DO11.10 Th0 or IL-5 and IL-13 producing CD4 cells (Th5/13) cells or PBS on day 1 as per Figure 
6.1A). Cells were grown in vitro as described in chapter 2.  A)  Total cell counts and B) eosinophil 
percentage in the BAL. Group size n=5-8 per group, (*p <0.05, ***p <0.001). 
 
6.2.1.2 Antigen sensitisation and challenge  
To study the acute allergic response in this experiment set a shorter 14 day 
model of allergic airways inflammation (AAI) adapted from Stock et al was 
chosen in preference to the traditional 28 day model452. Briefly, a sensitising i.p. 
injection of OVA along with an adjuvant is followed 8 days later by 3 consecutive 
OVA i.n. challenges as per Figure 6.3A. Initially, experiments were performed to 
robustly test this model. Mice were treated as per protocol in Figure 6.3A and 
demonstrated significantly increased total BAL total cell counts from 0.6 x105/ml 
in the PBS treated mice to 2.84 x105/ml in OVA treated mice (Figure 6.3B). The 
differential cell count showed a significant increase in all cell types analysed.  
Eosinophils in particular increased from 0 in PBS group to 0.89 x105/ml in OVA 
treated group (Figure 6.3C).   
Th2 cytokine production is classically elevated in murine asthma models and so 
cytokine levels were measured in the BAL fluid by ELISA (Figure 6.3D). Higher 
amounts of IL-4 and IL-5 were detected in OVA challenged compared to PBS 
challenged mice.  
A B
Chapter 6  222 
          
DAY
Cull
1
100μg OVA
+ alum i.p.
9 10 11 12
Sensitisation
Challenge
10 μg OVA 
or PBS i.n.
 
Total BALcells
0
0.5
1
1.5
2
2.5
3
3.5
4
PBS OVA
ce
lls
 (x
10
5 /m
l)
**
Differential BALcell count 
0
0.5
1
1.5
2
2.5
Mac Eos Neut
ce
lls
 x
 1
05
/m
l
PBS
OVA*
*
**
          
  
 BAL Cytokines
0
50
100
150
200
IL-4 IL-5 IFNγ
co
nc
 (p
g/
m
l)
PBS
OVA
**
***
      
Figure 6.3: The 12 day allergic airways inflammation protocol 
A) BALB/c mice were immunised with OVA (100μg) on day 1 and challenged with OVA (10μg) in 
30 μl of PBS on day 9, 10 and 11. Control mice were challenged with PBS alone. BAL and further 
samples were acquired 24 hours following final airway challenge. B) Total and C) differential cell 
count in the BAL. D) BAL cytokine levels measured by ELISA. Data shown mean ±SEM, n=5 per 
group. (*p <0.05, **p <0.01 ***p <0.001). Data representative of at least 3 experiments.  
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The antigen (Ag)-specific recall response in the DLN was examined by culturing 
freshly isolated cells with OVA in vitro. Increased levels of IL-5 and IL-4 were 
measured in cells from OVA-challenged compared to PBS-challenged mice 
(Figure 6.4 A and B). Spontaneous and OVA-stimulated proliferation was 
observed in OVA sensitised but PBS challenged mice however this was 
significantly increased in the OVA challenged mice (Figure 6.4C). This antigen 
sensitisation and challenge model was subsequently used for further experiments 
to investigate the role of IL-33/ST2 at sensitisation. 
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Figure 6.4: Antigen recall responses in 12 day allergic airways inflammation model 
BALB/c mice challenged with OVA or PBS as per Figure 6.3A had mediastinal draining lymph 
nodes (DLN) collected and single cell suspension from individual mice prepared. Cells with final 
concentration of 1x106/ml  were cultured with complete medium alone (CM), or OVA at 0.1/05/1 
mg/ml for 72 hours and culture supernatants collected and cytokines measured by ELISA  
Alternatively the cell suspension was stimulated in triplicate on 96 well plate with 3H-thymidine 
incorporated for final 8 hours. Proliferation measured using a scintillation counter. Data shown 
mean ±SD of experimental triplicates of individual mice, n=5 per group. (*p <0.05, **p <0.01 ***p 
<0.001). Data representative of at least 3 experiments.  
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6.2.2 IL-33 does not exacerbate allergic airways inflammation in 
usual ovalbumin model in mice 
A number of studies indicate ST2 modulates AAI 322,341. We have demonstrated 
ST2 deficiency attenuates the airway inflammation demonstrated in Figure 3.3 
496. This suggests a role for ST2/IL-33 in allergic airways inflammation, but 
neither the phase affected nor the mechanisms involved are clear. IL-33 drives 
production of CD4+IL-5+ cells in vitro suggesting it specifically plays a role in 
driving Ag-specific airway inflammation at sensitisation.   To assess this, 
following on from the experiment in Figure 6.4, this experimental protocol was 
repeated with the addition of IL-33 administered i.p. at sensitisation as in Figure 
6.5.   
Mice treated with IL-33 in addition to OVA at sensitisation showed no difference 
in total BAL cell counts compared to OVA-sensitised mice. There was a non-
significant increase in BAL eosinophilia, BAL IL-5, serum IL-13 and a decrease in 
BAL IL-4 (Figure 6.6 A-F).   
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Figure 6.5: IL-33 at sensitisation in 12 day allergic airways inflammation protocol 
AAI was induced in BALB/c mice as in Figure 6.3A.  Mice were additionally treated with three 
doses of 2 μg IL-33 or PBS at sensitisation on days 1-3.  BAL, serum, draining lymph nodes and 
lungs were obtained for analysis 24 hours following final i.n. dose. 
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Figure 6.6: BAL cellular inflammation is not affected by IL-33 at sensitisation in 12 day 
allergic airways inflammation protocol 
Mice treated as per protocol in Figure 6.5. A) Total cell counts and B) differential eosinophil counts 
in the BAL were analysed. Cytokine levels in the BAL C)-E) and serum F) were measured by 
ELISA. n=5-10 per group. Results shown are mean individual mice ±SEM p=ns for all comparisons. 
Data shown are representative of 2 experiments.  
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In the DLN, ST2 and intracellular cytokine expression was analysed by FACS.  
There was no difference in the expansion of CD4+ST2+ cells between the groups 
(6.15% vs. 5.9%). Gating on these cells showed an increase in single positive  IL-
4+ and IL-5+ in the group co-administered IL-33 at sensitisation (Figure 6.7) In 
vitro Ag-recall cultures did not demonstrate any significant changes in cytokine 
production between the groups (data not shown). 
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Figure 6.7: IL-33 at sensitisationincreases Th2 CD4+ IL-4+ as well as CD4+IL-5+IL-4- cells 
BALB/c mice were treated as per protocol in Figure 3.5A. Draining thoracic lymph nodes were 
collected and analysed by FACS. A) CD4+ ST2+ cells were identified with B) levels of IL-5+ and 
IFNγ and C) IL-4+ and IFNγ expression determined. Data from 1 experiment.  
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6.2.3 IL-33 at sensitisation induces CD4+IL-5+ cells and 
exacerbates allergic airways inflammation in a low dose 
ovalbumin model 
The dose of antigen and presence of mediating cytokines are important factors 
in determining the development of helper T cell subsets. Low dose antigen can 
induce tolerance but Sakai et al demonstrated an increasing sensitising dose 
actually attenuates all the key model features in an inversely proportional 
fashion 280.  To determine if any effect of exogenous IL-33 on the ovalbumin 
model at sensitisation was being obscured by high dose OVA; the dose of OVA 
was reduced. The sensitisation dose was reduced to 10 μg and the challenge 
dose to 2 μg (Figure 6.7A). 
6.2.3.1 IL-33 exacerbates cellular inflammation in the airway  
Using this model with a modified dose of OVA, the IL-33 at sensitisation was 
administered as shown in Figure 6.7A.  Mice given OVA only showed a modest 
increase in cell numbers compared to PBS sensitised mice but included a 
significantly increased number of eosinophils (Figure 6.7B and D). In contrast, 
mice given OVA and IL-33 at sensitisation developed a large influx of cells 
compared to OVA only sensitised mice (6.04 x 105/ml vs. 1.01x 105/ml) (Figure 
6.7B). The BAL differential count in mive given OVA+IL-33, composed 
approximately 50% macrophages and 50% eosinophils; a significantly higher 
proportion of eosinophils compared to the OVA-only sensitised mice (26% 
eosinophils) (Figure 6.7 C and D). Importantly, control mice given only IL-33 only 
at sensitisation and challenged with OVA, showed no increase in total or 
eosinophil cell counts in comparison to PBS treated mice. To demonstrate the 
specificity of IL-33, further control groups of ST2-/- mice were sensitised with 
OVA with or without IL-33 co-administration. ST2-/- mice developed attenuated 
responses consistent with the findings in the normal dose AAI model findings 
published by our group 496.  No differences were seen between mice co-
sensitised with IL-33 in the ST2-/- mice (Figure 6.7 B-E). 
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Figure 6.8: IL-33 exacerbates OVA-induced airway cellular inflammation 
Allergic airways inflammation was induced in WT or ST2-/- BALB/c mice using low dose 10 μg 
ovalbumin with 2% alum administered i.p. on day 1.  Mice were additionally treated with three 
doses of 2 μg IL-33 or PBS at sensitisation on days 1-3. All mice were given 3 i.n. challenges on 
days 9-11 and sacrificed on day 12 as per protocol in A). Further control groups of WT mice 
sensitised with either PBS or IL-33 alone and challenged with OVA were used as negative controls.  
BAL, serum, draining lymph nodes and lungs were obtained for analysis. Total cell counts in the 
BAL were analysed in B) and differential counts in C)-E). Data shown are representative of 2-3 
experiments, n=5-10 per group. Results shown are mean of individual mice +/- SEM. **p<0.01 
***p<0.001. 
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6.2.3.2 IL-33 exacerbates cellular inflammation and goblet cell mucus 
production within the lung 
Next the pathological changes in the lung were examined. Histological changes 
were examined on H&E stained slides as well as mucus staining on Periodic-acid 
Schiff (PAS) treated slides. Typical changes of peri-vascular and peri-bronchial 
eosinophilic inflammation along with epithelial shedding were demonstrated in 
the OVA sensitised group as shown previously (Figure 6.9B). These appeared less 
profound that usual dose OVA AAI model in keeping with the more modest BAL 
inflammation demonstrated in this low dose OVA model.  The combination of 
OVA and IL-33 at sensitisation significantly enhanced the inflammatory infiltrate 
compared to OVA-only sensitised mice as shown in Figure 6.9A and C. IL-33 at 
sensitisation appeared to enhance the mucus production in goblet cells 
compared to OVA-only sensitised mice (Figure 6.9 D-G). 
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Figure 6.9: IL-33 at sensitisation increases the inflammatory infiltrate and mucus production 
in the lung 
Mice treated as per protocol in Figure 6.8A had lungs removed and processed. H&E stained lung 
sections were examined by light microscopy and inflammatory cell infiltration and architecture 
assessed. Inflammation was quantitatively assessed using an arbitrary scoring system as 
described in chapter 2 A). Representative sections are shown in OVA only sensitised mice (OVA) 
B) and OVA and IL-33 sensitised mice (OVA+IL-33) C) original magnification x 20. Sections were 
also stained with PAS for mucus assessment in OVA D) and F) OVA+IL-33 E) and G). D) and E) 
x10 magnification and F) and G) x40.  n=5 per group. Results are mean ± SEM. **p<0.01 when 
compared to OVA group. 
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6.2.3.3 IL-33 at sensitisation exacerbates chemokine production in the 
airway 
IL-33 can directly influence cellular cytokine and chemokine production when 
administered into the airway. Therefore the effect IL-33, administered at the 
sensitisation phase, on these parameters in the BAL was assessed from 
experiments in Figure 6.8A. Levels of IL-5 and IL-4 were slightly elevated and 
reduced respectively in the BAL in mice treated with OVA and IL-33 at 
sensitisation compared to those treated only with OVA, but levels were low 
(Figure 6.10 A and B). The following were also detected at low levels but no 
difference between the groups was seen: IL-2, IL-10, IL-6, GM-CSF, VEGF, and 
TNF-α.  IL-13, IFNγ, IL-12, IL-1β or IL-17 were not detectable in the BAL of 
either group (data not shown).   
The most marked finding in the BAL fluid was in the level of chemokines 
detected.  Eotaxin/CCL11, eotaxin-2/CCL24 and TARC/CCL17 were measured at 
increased levels in mice treated with both IL-33 and OVA at sensitisation 
compared to mice treated with OVA alone (Figure 6.10 C-E). 
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Figure 6.10: Increased levels of BAL eotaxin and eotaxin-2 following IL-33 treatment at 
sensitisation 
24 hours following final i.n. OVA challenge, BAL from BALB/c mice treated with OVA or OVA+IL-33 
at sensitisation were collected and processed. Levels of cytokines and chemokines were 
determined: IL-4 and IL-5 by multiplex immunoassay; eotaxins by ELISA. Data represent mean ± 
SEM of measurements from individual mice. n=10 per group.(*p<0.05, ***p<0.001). Data are 
representative of 3 experiments. 
6.2.3.4 IL-33 at sensitisation increases levels of TARC in the serum 
All cytokines and chemokines measured in the BAL fluid were also assessed in 
the serum. Levels of TARC, IL-13 and IP-10 were elevated, but only TARC levels 
reached statistical significance in the OVA plus IL-33 treated compared to the 
OVA treated group (Figure 6.11 A-C).  No difference in the other analytes was 
demonstrated between the groups, including IL-5, eotaxin-1, eotaxin-2, GM-CSF 
and VEGF (data not shown).  As the antibody memory response is initiated at 
sensitisation, levels of total IgE were measured to ascertain any affect of IL-33 
but no differences were detected between the groups (Figure 6.11 D). 
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Figure 6.11: Increased levels of serum TARC following IL-33 treatment at sensitisation 
24 hours following final i.n. OVA challenge, serum from WT mice treated with OVA or OVA+IL-33 
were collected and processed. Levels of cytokines and chemokines were determined: by ELISA or 
multiplex immunoassay. Date represent means ±SEM of measurements from individual mice. n=10 
per group. (**p<0.01). Data are representative of 3 experiments. 
6.2.3.5 IL-33 at sensitisation increases the proportion of IL5+ T cells in DLN 
In vitro culture of CD4+ cells with IL-33 enhances IL-5 production. Therefore to 
further explore the differences demonstrated by addition of IL-33 at 
sensitisation to a model of AAI, the T cell phenotype and cytokine responses in 
the DLN were examined. DLN were removed following antigen challenge and 
following processing, total cell counts performed and ST2 expression and 
cytokine profile assessed by FACS. Mice co-sensitised with IL-33 had an increase 
in cell numbers compared to OVA-only sensitised mice (Figure 6.12). 
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Figure 6.12: IL-33 at sensitisation increases cell number in DLN 
Mice were treated and DLN removed 24 hours following final i.n. challenge. Full DLN counts were 
performed. Data are representative of mean of individual mice. n=10 per group (*p<0.05). 
 
OVA-sensitised WT mice showed a substantial increase in the numbers of 
CD4+ST2+ cells compared to PBS-sensitised WT mice with 9.45% and 0.9% of DLN 
cells respectively.  This was further substantially increased by co-administration 
of IL-33 with OVA to 16.7% CD4+ST2+ cells(Figure 6.13A). Intracellular staining of 
DLN CD4+ T cells revealed that IL-33 alone had no effect on Th2 cytokine profile 
but increased the percentage of IFN-γ+ cell population compared with the PBS 
group (Figure 6.13 B). In contrast, CD4+ cells from OVA-sensitised mice showed 
an increase in proportion of IL-4+ cells but not IL-5+ cells compared to IL-33 
alone of PBS-treated groups. The additional administration of IL-33 to OVA at 
sensitisation markedly enhanced the percentage of IL-5+ cells but decreased the 
IL-4+ cells compared to OVA group. The percentage of IFN-γ+ cells did not change 
between these groups.  There was no difference in cellular profile between OVA-
sensitised and OVA+IL-33-sensitised groups in the ST2-/- mice. ST2-/- mice had an 
increased proportion of IFN-γ+ cells compared to WT. 
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Figure 6.13: IL-33 increases the number of CD4+IL-5+ cells in the DLN 
WT and ST2-/- mice were treated as described in Figure 6.8A. Draining mediastinal lymph nodes 
were removed and mechanically disrupted to form a single cell suspension when the total count 
was measured. Cells were stained with surface markers and using FACS, the percentage of CD4+ 
cells and ST2+ cells were determined A). CD4+ DLN cells were stimulated with PMA-I and golgi-
stop before the presence intracellular cytokines IFNγ, IL-4 and IL-5 were assessed by FACS B). 
Data are representative of 2 experiments. n=5 per group. 
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6.2.3.6 IL-33 at sensitisation increases the antigen-specific recall response 
The Ag-recall response was ascertained by culturing freshly isolated DLN 
mediastinal nodes with OVA in vitro. Levels of cytokine and chemokine 
production were low in the modified low dose OVA model.  An increase in levels 
of TARC, IL-17 and non-significant increase in eotaxin/CCL11 and eotaxin-
2/CCL24 was detected in the supernatants of cell cultures from mice treated 
with OVA in addition to IL-33 compared to those treated with OVA alone (Figure 
6.14 A-D). A decreased IFN-γ and non-significant decreased IL-4 production was 
seen in the OVA only group (Figure 6.14E). 
No significant differences in the levels of IL-5, IL-13, IL-10, IL-2, IL-6, TNF-α, 
VEGF, GM-CSF, IP-10, KC or MIP-1α between the groups and no IL-12 was 
detected in the culture supernatants (data not shown). 
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Figure 6.14: The effect of IL-33 at sensitisation on the Ag-recall response  
WT mice were sensitised with OVA ± IL-33 and DLN removed following OVA allergen challenge. A 
single cell suspension was formed, counted and cultured with complete medium (cm) or with OVA 
1mg/ml.  Supernatants were collected after 72 hours and cytokine and chemokine levels were 
measured using multiplex immunoassay or ELISA for A) TARC, B) IL-17, C) eotaxin/CCL11, D) 
eotaxin-2/CCL24 and E)IFNγ. Unshaded bars OVA and shaded bars OVA plus IL-33. n=10 per 
group.(*p<0.05, **p<0.01, ***p<0.001). Data are representative of 3 experiments. 
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6.2.4 IL-33 at challenge induces allergic airways inflammation in 
ova sensitised mice 
The application of i.n. IL-33 in addition to OVA at the challenge phase of AAI 
further exacerbates the ongoing Th2 inflammatory response (Kewin PK, 2007, 
PhD Thesis, University of Glasgow). This could occur via direct effects on ST2L 
expressing innate cells, Th2 cells or via a combination. Data in chapter 3 
demonstrates i.n. IL-33 given directly into naïve lung induces an innate type-2 
response, with at least 3 doses required to elicit an increase in BAL eosinophilia.  
In this non-sensitised environment however, IL-33 also has a direct effect on Th2 
cells, increasing the expression of ST2L suggesting it has a role in modulating the 
adaptive immune response.  This effect is non-essential in innate IL-33 driven 
inflammation as shown by the experiments in RAG-/- mice. Following on from the 
results in this chapter indicating IL-33 at sensitisation exacerbates AAI, it was 
interesting to consider whether pre-sensitisation to antigen would have a role in 
the innate response to IL-33, in the absence of further exposure to specific 
antigen.   
Data shown in Figure 6.15 represents mice sensitised with OVA or PBS as in 
Figure 6.5 but these mice were given IL-33 at challenge only and not OVA. For 
comparison to the innate IL-33 experiments in chapter 4, C57BL/6 mice were 
used. The total number of cells in the BAL were low (Figure 6.15A) in keeping 
with experiments in chapter 4 when small number of eosinophils appear in BAL 
only following 3 days of i.n. IL-33.  The differential cell count shows a higher 
proportion of eosinophils in mice sensitised with OVA compared to those 
sensitised with PBS (9% vs. 1.96%) (Figure 6.15B) and elevated serum IL-5 levels 
(Figure 6.15D). Low levels of IL-5 in BAL and IL-4 in BAL and serum of OVA 
sensitised mice were recorded but no significant differences were seen between 
the groups (data not shown). Corresponding experiments were also performed in 
BALB/c mice with similar results (data not shown).  
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Figure 6.15: Sensitisation with OVA followed by IL-33 challenge exacerbates eosinophilic 
airway inflammation in C57BL/6 mice 
WT mice were sensitized with 100 μg ovalbumin in 2% alum or PBS administered i.p. on day 1. On 
days 9-11, 2 μg of IL-33 was administered i.n. to all mice. Mice were sacrificed on day 12 and BAL 
and serum samples collected and processed. Cell counts performed on the BAL and serum IL-5 
was measured by ELISA in supernatants. n=5. (*p<0.05, ***p<0.001). Data shown are 
representative of 2 independent experiments. 
 
6.2.5 IL-33 at sensitisation exacerbates allergic airways 
inflammation in IL-4-/- mice 
IL-4 is an important factor in Th2 cell differentiation and IgE production but its 
non-exclusive role in murine models of Th2 responses has been demonstrated 
46,587,588. To further investigate the relationship between IL-33 and IL-4 in 
polarisation and proliferation of IL-5 producing T cells and AAI, the experiments 
in section 6.2.3 were repeated in IL-4-/- mice. It was hypothesised that IL-33 
A B C 
D 
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given at sensitisation would exacerbate AAI via the IL-4 independent CD4+ST2+IL-
5+ pathway.  
Mice were treated as per protocol in Figure 6.8A. There was no significant 
difference between BAL total cell counts between the groups of IL-4-/- mice 
(Figure 6.16A). There was a trend to increased eosinophils numbers in mice 
treated with IL-33 in addition to OVA at sensitisation compared to mice treated 
with OVA alone when the BAL is analysed by differential cell count (Figure 
6.16B) or by FACS (Figure 6.16C) (FACS acquisition performed by Dr M Kurowska-
Stolarska). Overall, the low counts in the BAL in this low dose OVA model meant 
further differences could not be easily elicited.  
As expected, no IL-4 was measured in any sample. No statistically significant 
differences were measured in levels of IL-13 in the BAL (Figure 6.16E) and levels 
in the serum and DLN culture supernatants were low. Levels of IL-5 in culture 
supernatants from DLN stimulated with OVA antigen were higher in IL-4-/- mice 
sensitised with OVA plus IL-33 compared to groups sensitised with OVA plus PBS 
or PBS alone (Figure 6.16F). Levels of IL-5 in serum and BAL were low. No 
differences were seen in eotaxin/CCL11 levels in BAL or serum between groups.  
An increased susceptibility to morbidity and mortality was observed in the IL-4-/- 
mice in experimental repeats with neutrophils comprising a higher proportion of 
the BAL in these animals compared to WT groups. This gave rise to limited 
numbers of mice and concern about pathogen contamination. These 
experimental protocols were then performed by collaborators in another 
laboratory, where a reduction in inflammation in IL-4-/- mice compared to WT 
mice was seen. This deficiency was overcome by the application of IL-33 at 
sensitisation 496. 
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Figure 6.16: The effect of IL-33 at sensitisation in IL-4-/-mice 
AAI was induced in IL-4-/- mice as per protocol in Figure 6.8A.  BAL, serum, draining lymph nodes 
and lungs were obtained for analysis. A) Total cell and B) and D) differential cells counts in the BAL 
were analysed by haemocytometer and by C) cell surface marker analysis by FACS. Eosinophils 
population were identified as CD45+Siglec-Fhi. E) BAL IL-13 measured by ELISA. F) DLN cells 
were cultured CM and OVA (1mg/ml). Results shown are mean±SEM of individual mice. Data 
shown are representative of 2 experiments. n=3-6 per group.**p<0.001.  
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6.3 The role of IL-4 and ST2 in an alum free sensitisation 
ovalbumin model in mice 
Experiments in chapter 4 and presented in this chapter indicate a IL-33/ST2 
mediated pathway can occur independently of IL-4. To further investigate this, 
the effect of loss of endogenous IL-33 in AAI was assessed. Problems in 
generating the anticipated IL-33-/- mice meant the decision was taken to assess 
receptor-ST2 deficiency and to consider how the absence of IL-4 might affect 
the dominance of these apparent pathways in the asthma model. 
IL-4 is a mediator of Th2 biased sensitisation 42. However, there is evidence that 
IL-4 free sensitisation can occur: for example, by using an epicutaneous (e.c.) 
rather than i.p. method of sensitisation, the need for IL-4 is bypassed 587. 
Importantly, in these published experiments, no additional adjuvant was used in 
the sensitisation. Traditional allergen models use alum at time of sensitisation to 
boost response. The mechanism of this boosting action is unclear but a 
postulated mechanism is that IL- 4 induced by aluminium salts promote Th2 
responses (and by enhancing Th2 mediated antibody production and inhibition of 
Th1 responses) 277 588.   
The role of ST2 in conventional AAI models have had conflicting reports 
304,338,341,344.  In our laboratory using the short 12 day OVA model, ST2 gene 
deletion results in attenuated AI 496. This is in keeping with the finding that 
soluble ST2 has a beneficial effect in airway inflammation 341. 
Preliminary data in our laboratory (Pitman NI, 2012, PhD Thesis, University of 
Glasgow) has demonstrated a possible role for ST2 in an adjuvant free allergen 
long model of asthma. In this model, eosinophilia and IgE production but not AHR 
were partially ST2 dependent. This suggests the alternate or additional ST2/IL-
33 dependent sensitisation pathway is overcome or overwhelmed by the addition 
of an adjuvant; this is relevant as adjuvant free models are clearly more 
physiological and thus considered be more representative of clinical disease. 
The hypothesis tested is that ST2 and IL-4 are both independently necessary for 
sensitisation and AAI, and in the adjuvant model, alum overcomes ST2 
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deficiency. Furthermore, that a synergistic effect of IL-4 and IL-33 exists 
whereby IL-4 and ST2 double KO mice develop more attenuated AI compared to 
single KO mice. Experiments were designed to assess this hypothesis by the 
removal of cytokine function by receptor or cytokine knockout mice in alum and 
alum free models. 
6.3.1 Generating IL-4-/-ST2-/-mice 
To investigate hierarchy of IL-4 and ST2 at sensitisation in allergic airways 
disease, double knockout mice were generated. The genes of IL-4, IL-13 and IL-5 
are linked in an area on murine chromosome 11589. IL-4-/- mice were previously 
generated by directing targeting of IL-4 gene in BALB/c embryonic stem cells 450 
and provided by Dr J Alexander (University of Strathclyde, Glasgow, UK). ST2 
gene knockout mice are described in chapter 2.   A schematic of the breeding 
programme is illustrated in Figure 6.17. Following cross of IL-4-/- and ST2-/- mice, 
F1 heterozygotes are re-crossed with a 1 in 16 chance of a double homozygote.  
 
Genotype 
each 
parent F1 
IL4+ST2+ IL4+ST2- IL4-ST2+ IL4-ST2- 
IL4+ST2+ IL4++ST2++ IL4++ST2+- IL4+-ST2++ IL4+-ST2+- 
IL4+ST2- IL4++ST2+- IL4++ST2-- IL4+-ST2+- IL4+-ST2-- 
IL4-ST2+ IL4-+ST2++ IL4+-ST2+- IL4--ST2++ IL4--ST2+- 
IL4-ST2- IL4-+ST2+- IL4+-ST2-- IL4--ST2+- IL4--ST2-- 
 
Figure 6.17: Generation of IL-4-/-ST2-/- double knockout mice 
Table of potential F2 genotype. IL-4-/- were crossed with ST2-/- mice (F0) and the mice generated 
(F1) were self crossed to generated the double KO mice (F2).  A 1:16 chance exists of generating 
an IL4-/-ST2-/-mouse. 
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PCR screening of tail genomic DNA was used to detect heterozygotes in F2 
(Figure 6.18 A and B). Double knockout mice in F3 were confirmed by PCR 
(Figure 6.18 C and D) before breeding pairs established. 
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6.3.2 The role of ST2 at sensitisation is less important than IL-4 
AAI was induced in WT, ST2-/- , IL-4-/- and ST2-/-IL-4-/- mice. The protocol was 
based on a published adjuvant-free protocol and the same as that used in the 
laboratory pilot study 590. These mice also underwent the protocol with the 
addition of alum in line with the standard 28 day AAI model. The protocol is 
shown in Figure 6.19. 
 
  
Cull
200μg OVA i.n.
1
20 μg OVA 
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PBS i.p.
26 27 28 29
Challenge
15
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DAY
 
Figure 6.19: The adjuvant-free allergic airways inflammation model 
BALB/c WT ST2-/-,  IL-4-/-  and ST2-/-IL-4-/-  were administered OVA or OVA-alum or PBS on days 1 
and 15, followed by i.n. OVA challenge on days 26-29. Mice were sacrificed 24 hours following the 
final challenge when samples were collected. 
 
In keeping with published results, in the 28 day adjuvant model, no difference 
was seen in BAL cell counts between WT and ST2-/- mice (Figure 6.20A).  In the 
IL-4-/- mice, alum boosts the ST2 pathway and generates airway eosinophilia but 
does not overcome IL-4 deficiency (Figure 6.20B). In double knockout mice, a 
small amount of eosinophilia persists, suggesting a further additional non-ST2, 
non-IL-4 alum driven pathway. 
In the alum-free model, in contrast to pilot data, no difference was seen in 
eosinophilic inflammation in the BAL between WT and ST2-/- mice (Figure 6.20B). 
This suggests a ST2 dependent sensitisation pathway is not crucial in an adjuvant 
free environment as hypothesised. IL-4-/- mice exhibited very low levels of 
eosinophilia indicating that the ST2 pathway cannot overcome the importance of 
IL-4 in an alum-free model.  Virtually no eosinophils were seen in the IL-4-/-ST2-/- 
mice. However, given the already low levels in the IL-4-/- mice, the further 
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reduction of BAL eosinophils that could be considered dependent on the ST2 
pathway was difficult to assess, was not statistically significant and unlikely to 
be of phenotypic significance.  
Comparing conditions within mouse genotypes, in the adjuvant model as 
expected, the addition of alum exacerbated or boosts the immune response in 
WT mice. Similarly in ST2-/-mice, alum boosts the sensitisation response. In IL-4-
/- mice, the group given an adjuvant had a higher level of eosinophilia in BAL 
than in alum-free model mice, suggesting mechanism of alum is partially but not 
solely through IL-4. In IL-4-/-ST2-/ mice the loss of both pathways results in 
complete abrogation of AAI in the alum free group. 
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Figure 6.20: A. See over for legend. 
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Figure 6.20: BAL cell counts in an adjuvant and adjuvant-free model of asthma 
BALB/c WT ST2-/-, IL-4-/- and ST2-/-IL-4-/- were treated as per protocol in Figure 6.19. BAL was 
performed 24 hours following the final i.n. challenge. A) Total and B)-D) differential cell counts were 
performed on the BAL. (*p<0.05, **p<0.01 ***p<0.001). Data shown is mean ± SEM. 
Representative of 2 independent experiments. 
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The concentration of mediators measured in the BAL were at low levels. IL-4 
appeared to be lower in ST2-/- compared to WT mice in the OVA-alum sensitised 
group despite similar level of inflammation but this was not statistically 
significant (Figure 6.21A) . 
Production of MIG/CXCL9, appears dependent on ST2 as none is detected in the 
ST2-/- mice compared to WT or IL-4-/- in OVA-alum or OVA-only sensitisation 
groups (Figure 6.22B). Concentrations of IL-2, IL-13, IL-10, IL-17, KC, IL-12, 
MIP1α and FGF were very low or absent; and of IL-5, IFNγ, IL-1β, IL-6, GMCSF, 
TNFα, VEGF, MCP-1, IP-10, IL-1α low with no differences between the groups 
detected (data not shown).  
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Figure 6.21: BAL cytokines in an adjuvant and adjuvant-free model of asthma 
BALB/c WT ST2-/-, IL-4-/- and ST2-/-IL-4-/- Were treated as per protocol in Figure 6.19. BAL was 
performed 24 hours following the final i.n. challenge. Cytokine analysis was performed by ELISA or 
multiplex immunoassay. A) IL-4 and B) MIG (*p<0.05). Data shown is mean ± SEM. Representative 
of 1 experiment. 
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The compartments most likely to reflect significant mechanisms of differences in 
sensitisation are serum and the draining mediastinal lymph nodes.  In the serum, 
cytokine and chemokine concentrations were lower in OVA than OVA-alum 
treated mice reflecting lower levels of inflammation seen in the BAL. As such, 
any differences between groups sensitised with OVA were difficult to elucidate. 
As expected, no difference was seen in IL-5 levels between WT and ST2-/- in 
OVA-Alum group as no difference was seen in BAL eosinophilia. Lower IL-5 levels 
were seen in IL-4-/-and ST2-/-IL-4-/- compared to WT mice and in ST2-/-IL-4-/- 
compared to ST2-/-. Lower concentrations of serum IL-5 were seen in OVA 
sensitised WT and ST2-/- in comparison to OVA-alum sensitised mice (Figure 
6.22A). ST2-/- mice had reduced serum levels compared to IL-4 and a trend 
towards reduced levels compared to WT but this was not statistically significant 
(Figure 6.22B).   
Levels of IL-6 were lower in IL-4-/- and ST2-/-IL-4-/- compared to WT and ST2-/- 
mice in OVA-alum group (Figure 6.22C). Like in the BAL, MIG concentrations 
appeared to be partially dependent on ST2 (Figure 6.22D). Levels of IL-12 were 
higher in all the adjuvant treated groups compared to OVA-only treated mice 
(Figure 6.22 E). No differences were seen in concentrations of IL-2, GM-CSF, 
TNFα, VEGF, IL-17, KC, IP-10, FGF or IL-1β. Very low or absent levels of IL-13, 
IL-10, MIP1α or IL-1α were detected (data not shown).   
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Figure 6.22: A. See over for legend. 
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Figure 6.22:  B-D. See over for legend. 
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Figure 6.22:  Serum cytokines in an adjuvant and adjuvant-free model of asthma 
BALB/c WT ST2-/-, IL-4-/- and ST2-/-IL-4-/- were treated as per protocol in Figure 6.19. Serum was 
collected and processed 24 hours following the final i.n. challenge.  Serum cytokine and chemokine 
levels were measured by ELISA or multiplex immunoassay. A) IL-5, B) IL-4, C) IL-6, D) MIG and E) 
IL-12. (*p<0.05, **p<0.01 ***p<0.001). Data shown is mean ± SEM. Representative of 1 
experiment. 
 
IgE production is a critical aspect in animal models of asthma and so total and 
Ag-specific levels were measured in the serum.   There were no differences seen 
in levels of total IgE or OVA-specific IgE between WT and ST2-/- mice in OVA-
alum or OVA alone groups indicating ST2 deficiency in the absence of an 
adjuvant has no effect on IgE production; this is in disagreement with previous 
pilot results (Figure 6.23 A and B). As expected, IL-4 deficiency resulted in 
significantly reduced levels of total and OVA-specific IgE in the IL-4-/- and ST2-/-
IL-4-/- mice in comparison to WT or ST2-/- mice in the OVA/alum or OVA alone 
groups. Interestingly, the levels of OVA-specific IgE were enhanced in both IL-4 
knockout groups by the addition of alum at sensitisation (Figure 6.23B). 
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Figure 6.23: Serum IgE in an adjuvant and adjuvant-free model of asthma 
BALB/c WT ST2-/-, IL-4-/- and ST2-/-IL-4-/- were treated as per protocol in Figure 6.19. Serum was 
collected and processed 24 hours following the final i.n. challenge. A) Total and B) OVA-specific 
IgE levels were performed by ELISA. (*p<0.05, ***p<0.001). Data shown is mean ± SEM. 
Representative of 1 experiment. 
 
As isotype switching is likely to occur in the draining lymph nodes under 
influence of IL-4, experimental plans included analysis of the production of 
cytokines from the lymph node cells on re-stimulation with OVA. There was no 
significant change in lymph node cell counts between groups in OVA-alum 
protocol (data not shown). Unfortunately, cell culture supernatants were not 
available for the OVA treated mice so further analysis of cytokine profile could 
not be undertaken. Spleen weights were higher in WT mice compared to other 
groups in the OVA-alum sensitisation group (data not shown). 
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6.4 Conclusions 
Experiments in this chapter assessed the role of IL-33/ST2 in sensitisation of AAI. 
Firstly, the effect of adding IL-33 at the sensitisation phase of the asthma model 
was studied. This led to the exacerbation of airway inflammation by induction of 
Ag-specific CD4+IL-5+ cells.  Secondly, a synergistic effect of IL-4 and IL-33 at 
sensitisation using single and double receptor knockout mice was investigated. 
Initial experiments in this chapter served to develop a model where the effects 
of IL-33 at sensitisation could be assessed. Despite generating an airway 
eosinophilia using an in vitro generated transgenic T cell adoptive transfer 
model, this was at modest levels and this was dependent on the availability of a 
large number of CD4+IL-5+ cells for transfer. Thus, this increased requirement for 
animal numbers and effort to generate a sample size that would be useful for 
experiments favoured an alternative approach. 
Adoptive models are advantageous as T cells can be tracked but there are 
concerns about their artificial nature; the number of Ag-specific T-cells required 
to induce eosinophilic inflammation can be 5000 fold less than in vivo generated 
T-cells 591.  Antigen sensitisation models are the classical and most widely model 
to study asthma but with a significant degree of variety in protocol 500. For the 
experiments described here, a short 12 day protocol adapted from Stock et al  
was used and this has been validated in our laboratory with respect to airway 
eosinophilia, IgE production and AHR 452 and used by others 526. This short model 
may reflect a different phenotype compared to better established 28 day 
models.  Indeed, models reflective of remodelling changes associated with 
asthma have longer protocols with multiple challenges. Few studies to date have 
been performed using this short model but it seems likely to reflect the early 
and late asthmatic responses rather than sustained inflammation or remodelling 
features.  We and others have demonstrated dependence for ST2 in this short 
model, which has not been shown in 28 day model, supporting the suggestion of 
an alternative phenotype 421,496. One hypothesis is that this model may be 
somewhat dependent on mast cells; an alternative 12 day model showed 
dependence on mast cells 592 in contrast to the more established 28 day model 
showing no requirement for these cells in the development of AI 593.  
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The data presented here demonstrating that IL-33 given to WT mice during 
sensitisation exacerbates AAI is a novel finding.  The finding is specific as IL-33-
driven inflammation was not evident in ST2-/- mice. Furthermore, non-OVA 
sensitised mice given IL-33 and challenged with OVA did not show any significant 
eosinophilia in the BAL indicating an Ag-specific mechanism. DLN analysis 
demonstrated an increased number percentage of CD4+IL-5+ without increase 
CD4+IL-4+ population. Supportive parallel findings in our laboratory show IL-33 
polarises naïve CD4 cells in the presence of TCR stimulation (anti-CD3+ antibody 
or in presence of APC and OVA peptide antigen), to produce IL-5, IL-13 and not 
IL-4 496. This was found to be independent of IL-4, IL-4Rα as well as STAT6 and 
GATA3 signalling, which are essential for classical Th2 development 594. Instead, 
differentiation was dependent on MyD88, an adaptor protein recruited by IL-33 
activation of ST2 293. The ability to polarise T cells independently of IL-4 seems 
novel to IL-33. Polarised Th2 cells cultured with IL-33 and TCR stimulus produce 
IL-5 and IL-13 and is now well described 293,422.  As previously shown by our 
laboratory, IL-18, another member of the IL-1 cytokine family can similarly 
induce the production of IL-5 and IL-13 but also IL-4 production from T cells 337. 
IL-25 induces Th2 pathologies via IL-4, IL-5 and IL-13 production though from 
innate immune cells in vivo 161.  Both classical and IL-33-dependent IL-5+ T cells 
will co-exist following antigen sensitisation with IL-33 possibly indirectly 
stimulating the IL-4 dependent pathway with preference dependent on multiple 
local environmental factors. Taken together with these in vitro experiments, the 
in vivo results presented here suggest IL-33 drives Ag-specific airway 
inflammation by polarisation and proliferation of CD4+IL-5+ in vivo.  
The dose of the antigen used in the 12 day model was important to detect a 
response to exogenous IL-33, with a reduction in the dose used. Differences in 
dose and route of antigen delivery are common in the asthma model 500. 
Prolonged inhaled allergen exposure can induce tolerance 595. Antigen dose can 
also influence the development of a specific antibody response: a low dose of 
antigen induces the optimum IgE response, whereas a high dose induces an IgG2a 
response in vivo 596. Experiments performed here showed that a 100 μg OVA dose 
stimulates the classical pathway Th2-IL-4 dependent pathway with no difference 
in percentage of single positive CD4+IL-5+ T cells when IL-33 was added at 
sensitisation.  The sensitisation dose of 10 μg used in data presented here is in 
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keeping with reports in the literature.  Sakai  et al demonstrated that increasing 
the sensitising dose above 10μg OVA actually attenuated rather than 
exacerbated all features of AAI 280.   
The finding here that increased CD4+IFN-γ+ cells are produced in mice given only 
IL-33 at sensitisation indicates that under certain circumstances, IL-33 can 
induce Th1-type responses. This is in agreement with subsequent work by 
Smithgall et al showing IL-33 can amplify Th1- as well Th2-type responses from 
various cell types 326. IL-33 enhances the production of IFNγ from iNKT, NK as 
well as polarised Th2 cells. IL-18, preferentially differentiates Th1 or Th2 cells 
depending on cytokine environment and genetic background but it is not clear if 
this could be the case for IL-33 337. Whilst IL-33 stimulates T cells to CD4+IFN-γ+ 
producing Th1 there is no resultant phenotype which is dominated by the disease 
state Th2 response.  
IL-33 also enhances Ag-mediated Th2 inflammation in an Ag-independent 
manner. Mice sensitised with OVA, and subsequently challenged with IL-33 
without antigen, go on to demonstrate eosinophilic inflammation in the BAL. In 
vitro work from Smithgall et al demonstrates this Ag-dependent and Ag-
independent enhancement of polarised Th2 cell IL-5 production by IL-33 326. As 
well as by specific Ag-dependent and Ag-independent T cell responses, IL-33 
enhances ongoing type-2 responses non-specifically and its role in many disease 
states by Th-2 mediated immune responses has been described (Chapter 1). As 
asthma becomes severe and chronic it adopts an altered inflammatory profile 
towards a Th1 type response with neutrophilia and steroid unresponsiveness. 
IFNγ and TNFα have roles in this severe asthma phenotype 211,597. Thus, it would 
be interesting to examine the effects of IL-33 and its inhibition in chronic 
allergen models, considered reflective of chronic human asthma.  
Although IL-33 enhanced the production of CD4+IL-5+ cells without the 
requirement for IL-4, it was important to investigate whether: these cells could 
develop in a completely IL-4 free environment and;  are suffice to generate AAI 
in absence of classical CD4+IL-5+IL-4+cells. This was investigated in IL-4-/- mice. 
Pilot findings presented showing non-statistically significant changes and 
experiments were repeated in a collaborative laboratory using these protocols. 
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IL-33 enhanced AAI in absence of IL-4 via the mechanism of increasing the 
population of IL-5 producing T cells 496. Differences in my findings could be 
explained by incorrect sample size and altered microbial colonisation in 
different animal facilities. In particular, mice used in the data shown were not 
kept in barrier condition in local facilities and concomitant infection is possible. 
The IL-4 deficient mice used were generated by Noben-Trauth et al using 
targeted construct injection into embryonic cell lines 450.  IL-4 deficiency was 
confirmed here using tail genomic DNA PCR.  Naïve IL-4-/- mice do not display an 
abnormal phenotype with normal numbers of CD3, CD4 and CD8 cells 451. The 
effect of IL-4 deficiency is apparent in the disease state with susceptibility to 
Th2-mediated disease, in particular helminth parasitic infections.  Furthermore, 
Th1-mediated conditions lose a level of cross-regulation whereby Th2 helper 
cells regulate the development of the Th1 cell subset by the secretion of IL-4 42. 
IL-4 in parasitic infection is complex and this is demonstrated by its role in 
Leishmaniasis. In WT mice, IL-4 blockade reduced parasite burden and illness 
however IL-4-/- mice remained susceptible to infection and did not improve with 
anti-IL-4 therapy suggesting compensatory mechanisms 451. However, the 
opposite conclusion of IL-4 mediated resistance was reached by separate 
investigators using the same mice 598. The timing of the presence of the 
presence of IL-4 is important 599 and it can in some circumstances promote Th1 
responses 600.  
To confirm that the CD4+IL-5+IL-4- cells specifically mediated AAI in absence of 
IL-4,  the cells were adoptively transferred by collaborators into IL-4-/- mice 
which developed more BAL and tissue eosinophilia. Published data show CD4+Th2 
cells producing type 2 cytokines can develop from IL-4-dependent or IL-4-
independent pathways. In IL-4 deficient mice, eosinophilic airway inflammation 
was impaired but CD4 T cells from the IL-4-/-mice behaved in a similar fashion to 
wildtype, in a model of AAI46.  CD4 IL-4 independent responses are also seen in 
other airway or vaccination models as well in parasitic infections described 
587,588. Overall these findings demonstrate IL-33 drives the development of IL-4 
independent CD4+IL-5+ T cells in AAI and raises the possibility IL-33 could be an 
important mediator in other IL-4 independent responses.  However, it must be 
considered how IL-33 might be available in local environment to polarise Th2 
cells in an IL-4 independent fashion. 
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In agreement with a role for IL-33 at sensitisation, in published studies, blockade 
of endogenous IL-33 by anti-IL-33 antibody delivered at sensitisation and 
challenge results in abrogated AI, reduced cytokine and antibody production 601. 
Others have now found that IL-33 exacerbates AAI via effects on DCs suggesting 
this is the mechanism of action for IL-33 at sensitisation. IL-33 enhanced DC 
activation, maturation, cytokine production and initiation of Th2 responses. The 
transfer of IL-33 treated OVA-pulsed DCs worsened AAI following adoptive 
transfer and OVA i.n. challenge compared to mice receiving OVA-pulsed DCs 
without IL-33 pre-treatment421. These authors did not find IL-33 could polarise 
CD4 T cells without DC co-culture but the resultant cells were consistent with 
non-classical T cell producing IL-5 and IL-13 but not IL-4.  
Secondly in this chapter, the effect of ST2 deletion at sensitisation in AAI was 
assessed. The role of ST2 in the asthma model has been controversial. Our 
laboratory has found overall loss of ST2 in a 12 day model results in attenuated 
OVA-induced inflammation with reduced BAL eosinophilia,  IL-5 (but not IL-4 or 
IL-13) production as well as lower lung inflammation 496; however, using 28 day 
models, others have disagreed 338,344. These differences could to some degree be 
explained by model protocol and mouse strain differences. In the 12 day model 
we used, ST2 dependency could indicate loss of ST2 cells required at 
sensitisation, namely Th2 cells or commitment to a pathway that later requires 
ST2 at antigen challenge such as on Th2 cells or mast cells. In view of the effect 
of IL-33 at sensitisation demonstrated above and given that IL-4 was not required 
in these responses, the presence of ST2 mediated pathway at sensitisation which 
is not dependent on IL-4 was determined. Given the IL-4 independence, this 
pathway was hypothesised to be an adjuvant-free. Adjuvant use in vaccination 
and animal models is commonplace but the exact mechanism of the role of 
aluminium salts is not clear and it has been thought to enhance sensitisation via 
IL-4 602,603. As adjuvant-free models, thought to be more representative of 
clinical disease, have longer AAI protocols, a model based on this was chosen. 
Pilot data obtained in the laboratory indicate ST2 is critical in this 28 day 
adjuvant free model.    
No difference was seen in levels of AAI between WT and ST2-/- mice in the 
adjuvant model consistent with the 28 day model literature and our previous 
experience 338,344. This suggests any ST2 dependent pathway that does exist can 
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be overcome by alum, via IL-4 or non-specific enhancement. However, in the 
adjuvant free model, pilot data showing a clear requirement for ST2 at 
sensitisation in the development of eosinophilic airway inflammation was not 
confirmed. Despite this, some conclusions about the role of IL-4, ST2 and alum in 
these models can be drawn.   
In comparison to the effects of ST2 at sensitisation in adjuvant or adjuvant free 
conditions; the IL-4 mediated pathway is dominant.   IL-4 induces isotype 
switching, secretion of IgE by B lymphocytes along with the differentiation of 
Th2 lymphocytes which in turn leads to cytokine release 604. Whilst most animal 
models of asthma show a partial dependence on IL-4, this has not translated in 
major clinical advances from IL-4 blockade. In agreement with the results here, 
IL-4-/- mice have been shown to have impaired but not absent AAI without effect 
on AHR 46. Although AHR was not assessed in experiments here it is therefore 
unlikely any differences would be seen.  IL-4 independent pathways are known 
to exist 605 and as discussed, IL-33 can polarise Th2 cells to an IL-5+IL-4- 
producing cell independent of IL-4 496. IL-13 shares a cell-receptor IL-4R with IL-4 
thus providing compensatory mechanism for some roles 606.  IgE production can 
occur via IL-13 54 and of course non-atopic asthma can develop without IgE. 
Therefore, in the absence of IL-4 (in the adjuvant free model), a less dominant 
ST2 pathway may be able to be exert an effect. However, the loss of IL-4 in this 
model resulted in very low levels of inflammation, making further effects 
attributable to ST2 in the double knockout mice difficult to delineate.  
IL-5+IL-4-Th2 cells that develop at sensitisation with IL-33 treatment are 
sufficient to cause AAI following adoptive transfer to IL-4-/- mice. The 
subsequent IL-4/ST2 experiments now demonstrate (at least in this particular 
model) that these cells are not are essential for the development of AAI as in the 
absence of ST2, mice successfully sensitise and develop AAI. This suggests IL-33, 
if present endogenously, can exacerbate AAI via this pathway over the classical 
IL-4 dependent route should environmental conditions be favourable.  In BAL and 
serum of ST2-/- mice levels of IL-4 are lower, this in consistent with the notion 
that, IL-4 does not play a major role in IL-33/ST2 mediated AAI.  
ST2-/- mice in this AAI model have lower levels of MIG/CXCL9, contrasted by 
increased levels in IL-4-/- mice, suggesting a ST2-dependent, IL-4-independent 
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mechanism for monocyte/macrophage recruitment.  As discussed in chapter 4, a 
non-antigen colitis model which is exacerbated by IL-33 in an IL-4 dependent 
manner, levels of MIG were enhanced by IL-33 also in an IL-4 dependent fashion 
447. In humans, levels of elevated MIG/CXCL9 were associated with IL-33 in serum 
of patients with malaria but the mechanism could not be determined 607. In 
innate IL-33 AI in chapter 4, MIG/CXCL9 was not detected indicating differential 
Ag- and non-Ag-dependent responses. 
A similar pattern of enhanced immune response was seen in all groups co-
treated with alum at sensitisation. Alum contributes to development of 
inflammation in IL-4-/- mice suggesting alum does not act not solely via IL-4. 
Alum could act via ST2 and furthermore drive a small non-ST2, non-IL-4 
pathway. Aluminium adjuvants are the most common adjuvant in use and elicit 
strong humoral immune responses, but the mechanism of action is not well 
understood. As IL-4 is a key feature in the induction of Th2 responses it has been 
proposed to be important in mediating the boost in this response by alum 
277,608,609. Alum can preferentially induce CD4+ cells which in turn mediate 
differentiation of B cells that produce IgG1 and IgE 608.  This is in part by the 
generation of IL-4 from Gr1+ splenic eosinophils 603 but also by inhibiting Th1 
responses 609. The increase in IL-6 in IL-4-/- mice in data presented here is in 
keeping with loss of IL-4 inhibiting Th1 responses; however this difference was 
only seen in the OVA treated and not OVA-alum treated group. No changes 
however were seen in levels of IFNγ.  It has also previously been shown that 
alum can enhance Th2 responses in the absence of IL-4 and results presented 
here are consistent with this finding as OVA-alum treated IL-4-/- mice had 
increased levels of BAL eosinophilia compared to OVA treated IL-4-/- mice277,588. 
Despite this, the overall the magnitude of reduction of the Th2 response in the 
absence of IL-4 is considerable.  
More recently other mechanisms for the mode of action of alum have been 
postulated. Intraperitoneal OVA is taken up by DCs in DLN. In the presence of 
alum, inflammatory peritoneal monocytes can take up the OVA, mature to DCs 
which travel to DLN. Co-injection of alum is cytotoxic directly leading to (UA) 
uric acid production. UA activates DAMPs resulting in T cell effector rather than 
tolerance responses 610. Also, after alum injection it appears DAMP host DNA is 
Chapter 6  260 
released 611 but while this alum-induced DNA can be involved in DC-T cell 
interactions, the receptor pathway is uncertain 612.  The initial recognition of 
alum by the innate system has recently been suggested to occur via plasma 
membrane lipids on DCs, leading to activation of spleen tyrosine kinase (Syk-) 
and P13- kinase signalling. This pathway is implicated in PGE2 secretion and IgE 
production along with inhibition of IL-12p70 and thus Th1 responses613-615. 
Furthermore, UA alone can induce and amplify Th2 immunity via this DC 
pathway without alum or NLRP3 in a HDM model 616. Results shown here contrast 
with the IL-12 finding with increased IL-12 in all OVA-alum groups compared to 
OVA groups. It is unclear as to why Th1 responses are directly activated in all 
groups but could indirectly reflect a higher level of inflammation in these 
groups. However, the IL-4-/- mice had proportionately higher serum IL-12 in the 
OVA-alum group compared to ST2-/- mice and their respective control groups 
possibly indicating some loss of Th1 regulation by loss of IL-4.  
One of the key findings in relation to the properties of alum is that it activates 
the NLRP3 inflammasome. This in turn activates caspase-1 which has the ability 
to cleave pro-IL-1β, pro-IL-18 and pro-IL-33 383,610,617 although this mechanism 
appears dispensable for IL-33 release 618. In studies of AAI in NLRP3-/- mice, a 
critical role for NLRP3 was shown in the presence of alum617 but also in its 
absence in a low dose short model where DC migration and IL-33 levels were 
reduced421. The AAI models used were not identical but this suggests alum 
administration could actually be contributing to IL-33 (and IL-1α and IL-1β) 
generation but also in alums absence, NLRP3 could have an indirect or direct 
role in endogenous IL-33 production. Data presented here shows that as alum 
boosts the immune response in absence of ST2 therefore bypassing an IL-33 
pathway, IL-33 is not critical in the response to alum. However, alum dependent 
or independent enhanced IL-33 production could potentially enhance the NLRP3 
pathway at sensitisation. A further study examining the role of NLRP3 in vivo in 
several AAI models including alum-free, concluded there was no prominent role 
for the inflammasome regardless of model used. However, reduced IL-13 and IL-
33 levels were seen in NLRP3 mice confirming a potential role for NLRP3 in 
endogenous IL-33 processing 619. Overall, there are multiple simultaneously 
triggered responses, none of which are selectively responsible for the adjuvant 
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effect of alum, which reflects its role here in boosting non-ST2, non-IL-4 and 
non-ST2/IL-4 pathways.  
In this model, the loss of ST2 and IL-4 occurs not only at sensitisation but also 
downstream by loss on effector cells. Thus considering the generated antibody 
profile is more likely to identify a specific role of at sensitisation. Whilst the 
data presented here did not demonstrate that ST2 was required in an adjuvant 
free model for IgE production, it confirmed the crucial role of IL-4 in type-2 
antibody production.  In the absence of IL-4, it appears alum can boost this 
response, possibly via the NLRP3 inflammasome that boosts the adaptive 
response 617. IL-4 promotes adaptive immunity by class switching to IgE and IgG1 
producing isotypes in activated B cells 43. Loss of IL-4 results in slight reduction 
in IgG1, absent IgE and increased IgG2a without the inhibitory effects of IL-4 277.  
The IgE results presented in this thesis disagree but secondary mechanisms for 
IgE production in the absence of IL-4 have been described. The model used in 
these published studies involved an OVA-alum sensitisation followed by DLN OVA-
stimulation ex-vivo without an airway challenge thus potentially different 
kinetics may exist generating IgE via a non-IL-4 pathway. As IL-13 is able to play 
a partially compensatory role in IgE production in OVA-alum immunisation 606,620 
IL-4 receptor (IL-4R) knockout were also investigated 588. IL-4R-/- mice had similar 
results to IL-4-/- mice with IgG1 but not IgE produced, indicating independent 
function of IL-4 or IL-13. Indeed under certain circumstances, mice lacking IL-4 
and IL-13 have capacity for IgE production 86. Neither IgG2a and IgG1 subclass 
levels nor DLN recall were assessed in data presented here for comparison.  
The route of allergen delivery can affect the resultant Ag-specific response in IL-
4-/- mice.  Such IL-4 independent pathways have been described particularly with 
sensitisation via the e.c. route. Th2 responses were equivalent to those which 
developed in WT mice when an e.c. sensitisation route was followed by i.n. 
challenge, with the exception of the antibody profile, as no IgE was produced 
587.  In this study alum was not used to compare possible enhancement.  
Alternative sites for class switching and IgE production have been described.  In 
allergic rhinitis, class switching and local IgE production occur in the presence of 
IL-4 and or IL-13 77thus intranasal sensitisation is a route to be considered and 
where in AAI, the role of IL-4 is unknown. 
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Data presented did not agree with preliminary work suggesting that ST2 and IL-4 
are both independently necessary for sensitisation and AAI, and there are no 
comparable experiments in the literature to draw firm conclusions about the 
role of ST2/IL-4 synergistically at sensitisation. There are signals to suggest that 
a ST2 pathway at sensitisation can be elicited under certain circumstances. In 
the shorter model, ST2 has a role in alum and alum-free models 421,496.  In 
understanding possible reasons why these experiments did not come to the same 
conclusion regarding ST2 as the previous pilot data, many confounding 
experimental variables must be considered. Any requirement of IL-4 and IL-
33/ST2 at sensitisation cannot be studied without accounting for loss IL-4 and IL-
33/ST2 on effector cells at subsequent challenge. One approach would be to 
adoptively transfer T cells obtained post sensitisation from knock out mice and 
transfer into WT and knockout mice.  Although AAI can develop in IL-4-/- mice, 
the model used here was not validated in these knockout mice and they did not 
generate sufficient inflammation to ascertain any additional information about 
the contribution of ST2.  Because of the scale of these experiments and 
resources required, the number of mice per group was deemed sufficient by 
power calculations. However, statistical conclusions were limited by a decreased 
in final numbers in some groups.  This particularly affected IL-4-/- and ST2-/-IL-4-
/- mice with susceptibility to illness in the IL-4 mice suspected as discussed in 
chapter 4. Sterile conditions should be used in further studies.  
In summary, IL-4 plays a dominant role in this model but the role of the ST2 
pathway still merits further investigation due to potential potent effects of IL-
33. Studying alternative sensitisation pathways where IL-4 is not required along 
with using alternative allergens such as Der P1 could lead to discovery of critical 
IL-33/ST2 pathways reflecting different asthma phenotypes. Finally, as IL-4 
shares a receptor with IL-13, it should be anticipated to perform experiments in 
IL-4 and IL-4R-/- mice.  
The role of cytokine and a cytokine receptor should be considered separately 
due to potential cytokine redundancy. To further investigate the role of 
endogenous IL-33 in AAI, repeat experiments in IL-33-/- mice were intended.  The 
mice were unable to be generated in the laboratory during the timeframe 
available. Following the completion of the works presented in this thesis; studies 
looking at his have been published. In OVA-alum 28 day AAI, IL-33-/- mice showed 
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attenuated AI and AHR responses without change in cytokine and OVA-IgE levels. 
CD4+ST2+ cell and OVA-specific spleen responses were similar between IL-33-/- 
and IL-33+/+ mice. This indicates that at least in the presence of alum, IL-33 is 
not necessary for Ag-specific differentiation but in the Ag-dependent local 
response by a loss on effector cells515. With a similar protocol, another study in 
the same strain of mouse again showed lack of endogenous IL-33 affected 
cellular inflammation and not IgE but here this was associated with cytokine IL-5 
and 13 reduction andimpaired DLN responses but AHR was not affected 621.  
Overall IL-33 appears to have a role in sensitisation but an influence on the 
effector response predominates. 
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7.1 Summary 
At the outset of the experimental work presented in this thesis, the role of ST2 
in asthma was unclear and the ligand for this receptor, IL-33, had only recently 
been described. IL-33 is a potent cytokine with innate type 2 effects but its role 
in AI and asthma was unknown.  Since then, research has expanded massively 
into this field. In the following sections the data presented in this thesis will be 
summarised in the context of the current understanding of ST2/IL-33 
immunobiology with specific consideration to its role in the airway. 
7.2 ST2 in asthma 
7.2.1 Soluble ST2 
The studies in chapter 3 have demonstrated that ST2 and IL-33 are expressed in 
cells important in asthma pathophysiology. Measuring these determinants in 
induced sputum and plasma of asthmatics patients was found to be unrelated to 
clinical disease or smoking status, but interpretation was limited by available 
assays at the time. An unexpected finding was the increase in sST2 associated 
with CS treatment.  A number have studies have now described elevated levels 
of sputum IL-33 and sST2, the latest in young asthmatic children 479. 
A recent study investigating the effect of smoking on IL-33 expression shows a 
reduction in BAL IL-33 but not serum levels; the expression of IL-33 in the 
epithelium was increased. Accompanying in vitro studies indicate that 
expression, but not release of IL-33, is increased in EC exposed to cigarette 
smoke extract 622. Thus the findings of raised sST2 presented in this thesis could 
not be explained as a result of elevated IL-33, present but undetected in the 
samples. Other than sequestration, a non-canonical role has been described 
where sST2 is internalised into DCs; although this would not explain raised sST2 
levels seen in the CS treated patients, it suggests that other mechanisms for 
sST2 function exist 623. 
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Thus smoking influences both IL-33 and sST2 expression but the overall outcome 
is uncertain but this could suggest an intracellular/nuclear IL-33 pathway is 
activated by smoking.   
7.3 IL-33 and ST2 in airways disease 
The roles for IL-33/ST2 in airways disease are multifold; in sensitisation and 
challenge phases of AAI and asthma but also during exacerbations and in the 
resolution phase and remodelling. 
7.3.1 Sensitisation 
Despite compelling evidence regarding the role of Th2-mediated immune 
responses in asthma, the mechanisms underlying their initiation remain elusive. 
Results presented in this thesis in chapter 6 and supporting data show IL-33 can 
induce the differentiation of CD4+IL-5+IL-4- cells which exacerbate AAI  
suggesting a role for IL-33/ST2 at sensitisation 496. Further data in this thesis 
shows absence of endogenous IL-33/ST2 at sensitisation does not significantly 
alter inflammation. Interpretation of these results is difficult to dissect given 
the loss of ST2 in this model will affect sensitisation and challenge phases, and 
there the differing roles of ST2L and sST2 both potentially affected. Further 
studies of loss endogenous IL-33 in AAI have been performed.  Using IL-33-/- mice, 
attenuated responses in the AAI model was demonstrated with effects seen in 
the both phases; reduced numbers of DLN cells responsive to OVA-recall assay as 
well as inflammation in the BAL621. Whether the attenuated effector response is 
due to reduced CD4 cells is uncertain. Similarly, another study of endogenous IL-
33 blockade resulted in attenuated AAI when anti-IL-33 antibody was 
administered at both sensitisation and challenge phases 624. Blockage of 
endogenous IL-33 at sensitisation or challenge only may help to unravel these 
complexities. 
IL-33 also has a role on other cells important at sensitisation, in particular on 
DCs 421. DC-driven Th2 polarisation is ST2 dependent in an adjuvant-free cypress 
pollen model of AAI where increased levels of IL-33 were measured; this suggests 
co-presence of IL-33 could initiate the development of a Th2 response in 
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response to naturally occurring allergens 625.  Furthermore, IL-33 promotes DC/T 
cell interaction by enhancing the function of OX40/OX40L ligand 625,626.  
Data presented in chapter 6, did not confirm a significant additional role for ST2 
above IL-4 in the adjuvant-free pathway in AAI. The adjuvant-free ST2 pathway 
could well be important in alternate AAI sensitisation routes.  ST2-dependence 
was found in an e.c. sensitisation model when mice were challenged with i.n. 
allergen, in contrast to findings in the skin where repeated challenge did not 
demonstrate a critical ST2/IL-33 pathway 627. This also suggests important 
mechanisms in links between allergic skin and airways disease. In a HDM i.n. 
sensitisation model, where i.n. challenge was not performed, soluble ST2 (or 
anti-GM-CSF) given at sensitisation reduced the Th2 inflammation 469. The source 
of IL-33 (and GM-CSF) in this model was the epithelial cell. In the HDM AAI 
model, inflammation was significantly attenuated in IL-1R-/- mice and by using 
neutralising IL-1 antibodies at sensitisation, these investigators showed IL-1α was 
required. IL-1α induced EC cytokine production and so it appeared IL-1α was 
upstream in HDM-derived cytokine cascade including IL-33 in this particular 
model 469. 
Data presented in this thesis show that in the i.p. model of AAI sensitisation IL-4 
was critical. The source of IL-4 at Th2 differentiation in asthma/AAI has been 
unclear. In the case of protease allergens, directly activated basophils produce 
cytokines including IL-4, and TSLP in vivo 95. In other models and in asthma, the 
initial source for IL-4 is a mater of debate with other proposed sources including, 
γδ T cells, eosinophils, NKT cells, mast cells, ILC and naïve CD4 cells. This 
remains an outstanding unanswered question. 
Beyond Th2 responses, a new role for IL-33 in differentiation of Th1 and CD8 T 
cell responses is now being appreciated. This has implications in tumour and 
viral immunity as well as in immunisation where the role of IL-33 as an adjuvant 
may be more effective 628. IL-33 is now appears to be a pleiotropic cytokine with 
increasing functions likely to depend on the surrounding cytokine milleu. 
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7.3.2 Remodelling 
The role of IL-33 in AAI and asthma has extended into chronic inflammation and 
remodelling. The importance of the bronchial epithelium in this disease process 
is becoming clearer. Not only does EC produce IL-33, but data presented in this 
thesis indicates that as ST2 expressing cells, they have an additional role 
responding to IL-33. IL-33 stimulated ECs produce a number of mediators and 
drive VEGF-mediated angiogenesis in IL-33 driven AI.  
Less is known about the resolution of inflammation in AAI and asthma and how 
this is linked to clear development of remodelling. The IL-33/ST2 pathway was 
required for persistence of inflammation in a model of AAI which was mostly 
dependent on Th2 cells282. In a further study, the administration of anti-IL-33 or 
anti-ST2 antibody once AI was established, resulted in reduced AI and 
remodelling changes such as epithelial cell hyperplasia, goblet cell hyperplasia, 
collagen, smooth muscle hypertrophy and sub-epithelial fibrosis. Depletion of 
macrophages suppressed the remodelling changes, suggesting immune cells are 
also important contributors to IL-33-driven remodelling 629. 
Clinically, an association of IL-33 with parameters of airway remodelling is 
becoming clear. An increased expression of IL-33 in endobronchial biopsies 
associated with BM thickness from paediatric patients with severe steroid-
resistant asthma was observed 630. In an accompanying mouse model, this study 
showed that the remodelling effect was not inhibited by IL-13 blockade despite 
reduction in AHR; furthermore remodelling was absent in ST2-/- mice 630.  
Recently, another study in adult asthmatics demonstrated increased levels of 
serum IL-33 correlated with BM thickness 491. In vitro observations in both these 
studies show IL-33 induced fibroblasts fibronectin and collagen production 
contribute to this pathology 491,630. Importantly IL-33 mediated changes were 
steroid resistant, similar to the finding of VEGF-resistant production from EC 
demonstrated in this thesis in chapter 5.  
Overall these findings indicate a wider role for IL-33 in mechanisms of 
remodelling; this aspect of IL-33 driven disease merits further work, in particular 
the role of IL-33 in angiogenesis in AAI and asthma. 
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7.4 Cellular release of IL-33 
Whilst studying the effects of exogenous IL-33 is useful to determine biological 
actions, an important question in IL-33 immunobiology is what cell types are 
actually capable of releasing IL-33 in a biologically active form? Aside from 
nuclear IL-33, IL-33 is released from cells in various active forms although there 
is still some debate over bioactivity of these forms 631. The dominant hypothesis 
is that IL-33 is released after necrosis or cell damage but it can also be secreted.  
In relation to the airway, the epithelium is a primary source of released IL-33  
186,465,467 469,514 527. Ideally positioned to respond to inhaled triggers, 
straightforward damage dependent IL-33 release acting as an alarmin is logical. 
However, the situation appears more complex and directly activated release and 
secretion are reported, the later which could perpetuate inflammation, an 
important aspect of asthma.  
Direct release of IL-33 by TLR4 signalling is stimulated by HDM allergen or 
endogenous triggers 469. Alternatively, ATP-mediated non-TLR dependent non-
necrotic release in response to a fungal allergen is reported 467. 
EC derived enzyme transglutaminase 2 (TG2) was found to be important in IL-33 
expression and initiating IL-33 mediated Th2 (and Th17) responses in a OVA AAI 
model; this suggests IL-33 amplifies the OVA model via a common epithelial 
damage pathway for TG2 and IL-33 production 463. Another EC damage 
mechanism is the production of trefoil factor family peptide-2, an epithelial 
derived repair molecule, which promoted IL-33 production from EC but also 
alveolar macrophages and DCs to drive Th2 differentiation in vivo 574. 
Alveolar type 2 and mucus producing ECs have increased IL-33 gene expression in 
patients with severe Chronic Obstructive Pulmonary Diseases (COPD) and post-
viral infected EC in mice. IL-33 expression in the COPD epithelium was localised 
to the nuclei in the basal cells which are linked to progenitor function and ex-
vivo, IL-33 was found to be released in an ATP dependent fashion. This suggests 
a programmed excess IL-33 production in COPD 633. In this study, IL-33 drove the 
innate immune response in an IL-13 dependent manner akin to the innate IL-33 
model of AI data shown in chapter 4.  If similar mechanisms existed in asthma, 
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this is intriguing as these cells could potentially be a source of chronic IL-33 
production triggered by viral infection that perpetuates inflammation.  
The EC is at forefront of response to IL-33 in the airway but the mechanisms that 
underlie release of IL-33 by differing allergens, microbes, virus, smoke as well as 
endogenous triggers and subsequent signals triggered need to be clarified 
further.  
As well as being IL-33 responsive cells, data in chapter 3 demonstrates IL-33 
expression was most likely seen within alveolar macrophages. IL-33 production 
from the macrophages has now been demonstrated 408,527,574. A study by Polumuri 
et al used a range of TLR and non-TLR agonists and found distinct post 
transcriptional regulation dependent on the agonist, indicating multiple triggers 
for IL-33 production from macrophages 634. In considering virus as a major trigger 
of exacerbations in asthma this could indicate a mechanism for viral triggered 
IL-33 release and amplification of the Th2 response. Indeed, influenza results in 
increased production of IL-33 by NLRP3 inflammasome activation in macrophages 
which results in IL-13 dependent AHR in mice 408. 
7.5 IL-33 at challenge in AAI 
Blockade of endogenous IL-33 at both sensitisation and the challenge phase of 
AAI attenuates the inflammatory response 621,624. Thus the role of IL-33 in 
exacerbations of asthma requires further investigation. 
Data presented in chapter 4 shows innate IL-33-driven AI replicates many of the 
features of asthma. Neither the adaptive immune response nor IL-4 contributed 
to this effect, with the eotaxin chemokines partially responsible for mediating 
IL-33 effects along with IL-5 and IL-13. AAM play a crucial role in innate IL-33 
driven inflammation through production of eotaxin-2/CCL24. These innate 
responses may enhance the response to IL-33 when present at the challenge 
phase of AAI. A recent study looking at this important area of exacerbations in 
asthma, found IL-33 activated AAM to increase the inflammatory response 635. 
The model used in this study was a low allergen dose chronic airway 
inflammation model generated over many weeks, with exacerbation modelled by 
a single higher challenge. Markers of AAM were elevated as well as eotaxin-
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2/CCl24 levels, supporting the data presented in this thesis and extending the 
hypothesis that IL-33 innate response could exacerbate an ongoing allergic 
response. 
Another key area in considering how IL-33 might interact with asthma or AAI in 
exacerbation is in a role related to infective triggers. As mentioned, viral 
induced IL-33 is released mediating IL-13 dependent AHR. In this manner, IL-33 is 
released from EC as well as alveolar macrophages and DC 408. However, IL-33 
appears to augment anti-viral Tc responses IFN-γ production 425 426. Therefore 
the balance of these mechanisms will be important as surrounding mediators and 
timing of the viral stimulus seem to affect outcome 636. 
Glycolipids present on the Sphinogmonus bacterium induce AHR in WT but not 
ST2-/-mice as well as increasing IL-33 expression in ECs and DCs. These bacteria 
are present in the lungs of some patients with poorly controlled asthma and 
suggests a possible mechanism for bacteria-driven exacerbation 527. It is 
interesting to speculate that IL-33 could be a common pathway for many 
exacerbating factors in asthma and this merits further investigation.  
7.6 Cellular response to IL-33 
The number of immune cell types responding to IL-33 and therefore possibly 
implicated in the pathogenesis of asthma have been well studied. These include 
mast cells, basophils, eosinophils, T cells and DCs. The recent discovery of a 
novel population of cells, theILC) responsive to IL-33 has led to intense 
investigation in their potential role in AAI and asthma.  
Findings presented in chapter 4 demonstrated that the type-2 profile of IL-33 
driven AI was not dependent on the adaptive immune system. Thus the search 
for a critical responsive innate source of IL-5 and IL-13 was undertaken.  In now 
appears that pulmonary ILC are a major source of IL-5 and IL-13 seen in IL-33 
induced AI 58,526,527. IL-33 mediated ILC IL-13 production was sufficient for 
development of AHR in absence of adaptive immune response 527. Furthermore, 
in allergen models, IL-33 induced ILC IL-5 and IL-13 production were critical in a 
protease allergen induced AAI 525,526. In the ovalbumin AAI model, ILC were 
present in the lungs in increased numbers following challenge and were the 
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source of IL-13 mediated AHR 526. ILC derived IL-5 and IL-13 mediated 
downstream type 2 effects in the absence of allergen as well as promoting an 
allergic response to a fungal allergen 528. 
Together with CD4 T cells, ILC may contribute to the induction and maintenance 
of allergic inflammation and evidence shows ILC and CD4 cells actually 
cooperate in development of response to allergen. Allergen-induced Th2 
differentiation was dependent on ILC-derived IL-13 with ILC activation further 
promoted by EC IL-33 production 637.  Further recent studies indicate these cells 
can modulate each others function, both contributing to the promotion of 
adaptive immunity and Th2 inflammation 535,638. ILC are described in humans but 
further work is needed to confirm role of ILC in human disease 163.  
Other IL-33 responsive cells include EC which clearly express ST2 and are 
capable of responding to IL-33 as shown in chapter 5.  As discussed, IL-33-
stimulated EC contributed to angiogenesis but other factors were released on IL-
33 exposure. Some recent studies have extended this research into the role of 
IL-33 on differentiated EC 556. Using improved models of primary AEC on native 
BMs and on established models of the EMTU and chronic AAI models should help 
to further elucidate some of these mechanisms more akin to an in vivo setting. 
As EC are now viewed as central in the pathogenesis of asthma, the elucidation 
of how IL-33 interacts with them is crucial 639.  
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Figure 7.1: The role of ST2 and IL-33 in the airway 
Illustrative summary of the main cellular response generated by epithelial cell released IL-33.  
Release of IL-33 as a consequence of allergen, virus or epithelial damage. DLN=draining lymph 
node, DC=dendritic cell, Mac=macrophage, Eos=eosinophil, Baso=basophil, MC=mast cell, 
ILC=innate lymphoid cell, ASM=airway smooth muscle 
 
7.7 Clinical asthma 
Along with areas discussed which mechanistically link IL-33 and AAI, genetic 
studies in humans suggest variations in the IL-33 gene are associated with 
increased susceptibility to asthma 640. Asthma is heterogenous thus a better 
understating of clinical phenotypes in asthma and AAI models has led to clinical 
trials targeting cytokines with targeted patient selection and improved 
outcomes. Atopic asthma affects up to 50% those with the disease and severe 
asthma remains a major cause of illness. It could be postulated that greater 
benefit might be achieved by blocking an upstream target like IL-33. Although no 
studies in man have so far targeted IL-33, these are no doubt anticipated.  
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7.8 Concluding remarks 
IL-33 binds to its receptor, ST2, and triggers AI and contributes to AAI by 
interacting with both the innate and adaptive arms of the immune system. Data 
presented in this thesis contribute to the increased understanding of IL-33 
biology.  
Exogenous and endogenous stimuli induce EC and other cells to produce IL-33 
which acts on DCs, ILCs andCD4 cells initiating the release of Th2 cytokines, 
principally IL-5 and IL-13. These cytokines act in an autocrine and paracrine 
manner and on cells including macrophages and ECs.  
This leads to the release of further mediators including chemokines and 
remodelling factors which drive the pathological response of AI, AHR and 
remodelling, akin to asthma and could contribute to symptomatic disease in 
vivo. 
Many of the questions generated from the data presented in this thesis have 
been addressed in recent studies. Outstanding areas of knowledge in ST2/IL-33 
biology include understanding: the role of ST2 in non-adjuvant sensitisation and 
IL-33 as an adjuvant; the exact role of sST2 and the possibility it may have a role 
independent of IL-33; defining the function of intranuclear IL-33 in expressing 
cells; further investigation of ILCs particularly in humans; and the role of IL-33 in 
asthma exacerbations requires further attention. 
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